{"id": "10891991_1", "context": "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[160]], "entity_id": ["T5"]}, "Subject": {"text": [["women of reproductive age"]], "start": [[72]], "entity_id": ["T3"], "Gender": {"text": [["women"]], "start": [[72]], "entity_id": ["T7"]}, "Age": {"text": [["reproductive age"]], "start": [[81]], "entity_id": ["T8"]}}, "Treatment": {"text": [["valproate for epilepsy"]], "start": [[117]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[117]], "entity_id": ["T9"]}, "Disorder": {"text": [["epilepsy"]], "start": [[131]], "entity_id": ["T10"]}}, "Effect": {"text": [["menstrual cycle disturbances"]], "start": [[168]], "entity_id": ["T6"]}}]}]}
{"id": "4044222_1", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[44]], "entity_id": ["T5"]}, "Subject": {"text": [["A 54-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["54-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Treatment": {"text": [["amiodarone"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[32]], "entity_id": ["T9"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[54]], "entity_id": ["T6"]}}]}]}
{"id": "8936932_1", "context": "Acute esmolol toxicity may be self-limiting because of its extremely short half-life.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["be"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["esmolol"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["esmolol"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["toxicity"]], "start": [[14]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[23]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "14742791_4", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[57]], "entity_id": ["T5"]}, "Effect": {"text": [["AIN"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["pantoprazole"]], "start": [[86]], "entity_id": ["T6"], "Drug": {"text": [["pantoprazole"]], "start": [[86]], "entity_id": ["T8"]}}, "Subject": {"text": [["patient"]], "start": [[115]], "entity_id": ["T7"]}, "Speculated": {"text": [["highly probable"]], "start": [[41]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "748238_1", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[67]], "entity_id": ["T5"]}, "Treatment": {"text": [["chronic diphenylhydantoin therapy."]], "start": [[70]], "entity_id": ["T6"], "Dosage": {"text": [["chronic"]], "start": [[70]], "entity_id": ["T9"]}, "Drug": {"text": [["diphenylhydantoin"]], "start": [[78]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient"]], "start": [[57]], "entity_id": ["T7"]}, "Effect": {"text": [["Monoclonal gammopathy and subsequent multiple myeloma"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "9433539_2", "context": "Agranulocytosis associated with ticlopidine: a possible benefit with filgastim.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T3"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["ticlopidine"]], "start": [[32]], "entity_id": ["T6"]}}, "Effect": {"text": [["Agranulocytosis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "18676387_2", "context": "To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[80]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["paroxetine", "fentanyl"]], "start": [[113, 177]], "entity_id": ["T11"], "Drug": {"text": [["paroxetine"], ["fentanyl"]], "start": [[113], [177]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[93]], "entity_id": ["T14"]}, "Drug": {"text": [["paroxetine"], ["fentanyl"]], "start": [[113], [177]], "entity_id": ["T12", "T13"]}}]}}]}]}
{"id": "12494253_2", "context": "Anaphylaxis to cisplatin following nine previous uncomplicated cycles.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["cisplatin following nine previous uncomplicated cycles"]], "start": [[15]], "entity_id": ["T5"], "Drug": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T6"]}, "Duration": {"text": [["nine previous uncomplicated cycles"]], "start": [[35]], "entity_id": ["T7"]}}}]}]}
{"id": "8149366_2", "context": "We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[72]], "entity_id": ["T5"]}, "Treatment": {"text": [["levo-dopa"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["levo-dopa"]], "start": [[62]], "entity_id": ["T8"]}, "Disorder": {"text": [["parkinsonian"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["diphasic dyskinesias"]], "start": [[80]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reduce"]], "start": [[143]], "entity_id": ["T15"]}, "Treatment": {"text": [["subcutaneous apomorphine"]], "start": [[115]], "entity_id": ["T13"], "Drug": {"text": [["subcutaneous apomorphine"]], "start": [[115]], "entity_id": ["T14"]}, "Disorder": {"text": [["levo-dopa-induced diphasic dyskinesias"]], "start": [[62]], "entity_id": ["T11"]}}, "Subject": {"text": [["parkinsonian patients"]], "start": [[35]], "entity_id": ["T3"]}, "Effect": {"text": [["abnormal movements"]], "start": [[166]], "entity_id": ["T12"]}}]}]}
{"id": "3693034_1", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["19 days of treatment with 5-fluorocytosine and amphotericin B"]], "start": [[42]], "entity_id": ["T5"], "Time_elapsed": {"text": [["19 days"]], "start": [[42]], "entity_id": ["T7"]}, "Drug": {"text": [["5-fluorocytosine"], ["amphotericin B"]], "start": [[68], [89]], "entity_id": ["T8", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[85]], "entity_id": ["T9"]}, "Drug": {"text": [["5-fluorocytosine"], ["amphotericin B"]], "start": [[68], [89]], "entity_id": ["T8", "T10"]}}]}, "Effect": {"text": [["Toxic epidermal necrolysis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "23006440_5", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interact"]], "start": [[341]], "entity_id": ["T13"]}, "Subject": {"text": [["In this case"]], "start": [[0]], "entity_id": ["T11"]}, "Effect": {"text": [["secondary effects of antitumor agents on other drugs"]], "start": [[270]], "entity_id": ["T14"]}, "Treatment": {"text": [["5-FU increased PHT, which in turn may have increased the PB concentration,"]], "start": [[14]], "entity_id": ["T12"], "Drug": {"text": [["5-FU"], ["PHT"], ["PB"]], "start": [[14], [29], [71]], "entity_id": ["T15", "T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["increased"]], "start": [[19]], "entity_id": ["T18"]}, "Drug": {"text": [["5-FU"], ["PHT"], ["PB"]], "start": [[14], [29], [71]], "entity_id": ["T15", "T16", "T17"]}}]}}]}]}
{"id": "6197014_1", "context": "Salicylate hepato toxicity in rheumatic fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["rheumatic fever"]], "start": [[30]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepato toxicity"]], "start": [[11]], "entity_id": ["T4"]}}]}]}
{"id": "1420650_3", "context": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[82]], "entity_id": ["T12"]}, "Treatment": {"text": [["even at low or moderate dosage levels", "certain drugs as lithium or clozapine are used in combination with CBZ"]], "start": [[88, 130]], "entity_id": ["T9"], "Drug": {"text": [["CBZ"], ["lithium"], ["clozapine"]], "start": [[197], [147], [158]], "entity_id": ["T15", "T16", "T17"]}, "Dosage": {"text": [["low or moderate dosage"]], "start": [[96]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[180]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["lithium"]], "start": [[197], [147]], "entity_id": ["T15", "T16"]}}, {"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[180]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["clozapine"]], "start": [[197], [158]], "entity_id": ["T15", "T17"]}}]}, "Effect": {"text": [["asterixis"]], "start": [[12]], "entity_id": ["T10"]}, "Speculated": {"text": [["may"]], "start": [[78]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "7978578_2", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responding to"]], "start": [[69]], "entity_id": ["T7"]}, "Treatment": {"text": [["treatment with flumazenil"]], "start": [[83]], "entity_id": ["T8"], "Disorder": {"text": [["promethazine-induced coma"]], "start": [[43]], "entity_id": ["T3"]}, "Drug": {"text": [["flumazenil"]], "start": [[98]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient"]], "start": [[28]], "entity_id": ["T2"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[28]], "entity_id": ["T2"]}, "Treatment": {"text": [["promethazine"]], "start": [[43]], "entity_id": ["T4"], "Drug": {"text": [["promethazine"]], "start": [[43]], "entity_id": ["T10"]}}, "Effect": {"text": [["coma"]], "start": [[64]], "entity_id": ["T1"]}}]}]}
{"id": "12022905_5", "context": "Priapism associated with zuclopenthixol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["zuclopenthixol"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["zuclopenthixol"]], "start": [[25]], "entity_id": ["T6"]}}, "Effect": {"text": [["Priapism"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "9619226_1", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Cardiac arrest"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sulprostone"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["sulprostone"]], "start": [[31]], "entity_id": ["T6"]}}}]}]}
{"id": "18784429_3", "context": "High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[94]], "entity_id": ["T6"]}, "Treatment": {"text": [["High-dose methylprednisolone"]], "start": [[0]], "entity_id": ["T4"], "Dosage": {"text": [["High-dose"]], "start": [[0]], "entity_id": ["T10"]}, "Drug": {"text": [["methylprednisolone"]], "start": [[10]], "entity_id": ["T11"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[54]], "entity_id": ["T12"]}}, "Effect": {"text": [["adrenal suppression in her newborn"]], "start": [[74]], "entity_id": ["T5"]}, "Subject": {"text": [["a pregnant woman with Crohn's disease"]], "start": [[32]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[43]], "entity_id": ["T7"]}, "Disorder": {"text": [["pregnant"]], "start": [[34]], "entity_id": ["T8"]}}}]}]}
{"id": "6311654_6", "context": "It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accumulative effect"]], "start": [[69]], "entity_id": ["T8"]}, "Effect": {"text": [["cerebral atrophy"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["ACTH"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["ACTH"]], "start": [[92]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[52]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19034138_5", "context": "PURPOSE: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[63]], "entity_id": ["T6"]}, "Effect": {"text": [["bilateral corneal endothelial dysfunction"]], "start": [[21]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with Parkinson disease"]], "start": [[66]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term amantadine"]], "start": [[120]], "entity_id": ["T5"], "Disorder": {"text": [["Parkinson disease"]], "start": [[81]], "entity_id": ["T8"]}, "Drug": {"text": [["amantadine"]], "start": [[130]], "entity_id": ["T9"]}, "Duration": {"text": [["ong-term"]], "start": [[121]], "entity_id": ["T10"]}}}]}]}
{"id": "3868420_1", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[112]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with alveolar hydatid disease"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["mebendazole"]], "start": [[90]], "entity_id": ["T6"], "Drug": {"text": [["mebendazole"]], "start": [[90]], "entity_id": ["T10"]}, "Disorder": {"text": [["alveolar hydatid disease"]], "start": [[43]], "entity_id": ["T11"]}}, "Effect": {"text": [["alopecia and granulocytopenia"]], "start": [[135]], "entity_id": ["T8"]}}]}]}
{"id": "15685264_6", "context": "She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[13]], "entity_id": ["T8"]}, "Treatment": {"text": [["Carbamazepine 1000 mg/day"]], "start": [[24]], "entity_id": ["T6"], "Disorder": {"text": [["neuropathic pain"]], "start": [[54]], "entity_id": ["T7"]}, "Drug": {"text": [["Carbamazepine"]], "start": [[24]], "entity_id": ["T10"]}, "Dosage": {"text": [["1000 mg/day"]], "start": [[38]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["2 years"]], "start": [[75]], "entity_id": ["T13"]}}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "10516999_1", "context": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute hyperphosphatemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sodium phosphate enema"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["sodium phosphate"]], "start": [[34]], "entity_id": ["T8"]}, "Route": {"text": [["enema"]], "start": [[51]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient with liver dysfunction and chronic renal failure"]], "start": [[60]], "entity_id": ["T6"], "Disorder": {"text": [["liver dysfunction and chronic renal failure"]], "start": [[75]], "entity_id": ["T9"]}}}]}]}
{"id": "1827039_1", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["hepatocellular dysfunction"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyproterone acetate"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["cyproterone acetate"]], "start": [[44]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "1849334_2", "context": "We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T8"]}, "Treatment": {"text": [["a high dosage of the new diuretic muzolimine"]], "start": [[89]], "entity_id": ["T9"], "Drug": {"text": [["diuretic muzolimine"]], "start": [[114]], "entity_id": ["T16"]}, "Dosage": {"text": [["range 240 to 1440 mg"]], "start": [[135]], "entity_id": ["T17"]}, "Freq": {"text": [["per day"]], "start": [[156]], "entity_id": ["T18"]}}, "Effect": {"text": [["fatal neuromyeloencephalopathy"]], "start": [[165]], "entity_id": ["T10"]}, "Subject": {"text": [["7 patients (2 women, 5 men) with chronic renal failure"]], "start": [[13]], "entity_id": ["T12"], "Disorder": {"text": [["chronic renal failure"]], "start": [[46]], "entity_id": ["T7"]}, "Population": {"text": [["7"], ["2"], ["5"]], "start": [[13], [25], [34]], "entity_id": ["T11", "T6", "T14"]}, "Gender": {"text": [["women"], ["men"]], "start": [[27], [36]], "entity_id": ["T13", "T15"]}}}]}]}
{"id": "7787496_1", "context": "Sotalol-induced bradycardia reversed by glucagon.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversed"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["glucagon"]], "start": [[40]], "entity_id": ["T6"], "Disorder": {"text": [["Sotalol-induced bradycardia"]], "start": [[0]], "entity_id": ["T3"]}, "Drug": {"text": [["glucagon"]], "start": [[40]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T8"]}, "Treatment": {"text": [["Sotalol"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Sotalol"]], "start": [[0]], "entity_id": ["T5"]}}, "Effect": {"text": [["bradycardia"]], "start": [[16]], "entity_id": ["T10"]}}]}]}
{"id": "8276031_6", "context": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[25]], "entity_id": ["T9"]}, "Subject": {"text": [["children"]], "start": [[120]], "entity_id": ["T6"], "Age": {"text": [["children"]], "start": [[120]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Imidazoline", "overdose", "accidental ingestion", "normal therapeutic usage"]], "start": [[0, 32, 44, 80]], "entity_id": ["T7"], "Drug": {"text": [["Imidazoline"]], "start": [[0]], "entity_id": ["T11"]}, "Dosage": {"text": [["overdose"]], "start": [[32]], "entity_id": ["T12"]}, "Route": {"text": [["accidental ingestion"]], "start": [[44]], "entity_id": ["T13"]}}, "Effect": {"text": [["intoxication"]], "start": [[12]], "entity_id": ["T8"]}}]}]}
{"id": "6405633_2", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[87]], "entity_id": ["T4"]}, "Subject": {"text": [["Two patients with bipolar affective disorder and a history of bronchospastic phenomena"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["a history of bronchospastic phenomena"]], "start": [[49]], "entity_id": ["T1"]}}, "Effect": {"text": [["tremor"]], "start": [[99]], "entity_id": ["T5"]}, "Treatment": {"text": [["lithium carbonate therapy"]], "start": [[113]], "entity_id": ["T6"], "Drug": {"text": [["lithium carbonate"]], "start": [[113]], "entity_id": ["T9"]}, "Disorder": {"text": [["bipolar affective disorder"]], "start": [[18]], "entity_id": ["T2"]}}}]}]}
{"id": "8255797_2", "context": "Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[42]], "entity_id": ["T4"]}, "Effect": {"text": [["Neutropenia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["the angiotensin-converting enzyme (ACE) inhibitor, captopril"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["captopril"]], "start": [[121]], "entity_id": ["T6"]}}}]}]}
{"id": "11034877_2", "context": "We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[68]], "entity_id": ["T8"]}, "Treatment": {"text": [["gabapentin (GBP)"]], "start": [[34]], "entity_id": ["T7"], "Drug": {"text": [["gabapentin"]], "start": [[34]], "entity_id": ["T12"]}}, "Effect": {"text": [["behavioural side effects"]], "start": [[78]], "entity_id": ["T9"]}, "Subject": {"text": [["two adults"]], "start": [[10]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T10"]}, "Age": {"text": [["adults"]], "start": [[14]], "entity_id": ["T11"]}}}]}]}
{"id": "16529136_4", "context": "Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitate"]], "start": [[178]], "entity_id": ["T8"]}, "Treatment": {"text": [["monoamine oxidase inhibitors (MAOIs)"]], "start": [[29]], "entity_id": ["T6"], "Drug": {"text": [["monoamine oxidase inhibitors"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypertensive crisis or serotonin syndrome"]], "start": [[192]], "entity_id": ["T7"]}}]}]}
{"id": "2857534_1", "context": "Alprazolam-induced mania: two clinical cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Alprazolam"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Alprazolam"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["mania"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["two clinical cases"]], "start": [[26]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[26]], "entity_id": ["T7"]}}}]}]}
{"id": "10660641_2", "context": "A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[10]], "entity_id": ["T6"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["itraconazole (ITCZ)"]], "start": [[23]], "entity_id": ["T5"], "Drug": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T9"]}, "Disorder": {"text": [["Aspergillus flavus-induced chronic hypertrophic pachymeningitis"]], "start": [[66]], "entity_id": ["T10"]}}}]}]}
{"id": "11545487_6", "context": "The renal consequences of indinavir-associated nephrotoxicity are uncertain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["indinavir"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["indinavir"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[47]], "entity_id": ["T5"]}, "Speculated": {"text": [["uncertain"]], "start": [[66]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "19382926_6", "context": "A drug interaction between the alpha(2)-adrenergic agonist medetomidine and lignocaine is suspected and highlights the potential for seizures following the subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[142]], "entity_id": ["T12"]}, "Effect": {"text": [["seizures"]], "start": [[133]], "entity_id": ["T11"]}, "Treatment": {"text": [["subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation"]], "start": [[156]], "entity_id": ["T13"], "Drug": {"text": [["lignocaine"], ["medetomidine"]], "start": [[213], [230]], "entity_id": ["T14", "T15"]}, "Route": {"text": [["subcutaneous"]], "start": [[156]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["under"]], "start": [[224]], "entity_id": ["T17"]}, "Drug": {"text": [["medetomidine"], ["lignocaine"]], "start": [[230], [213]], "entity_id": ["T15", "T14"]}}]}, "Speculated": {"text": [["potential"]], "start": [[119]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "7428724_2", "context": "Oesophageal ulceration due to emepronium bromide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Oesophageal ulceration"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["emepronium bromide"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["emepronium bromide"]], "start": [[30]], "entity_id": ["T6"]}}}]}]}
{"id": "6697887_3", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[42]], "entity_id": ["T4"]}, "Effect": {"text": [["sustained hypotension"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["administration of parenteral verapamil"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["verapamil"]], "start": [[77]], "entity_id": ["T6"]}}}]}]}
{"id": "15300114_2", "context": "In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["evident"]], "start": [[109]], "entity_id": ["T5"]}, "Treatment": {"text": [["topical bimatoprost"]], "start": [[134]], "entity_id": ["T6"], "Drug": {"text": [["bimatoprost"]], "start": [[142]], "entity_id": ["T10"]}, "Route": {"text": [["topical"]], "start": [[134]], "entity_id": ["T11"]}}, "Subject": {"text": [["three reported patients"]], "start": [[15]], "entity_id": ["T7"], "Population": {"text": [["three"]], "start": [[15]], "entity_id": ["T9"]}}, "Effect": {"text": [["alteration of eyelid appearance with deepening of the lid sulcus"]], "start": [[40]], "entity_id": ["T8"]}}]}]}
{"id": "21789791_2", "context": "The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["induced"]], "start": [[86]], "entity_id": ["T8"]}, "Effect": {"text": [["apoptosis in several human cancers"]], "start": [[94]], "entity_id": ["T9"]}, "Treatment": {"text": [["proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL"]], "start": [[4]], "entity_id": ["T7"], "Drug": {"text": [["Bortezomib"], ["TRAIL"]], "start": [[25], [80]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["enhancer"]], "start": [[68]], "entity_id": ["T10"]}, "Drug": {"text": [["TRAIL"], ["Bortezomib"]], "start": [[80], [25]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "9366852_1", "context": "Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[14]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with antiphospholipid antibody syndrome"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["Skin necrosis"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["low-molecular weight heparin"]], "start": [[27]], "entity_id": ["T9"], "Drug": {"text": [["low-molecular weight heparin"]], "start": [[27]], "entity_id": ["T11"]}, "Disorder": {"text": [["antiphospholipid antibody syndrome"]], "start": [[74]], "entity_id": ["T12"]}}}]}]}
{"id": "15941649_4", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["explored"]], "start": [[3]], "entity_id": ["T6"]}, "Effect": {"text": [["ophthalmic and neurologic findings"]], "start": [[12]], "entity_id": ["T3"]}, "Subject": {"text": [["two children"]], "start": [[50]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[50]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[54]], "entity_id": ["T8"]}}, "Treatment": {"text": [["exposed prenatally to VGB"], ["VGB"]], "start": [[77], [99]], "entity_id": ["T5", "T9"]}}]}]}
{"id": "160443_1", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T4"]}, "Subject": {"text": [["younger individuals"]], "start": [[59]], "entity_id": ["T3"], "Age": {"text": [["younger"]], "start": [[59]], "entity_id": ["T7"]}}, "Treatment": {"text": [["intake of clioquinol"]], "start": [[85]], "entity_id": ["T5"], "Route": {"text": [["intake"]], "start": [[85]], "entity_id": ["T8"]}, "Drug": {"text": [["clioquinol"]], "start": [[95]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute amnestic episode"]], "start": [[33]], "entity_id": ["T6"]}}]}]}
{"id": "1642627_1", "context": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[119]], "entity_id": ["T4"]}, "Treatment": {"text": [["triazolam"]], "start": [[109]], "entity_id": ["T3"], "Drug": {"text": [["triazolam"]], "start": [[109]], "entity_id": ["T6"]}}, "Effect": {"text": [["eating disorder"]], "start": [[127]], "entity_id": ["T5"]}}]}]}
{"id": "20349794_2", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[80]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix"]], "start": [[114]], "entity_id": ["T8"]}, "Effect": {"text": [["syndrome of inappropriate antidiuretic hormone (SIADH)"]], "start": [[25]], "entity_id": ["T10"]}, "Treatment": {"text": [["cisplatin therapy"]], "start": [[93]], "entity_id": ["T11"], "Drug": {"text": [["cisplatin"]], "start": [[93]], "entity_id": ["T13"]}, "Disorder": {"text": [["advanced-stage large cell neuroendocrine carcinoma of the cervix"]], "start": [[129]], "entity_id": ["T14"]}}}]}]}
{"id": "20925534_12", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[24]], "entity_id": ["T13"]}, "Effect": {"text": [["cardiovascular event"]], "start": [[30]], "entity_id": ["T7"]}, "Treatment": {"text": [["4.9% with omeprazole and 5.7% with placebo"]], "start": [[72]], "entity_id": ["T10"], "Drug": {"text": [["omeprazole"], ["placebo"]], "start": [[82], [107]], "entity_id": ["T8", "T9"]}}, "Subject": {"text": [["109 patients"]], "start": [[11]], "entity_id": ["T11"], "Population": {"text": [["109"]], "start": [[11]], "entity_id": ["T12"]}}}]}]}
{"id": "12776809_2", "context": "Coumarin is reported to elevate liver function tests (LFT) values.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Coumarin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Coumarin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["elevate liver function tests (LFT) values"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "9723127_3", "context": "Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Decreased plasma cortisol level"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["alprazolam"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["alprazolam"]], "start": [[39]], "entity_id": ["T6"]}, "Disorder": {"text": [["panic disorder"]], "start": [[63]], "entity_id": ["T7"]}}}]}]}
{"id": "6837655_3", "context": "Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[114]], "entity_id": ["T7"]}, "Treatment": {"text": [["Within 3 weeks of beginning continuous daily isoniazid and rifampin"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[80]], "entity_id": ["T5"]}, "Time_elapsed": {"text": [["Within 3 weeks of beginning"]], "start": [[0]], "entity_id": ["T9"]}, "Freq": {"text": [["daily"]], "start": [[39]], "entity_id": ["T10"]}, "Drug": {"text": [["isoniazid"], ["rifampin"]], "start": [[45], [59]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[55]], "entity_id": ["T13"]}, "Drug": {"text": [["isoniazid"], ["rifampin"]], "start": [[45], [59]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["a patient"]], "start": [[104]], "entity_id": ["T6"]}, "Effect": {"text": [["acute renal failure"]], "start": [[124]], "entity_id": ["T8"]}}]}]}
{"id": "7375145_1", "context": "Diagnosis: practolol induced sclerosing peritonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["practolol"]], "start": [[11]], "entity_id": ["T4"], "Drug": {"text": [["practolol"]], "start": [[11]], "entity_id": ["T6"]}}, "Effect": {"text": [["sclerosing peritonitis"]], "start": [[29]], "entity_id": ["T5"]}}]}]}
{"id": "10465148_6", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[108]], "entity_id": ["T8"]}, "Effect": {"text": [["anterior lumbosacral radiculopathy"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["intrathecal methotrexate"]], "start": [[124]], "entity_id": ["T7"], "Route": {"text": [["intrathecal"]], "start": [[124]], "entity_id": ["T9"]}, "Drug": {"text": [["methotrexate"]], "start": [[136]], "entity_id": ["T10"]}}}]}]}
{"id": "2738729_2", "context": "Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[42]], "entity_id": ["T5"]}, "Effect": {"text": [["Withdrawal emergent syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["an infant"]], "start": [[32]], "entity_id": ["T4"], "Age": {"text": [["infant"]], "start": [[35]], "entity_id": ["T7"]}}, "Treatment": {"text": [["maternal haloperidol therapy"]], "start": [[58]], "entity_id": ["T6"], "Drug": {"text": [["haloperidol"]], "start": [[67]], "entity_id": ["T8"]}}}]}]}
{"id": "3438585_1", "context": "Gold-induced pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[5]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gold"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gold"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "16029707_3", "context": "The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[63]], "entity_id": ["T7"]}, "Effect": {"text": [["multiple comedones and ruptured epidermoid cysts"]], "start": [[4]], "entity_id": ["T5"]}, "Treatment": {"text": [["imiquimod therapy"]], "start": [[91]], "entity_id": ["T6"], "Drug": {"text": [["imiquimod"]], "start": [[91]], "entity_id": ["T8"]}}}]}]}
{"id": "3753891_3", "context": "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[112]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient without coronary artery disease"]], "start": [[180]], "entity_id": ["T5"]}, "Treatment": {"text": [["amsacrine"]], "start": [[166]], "entity_id": ["T6"], "Drug": {"text": [["amsacrine"]], "start": [[166]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute myocardial infarction"]], "start": [[84]], "entity_id": ["T7"]}}]}]}
{"id": "23624139_1", "context": "Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[26]], "entity_id": ["T6"]}, "Effect": {"text": [["water intoxication"]], "start": [[7]], "entity_id": ["T7"]}, "Treatment": {"text": [["the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin"]], "start": [[39]], "entity_id": ["T8"], "Drug": {"text": [["desmopressin"], ["non-steroidal anti-inflammatory drugs"]], "start": [[107], [65]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant intake"]], "start": [[43]], "entity_id": ["T11"]}, "Drug": {"text": [["non-steroidal anti-inflammatory drugs"], ["desmopressin"]], "start": [[65], [107]], "entity_id": ["T10", "T9"]}}]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "12196060_12", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[102]], "entity_id": ["T11"]}, "Treatment": {"text": [["Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["phenytoin"], ["isradipine"]], "start": [[63], [77]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interactions"]], "start": [[42]], "entity_id": ["T13"]}, "Drug": {"text": [["phenytoin"], ["isradipine"]], "start": [[63], [77]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["the lethargy, dysarthria, ataxia, and weakness"]], "start": [[118]], "entity_id": ["T12"]}, "Speculated": {"text": [["probably"]], "start": [[93]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "11435808_2", "context": "Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[19]], "entity_id": ["T10"]}, "Treatment": {"text": [["Massive CBZ OD"]], "start": [[0]], "entity_id": ["T9"], "Dosage": {"text": [["OD"]], "start": [[12]], "entity_id": ["T12"]}, "Drug": {"text": [["CBZ"]], "start": [[8]], "entity_id": ["T13"]}}, "Effect": {"text": [["reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia"]], "start": [[29]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[15]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "10755579_3", "context": "This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["fluoxetine"]], "start": [[30]], "entity_id": ["T9"]}}, "Effect": {"text": [["death"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism"]], "start": [[58]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[60]], "entity_id": ["T7"]}, "Disorder": {"text": [["genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism"]], "start": [[83]], "entity_id": ["T10"]}}}]}]}
{"id": "12477460_1", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[84]], "entity_id": ["T5"]}, "Effect": {"text": [["malignant transformation of endometriosis"]], "start": [[92]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[74]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[74]], "entity_id": ["T6"]}}}]}]}
{"id": "1722991_1", "context": "Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[62]], "entity_id": ["T7"]}, "Treatment": {"text": [["heparin"]], "start": [[54]], "entity_id": ["T8"], "Drug": {"text": [["heparin"]], "start": [[54]], "entity_id": ["T10"]}}, "Effect": {"text": [["thrombocytopenia and thrombosis"]], "start": [[73]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Usefulness"]], "start": [[0]], "entity_id": ["T11"]}, "Treatment": {"text": [["antiplatelet drugs"]], "start": [[14]], "entity_id": ["T12"], "Disorder": {"text": [["heparin-associated thrombocytopenia and thrombosis"]], "start": [[54]], "entity_id": ["T14"]}, "Drug": {"text": [["antiplatelet drugs"]], "start": [[14]], "entity_id": ["T13"]}}}]}]}
{"id": "8844232_2", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[84]], "entity_id": ["T5"]}, "Effect": {"text": [["poisoning", "creatinine phosphokinase level markedly higher"]], "start": [[22, 159]], "entity_id": ["T3"]}, "Treatment": {"text": [["3,4-methylenedioxymet-amphetamine Ecstasy"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["3,4-methylenedioxymet-amphetamine Ecstasy"]], "start": [[37]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T6"]}, "Speculated": {"text": [["suggestive"]], "start": [[116]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17983451_1", "context": "Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[62]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T6"]}, "Disorder": {"text": [["Mycobacterium marinum infection"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "1977935_4", "context": "This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[108]], "entity_id": ["T8"]}, "Treatment": {"text": [["terfenadine", "in addition to cefaclor, ketoconazole, and medroxyprogesterone"]], "start": [[134, 219]], "entity_id": ["T9"], "Drug": {"text": [["terfenadine"], ["cefaclor"], ["ketoconazole"], ["medroxyprogesterone"]], "start": [[134], [234], [244], [262]], "entity_id": ["T12", "T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["in addition"]], "start": [[219]], "entity_id": ["T13"]}, "Drug": {"text": [["cefaclor"], ["ketoconazole"], ["medroxyprogesterone"]], "start": [[234], [244], [262]], "entity_id": ["T14", "T15", "T16"]}}]}, "Subject": {"text": [["a patient who was taking the recommended prescribed dose of this drug"]], "start": [[149]], "entity_id": ["T10"]}, "Effect": {"text": [["symptomatic torsades de pointes"]], "start": [[76]], "entity_id": ["T11"]}}]}]}
{"id": "10467499_1", "context": "A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T12"]}, "Effect": {"text": [["fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption"]], "start": [[34]], "entity_id": ["T11"]}, "Treatment": {"text": [["minocycline therapy"]], "start": [[165]], "entity_id": ["T13"], "Time_elapsed": {"text": [["3 weeks"]], "start": [[142]], "entity_id": ["T17"]}, "Drug": {"text": [["minocycline"]], "start": [[165]], "entity_id": ["T18"]}, "Disorder": {"text": [["acne"]], "start": [[189]], "entity_id": ["T19"]}}, "Subject": {"text": [["A 22-year-old black man"]], "start": [[0]], "entity_id": ["T14"], "Age": {"text": [["22-year-old"]], "start": [[2]], "entity_id": ["T15"]}, "Race": {"text": [["black"]], "start": [[14]], "entity_id": ["T16"]}, "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T20"]}}}]}]}
{"id": "7661076_2", "context": "Life-threatening alterations in heart rate after the use of adenosine in atrial flutter.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["adenosine"]], "start": [[60]], "entity_id": ["T4"], "Drug": {"text": [["adenosine"]], "start": [[60]], "entity_id": ["T7"]}}, "Effect": {"text": [["Life-threatening alterations in heart rate"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["Life-threatening"]], "start": [[0]], "entity_id": ["T6"], "value": "Medium"}}]}]}
{"id": "16204273_1", "context": "The major side effect of infliximab is infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T6"]}}, "Effect": {"text": [["infection"]], "start": [[39]], "entity_id": ["T4"]}}]}]}
{"id": "11545487_1", "context": "An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["An asymptomatic HIV-infected woman"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[29]], "entity_id": ["T8"]}}, "Effect": {"text": [["right-sided renal colicky pain"]], "start": [[47]], "entity_id": ["T4"]}, "Treatment": {"text": [["indinavir"]], "start": [[100]], "entity_id": ["T6"], "Disorder": {"text": [["asymptomatic HIV-infected"]], "start": [[3]], "entity_id": ["T9"]}, "Drug": {"text": [["indinavir"]], "start": [[100]], "entity_id": ["T10"]}}}]}]}
{"id": "11487721_1", "context": "Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[140]], "entity_id": ["T5"]}, "Treatment": {"text": [["taxol"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["taxol"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[74]], "entity_id": ["T4"]}}]}]}
{"id": "19017039_2", "context": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["Syringotropic hypersensitivity reaction"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab and leflunomide combination therapy"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["infliximab"], ["leflunomide"]], "start": [[56], [71]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["psoriatic arthritis"]], "start": [[119]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[83]], "entity_id": ["T12"]}, "Drug": {"text": [["leflunomide"], ["infliximab"]], "start": [[71], [56]], "entity_id": ["T11", "T10"]}}]}, "Subject": {"text": [["a child with psoriatic arthritis"]], "start": [[106]], "entity_id": ["T7"], "Age": {"text": [["child"]], "start": [[108]], "entity_id": ["T8"]}}}]}]}
{"id": "3438585_5", "context": "Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improvement"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["Corticosteroid", "for 8 months"]], "start": [[0, 37]], "entity_id": ["T5"], "Disorder": {"text": [["pulmonary function"]], "start": [[87]], "entity_id": ["T6"]}, "Drug": {"text": [["Corticosteroid"]], "start": [[0]], "entity_id": ["T7"]}, "Duration": {"text": [["for 8 months"]], "start": [[37]], "entity_id": ["T9"]}}}]}]}
{"id": "19567656_3", "context": "OBJECTIVE: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["sertraline"]], "start": [[33]], "entity_id": ["T4"], "Disorder": {"text": [["comorbidities"], ["dementia"]], "start": [[107], [94]], "entity_id": ["T9", "T11"]}, "Drug": {"text": [["sertraline"]], "start": [[33]], "entity_id": ["T10"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[52]], "entity_id": ["T6"]}, "Subject": {"text": [["an elderly patient with dementia and comorbidities"]], "start": [[70]], "entity_id": ["T7"], "Age": {"text": [["elderly"]], "start": [[73]], "entity_id": ["T3"]}}}]}]}
{"id": "9491301_2", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[10]], "entity_id": ["T4"]}, "Subject": {"text": [["Patient 1"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["bilateral ballism"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravenous heroin injection"]], "start": [[51]], "entity_id": ["T6"], "Route": {"text": [["intravenous", "injection"]], "start": [[51, 70]], "entity_id": ["T7"]}, "Drug": {"text": [["heroin"]], "start": [[63]], "entity_id": ["T8"]}}}]}]}
{"id": "3718111_1", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[68]], "entity_id": ["T6"]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hyperkalemic"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["timolol"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["timolol"], ["normokalemic"]], "start": [[43], [55]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[51]], "entity_id": ["T10"]}, "Drug": {"text": [["timolol"], ["normokalemic"]], "start": [[43], [55]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "4054170_3", "context": "EEG abnormalities were observed in two of the nine children during chlorambucil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["chlorambucil"]], "start": [[67]], "entity_id": ["T3"], "Drug": {"text": [["chlorambucil"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["EEG abnormalities"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["two of the nine children"]], "start": [[35]], "entity_id": ["T6"], "Population": {"text": [["two of the nine"]], "start": [[35]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[51]], "entity_id": ["T8"]}}}]}]}
{"id": "9111724_1", "context": "Discontinuation of the itraconazole caused resolution of the drug eruption.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["drug eruption"]], "start": [[61]], "entity_id": ["T5"]}}]}]}
{"id": "9347384_2", "context": "During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T19"]}, "Subject": {"text": [["four out of the seven patients"]], "start": [[40]], "entity_id": ["T18"], "Population": {"text": [["four out of the seven"]], "start": [[40]], "entity_id": ["T21"]}}, "Treatment": {"text": [["During clarithromycin coadministration", "carbamazepine"]], "start": [[0, 118]], "entity_id": ["T17"], "Time_elapsed": {"text": [["During"]], "start": [[0]], "entity_id": ["T22"]}, "Drug": {"text": [["clarithromycin"], ["carbamazepine"]], "start": [[7], [118]], "entity_id": ["T23", "T25"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[22]], "entity_id": ["T24"]}, "Drug": {"text": [["clarithromycin"], ["carbamazepine"]], "start": [[7], [118]], "entity_id": ["T23", "T25"]}}]}, "Effect": {"text": [["moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia"]], "start": [[81]], "entity_id": ["T20"]}, "Severity": {"text": [["severe"]], "start": [[93]], "entity_id": ["T29"], "value": "Medium"}}, {"event_id": "E3", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[182]], "entity_id": ["T27"]}, "Treatment": {"text": [["5 days after clarithromycin discontinuation"]], "start": [[198]], "entity_id": ["T28"], "Drug": {"text": [["clarithromycin"]], "start": [[211]], "entity_id": ["T30"]}, "Disorder": {"text": [["moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia"]], "start": [[81]], "entity_id": ["T31"]}}}]}]}
{"id": "8404753_9", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[37]], "entity_id": ["T7"]}, "Treatment": {"text": [["CBZ"]], "start": [[29]], "entity_id": ["T6"], "Drug": {"text": [["CBZ"]], "start": [[29]], "entity_id": ["T11"]}}, "Effect": {"text": [["simple motor tics"]], "start": [[44]], "entity_id": ["T8"]}, "Subject": {"text": [["children"]], "start": [[65]], "entity_id": ["T9"], "Age": {"text": [["children"]], "start": [[65]], "entity_id": ["T10"]}}}]}]}
{"id": "7387219_3", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients with rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[61]], "entity_id": ["T6"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["D-penicillamine"]], "start": [[92]], "entity_id": ["T9"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[18]], "entity_id": ["T10"]}}}]}]}
{"id": "9352164_3", "context": "She was thus diagnosed as having AZ intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["having"]], "start": [[26]], "entity_id": ["T4"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["AZ"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["AZ"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["intoxication"]], "start": [[36]], "entity_id": ["T6"]}}]}]}
{"id": "15383642_11", "context": "The reaction in our patient appeared after tizanidine initiation and improved after both lisinopril and tizanidine were discontinued.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[69]], "entity_id": ["T10"]}, "Subject": {"text": [["patient"]], "start": [[20]], "entity_id": ["T8"]}, "Treatment": {"text": [["both lisinopril and tizanidine were discontinued"]], "start": [[84]], "entity_id": ["T9"], "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[89], [104]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[100]], "entity_id": ["T12"]}, "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[89], [104]], "entity_id": ["T13", "T14"]}}]}, "Effect": {"text": [["tizanidine initiation"]], "start": [[43]], "entity_id": ["T11"]}}]}]}
{"id": "18836269_1", "context": "After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[6]], "entity_id": ["T3"]}, "Treatment": {"text": [["a beta-sympathomimetic drug (Partusisten)"]], "start": [[21]], "entity_id": ["T4"], "Drug": {"text": [["Partusisten"]], "start": [[50]], "entity_id": ["T9"]}}, "Subject": {"text": [["one fetus"]], "start": [[63]], "entity_id": ["T5"], "Population": {"text": [["one"]], "start": [[63]], "entity_id": ["T7"]}, "Age": {"text": [["fetus"]], "start": [[67]], "entity_id": ["T8"]}}, "Effect": {"text": [["supraventricular tachycardia."]], "start": [[83]], "entity_id": ["T6"]}}]}]}
{"id": "12921505_1", "context": "After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["argatroban"]], "start": [[18]], "entity_id": ["T3"], "Time_elapsed": {"text": [["39 hours"], ["100 seconds."]], "start": [[6], [154]], "entity_id": ["T6", "T8"]}, "Drug": {"text": [["argatroban"]], "start": [[18]], "entity_id": ["T7"]}}, "Effect": {"text": [["minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds"]], "start": [[60]], "entity_id": ["T4"]}}]}]}
{"id": "15279668_2", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[85]], "entity_id": ["T11"]}, "Subject": {"text": [["a case"]], "start": [[11]], "entity_id": ["T9"]}, "Effect": {"text": [["significant progressive peripheral neurological deterioration"]], "start": [[23]], "entity_id": ["T10"]}, "Treatment": {"text": [["fludarabine and cytarabine", "FLA (fludarabine and cytarabine) regime"]], "start": [[118, 160]], "entity_id": ["T12"], "Drug": {"text": [["fludarabine"], ["cytarabine"], ["FLA (fludarabine and cytarabine)"]], "start": [[118], [134], [160]], "entity_id": ["T13", "T14", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[130]], "entity_id": ["T15"]}, "Drug": {"text": [["fludarabine"], ["cytarabine"]], "start": [[118], [134]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "1359782_1", "context": "A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["taking sulfasalazine"]], "start": [[136]], "entity_id": ["T8"], "Drug": {"text": [["sulfasalazine"]], "start": [[143]], "entity_id": ["T10"]}, "Disorder": {"text": [["ulcerative colitis"]], "start": [[15]], "entity_id": ["T11"]}}, "Subject": {"text": [["A patient with ulcerative colitis"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology"]], "start": [[44]], "entity_id": ["T7"]}}]}]}
{"id": "10555917_2", "context": "Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["followed"]], "start": [[64]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cessation of D-Pen and the start of corticosteroid therapy"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["corticosteroid"], ["D-Pen"]], "start": [[36], [13]], "entity_id": ["T3", "T8"]}, "Disorder": {"text": [["bicytopenia"]], "start": [[90]], "entity_id": ["T7"]}}, "Effect": {"text": [["recovery from bicytopenia"]], "start": [[76]], "entity_id": ["T6"]}}]}]}
{"id": "12488741_2", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[67]], "entity_id": ["T5"]}, "Effect": {"text": [["persistent lactate elevation"]], "start": [[38]], "entity_id": ["T3"]}, "Treatment": {"text": [["metronidazole"]], "start": [[74]], "entity_id": ["T4"], "Drug": {"text": [["metronidazole"]], "start": [[74]], "entity_id": ["T6"]}}}]}]}
{"id": "25538343_1", "context": "Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T10"]}, "Treatment": {"text": [["Duloxetine"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Duloxetine"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["hyponatremia"]], "start": [[19]], "entity_id": ["T11"]}, "Subject": {"text": [["an elderly patient"]], "start": [[35]], "entity_id": ["T7"], "Age": {"text": [["elderly"]], "start": [[38]], "entity_id": ["T8"]}}}]}]}
{"id": "1422497_1", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravesical alum irrigations"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["alum"]], "start": [[52]], "entity_id": ["T8"]}, "Route": {"text": [["intravesical"], ["irrigations"]], "start": [[39], [57]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["Encephalopathy and seizures"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "10466445_2", "context": "Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["Arsenic trioxide"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Arsenic trioxide"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["refractory acute promyelocytic leukemia (APL)"]], "start": [[80]], "entity_id": ["T9"]}}}]}]}
{"id": "18628507_2", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["as"]], "start": [[13]], "entity_id": ["T5"]}, "Effect": {"text": [["Angio-oedema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["voriconazole"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["voriconazole"]], "start": [[52]], "entity_id": ["T6"]}}}]}]}
{"id": "12751276_1", "context": "Isoniazid-induced anaphylaxis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "18262450_8", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reduced"]], "start": [[21]], "entity_id": ["T7"]}, "Treatment": {"text": [["Oxycodone-gabapentin"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["pain"]], "start": [[29]], "entity_id": ["T8"]}, "Drug": {"text": [["Oxycodone"], ["gabapentin"]], "start": [[0], [10]], "entity_id": ["T12", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[9]], "entity_id": ["T11"]}, "Drug": {"text": [["Oxycodone"], ["gabapentin"]], "start": [[0], [10]], "entity_id": ["T12", "T10"]}}]}, "Effect": {"text": [["reduced pain score by 33% from baseline"]], "start": [[21]], "entity_id": ["T9"]}}]}]}
{"id": "11352235_5", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[63]], "entity_id": ["T6"]}, "Subject": {"text": [["Five of 70 patients"]], "start": [[9]], "entity_id": ["T3"], "Population": {"text": [["Five of 70"]], "start": [[9]], "entity_id": ["T7"]}}, "Treatment": {"text": [["leflunomide"]], "start": [[43]], "entity_id": ["T4"], "Drug": {"text": [["leflunomide"]], "start": [[43]], "entity_id": ["T8"]}}, "Effect": {"text": [["significant weight loss"]], "start": [[67]], "entity_id": ["T5"]}}]}]}
{"id": "16018164_2", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["links"]], "start": [[16]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenylpropanolamine"]], "start": [[22]], "entity_id": ["T3"], "Drug": {"text": [["phenylpropanolamine"]], "start": [[22]], "entity_id": ["T8"]}}, "Effect": {"text": [["intracerebral hemorrhage"]], "start": [[60]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with an AVM"]], "start": [[88]], "entity_id": ["T5"], "Disorder": {"text": [["AVM"]], "start": [[106]], "entity_id": ["T7"]}}}]}]}
{"id": "7919557_1", "context": "CASE SUMMARY: A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["starting"]], "start": [[88]], "entity_id": ["T3"]}, "Treatment": {"text": [["quinapril therapy"]], "start": [[97]], "entity_id": ["T4"], "Drug": {"text": [["quinapril"]], "start": [[97]], "entity_id": ["T9"]}}, "Subject": {"text": [["A 68-year-old woman"]], "start": [[14]], "entity_id": ["T5"], "Age": {"text": [["68-year-old"]], "start": [[16]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[28]], "entity_id": ["T8"]}}, "Effect": {"text": [["a dry, irritating cough"]], "start": [[44]], "entity_id": ["T6"]}}]}]}
{"id": "16649344_3", "context": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["for"]], "start": [[88]], "entity_id": ["T9"]}, "Effect": {"text": [["increased lipid levels"]], "start": [[92]], "entity_id": ["T7"]}, "Treatment": {"text": [["sirolimus"]], "start": [[148]], "entity_id": ["T8"], "Drug": {"text": [["sirolimus"]], "start": [[148]], "entity_id": ["T11"]}}}]}]}
{"id": "15729090_1", "context": "Quetiapine-induced myoclonus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Quetiapine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Quetiapine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["myoclonus"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "15719254_3", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[18]], "entity_id": ["T4"]}, "Treatment": {"text": [["Retinoic acid"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Retinoic acid"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["bone marrow transplant nephropathy"]], "start": [[39]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[14]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "3391110_1", "context": "Dyspnea possibly associated with controlled-release morphine sulfate tablets.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Dyspnea"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["controlled-release morphine sulfate tablets"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["morphine sulfate"]], "start": [[52]], "entity_id": ["T7"]}, "Route": {"text": [["tablets"]], "start": [[69]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possibly"]], "start": [[8]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10465148_2", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[111]], "entity_id": ["T8"]}, "Subject": {"text": [["central nervous system leukemia in children"]], "start": [[124]], "entity_id": ["T7"], "Age": {"text": [["children"]], "start": [[159]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Intrathecal chemotherapy with methotrexate or cytosine arabinoside"]], "start": [[0]], "entity_id": ["T9"], "Route": {"text": [["Intrathecal"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["methotrexate"], ["cytosine arabinoside"]], "start": [[30], [46]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["central nervous system leukemia"]], "start": [[124]], "entity_id": ["T14"]}}}]}]}
{"id": "11144696_4", "context": "Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hospitalized"]], "start": [[75]], "entity_id": ["T7"]}, "Treatment": {"text": [["Eleven days after increase of the trimipramine dosage to 100 mg/d"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["trimipramine"]], "start": [[34]], "entity_id": ["T10"]}, "Dosage": {"text": [["100 mg/d"]], "start": [[57]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["Eleven days after"]], "start": [[0]], "entity_id": ["T13"]}}, "Subject": {"text": [["she"]], "start": [[67]], "entity_id": ["T6"], "Gender": {"text": [["she"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["seizures suggesting a secondary generalized grand-mal episode"]], "start": [[99]], "entity_id": ["T8"]}}]}]}
{"id": "16531969_4", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T7"]}, "Subject": {"text": [["three cases"]], "start": [[10]], "entity_id": ["T5"], "Population": {"text": [["three"]], "start": [[10]], "entity_id": ["T9"]}}, "Treatment": {"text": [["IFN beta"]], "start": [[25]], "entity_id": ["T6"], "Drug": {"text": [["IFN beta"]], "start": [[25]], "entity_id": ["T10"]}}, "Effect": {"text": [["hepatitis in MS"]], "start": [[42]], "entity_id": ["T8"]}}]}]}
{"id": "14530108_2", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T8"]}, "Effect": {"text": [["RTA"], ["nephrotoxicity"]], "start": [[0], [19]], "entity_id": ["T5", "T6"]}, "Treatment": {"text": [["FK506"]], "start": [[45]], "entity_id": ["T7"], "Drug": {"text": [["FK506"]], "start": [[45]], "entity_id": ["T9"]}}}]}]}
{"id": "9562211_3", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[53]], "entity_id": ["T3"]}, "Effect": {"text": [["tardive dyskinesia"]], "start": [[61]], "entity_id": ["T4"]}, "Treatment": {"text": [["risperidone"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["risperidone"]], "start": [[41]], "entity_id": ["T8"]}}, "Subject": {"text": [["a potential case"]], "start": [[21]], "entity_id": ["T9"]}, "Speculated": {"text": [["potential"]], "start": [[23]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10395123_3", "context": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[79]], "entity_id": ["T4"]}, "Effect": {"text": [["fixed drug eruption"]], "start": [[54]], "entity_id": ["T3"]}, "Treatment": {"text": [["omeprazole"]], "start": [[95]], "entity_id": ["T5"], "Drug": {"text": [["omeprazole"]], "start": [[95]], "entity_id": ["T6"]}}}]}]}
{"id": "11225565_6", "context": "Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consistent with"]], "start": [[85]], "entity_id": ["T12"]}, "Treatment": {"text": [["Delavirdine and efavirenz (but not nevirapine)"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Delavirdine"], ["efavirenz"]], "start": [[0], [16]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[12]], "entity_id": ["T15"]}, "Drug": {"text": [["Delavirdine"], ["efavirenz"]], "start": [[0], [16]], "entity_id": ["T13", "T14"]}}]}, "Effect": {"text": [["clinical hazards"]], "start": [[101]], "entity_id": ["T11"]}}]}]}
{"id": "14526130_1", "context": "Can roxithromycin and betamethasone induce acute pancreatitis? A case report.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["roxithromycin and betamethasone"]], "start": [[4]], "entity_id": ["T4"], "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[4], [22]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[18]], "entity_id": ["T10"]}, "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[4], [22]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[43]], "entity_id": ["T6"]}, "Speculated": {"text": [["?"]], "start": [[61]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12923827_1", "context": "Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[33]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[49]], "entity_id": ["T4"], "Drug": {"text": [["fluvoxamine"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["Schneiderian first-rank symptoms"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "9013348_1", "context": "A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[86]], "entity_id": ["T10"]}, "Subject": {"text": [["A 49-year-old man with Crohn's disease"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["49-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T14"]}}, "Effect": {"text": [["worsening respiratory distress and fever."]], "start": [[96]], "entity_id": ["T11"]}, "Treatment": {"text": [["prednisone and mesalamine (5-ASA)"]], "start": [[52]], "entity_id": ["T12"], "Drug": {"text": [["prednisone"], ["mesalamine"]], "start": [[52], [67]], "entity_id": ["T16", "T17"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[23]], "entity_id": ["T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[63]], "entity_id": ["T18"]}, "Drug": {"text": [["prednisone"], ["mesalamine"]], "start": [[52], [67]], "entity_id": ["T16", "T17"]}}]}}]}]}
{"id": "18721173_3", "context": "OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[86]], "entity_id": ["T3"]}, "Treatment": {"text": [["gabapentin"]], "start": [[93]], "entity_id": ["T4"], "Drug": {"text": [["gabapentin"]], "start": [[93]], "entity_id": ["T7"]}}, "Effect": {"text": [["a significant type of morbidity"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["This case"]], "start": [[11]], "entity_id": ["T6"]}}]}]}
{"id": "16122280_3", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[129]], "entity_id": ["T8"]}, "Subject": {"text": [["infectious patients"]], "start": [[23]], "entity_id": ["T5"], "Disorder": {"text": [["infectious"]], "start": [[23]], "entity_id": ["T9"]}}, "Treatment": {"text": [["oral telithromycin 800mg once daily for 5-10 days"]], "start": [[58]], "entity_id": ["T6"], "Drug": {"text": [["telithromycin"]], "start": [[63]], "entity_id": ["T10"]}, "Dosage": {"text": [["800mg"]], "start": [[77]], "entity_id": ["T11"]}, "Freq": {"text": [["once daily"]], "start": [[83]], "entity_id": ["T12"]}, "Duration": {"text": [["5-10 days"]], "start": [[98]], "entity_id": ["T13"]}, "Disorder": {"text": [["community-acquired upper and lower respiratory tract infections"]], "start": [[142]], "entity_id": ["T14"]}, "Route": {"text": [["oral"]], "start": [[58]], "entity_id": ["T15"]}}}]}]}
{"id": "15162903_4", "context": "The day after methotrexate administration, the patient complained of severe back pain and urinary retention.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complained"]], "start": [[55]], "entity_id": ["T6"]}, "Treatment": {"text": [["The day after methotrexate administration"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[14]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["The day after"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["severe back pain and urinary retention"]], "start": [[69]], "entity_id": ["T7"]}}]}]}
{"id": "18347524_2", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[72]], "entity_id": ["T10"]}, "Subject": {"text": [["a young man"]], "start": [[22]], "entity_id": ["T8"], "Age": {"text": [["young"]], "start": [[24]], "entity_id": ["T12"]}}, "Effect": {"text": [["a rapid-onset short-of-breath, hemoptysis, and severe weakness"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["about 2 weeks after the administration of leflunomide"]], "start": [[146]], "entity_id": ["T11"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[47]], "entity_id": ["T13"]}, "Drug": {"text": [["leflunomide"]], "start": [[188]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["2 weeks"]], "start": [[152]], "entity_id": ["T15"]}, "Route": {"text": [["the administration"]], "start": [[166]], "entity_id": ["T16"]}}, "Speculated": {"text": [["severe"]], "start": [[129]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "9205466_3", "context": "CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["may not reduce"]], "start": [[134]], "entity_id": ["T6"]}, "Effect": {"text": [["endometrial lesions"], ["carcinoma"]], "start": [[163], [194]], "entity_id": ["T7", "T8"]}, "Treatment": {"text": [["addition of progestogens to tamoxifen"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["progestogens"], ["tamoxifen"]], "start": [[108], [124]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[96]], "entity_id": ["T12"]}, "Drug": {"text": [["progestogens"], ["tamoxifen"]], "start": [[108], [124]], "entity_id": ["T10", "T11"]}}]}, "Speculated": {"text": [["may"]], "start": [[134]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7752014_1", "context": "Furosemide-associated fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Furosemide"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Furosemide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["fever"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "15072497_2", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[58]], "entity_id": ["T3"]}, "Treatment": {"text": [["high dose colchicine treatment"]], "start": [[65]], "entity_id": ["T4"], "Dosage": {"text": [["high dose"]], "start": [[65]], "entity_id": ["T8"]}, "Drug": {"text": [["colchicine"]], "start": [[75]], "entity_id": ["T9"]}}, "Effect": {"text": [["PD"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["two patients,"]], "start": [[25]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[25]], "entity_id": ["T7"]}}}]}]}
{"id": "3609047_3", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["a single oral dose of amiodarone (1400 mg or 30 mg kg-1)"]], "start": [[49]], "entity_id": ["T4"], "Route": {"text": [["oral"]], "start": [[58]], "entity_id": ["T7"]}, "Drug": {"text": [["amiodarone"]], "start": [[71]], "entity_id": ["T8"]}, "Dosage": {"text": [["1400 mg or 30 mg kg-1"]], "start": [[83]], "entity_id": ["T9"]}}, "Effect": {"text": [["torsade de pointes"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "16225183_1", "context": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[51]], "entity_id": ["T11"]}, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["patient"]], "start": [[43]], "entity_id": ["T9"]}, "Treatment": {"text": [["interferon beta 1a"]], "start": [[64]], "entity_id": ["T10"], "Disorder": {"text": [["multiple sclerosis"]], "start": [[24]], "entity_id": ["T8"]}, "Drug": {"text": [["interferon beta 1a."]], "start": [[64]], "entity_id": ["T12"]}}}]}]}
{"id": "18453852_16", "context": "Liver function should be carefully monitored when rifampicin and lopinavir/ritonavir are combined in patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[45]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[101]], "entity_id": ["T7"]}, "Effect": {"text": [["Liver function"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["rifampicin and lopinavir/ritonavir are combined"]], "start": [[50]], "entity_id": ["T8"], "Drug": {"text": [["rifampicin"], ["lopinavir/ritonavir"]], "start": [[50], [65]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[89]], "entity_id": ["T13"]}, "Drug": {"text": [["lopinavir/ritonavir"], ["rifampicin"]], "start": [[65], [50]], "entity_id": ["T12", "T11"]}}]}, "Speculated": {"text": [["monitored"]], "start": [[35]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "8828999_3", "context": "Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["considered"]], "start": [[32]], "entity_id": ["T8"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["Creutzfeldt-Jakob disease"]], "start": [[46]], "entity_id": ["T7"]}, "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[8]], "entity_id": ["T6"]}}]}]}
{"id": "15239684_2", "context": "The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[66]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravenous administration of phenytoin"]], "start": [[82]], "entity_id": ["T6"], "Drug": {"text": [["phenytoin"]], "start": [[112]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous"]], "start": [[82]], "entity_id": ["T9"]}}, "Effect": {"text": [["soft-tissue injury"]], "start": [[47]], "entity_id": ["T7"]}}]}]}
{"id": "10749332_1", "context": "However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[93]], "entity_id": ["T3"]}, "Treatment": {"text": [["troglitazone"]], "start": [[80]], "entity_id": ["T4"], "Drug": {"text": [["troglitazone"]], "start": [[80]], "entity_id": ["T6"]}}, "Effect": {"text": [["liver injury is insidious and temporally variable"]], "start": [[101]], "entity_id": ["T5"]}}]}]}
{"id": "7420580_2", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[77]], "entity_id": ["T4"]}, "Treatment": {"text": [["a high dose of vinblastine"]], "start": [[161]], "entity_id": ["T3"], "Dosage": {"text": [["high dose"]], "start": [[163]], "entity_id": ["T8"]}, "Drug": {"text": [["vinblastine"]], "start": [[176]], "entity_id": ["T9"]}, "Disorder": {"text": [["embryonal teratocarcinoma of the testicle"]], "start": [[31]], "entity_id": ["T10"]}}, "Effect": {"text": [["syndrome of inappropriate secretion of antidiuretic hormone"]], "start": [[85]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with an embryonal teratocarcinoma of the testicle"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "8864370_4", "context": "Methotrexate-induced liver cirrhosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T5"]}, "Effect": {"text": [["liver cirrhosis"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "2320800_1", "context": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[14]], "entity_id": ["T12"]}, "Subject": {"text": [["a breast cancer patient with an impaired renal function"]], "start": [[64]], "entity_id": ["T9"], "Disorder": {"text": [["an impaired renal function"]], "start": [[93]], "entity_id": ["T1"]}}, "Treatment": {"text": [["high dose ifosfamide chemotherapy"]], "start": [[27]], "entity_id": ["T10"], "Disorder": {"text": [["breast cancer"]], "start": [[66]], "entity_id": ["T13"]}, "Drug": {"text": [["ifosfamide"]], "start": [[37]], "entity_id": ["T14"]}, "Route": {"text": [["chemotherapy"]], "start": [[48]], "entity_id": ["T16"]}, "Dosage": {"text": [["high dose"]], "start": [[27]], "entity_id": ["T17"]}}, "Effect": {"text": [["anuria"]], "start": [[7]], "entity_id": ["T11"]}, "Severity": {"text": [["Lethal"]], "start": [[0]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "17619811_3", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "4075534_2", "context": "Spindle coma in benzodiazepine toxicity: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["benzodiazepine"]], "start": [[16]], "entity_id": ["T4"], "Drug": {"text": [["benzodiazepine"]], "start": [[16]], "entity_id": ["T6"]}}, "Effect": {"text": [["Spindle coma"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "3569037_4", "context": "We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["subsequent to"]], "start": [[101]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with typhoid fever"]], "start": [[28]], "entity_id": ["T3"]}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["the infusion of chloramphenicol sodium succinate"]], "start": [[115]], "entity_id": ["T6"], "Disorder": {"text": [["typhoid fever"]], "start": [[43]], "entity_id": ["T7"]}, "Drug": {"text": [["chloramphenicol sodium succinate"]], "start": [[131]], "entity_id": ["T8"]}, "Route": {"text": [["infusion"]], "start": [[119]], "entity_id": ["T9"]}}}]}]}
{"id": "3310776_3", "context": "This confirmed the history of captopril-related asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["captopril"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["asthma"]], "start": [[48]], "entity_id": ["T5"]}}]}]}
{"id": "6362443_1", "context": "A case of mania associated with fluoxetine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["mania"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[32]], "entity_id": ["T6"], "Drug": {"text": [["fluoxetine"]], "start": [[32]], "entity_id": ["T7"]}}}]}]}
{"id": "9619226_2", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[43]], "entity_id": ["T7"]}, "Treatment": {"text": [["sulprostone"]], "start": [[31]], "entity_id": ["T6"], "Drug": {"text": [["sulprostone"]], "start": [[31]], "entity_id": ["T9"]}}, "Effect": {"text": [["coronary spasm that resulted in cardiac arrest"]], "start": [[64]], "entity_id": ["T8"]}, "Speculated": {"text": [["postulate"]], "start": [[3]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "3677571_4", "context": "She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[134]], "entity_id": ["T9"]}, "Effect": {"text": [["leukopenia"]], "start": [[145]], "entity_id": ["T7"]}, "Treatment": {"text": [["carbamazepine 200 mg four times daily"]], "start": [[47]], "entity_id": ["T8"], "Drug": {"text": [["carbamazepine"]], "start": [[47]], "entity_id": ["T10"]}, "Dosage": {"text": [["200 mg"]], "start": [[61]], "entity_id": ["T11"]}, "Freq": {"text": [["four times daily"]], "start": [[68]], "entity_id": ["T12"]}}}]}]}
{"id": "8222875_4", "context": "We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T7"]}, "Subject": {"text": [["two women"]], "start": [[12]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T9"]}, "Gender": {"text": [["women"]], "start": [[16]], "entity_id": ["T10"]}}, "Effect": {"text": [["HUS", "massive pulmonary bleeding"]], "start": [[36, 72]], "entity_id": ["T6"]}, "Treatment": {"text": [["MMC"]], "start": [[46]], "entity_id": ["T8"], "Drug": {"text": [["MMC"]], "start": [[46]], "entity_id": ["T11"]}}}]}]}
{"id": "11837564_2", "context": "Warfarin-associated bleeding complication saved life.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["bleeding complication saved life"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "15028964_5", "context": "We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone-induced thyrotoxicosis heralded by a significant decrease in warfarin requirements.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T12"]}, "Subject": {"text": [["3 patients"]], "start": [[12]], "entity_id": ["T10"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T14"]}}, "Treatment": {"text": [["concomitant amiodarone and warfarin"]], "start": [[26]], "entity_id": ["T11"], "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[38], [53]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[26]], "entity_id": ["T17"]}, "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[38], [53]], "entity_id": ["T18", "T19"]}}]}, "Effect": {"text": [["amiodarone-induced thyrotoxicosis"]], "start": [[76]], "entity_id": ["T16"]}}]}]}
{"id": "11099623_1", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffered"]], "start": [[47]], "entity_id": ["T7"]}, "Effect": {"text": [["significant morbidity immediately"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["2 children with cerebral palsy"]], "start": [[12]], "entity_id": ["T3"], "Population": {"text": [["2"]], "start": [[12]], "entity_id": ["T6"]}, "Age": {"text": [["children"]], "start": [[14]], "entity_id": ["T8"]}}, "Treatment": {"text": [["treatment with hyperbaric oxygen"]], "start": [[96]], "entity_id": ["T4"], "Drug": {"text": [["hyperbaric oxygen"]], "start": [[111]], "entity_id": ["T11"]}, "Disorder": {"text": [["cerebral palsy"]], "start": [[28]], "entity_id": ["T12"]}}, "Severity": {"text": [["significant"]], "start": [[56]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "9695308_2", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[75]], "entity_id": ["T3"]}, "Treatment": {"text": [["propylthiouracil therapy"]], "start": [[91]], "entity_id": ["T4"], "Drug": {"text": [["propylthiouracil"]], "start": [[91]], "entity_id": ["T6"]}}, "Effect": {"text": [["Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "11881322_5", "context": "The occurrence of acute hepatitis is best known for ketoconazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["for"]], "start": [[48]], "entity_id": ["T5"]}, "Treatment": {"text": [["ketoconazole"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["ketoconazole"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute hepatitis"]], "start": [[18]], "entity_id": ["T4"]}}]}]}
{"id": "10510017_1", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[55]], "entity_id": ["T3"]}, "Treatment": {"text": [["anticoagulation therapy"]], "start": [[71]], "entity_id": ["T4"], "Drug": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[16]], "entity_id": ["T5"]}, "Severity": {"text": [["serious"]], "start": [[47]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "19520277_1", "context": "Stupor and fast activity on electroencephalography in a child treated with valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[70]], "entity_id": ["T6"]}, "Subject": {"text": [["a child"]], "start": [[54]], "entity_id": ["T3"], "Age": {"text": [["child"]], "start": [[56]], "entity_id": ["T7"]}}, "Treatment": {"text": [["valproate"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[75]], "entity_id": ["T8"]}}, "Effect": {"text": [["Stupor and fast activity on electroencephalography"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7606071_5", "context": "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[83]], "entity_id": ["T11"]}, "Treatment": {"text": [["her third cycle", "cisplatin 100 mg/m2 over 30 minutes"]], "start": [[7, 43]], "entity_id": ["T9"], "Drug": {"text": [["cisplatin"]], "start": [[43]], "entity_id": ["T14"]}, "Dosage": {"text": [["100 mg/m2"]], "start": [[53]], "entity_id": ["T15"]}, "Freq": {"text": [["her third cycle"]], "start": [[7]], "entity_id": ["T16"]}}, "Subject": {"text": [["she"]], "start": [[24]], "entity_id": ["T10"], "Gender": {"text": [["she"]], "start": [[24]], "entity_id": ["T13"]}}, "Effect": {"text": [["palmar pruritus, urticaria, and edema"]], "start": [[93]], "entity_id": ["T12"]}}]}]}
{"id": "9169264_3", "context": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["cephalexin"]], "start": [[65]], "entity_id": ["T3"], "Drug": {"text": [["cephalexin"]], "start": [[65]], "entity_id": ["T8"]}, "Disorder": {"text": [["infectious mononucleosis"]], "start": [[27]], "entity_id": ["T9"]}}, "Effect": {"text": [["rash"]], "start": [[95]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with infectious mononucleosis"]], "start": [[12]], "entity_id": ["T5"]}}]}]}
{"id": "19648225_2", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["damage to the urothelium"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["ketamine"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["ketamine"]], "start": [[52]], "entity_id": ["T7"]}}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "9161656_1", "context": "Acute asthma associated with sustained-release verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["sustained-release verapamil"]], "start": [[29]], "entity_id": ["T5"], "Drug": {"text": [["sustained-release verapamil"]], "start": [[29]], "entity_id": ["T7"]}}, "Effect": {"text": [["Acute asthma"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15878975_1", "context": "A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[103]], "entity_id": ["T7"]}, "Subject": {"text": [["15 patients"]], "start": [[36]], "entity_id": ["T5"], "Population": {"text": [["15"]], "start": [[36]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute hemoglobinemia or hemoglobinuria"]], "start": [[64]], "entity_id": ["T6"]}, "Treatment": {"text": [["anti-D IGIV"]], "start": [[113]], "entity_id": ["T8"], "Disorder": {"text": [["ITP or secondary thrombocytopenia"]], "start": [[144]], "entity_id": ["T9"]}, "Drug": {"text": [["anti-D IGIV"]], "start": [[113]], "entity_id": ["T11"]}, "Route": {"text": [["administration"]], "start": [[125]], "entity_id": ["T12"]}}}]}]}
{"id": "19217693_2", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["taking"]], "start": [[51]], "entity_id": ["T7"]}, "Effect": {"text": [["Persistent hypoglycemia"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with diabetes"]], "start": [[27]], "entity_id": ["T4"], "Disorder": {"text": [["diabetes"]], "start": [[42]], "entity_id": ["T1"]}}, "Treatment": {"text": [["etanercept"]], "start": [[58]], "entity_id": ["T5"], "Disorder": {"text": [["psoriasis"]], "start": [[90]], "entity_id": ["T6"]}, "Drug": {"text": [["etanercept"]], "start": [[58]], "entity_id": ["T8"]}}}]}]}
{"id": "9443627_1", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[50]], "entity_id": ["T8"]}, "Treatment": {"text": [["ifosfamide"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["ifosfamide"]], "start": [[39]], "entity_id": ["T7"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[58]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reverse"]], "start": [[31]], "entity_id": ["T11"]}, "Treatment": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["ifosfamide-related neurotoxicity."]], "start": [[39]], "entity_id": ["T3"]}}}]}]}
{"id": "18076602_2", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[68]], "entity_id": ["T5"]}, "Effect": {"text": [["Palpable purpuric skin lesions on the anterior surface of both legs"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["55th day of amphotericin B treatment"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["amphotericin B"]], "start": [[96]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["55th day"]], "start": [[84]], "entity_id": ["T7"]}}}]}]}
{"id": "15965422_1", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Cutaneous necrosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["injection of polyethylene glycol-modified interferon alfa"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["polyethylene glycol-modified interferon alfa."]], "start": [[38]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[25]], "entity_id": ["T7"]}}}]}]}
{"id": "3586163_3", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[169]], "entity_id": ["T6"]}, "Effect": {"text": [["simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder"]], "start": [[29]], "entity_id": ["T5"]}, "Treatment": {"text": [["chronic cyclophosphamide therapy"]], "start": [[175]], "entity_id": ["T9"], "Drug": {"text": [["cyclophosphamide"]], "start": [[183]], "entity_id": ["T8"]}, "Disorder": {"text": [["nonHodgkin's lymphoma"]], "start": [[212]], "entity_id": ["T10"]}, "Duration": {"text": [["chronic"]], "start": [[175]], "entity_id": ["T11"]}}}]}]}
{"id": "20118434_4", "context": "OBJECTIVE: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["interferon"]], "start": [[43]], "entity_id": ["T9"]}, "Disorder": {"text": [["hepatitis C"]], "start": [[204]], "entity_id": ["T10"]}}, "Effect": {"text": [["psychosis"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["psychiatrically ill patients with hepatitis C"]], "start": [[170]], "entity_id": ["T3"], "Disorder": {"text": [["psychiatrically ill"]], "start": [[170]], "entity_id": ["T7"]}}}]}]}
{"id": "11597289_14", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased"]], "start": [[80]], "entity_id": ["T10"]}, "Treatment": {"text": [["antithrombin III and concomitant heparin"]], "start": [[22]], "entity_id": ["T8"], "Drug": {"text": [["antithrombin III"], ["heparin"]], "start": [[22], [55]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[39]], "entity_id": ["T14"]}, "Drug": {"text": [["heparin"], ["antithrombin III"]], "start": [[55], [22]], "entity_id": ["T13", "T12"]}}]}, "Subject": {"text": [["patients"]], "start": [[3]], "entity_id": ["T9"]}, "Effect": {"text": [["bleeding incidence"]], "start": [[90]], "entity_id": ["T11"]}}]}]}
{"id": "15097937_1", "context": "Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[187]], "entity_id": ["T6"]}, "Treatment": {"text": [["combinations of belladonna, ergotamine, and phenobarbital"]], "start": [[9]], "entity_id": ["T5"], "Disorder": {"text": [["menopausal symptoms"]], "start": [[107]], "entity_id": ["T9"]}, "Drug": {"text": [["belladonna"], ["ergotamine"], ["phenobarbital"]], "start": [[25], [37], [53]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combinations"]], "start": [[9]], "entity_id": ["T13"]}, "Drug": {"text": [["belladonna"], ["ergotamine"], ["phenobarbital"]], "start": [[25], [37], [53]], "entity_id": ["T10", "T11", "T12"]}}]}, "Effect": {"text": [["anticonvulsant hypersensitivity syndrome"]], "start": [[204]], "entity_id": ["T7"]}}]}]}
{"id": "897744_2", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T11"]}, "Subject": {"text": [["A drug addict"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["drug addict"]], "start": [[2]], "entity_id": ["T13"]}}, "Treatment": {"text": [["methicillin"]], "start": [[60]], "entity_id": ["T10"], "Disorder": {"text": [["staphylococcal endocarditis"]], "start": [[19]], "entity_id": ["T14"]}, "Drug": {"text": [["methicillin"]], "start": [[60]], "entity_id": ["T15"]}}, "Effect": {"text": [["massive proteinuria and acute nephritic syndrome"]], "start": [[87]], "entity_id": ["T12"]}}]}]}
{"id": "7035691_3", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[87]], "entity_id": ["T10"]}, "Treatment": {"text": [["captopril"]], "start": [[179]], "entity_id": ["T9"], "Disorder": {"text": [["hypertension associated with chronic renal failure"]], "start": [[101]], "entity_id": ["T11"]}, "Drug": {"text": [["captopril"]], "start": [[179]], "entity_id": ["T14"]}}, "Subject": {"text": [["a patient with decreased renal function"]], "start": [[218]], "entity_id": ["T12"], "Disorder": {"text": [["decreased renal function"]], "start": [[233]], "entity_id": ["T13"]}}}]}]}
{"id": "2728526_2", "context": "Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T10"]}, "Treatment": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia"]], "start": [[63]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[32]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "2051906_2", "context": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["azathioprine"]], "start": [[66]], "entity_id": ["T3"], "Drug": {"text": [["azathioprine"]], "start": [[66]], "entity_id": ["T6"]}}, "Effect": {"text": [["cholestasis"]], "start": [[87]], "entity_id": ["T4"]}}]}]}
{"id": "556126_1", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[100]], "entity_id": ["T3"]}, "Treatment": {"text": [["Bromocryptine"]], "start": [[106]], "entity_id": ["T4"], "Disorder": {"text": [["amenorrhea-galactorrhea syndrome"]], "start": [[26]], "entity_id": ["T7"]}, "Drug": {"text": [["Bromocryptine"]], "start": [[106]], "entity_id": ["T8"]}}, "Effect": {"text": [["lost vision"]], "start": [[59]], "entity_id": ["T5"]}, "Subject": {"text": [["An infertile patient with amenorrhea-galactorrhea syndrome"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["infertile"]], "start": [[3]], "entity_id": ["T1"]}}}]}]}
{"id": "15580406_2", "context": "Retinal abnormalities, including retinal hemorrhage and \"cotton-wool\" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[83]], "entity_id": ["T8"]}, "Effect": {"text": [["Retinal abnormalities, including retinal hemorrhage and \"cotton-wool\" spots"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["interferon"]], "start": [[131]], "entity_id": ["T9"], "Time_elapsed": {"text": [["8 weeks"]], "start": [[106]], "entity_id": ["T12"]}, "Drug": {"text": [["interferon"]], "start": [[131]], "entity_id": ["T13"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[167]], "entity_id": ["T14"]}}, "Subject": {"text": [["patients with chronic hepatitis C"]], "start": [[153]], "entity_id": ["T10"]}}]}]}
{"id": "18487000_2", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[23]], "entity_id": ["T7"]}, "Treatment": {"text": [["sibutramine"]], "start": [[26]], "entity_id": ["T5"], "Dosage": {"text": [["sibutramine"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypertension and tachycardia"]], "start": [[43]], "entity_id": ["T6"]}}]}]}
{"id": "9737132_1", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[111]], "entity_id": ["T7"]}, "Subject": {"text": [["A 47 year-old woman"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["47 year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}, "Treatment": {"text": [["a 4-year history of intramuscular pentazocine injections in the lower extremities"]], "start": [[28]], "entity_id": ["T6"], "Route": {"text": [["intramuscular", "injections"]], "start": [[48, 74]], "entity_id": ["T11"]}, "Drug": {"text": [["pentazocine"]], "start": [[62]], "entity_id": ["T12"]}, "Duration": {"text": [["4-year"]], "start": [[30]], "entity_id": ["T13"]}}, "Effect": {"text": [["gradual stiffness and weakness of the lower extremities"]], "start": [[121]], "entity_id": ["T8"]}}]}]}
{"id": "19299370_1", "context": "According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[96]], "entity_id": ["T3"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["enoxaparin"]], "start": [[68]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[105]], "entity_id": ["T5"]}, "Subject": {"text": [["this patient"]], "start": [[123]], "entity_id": ["T6"]}, "Speculated": {"text": [["probable"]], "start": [[87]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11788010_5", "context": "This is the first reported case of hepatolithiasis during octreotide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[51]], "entity_id": ["T5"]}, "Effect": {"text": [["hepatolithiasis"]], "start": [[35]], "entity_id": ["T3"]}, "Treatment": {"text": [["octreotide"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["octreotide"]], "start": [[58]], "entity_id": ["T6"]}}}]}]}
{"id": "2781955_2", "context": "Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[13]], "entity_id": ["T6"]}}, "Effect": {"text": [["thyrotoxicosis (AIT)"]], "start": [[32]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["ineffective"]], "start": [[103]], "entity_id": ["T13"]}, "Treatment": {"text": [["thionamide, lithium or radioactive iodine"]], "start": [[58]], "entity_id": ["T9"], "Drug": {"text": [["thionamide"], ["lithium"], ["radioactive iodine"]], "start": [[58], [70], [81]], "entity_id": ["T10", "T11", "T12"]}, "Disorder": {"text": [["amiodarone-induced thyrotoxicosis (AIT)"]], "start": [[13]], "entity_id": ["T8"]}}, "Negated": {"text": [["ineffective"]], "start": [[103]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "10099659_9", "context": "We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[29]], "entity_id": ["T11"]}, "Effect": {"text": [["side effects"]], "start": [[16]], "entity_id": ["T13"]}, "Subject": {"text": [["colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit"]], "start": [[42]], "entity_id": ["T9"], "Disorder": {"text": [["mucositis"], ["desquamating dermatitis"], ["myelosuppression"], ["neurologic toxicity"]], "start": [[83], [94], [129], [151]], "entity_id": ["T15", "T16", "T17", "T18"]}}, "Treatment": {"text": [["5-FU"]], "start": [[32]], "entity_id": ["T10"], "Drug": {"text": [["5-FU"]], "start": [[32]], "entity_id": ["T12"]}, "Disorder": {"text": [["colon cancer"]], "start": [[42]], "entity_id": ["T19"]}}}]}]}
{"id": "12196060_2", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T10"]}, "Effect": {"text": [["acute neurologic symptoms"]], "start": [[49]], "entity_id": ["T9"]}, "Treatment": {"text": [["isradipine"]], "start": [[81]], "entity_id": ["T11"], "Drug": {"text": [["isradipine"]], "start": [[81]], "entity_id": ["T15"]}}, "Subject": {"text": [["a young man"]], "start": [[10]], "entity_id": ["T8"], "Age": {"text": [["young"]], "start": [[12]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[18]], "entity_id": ["T13"]}}, "Speculated": {"text": [["possible"]], "start": [[148]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "3003260_1", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[107]], "entity_id": ["T9"]}, "Subject": {"text": [["A young diamond dealer"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["young"]], "start": [[2]], "entity_id": ["T12"]}}, "Effect": {"text": [["visual impairment attributed to bilateral posterior subcapsular cataracts"]], "start": [[33]], "entity_id": ["T8"]}, "Treatment": {"text": [["only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen"]], "start": [[117]], "entity_id": ["T10"], "Disorder": {"text": [["cisplatin-associated nausea"]], "start": [[211]], "entity_id": ["T11"]}, "Drug": {"text": [["Decadron"], ["five-drug antiemetic regimen"]], "start": [[151], [178]], "entity_id": ["T13", "T15"]}, "Dosage": {"text": [["four courses"]], "start": [[122]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["part of a"]], "start": [[168]], "entity_id": ["T16"]}, "Drug": {"text": [["Decadron"], ["five-drug antiemetic regimen"]], "start": [[151], [178]], "entity_id": ["T13", "T15"]}}]}}]}]}
{"id": "19520277_2", "context": "The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproate"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["stupor and electroencephalographic pattern of increased fast activity"]], "start": [[53]], "entity_id": ["T5"]}, "Subject": {"text": [["a 4-year-old girl"]], "start": [[12]], "entity_id": ["T6"], "Age": {"text": [["4-year-old"]], "start": [[14]], "entity_id": ["T7"]}, "Gender": {"text": [["girl"]], "start": [[25]], "entity_id": ["T8"]}}}]}]}
{"id": "16341621_2", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading"]], "start": [[62]], "entity_id": ["T8"]}, "Effect": {"text": [["granulomatous reaction"], ["urethral prolapse"]], "start": [[39], [73]], "entity_id": ["T5", "T6"]}, "Treatment": {"text": [["3 months after the transurethral injection of calcium hydroxylapatite"]], "start": [[92]], "entity_id": ["T7"], "Time_elapsed": {"text": [["3 months"]], "start": [[92]], "entity_id": ["T9"]}, "Route": {"text": [["transurethral injection"]], "start": [[111]], "entity_id": ["T10"]}, "Drug": {"text": [["calcium hydroxylapatite"]], "start": [[138]], "entity_id": ["T11"]}}, "Subject": {"text": [["a case report"]], "start": [[20]], "entity_id": ["T12"]}}]}]}
{"id": "15729090_3", "context": "A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[37]], "entity_id": ["T8"]}, "Subject": {"text": [["A 64-year-old man with schizophrenia"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["64-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T12"]}}, "Effect": {"text": [["myoclonic jerks"]], "start": [[47]], "entity_id": ["T9"]}, "Treatment": {"text": [["given higher doses of quetiapine"]], "start": [[68]], "entity_id": ["T10"], "Drug": {"text": [["higher doses"], ["quetiapine"]], "start": [[74], [90]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["schizophrenia"]], "start": [[23]], "entity_id": ["T13"]}}}]}]}
{"id": "21712512_10", "context": "Iatrogenic Cushing syndrome has been reported in patients with CF treated concomitantly, and for extended duration, with inhaled corticosteroids and CYP3A4 inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[37]], "entity_id": ["T9"]}, "Treatment": {"text": [["concomitantly, and for extended duration, with inhaled corticosteroids and CYP3A4 inhibitors"]], "start": [[74]], "entity_id": ["T8"], "Disorder": {"text": [["CF"]], "start": [[63]], "entity_id": ["T13"]}, "Drug": {"text": [["corticosteroids"], ["CYP3A4 inhibitors"]], "start": [[129], [149]], "entity_id": ["T14", "T15"]}, "Duration": {"text": [["extended duration"]], "start": [[97]], "entity_id": ["T17"]}, "Route": {"text": [["inhaled"]], "start": [[121]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[145]], "entity_id": ["T16"]}, "Drug": {"text": [["corticosteroids"], ["CYP3A4 inhibitors"]], "start": [[129], [149]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["Iatrogenic Cushing syndrome"]], "start": [[0]], "entity_id": ["T10"]}, "Subject": {"text": [["patients with CF"]], "start": [[49]], "entity_id": ["T11"]}}]}]}
{"id": "150825_2", "context": "A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[29]], "entity_id": ["T6"]}, "Effect": {"text": [["jaundice"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravaginal administration of a mixture of furazolidone and nifuroxime"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["furazolidone"], ["nifuroxime"]], "start": [[86], [103]], "entity_id": ["T8", "T9"]}, "Route": {"text": [["intravaginal administration"]], "start": [[42]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["mixture"]], "start": [[75]], "entity_id": ["T7"]}, "Drug": {"text": [["furazolidone"], ["nifuroxime"]], "start": [[86], [103]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "15779196_1", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complaints"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["Four days after intravenous Zoledronic acid"]], "start": [[0]], "entity_id": ["T5"], "Time_elapsed": {"text": [["Four days after"]], "start": [[0]], "entity_id": ["T9"]}, "Route": {"text": [["intravenous"]], "start": [[16]], "entity_id": ["T10"]}, "Drug": {"text": [["Zoledronic acid"]], "start": [[28]], "entity_id": ["T11"]}}, "Subject": {"text": [["patient"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["carpopedal spasm and bronchospasm"]], "start": [[104]], "entity_id": ["T7"]}}]}]}
{"id": "3242521_2", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[52]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraventricular administration of nafcillin"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["nafcillin"]], "start": [[103]], "entity_id": ["T9"]}, "Route": {"text": [["intraventricular"]], "start": [[68]], "entity_id": ["T10"]}}, "Effect": {"text": [["seizures"]], "start": [[43]], "entity_id": ["T5"]}, "Subject": {"text": [["a premature infant"]], "start": [[10]], "entity_id": ["T6"], "Disorder": {"text": [["premature"]], "start": [[12]], "entity_id": ["T7"]}, "Age": {"text": [["infant"]], "start": [[22]], "entity_id": ["T8"]}}}]}]}
{"id": "8840640_2", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Metabolic acidosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cetrimide-chlorhexidine solution"]], "start": [[30]], "entity_id": ["T6"], "Drug": {"text": [["cetrimide"], ["chlorhexidine"]], "start": [[30], [40]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["chlorhexidine"], ["cetrimide"]], "start": [[40], [30]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "17444802_2", "context": "AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[73]], "entity_id": ["T10"]}, "Subject": {"text": [["conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure"]], "start": [[140]], "entity_id": ["T7"]}, "Treatment": {"text": [["topical interferon (INF) alpha 2-beta"]], "start": [[89]], "entity_id": ["T8"], "Route": {"text": [["topical"]], "start": [[89]], "entity_id": ["T12"]}, "Drug": {"text": [["interferon", "alpha 2-beta"]], "start": [[97, 114]], "entity_id": ["T13"]}, "Disorder": {"text": [["conjunctiva-cornea intraepithelial neoplasia"]], "start": [[140]], "entity_id": ["T14"]}}, "Effect": {"text": [["tumor side effects"]], "start": [[67]], "entity_id": ["T9"]}}]}]}
{"id": "17044380_1", "context": "Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["warfarin"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["warfarin"]], "start": [[49]], "entity_id": ["T8"]}}, "Effect": {"text": [["skin necrosis"]], "start": [[66]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[92]], "entity_id": ["T11"]}, "Treatment": {"text": [["heparin"]], "start": [[84]], "entity_id": ["T10"], "Drug": {"text": [["heparin"]], "start": [[84]], "entity_id": ["T13"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[100]], "entity_id": ["T12"]}}]}]}
{"id": "15694139_7", "context": "Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["detect"]], "start": [[94]], "entity_id": ["T12"]}, "Subject": {"text": [["Children"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["Children"]], "start": [[0]], "entity_id": ["T13"]}}, "Treatment": {"text": [["thalidomide"]], "start": [[22]], "entity_id": ["T10"], "Drug": {"text": [["thalidomide"]], "start": [[22]], "entity_id": ["T15"]}}, "Effect": {"text": [["presymptomatic or progressive peripheral neuropathy"]], "start": [[101]], "entity_id": ["T11"]}, "Speculated": {"text": [["should"]], "start": [[34]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "9315405_1", "context": "We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T5"]}, "Subject": {"text": [["a fit 41-year-old patient with malignant teratoma"]], "start": [[118]], "entity_id": ["T3"], "Age": {"text": [["41-year-old"]], "start": [[124]], "entity_id": ["T7"]}}, "Treatment": {"text": [["cisplatin"]], "start": [[70]], "entity_id": ["T4"], "Disorder": {"text": [["malignant teratoma"]], "start": [[149]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[70]], "entity_id": ["T9"]}}, "Effect": {"text": [["renal tubular salt wasting"]], "start": [[88]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[63]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "15522120_9", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T8"]}, "Effect": {"text": [["An adverse drug reaction (ADR)"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[42]], "entity_id": ["T9"], "Drug": {"text": [["fluoxetine"], ["fluoxetine"]], "start": [[42], [71]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "11816261_5", "context": "She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[75]], "entity_id": ["T11"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[21]], "entity_id": ["T9"], "Disorder": {"text": [["nausea"]], "start": [[47]], "entity_id": ["T10"]}, "Drug": {"text": [["metoclopramide"]], "start": [[21]], "entity_id": ["T13"]}, "Time_elapsed": {"text": [["within 2 hours"]], "start": [[59]], "entity_id": ["T1"]}}, "Effect": {"text": [["agitation, dysarthria, diaphoresis, and a movement disorder"]], "start": [[85]], "entity_id": ["T12"]}}]}]}
{"id": "12584153_3", "context": "Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[97]], "entity_id": ["T9"]}, "Treatment": {"text": [["Amprenavir"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["HIV-infected"]], "start": [[103]], "entity_id": ["T13"]}, "Drug": {"text": [["Amprenavir"]], "start": [[0]], "entity_id": ["T14"]}}, "Subject": {"text": [["children"]], "start": [[116]], "entity_id": ["T11"], "Age": {"text": [["children"]], "start": [[116]], "entity_id": ["T12"]}}}]}]}
{"id": "18203308_2", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[29]], "entity_id": ["T6"]}, "Treatment": {"text": [["etanercept"]], "start": [[84]], "entity_id": ["T3"], "Disorder": {"text": [["active ankylosing spondylitis"]], "start": [[49]], "entity_id": ["T4"]}, "Drug": {"text": [["etanercept"]], "start": [[84]], "entity_id": ["T7"]}}, "Effect": {"text": [["New onset of Crohn's disease"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "19733945_2", "context": "On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T16"]}, "Treatment": {"text": [["linezolid"]], "start": [[12]], "entity_id": ["T13"], "Drug": {"text": [["linezolid"]], "start": [[12]], "entity_id": ["T17"]}}, "Subject": {"text": [["the patient"]], "start": [[33]], "entity_id": ["T14"]}, "Effect": {"text": [["pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level", "hepatitis"]], "start": [[62, 166]], "entity_id": ["T15"]}, "Severity": {"text": [["severe"], ["mild"]], "start": [[55], [161]], "entity_id": ["T18", "T19"], "value": "Medium"}}]}]}
{"id": "14971874_1", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[65]], "entity_id": ["T5"]}, "Treatment": {"text": [["infliximab"]], "start": [[6]], "entity_id": ["T6"], "Disorder": {"text": [["pathophysiology of sleep apnea"]], "start": [[175]], "entity_id": ["T8"]}, "Drug": {"text": [["infliximab"]], "start": [[6]], "entity_id": ["T9"]}}, "Effect": {"text": [["increase in the number of apneic events and SaO2 dips"]], "start": [[65]], "entity_id": ["T7"]}}]}]}
{"id": "2406680_3", "context": "The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["got"]], "start": [[76]], "entity_id": ["T7"]}, "Effect": {"text": [["reversible hearing loss"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["quinine"]], "start": [[111]], "entity_id": ["T6"], "Disorder": {"text": [["falciparum malaria disease"]], "start": [[45]], "entity_id": ["T10"]}, "Drug": {"text": [["quinine"]], "start": [[111]], "entity_id": ["T11"]}}, "Subject": {"text": [["a 29-year-old man suffering from falciparum malaria disease"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["29-year-old"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[26]], "entity_id": ["T9"]}}}]}]}
{"id": "19537383_4", "context": "This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[127]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib therapy"]], "start": [[143]], "entity_id": ["T5"], "Drug": {"text": [["sorafenib"]], "start": [[143]], "entity_id": ["T7"]}}, "Effect": {"text": [["an atypical localized cutaneous eruption with an unusual course and protracted resolution time"]], "start": [[32]], "entity_id": ["T6"]}}]}]}
{"id": "1624172_3", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Thyroid dysfunction"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with malignant disease"]], "start": [[41]], "entity_id": ["T5"]}, "Treatment": {"text": [["recombinant alpha interferon"]], "start": [[86]], "entity_id": ["T6"], "Disorder": {"text": [["malignant disease"]], "start": [[55]], "entity_id": ["T7"]}, "Drug": {"text": [["alpha interferon"]], "start": [[98]], "entity_id": ["T8"]}}}]}]}
{"id": "16480245_1", "context": "METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[37]], "entity_id": ["T12"]}, "Subject": {"text": [["two patients"]], "start": [[20]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[20]], "entity_id": ["T8"]}}, "Treatment": {"text": [["quetiapine and risperidone"]], "start": [[95]], "entity_id": ["T6"], "Drug": {"text": [["quetiapine"], ["risperidone"]], "start": [[95], [110]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["diabetic ketoacidosis"]], "start": [[52]], "entity_id": ["T7"]}}]}]}
{"id": "9855339_4", "context": "We suspect that nefazodone inhibits metabolism of tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inhibits"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["nefazodone"]], "start": [[16]], "entity_id": ["T4"], "Drug": {"text": [["nefazodone"]], "start": [[16]], "entity_id": ["T7"]}}, "Effect": {"text": [["metabolism of tacrolimus"]], "start": [[36]], "entity_id": ["T6"]}, "Speculated": {"text": [["suspect"]], "start": [[3]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "16498048_1", "context": "Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effect"]], "start": [[39]], "entity_id": ["T7"]}, "Effect": {"text": [["Autoimmune thyroid disease"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon-alpha (IFN-alpha)"]], "start": [[54]], "entity_id": ["T5"], "Disorder": {"text": [["viral hepatitis C"]], "start": [[96]], "entity_id": ["T6"]}, "Drug": {"text": [["interferon-alpha"]], "start": [[54]], "entity_id": ["T9"]}}}]}]}
{"id": "19745701_2", "context": "Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[11]], "entity_id": ["T3"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[117]], "entity_id": ["T7"]}, "Drug": {"text": [["methotrexate"]], "start": [[11]], "entity_id": ["T8"]}}, "Effect": {"text": [["lymphoproliferative disorder"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[102]], "entity_id": ["T6"]}}]}]}
{"id": "11077455_5", "context": "The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["withdrawn"]], "start": [[97]], "entity_id": ["T5"]}, "Effect": {"text": [["field defects and some electrophysiological abnormalities persist"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin therapy is withdrawn"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["vigabatrin"]], "start": [[75]], "entity_id": ["T6"]}}}]}]}
{"id": "1893404_2", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["given"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"]], "start": [[50]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["Diabetes Mellitus"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "12410494_2", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[70]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient"]], "start": [[60]], "entity_id": ["T9"]}, "Treatment": {"text": [["a statin and a protease inhibitor"]], "start": [[83]], "entity_id": ["T11"], "Drug": {"text": [["statin"], ["protease inhibitor"]], "start": [[85], [98]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[157]], "entity_id": ["T15"]}, "Drug": {"text": [["statin"], ["protease inhibitor"]], "start": [[85], [98]], "entity_id": ["T13", "T14"]}}]}, "Effect": {"text": [["death associated with rhabdomyolysis"]], "start": [[20]], "entity_id": ["T12"]}}]}]}
{"id": "12875956_3", "context": "The psychotic behavior resolved completely soon after the discontinuation of levetiracetam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["discontinuation of levetiracetam"]], "start": [[58]], "entity_id": ["T4"], "Disorder": {"text": [["psychotic behavior"]], "start": [[4]], "entity_id": ["T3"]}, "Time_elapsed": {"text": [["soon after"]], "start": [[43]], "entity_id": ["T6"]}, "Drug": {"text": [["levetiracetam"]], "start": [[77]], "entity_id": ["T7"]}}}]}]}
{"id": "24163322_4", "context": "Warfarin was initiated for deep vein thrombosis prophylaxis due to the patient's inability to ambulate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[48]], "entity_id": ["T6"]}, "Subject": {"text": [["patient's inability to ambulate"]], "start": [[71]], "entity_id": ["T7"], "Disorder": {"text": [["inability to ambulate"]], "start": [[81]], "entity_id": ["T8"]}}, "Treatment": {"text": [["Warfarin was initiated for deep vein thrombosis"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["deep vein thrombosis"]], "start": [[27]], "entity_id": ["T5"]}, "Drug": {"text": [["a"]], "start": [[4]], "entity_id": ["T9"]}}}]}]}
{"id": "17404582_2", "context": "Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["Meibomian duct inflammation and blockage leading to chalazion formation"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "2830062_2", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[36]], "entity_id": ["T7"]}, "Subject": {"text": [["Two patients with adrenal carcinoma"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T9"]}}, "Treatment": {"text": [["2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy"]], "start": [[49]], "entity_id": ["T8"], "Drug": {"text": [["2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane"]], "start": [[49]], "entity_id": ["T11"]}, "Disorder": {"text": [["adrenal carcinoma"]], "start": [[18]], "entity_id": ["T12"]}}}]}]}
{"id": "11212595_1", "context": "Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[101]], "entity_id": ["T9"]}, "Effect": {"text": [["obsessive-compulsive symptoms (OCS)"], ["OCS"]], "start": [[15], [109]], "entity_id": ["T7", "T6"]}, "Treatment": {"text": [["antipsychotic"]], "start": [[87]], "entity_id": ["T8"], "Drug": {"text": [["antipsychotic"]], "start": [[87]], "entity_id": ["T11"]}}}]}]}
{"id": "16531969_1", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon-beta (IFN-beta"]], "start": [[39]], "entity_id": ["T5"], "Disorder": {"text": [["multiple sclerosis"]], "start": [[69]], "entity_id": ["T6"]}, "Drug": {"text": [["interferon-beta"]], "start": [[39]], "entity_id": ["T8"]}}, "Effect": {"text": [["liver injury"]], "start": [[13]], "entity_id": ["T7"]}}]}]}
{"id": "17157086_4", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receiving"]], "start": [[40]], "entity_id": ["T10"]}, "Treatment": {"text": [["a leukotriene receptor antagonist (montelukast) for 5 years"]], "start": [[50]], "entity_id": ["T11"], "Disorder": {"text": [["chronic asthma"]], "start": [[11]], "entity_id": ["T9"]}, "Duration": {"text": [["5 years"]], "start": [[102]], "entity_id": ["T12"]}, "Drug": {"text": [["leukotriene receptor antagonist"]], "start": [[52]], "entity_id": ["T13"]}}, "Subject": {"text": [["she"]], "start": [[27]], "entity_id": ["T7"], "Gender": {"text": [["she"]], "start": [[27]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[296]], "entity_id": ["T15"]}, "Treatment": {"text": [["Garcinia Cambogia"]], "start": [[266]], "entity_id": ["T14"], "Drug": {"text": [["Garcinia Cambogia"]], "start": [[266]], "entity_id": ["T17"]}}, "Effect": {"text": [["hepatitis"]], "start": [[325]], "entity_id": ["T16"]}}]}]}
{"id": "10482872_2", "context": "The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposure"]], "start": [[68]], "entity_id": ["T9"]}, "Treatment": {"text": [["CP"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["CP"]], "start": [[65]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiple congenital anomalies", "CP embryopathy"]], "start": [[82, 141]], "entity_id": ["T6"]}}]}]}
{"id": "1275625_4", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[108]], "entity_id": ["T9"]}, "Treatment": {"text": [["magnesium sulfate"]], "start": [[145]], "entity_id": ["T8"], "Disorder": {"text": [["toxemia of pregnancy"]], "start": [[167]], "entity_id": ["T7"]}, "Drug": {"text": [["magnesium sulfate"]], "start": [[145]], "entity_id": ["T11"]}}, "Effect": {"text": [["severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration"]], "start": [[28]], "entity_id": ["T10"]}}]}]}
{"id": "14674674_4", "context": "Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[38]], "entity_id": ["T8"]}, "Treatment": {"text": [["Treatment with infliximab"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T10"]}}, "Effect": {"text": [["increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease"]], "start": [[49]], "entity_id": ["T9"]}}]}]}
{"id": "8276031_1", "context": "Imidazoline intoxication in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intoxication"]], "start": [[12]], "entity_id": ["T6"]}, "Subject": {"text": [["children"]], "start": [[28]], "entity_id": ["T5"], "Age": {"text": [["children"]], "start": [[28]], "entity_id": ["T9"]}}, "Treatment": {"text": [["Imidazoline"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Imidazoline"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["Imidazoline intoxication"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "2204409_1", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[73]], "entity_id": ["T6"]}, "Effect": {"text": [["leukoencephalopathy"]], "start": [[14]], "entity_id": ["T4"]}, "Subject": {"text": [["a 13-year-old girl"]], "start": [[49]], "entity_id": ["T5"], "Age": {"text": [["13-year-old"]], "start": [[51]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[63]], "entity_id": ["T9"]}}, "Treatment": {"text": [["standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate"]], "start": [[79]], "entity_id": ["T7"], "Disorder": {"text": [["medulloblastoma"]], "start": [[123]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"], ["methotrexate"]], "start": [[220], [255]], "entity_id": ["T11", "T15"]}, "Route": {"text": [["infusion"], ["intrathecal"]], "start": [[198], [243]], "entity_id": ["T12", "T14"]}, "Dosage": {"text": [["500 mg/m2"], ["12 mg"]], "start": [[210], [237]], "entity_id": ["T13", "T16"]}, "Duration": {"text": [["8 treatments"], ["4-hour"]], "start": [[149], [191]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[233]], "entity_id": ["T17"]}, "Drug": {"text": [["methotrexate"], ["methotrexate"]], "start": [[220], [255]], "entity_id": ["T11", "T15"]}}]}}]}]}
{"id": "7351000_4", "context": "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["the total cumulative dosage of Treosulfan"]], "start": [[95]], "entity_id": ["T3"], "Drug": {"text": [["Treosulfan"]], "start": [[126]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute leukemia"]], "start": [[30]], "entity_id": ["T5"]}, "Negated": {"text": [["not"]], "start": [[63]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "15331204_4", "context": "RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["achieve"]], "start": [[265]], "entity_id": ["T14"]}, "Treatment": {"text": [["6-month period of monotherapy with indapamide (2.5 mg/day)"]], "start": [[145]], "entity_id": ["T31"], "Time_elapsed": {"text": [["6-month period"]], "start": [[145]], "entity_id": ["T23"]}, "Drug": {"text": [["indapamide"]], "start": [[180]], "entity_id": ["T25"]}, "Dosage": {"text": [["2.5 mg/day"]], "start": [[192]], "entity_id": ["T26"]}}, "Effect": {"text": [["diabetes"]], "start": [[285]], "entity_id": ["T13"]}, "Subject": {"text": [["one patient"]], "start": [[207]], "entity_id": ["T32"], "Population": {"text": [["one"]], "start": [[207]], "entity_id": ["T33"]}}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["achieve"]], "start": [[265]], "entity_id": ["T14"]}, "Treatment": {"text": [["After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day)"]], "start": [[9]], "entity_id": ["T12"], "Drug": {"text": [["indapamide"], ["fosinopril"]], "start": [[72], [100]], "entity_id": ["T17", "T18"]}, "Dosage": {"text": [["2.5 mg/day"], ["10 mg/day"]], "start": [[84], [112]], "entity_id": ["T19", "T21"]}, "Duration": {"text": [["4- to 14-month"]], "start": [[15]], "entity_id": ["T29"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[57]], "entity_id": ["T16"]}, "Drug": {"text": [["indapamide"], ["fosinopril"]], "start": [[72], [100]], "entity_id": ["T17", "T18"]}}]}, "Subject": {"text": [["three patients"]], "start": [[126]], "entity_id": ["T24"], "Population": {"text": [["three"]], "start": [[126]], "entity_id": ["T28"]}}, "Effect": {"text": [["diabetes"]], "start": [[285]], "entity_id": ["T30"]}}]}]}
{"id": "16404563_4", "context": "Nocardia is an important opportunistic infectious agent in immunocompromised hosts, i.e. in patients taking corticosteroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["infectious agent"]], "start": [[39]], "entity_id": ["T8"]}, "Treatment": {"text": [["corticosteroids"]], "start": [[108]], "entity_id": ["T5"], "Drug": {"text": [["corticosteroids"]], "start": [[108]], "entity_id": ["T10"]}}, "Subject": {"text": [["immunocompromised hosts"]], "start": [[59]], "entity_id": ["T6"], "Disorder": {"text": [["immunocompromised"]], "start": [[59]], "entity_id": ["T9"]}}, "Effect": {"text": [["Nocardia"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "8835752_1", "context": "Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T5"]}, "Effect": {"text": [["Hepatobiliary disorders"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["orally administered terbinafine"]], "start": [[40]], "entity_id": ["T6"], "Route": {"text": [["orally"]], "start": [[40]], "entity_id": ["T7"]}, "Drug": {"text": [["terbinafine"]], "start": [[60]], "entity_id": ["T8"]}}}]}]}
{"id": "12581772_1", "context": "Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[25]], "entity_id": ["T4"]}, "Effect": {"text": [["Interstitial pneumonitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sirolimus"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["sirolimus"]], "start": [[41]], "entity_id": ["T6"]}}}]}]}
{"id": "19667003_15", "context": "He had also developed elevated serum ammonia levels while on valproic acid.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T4"]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["elevated serum ammonia levels"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproic acid"]], "start": [[61]], "entity_id": ["T6"], "Drug": {"text": [["valproic acid"]], "start": [[61]], "entity_id": ["T8"]}}}]}]}
{"id": "7797283_1", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[23]], "entity_id": ["T3"]}, "Effect": {"text": [["Esophageal candidiasis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["omeprazole"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["omeprazole"]], "start": [[33]], "entity_id": ["T8"]}}, "Subject": {"text": [["two cases"]], "start": [[65]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[65]], "entity_id": ["T7"]}}}]}]}
{"id": "8140860_5", "context": "In this case, the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin, other possible causes having been eliminated.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[69]], "entity_id": ["T9"]}, "Effect": {"text": [["the increase in the INR value with associated bruising"]], "start": [[14]], "entity_id": ["T8"]}, "Treatment": {"text": [["amoxycillin"]], "start": [[91]], "entity_id": ["T10"], "Drug": {"text": [["amoxycillin"], ["acenocoumarol"], ["amoxycillin"]], "start": [[91], [139], [157]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[153]], "entity_id": ["T14"]}, "Drug": {"text": [["acenocoumarol"], ["amoxycillin"]], "start": [[139], [157]], "entity_id": ["T12", "T13"]}}]}}]}]}
{"id": "16889287_1", "context": "It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[7]], "entity_id": ["T6"]}, "Treatment": {"text": [["dapsone"]], "start": [[81]], "entity_id": ["T3"], "Drug": {"text": [["dapsone"]], "start": [[81]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypersensitivity syndrome"], ["a severe adverse drug reaction"]], "start": [[89], [13]], "entity_id": ["T4", "T5"]}, "Speculated": {"text": [["may"]], "start": [[3]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1124417_2", "context": "Renal failure associated with acetazolamide therapy for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["Renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["acetazolamide therapy"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["acetazolamide"]], "start": [[30]], "entity_id": ["T7"]}, "Disorder": {"text": [["glaucoma"]], "start": [[56]], "entity_id": ["T8"]}}}]}]}
{"id": "11373877_1", "context": "Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Avascular necrosis of the femoral head"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with prostate cancer"]], "start": [[42]], "entity_id": ["T4"]}, "Treatment": {"text": [["cyproterone acetate and radiotherapy"]], "start": [[85]], "entity_id": ["T5"], "Disorder": {"text": [["prostate cancer"]], "start": [[56]], "entity_id": ["T8"]}, "Drug": {"text": [["cyproterone acetate"]], "start": [[85]], "entity_id": ["T10"]}, "Route": {"text": [["radiotherapy"]], "start": [[109]], "entity_id": ["T1"]}}}]}]}
{"id": "3465489_1", "context": "Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[87]], "entity_id": ["T6"]}, "Treatment": {"text": [["6-mercaptopurine"]], "start": [[32]], "entity_id": ["T3"], "Drug": {"text": [["6-mercaptopurine"]], "start": [[32]], "entity_id": ["T9"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[104]], "entity_id": ["T10"]}}, "Effect": {"text": [["myelotoxicity and therapeutic failure"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["children with acute lymphoblastic leukemia"]], "start": [[90]], "entity_id": ["T5"], "Age": {"text": [["children"]], "start": [[90]], "entity_id": ["T7"]}}}]}]}
{"id": "11093071_3", "context": "While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevent"]], "start": [[94]], "entity_id": ["T4"]}, "Treatment": {"text": [["antidepressants"]], "start": [[74]], "entity_id": ["T3"], "Disorder": {"text": [["changes in serotonergic or noradrenergic neurotransmission"]], "start": [[102]], "entity_id": ["T6"]}, "Drug": {"text": [["antidepressants"]], "start": [[74]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[90]], "entity_id": ["T7"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[161]], "entity_id": ["T9"]}, "Treatment": {"text": [["IFN-alpha"]], "start": [[171]], "entity_id": ["T10"], "Drug": {"text": [["IFN-alpha"]], "start": [[171]], "entity_id": ["T11"]}}, "Effect": {"text": [["changes in serotonergic or noradrenergic neurotransmission"]], "start": [[102]], "entity_id": ["T5"]}}]}]}
{"id": "17381671_2", "context": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[20]], "entity_id": ["T7"]}, "Treatment": {"text": [["nteraction between fentanyl and citalopram"]], "start": [[56]], "entity_id": ["T9"], "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[75], [88]], "entity_id": ["T8", "T11"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[55]], "entity_id": ["T12"]}, "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[75], [88]], "entity_id": ["T8", "T11"]}}]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T13"]}}]}]}
{"id": "1295628_1", "context": "Carbamazepine-induced systemic lupus erythematosus-like disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T1"]}}, "Effect": {"text": [["systemic lupus erythematosus-like disease"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "3136101_3", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["cessation of prolonged ACTH"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["ACTH"]], "start": [[72]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[177]], "entity_id": ["T4"]}}]}]}
{"id": "6401771_1", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[28]], "entity_id": ["T5"]}, "Effect": {"text": [["Haemolytic-uraemic syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term mitomycin C and 5-fluorouracil therapy"]], "start": [[41]], "entity_id": ["T6"], "Disorder": {"text": [["gastric carcinoma"]], "start": [[94]], "entity_id": ["T8"]}, "Drug": {"text": [["5-fluorouracil"], ["mitomycin C"]], "start": [[67], [51]], "entity_id": ["T9", "T10"]}, "Duration": {"text": [["long-term"]], "start": [[41]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[63]], "entity_id": ["T11"]}, "Drug": {"text": [["5-fluorouracil"], ["mitomycin C"]], "start": [[67], [51]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "15203443_2", "context": "We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[122]], "entity_id": ["T3"]}, "Treatment": {"text": [["subcutaneous naltrexone implant"]], "start": [[147]], "entity_id": ["T4"], "Disorder": {"text": [["heroin abuser"]], "start": [[14]], "entity_id": ["T7"]}, "Route": {"text": [["subcutaneous"]], "start": [[147]], "entity_id": ["T8"]}, "Drug": {"text": [["naltrexone"]], "start": [[160]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute hepatitis B and C"]], "start": [[78]], "entity_id": ["T5"]}, "Subject": {"text": [["a heroin abuser"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "1504404_2", "context": "Ciprofloxacin-induced psychosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["psychosis"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "15694139_2", "context": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[53]], "entity_id": ["T4"]}, "Effect": {"text": [["teratogenic effects"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "24318743_1", "context": "Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[24]], "entity_id": ["T9"]}, "Treatment": {"text": [["Weekly AUC2 carboplatin", "with or without oral phenoxodiol"]], "start": [[0, 70]], "entity_id": ["T8"], "Freq": {"text": [["Weekly"]], "start": [[0]], "entity_id": ["T10"]}, "Drug": {"text": [["AUC2 carboplatin"], ["phenoxodiol"]], "start": [[7], [91]], "entity_id": ["T11", "T13"]}, "Disorder": {"text": [["platinum-resistant ovarian cancer"]], "start": [[36]], "entity_id": ["T12"]}, "Route": {"text": [["oral"]], "start": [[86]], "entity_id": ["T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with or without"]], "start": [[70]], "entity_id": ["T14"]}, "Drug": {"text": [["phenoxodiol"], ["AUC2 carboplatin"]], "start": [[91], [7]], "entity_id": ["T13", "T11"]}}]}}]}]}
{"id": "15806568_2", "context": "To date, there have been few reports of visual disturbances associated with BTX-B use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[60]], "entity_id": ["T6"]}, "Treatment": {"text": [["BTX-B"]], "start": [[76]], "entity_id": ["T3"], "Drug": {"text": [["BTX-B"]], "start": [[76]], "entity_id": ["T7"]}}, "Effect": {"text": [["visual disturbances"]], "start": [[40]], "entity_id": ["T5"]}}]}]}
{"id": "19116715_1", "context": "Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hemolytic uremic syndrome"]], "start": [[39]], "entity_id": ["T7"]}, "Severity": {"text": [["fatal"]], "start": [[103]], "entity_id": ["T10"], "value": "High"}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["intervention"]], "start": [[133]], "entity_id": ["T16"]}, "Treatment": {"text": [["with steroids, plasmapheresis and hemodialysis"]], "start": [[146]], "entity_id": ["T11"], "Drug": {"text": [["steroids"], ["plasmapheresis"], ["hemodialysis"]], "start": [[151], [161], [180]], "entity_id": ["T12", "T13", "T14"]}, "Disorder": {"text": [["a rapidly fatal"]], "start": [[93]], "entity_id": ["T15"]}}}]}]}
{"id": "17952482_1", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[51]], "entity_id": ["T13"]}, "Subject": {"text": [["58-year-old woman with rheumatoid arthritis (RA)"]], "start": [[2]], "entity_id": ["T9"], "Age": {"text": [["58-year-old"]], "start": [[2]], "entity_id": ["T14"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T15"]}}, "Effect": {"text": [["fever, skin eruptions, leukocytopenia, and thrombocytopenia"]], "start": [[61]], "entity_id": ["T11"]}, "Treatment": {"text": [["3 weeks after treatment with sulfasalazine"]], "start": [[122]], "entity_id": ["T12"], "Time_elapsed": {"text": [["3 weeks"]], "start": [[122]], "entity_id": ["T16"]}, "Drug": {"text": [["sulfasalazine"]], "start": [[151]], "entity_id": ["T17"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[25]], "entity_id": ["T18"]}}}]}]}
{"id": "2956288_4", "context": "Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[127]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["ethambutol"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["serum concentration elevations of ethambutol sufficient to produce optic neuropathy"]], "start": [[135]], "entity_id": ["T5"]}}]}]}
{"id": "2006943_2", "context": "A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[17]], "entity_id": ["T7"]}, "Treatment": {"text": [["intravenous ritodrine therapy"]], "start": [[20]], "entity_id": ["T8"], "Route": {"text": [["intravenous"]], "start": [[20]], "entity_id": ["T11"]}, "Drug": {"text": [["ritodrine"]], "start": [[32]], "entity_id": ["T12"]}}, "Effect": {"text": [["an episode of acute chest pain"]], "start": [[81]], "entity_id": ["T9"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "3549808_1", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[67]], "entity_id": ["T12"]}, "Subject": {"text": [["One of the subjects"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T10"]}}, "Treatment": {"text": [["extemporaneous topical minoxidil"]], "start": [[34]], "entity_id": ["T8"], "Route": {"text": [["topical"]], "start": [[49]], "entity_id": ["T13"]}, "Drug": {"text": [["minoxidil"]], "start": [[57]], "entity_id": ["T14"]}}, "Effect": {"text": [["hypertension and arteriosclerotic disease"]], "start": [[71]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["died"]], "start": [[127]], "entity_id": ["T15"]}, "Treatment": {"text": [["extemporaneous topical minoxidil"]], "start": [[34]], "entity_id": ["T8"], "Route": {"text": [["topical"]], "start": [[49]], "entity_id": ["T13"]}, "Drug": {"text": [["minoxidil"]], "start": [[57]], "entity_id": ["T14"]}}, "Effect": {"text": [["died of a myocardial infarction"]], "start": [[127]], "entity_id": ["T11"]}, "Subject": {"text": [["the other"]], "start": [[117]], "entity_id": ["T16"]}, "Severity": {"text": [["died"]], "start": [[127]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "8053440_5", "context": "Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[45]], "entity_id": ["T9"]}, "Treatment": {"text": [["ampicillin"]], "start": [[34]], "entity_id": ["T7"], "Drug": {"text": [["ampicillin"]], "start": [[34]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["Three years later"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["cholestatic hepatitis with cholestasis and duct paucity on rebiopsy"]], "start": [[71]], "entity_id": ["T8"]}}]}]}
{"id": "8071504_5", "context": "METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[65]], "entity_id": ["T11"]}, "Subject": {"text": [["A patient", "pulmonary tuberculosis"]], "start": [[9, 135]], "entity_id": ["T7"]}, "Treatment": {"text": [["9-month course of treatment with ethambutol and isoniazid"]], "start": [[73]], "entity_id": ["T9"], "Time_elapsed": {"text": [["9-month course"]], "start": [[73]], "entity_id": ["T13"]}, "Drug": {"text": [["ethambutol"], ["isoniazid"]], "start": [[106], [121]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[135]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[117]], "entity_id": ["T16"]}, "Drug": {"text": [["isoniazid"], ["ethambutol"]], "start": [[121], [106]], "entity_id": ["T15", "T14"]}}]}, "Effect": {"text": [["permanent vision loss"]], "start": [[43]], "entity_id": ["T8"]}, "Severity": {"text": [["dramatic"]], "start": [[33]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "16239768_2", "context": "The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[60]], "entity_id": ["T7"]}, "Subject": {"text": [["a woman"]], "start": [[72]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[74]], "entity_id": ["T9"]}}, "Effect": {"text": [["urinary incontinence (UI)"]], "start": [[29]], "entity_id": ["T6"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[104]], "entity_id": ["T8"], "Drug": {"text": [["venlafaxine"]], "start": [[104]], "entity_id": ["T10"]}}}]}]}
{"id": "8651254_3", "context": "The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accelerated"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["M-CSF"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["M-CSF"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome"]], "start": [[57]], "entity_id": ["T7"]}, "Speculated": {"text": [["possibility"]], "start": [[4]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2357706_3", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulpiride"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["sulpiride"]], "start": [[26]], "entity_id": ["T6"]}}, "Effect": {"text": [["tardive dyskinesia"]], "start": [[46]], "entity_id": ["T4"]}}]}]}
{"id": "1440123_1", "context": "This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[73]], "entity_id": ["T6"]}, "Subject": {"text": [["38-year-old male", "a seizure disorder"]], "start": [[29, 124]], "entity_id": ["T3"], "Age": {"text": [["38-year-old"]], "start": [[29]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[41]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Tegretol"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["Tegretol"]], "start": [[96]], "entity_id": ["T11"]}, "Disorder": {"text": [["seizure"]], "start": [[126]], "entity_id": ["T12"]}}, "Effect": {"text": [["SIADH"]], "start": [[54]], "entity_id": ["T7"]}}]}]}
{"id": "4063627_1", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[92]], "entity_id": ["T5"]}, "Subject": {"text": [["A 35-year-old man with seropositive rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["35-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["selective IgA deficiency"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["fenclofenac"]], "start": [[114]], "entity_id": ["T6"], "Drug": {"text": [["fenclofenac"]], "start": [[114]], "entity_id": ["T10"]}, "Disorder": {"text": [["seropositive rheumatoid arthritis"]], "start": [[23]], "entity_id": ["T11"]}}}]}]}
{"id": "15895899_3", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[46]], "entity_id": ["T6"]}, "Treatment": {"text": [["infliximab"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["infliximab"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis"]], "start": [[56]], "entity_id": ["T7"]}, "Speculated": {"text": [["possibly"]], "start": [[37]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12477460_4", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["under"]], "start": [[97]], "entity_id": ["T5"]}, "Subject": {"text": [["a postmenopausal woman"]], "start": [[74]], "entity_id": ["T3"], "Age": {"text": [["postmenopausal"]], "start": [[76]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[91]], "entity_id": ["T8"]}}, "Effect": {"text": [["Ovarian endometrioid adenocarcinoma"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[103]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[103]], "entity_id": ["T9"]}, "Disorder": {"text": [["breast cancer"]], "start": [[125]], "entity_id": ["T1"]}}}]}]}
{"id": "9892272_1", "context": "Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["Massive subfascial hematoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["alteplase therapy"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["alteplase"]], "start": [[34]], "entity_id": ["T7"]}, "Disorder": {"text": [["acute myocardial infarction"]], "start": [[56]], "entity_id": ["T8"]}}}]}]}
{"id": "8610807_1", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["systemic tissue plasminogen activator"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["tissue plasminogen activator"]], "start": [[46]], "entity_id": ["T6"]}}, "Effect": {"text": [["Choroidal hemorrhage"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "17665812_1", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["chronic schizophrenia with suicidal tendencies"]], "start": [[74]], "entity_id": ["T8"]}, "Drug": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["eosinophilia"]], "start": [[18]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with chronic schizophrenia with suicidal tendencies"]], "start": [[59]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["switch"]], "start": [[35]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient with chronic schizophrenia with suicidal tendencies"]], "start": [[59]], "entity_id": ["T5"]}, "Treatment": {"text": [["quetiapine"]], "start": [[45]], "entity_id": ["T11"], "Drug": {"text": [["quetiapine"]], "start": [[45]], "entity_id": ["T10"]}}}]}]}
{"id": "15362597_1", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[24]], "entity_id": ["T6"]}, "Effect": {"text": [["Refractory hypoglycemia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["ciprofloxacin and glyburide interaction"]], "start": [[29]], "entity_id": ["T5"], "Drug": {"text": [["ciprofloxacin"], ["glyburide"]], "start": [[29], [47]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[57]], "entity_id": ["T9"]}, "Drug": {"text": [["glyburide"], ["ciprofloxacin"]], "start": [[47], [29]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "18675768_1", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["propafenone", "long-term therapy with the addition of citalopram"]], "start": [[19, 37]], "entity_id": ["T6"], "Time_elapsed": {"text": [["long-term"]], "start": [[37]], "entity_id": ["T8"]}, "Drug": {"text": [["citalopram"], ["propafenone"]], "start": [[76], [19]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[64]], "entity_id": ["T11"]}, "Drug": {"text": [["propafenone"], ["citalopram"]], "start": [[19], [76]], "entity_id": ["T10", "T9"]}}]}, "Effect": {"text": [["Adverse effects"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "7781845_10", "context": "Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoglycaemia"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["mefloquine and some other anti-malarial quinine analogues"]], "start": [[62]], "entity_id": ["T7"], "Drug": {"text": [["mefloquine"], ["quinine analogues"]], "start": [[62], [102]], "entity_id": ["T8", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T9"]}, "Drug": {"text": [["mefloquine"], ["quinine analogues"]], "start": [[62], [102]], "entity_id": ["T8", "T10"]}}]}}]}]}
{"id": "11414270_15", "context": "Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[48]], "entity_id": ["T9"]}, "Treatment": {"text": [["nondepolarizing muscle relaxants"]], "start": [[5]], "entity_id": ["T6"], "Drug": {"text": [["nondepolarizing muscle relaxants"]], "start": [[5]], "entity_id": ["T11"]}}, "Subject": {"text": [["patients who are at risk for mucositis"]], "start": [[56]], "entity_id": ["T8"], "Disorder": {"text": [["mucositis"]], "start": [[85]], "entity_id": ["T12"]}}, "Speculated": {"text": [["should"]], "start": [[38]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "3767790_1", "context": "Duodenal ulceration: a complication of tolazoline therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["tolazoline"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["tolazoline"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Duodenal ulceration"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7900744_1", "context": "Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["syndrome"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["mannitol"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["mannitol"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[22]], "entity_id": ["T4"]}, "Subject": {"text": [["Case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "21350204_1", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[94]], "entity_id": ["T9"]}, "Treatment": {"text": [["tissue plasminogen activator"]], "start": [[107]], "entity_id": ["T8"], "Disorder": {"text": [["ischemic strokes"]], "start": [[77]], "entity_id": ["T11"]}, "Drug": {"text": [["tissue plasminogen activator"]], "start": [[107]], "entity_id": ["T14"]}}}]}]}
{"id": "15752306_6", "context": "These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effect"]], "start": [[74]], "entity_id": ["T7"]}, "Subject": {"text": [["These cases"]], "start": [[0]], "entity_id": ["T6"]}, "Effect": {"text": [["livedo reticularis"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[89]], "entity_id": ["T8"], "Drug": {"text": [["interferon alpha"]], "start": [[89]], "entity_id": ["T9"]}}}]}]}
{"id": "21104646_1", "context": "Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Abnormal"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["Abnormal dexamethasone suppression tests"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["rifampicin"]], "start": [[46]], "entity_id": ["T7"], "Drug": {"text": [["rifampicin"]], "start": [[46]], "entity_id": ["T10"]}}, "Subject": {"text": [["patient with suspected Cushing's syndrome"]], "start": [[65]], "entity_id": ["T8"]}}]}]}
{"id": "16109609_2", "context": "Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["carcinoma"]], "start": [[102]], "entity_id": ["T8"]}}, "Effect": {"text": [["radiation recall reactions"]], "start": [[45]], "entity_id": ["T5"]}}]}]}
{"id": "11020127_3", "context": "Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acted"]], "start": [[10]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ritonavir"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Ritonavir"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity"]], "start": [[21]], "entity_id": ["T9"]}}]}]}
{"id": "11332679_1", "context": "An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[128]], "entity_id": ["T3"]}, "Treatment": {"text": [["a combination of allopurinol and ketoconazole"]], "start": [[141]], "entity_id": ["T4"], "Drug": {"text": [["allopurinol"], ["ketoconazole"]], "start": [[158], [174]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[143]], "entity_id": ["T8"]}, "Drug": {"text": [["allopurinol"], ["ketoconazole"]], "start": [[158], [174]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["pancreatitis"]], "start": [[24]], "entity_id": ["T5"]}, "Subject": {"text": [["An infant"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["infant"]], "start": [[3]], "entity_id": ["T7"]}}}]}]}
{"id": "10510017_2", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["management"]], "start": [[44]], "entity_id": ["T3"]}, "Subject": {"text": [["Pediatric"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["Pediatric"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Danaparoid (orgaran)"]], "start": [[60]], "entity_id": ["T4"], "Disorder": {"text": [["heparin-induced thrombocytopenia"]], "start": [[10]], "entity_id": ["T5"]}, "Drug": {"text": [["Danaparoid"]], "start": [[60]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[18]], "entity_id": ["T10"]}, "Treatment": {"text": [["heparin"]], "start": [[10]], "entity_id": ["T11"], "Drug": {"text": [["heparin"]], "start": [[10]], "entity_id": ["T12"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[26]], "entity_id": ["T13"]}}]}]}
{"id": "12365708_5", "context": "While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[38]], "entity_id": ["T8"]}, "Treatment": {"text": [["amiodarone and digoxin"]], "start": [[11]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"], ["digoxin"]], "start": [[11], [26]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[22]], "entity_id": ["T12"]}, "Drug": {"text": [["amiodarone"], ["digoxin"]], "start": [[11], [26]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["permanent visual changes"]], "start": [[44]], "entity_id": ["T9"]}}]}]}
{"id": "12699871_4", "context": "Tacrolimus (FK506)-induced mutism after liver transplant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["Tacrolimus (FK506"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Tacrolimus"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["mutism"]], "start": [[27]], "entity_id": ["T6"]}}]}]}
{"id": "7789881_3", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[83]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[99]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[99]], "entity_id": ["T6"]}}, "Effect": {"text": [["secretory carcinoma of the endometrium"]], "start": [[44]], "entity_id": ["T5"]}}]}]}
{"id": "3513544_1", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[57]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[70]], "entity_id": ["T4"], "Drug": {"text": [["cyclosporine"]], "start": [[70]], "entity_id": ["T8"]}, "Disorder": {"text": [["renal transplant"]], "start": [[32]], "entity_id": ["T9"]}}, "Effect": {"text": [["Herpes simplex esophagitis"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["renal transplant patient"]], "start": [[32]], "entity_id": ["T6"]}}]}]}
{"id": "9232614_1", "context": "Acute leukaemia during tamoxifen therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[16]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute leukaemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[23]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[23]], "entity_id": ["T6"]}}}]}]}
{"id": "15190230_2", "context": "In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[135]], "entity_id": ["T3"]}, "Treatment": {"text": [["the first dose of pegylated interferon alpha."]], "start": [[141]], "entity_id": ["T4"], "Dosage": {"text": [["the first dose"]], "start": [[141]], "entity_id": ["T8"]}, "Drug": {"text": [["pegylated interferon alpha"]], "start": [[159]], "entity_id": ["T9"]}, "Disorder": {"text": [["chronic hepatitis B"]], "start": [[80]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute dystonia"]], "start": [[115]], "entity_id": ["T5"]}, "Subject": {"text": [["a case with chronic hepatitis B"]], "start": [[68]], "entity_id": ["T6"]}}]}]}
{"id": "2937155_2", "context": "The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[13]], "entity_id": ["T6"]}, "Treatment": {"text": [["vancomycin"]], "start": [[130]], "entity_id": ["T7"], "Drug": {"text": [["vancomycin"]], "start": [[130]], "entity_id": ["T10"]}}, "Effect": {"text": [["drug-induced vasculitis or lupus-like syndrome"]], "start": [[30]], "entity_id": ["T8"]}, "Speculated": {"text": [["possible"]], "start": [[4]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "22735246_4", "context": "We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[51]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[21]], "entity_id": ["T7"]}, "Subject": {"text": [["a patien"]], "start": [[84]], "entity_id": ["T8"]}, "Treatment": {"text": [["long-term treatment with sertraline, a selective serotonin reuptake inhibitor"]], "start": [[122]], "entity_id": ["T9"], "Drug": {"text": [["sertraline"]], "start": [[147]], "entity_id": ["T11"]}, "Duration": {"text": [["long-term"]], "start": [[122]], "entity_id": ["T12"]}}}]}]}
{"id": "19789372_6", "context": "Of the 15 patients treated with tizanidine and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and dry mouth in the retrospective survey.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[81]], "entity_id": ["T14"]}, "Treatment": {"text": [["tizanidine and mexiletine"]], "start": [[32]], "entity_id": ["T13"], "Drug": {"text": [["tizanidine"], ["mexiletine"], ["tizanidine"]], "start": [[32], [47], [70]], "entity_id": ["T17", "T18", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[43]], "entity_id": ["T19"]}, "Drug": {"text": [["tizanidine"], ["mexiletine"]], "start": [[32], [47]], "entity_id": ["T17", "T18"]}}]}, "Effect": {"text": [["drowsiness and dry mouth"]], "start": [[113]], "entity_id": ["T15"]}, "Subject": {"text": [["15 patients"], ["4"]], "start": [[7], [59]], "entity_id": ["T12", "T20"], "Population": {"text": [["15"]], "start": [[7]], "entity_id": ["T16"]}}}]}]}
{"id": "20412003_1", "context": "After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["determined"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[62]], "entity_id": ["T5"], "Drug": {"text": [["TMP"], ["SMX"]], "start": [[62], [66]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[65]], "entity_id": ["T10"]}, "Drug": {"text": [["TMP"], ["SMX"]], "start": [[62], [66]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["acute liver toxicity"]], "start": [[108]], "entity_id": ["T7"]}}]}]}
{"id": "12365708_2", "context": "Biomicroscopy revealed amiodarone corneal deposits.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["revealed"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Biomicroscopy"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Biomicroscopy"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["amiodarone corneal deposits"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "14601701_5", "context": "This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["unpredictable"]], "start": [[61]], "entity_id": ["T10"]}, "Treatment": {"text": [["ethambutol"]], "start": [[85]], "entity_id": ["T11"], "Drug": {"text": [["ethambutol"]], "start": [[85]], "entity_id": ["T13"]}}, "Effect": {"text": [["irreversible vision loss"]], "start": [[127]], "entity_id": ["T9"]}, "Speculated": {"text": [["potential"]], "start": [[113]], "entity_id": ["T12"], "value": true}, "Severity": {"text": [["severe"]], "start": [[50]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "9347384_1", "context": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T6"]}, "Subject": {"text": [["psychiatric patients"]], "start": [[69]], "entity_id": ["T4"], "Disorder": {"text": [["psychiatric"]], "start": [[69]], "entity_id": ["T5"]}}, "Effect": {"text": [["Carbamazepine toxicity"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["clarithromycin coadministration"]], "start": [[34]], "entity_id": ["T8"], "Drug": {"text": [["clarithromycin"], ["Carbamazepine"]], "start": [[34], [0]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["by"]], "start": [[31]], "entity_id": ["T11"]}, "Drug": {"text": [["Carbamazepine"], ["clarithromycin"]], "start": [[0], [34]], "entity_id": ["T10", "T9"]}}]}}]}]}
{"id": "12692521_2", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["administration"]], "start": [[101]], "entity_id": ["T5"]}, "Subject": {"text": [["two cases in which both patients suffered with CLS"]], "start": [[11]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[11]], "entity_id": ["T4"]}}, "Effect": {"text": [["CLS"]], "start": [[58]], "entity_id": ["T7"]}, "Treatment": {"text": [["granulocyte colony-stimulating factor"]], "start": [[119]], "entity_id": ["T6"], "Drug": {"text": [["granulocyte colony-stimulating facto"]], "start": [[119]], "entity_id": ["T10"]}}, "Speculated": {"text": [["believe"]], "start": [[72]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "10082597_2", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[45]], "entity_id": ["T4"]}, "Treatment": {"text": [["Naproxen"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Naproxen"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["erythropoietic protoporphyria"]], "start": [[134]], "entity_id": ["T5"]}, "Subject": {"text": [["pediatric population"]], "start": [[171]], "entity_id": ["T6"], "Age": {"text": [["pediatric"]], "start": [[171]], "entity_id": ["T7"]}}}]}]}
{"id": "15549981_1", "context": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[129]], "entity_id": ["T9"]}, "Subject": {"text": [["two cases"]], "start": [[11]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[11]], "entity_id": ["T5"]}}, "Effect": {"text": [["anaphylaxis under anaesthesia"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["administration of the alpha-agonist metaraminol"]], "start": [[152]], "entity_id": ["T7"], "Drug": {"text": [["alpha-agonist metaraminol"]], "start": [[174]], "entity_id": ["T8"]}}}]}]}
{"id": "17667887_8", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produced"]], "start": [[54]], "entity_id": ["T7"]}, "Treatment": {"text": [["a combination of an antidepressant and an atypical antipsychotic"]], "start": [[66]], "entity_id": ["T8"], "Drug": {"text": [["antidepressant"], ["atypical antipsychotic"]], "start": [[86], [108]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[68]], "entity_id": ["T13"]}, "Drug": {"text": [["antidepressant"], ["atypical antipsychotic"]], "start": [[86], [108]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[31]], "entity_id": ["T9"]}, "Subject": {"text": [["In both cases"]], "start": [[0]], "entity_id": ["T14"], "Population": {"text": [["both"]], "start": [[3]], "entity_id": ["T15"]}}, "Speculated": {"text": [["believe"]], "start": [[18]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "3620420_6", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[12]], "entity_id": ["T7"]}, "Treatment": {"text": [["Cyclosporin"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Cyclosporin"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests."]], "start": [[34]], "entity_id": ["T9"]}}]}]}
{"id": "18421192_1", "context": "A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["A 51-year-old man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["51-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T10"]}}, "Effect": {"text": [["type 1 diabetes mellitus"]], "start": [[28]], "entity_id": ["T6"]}, "Treatment": {"text": [["recombinant alpha-2b peginterferon plus ribavirin"]], "start": [[90]], "entity_id": ["T7"], "Drug": {"text": [["alpha-2b peginterferon"], ["ribavirin"]], "start": [[102], [130]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[144]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["24 weeks"]], "start": [[63]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[125]], "entity_id": ["T13"]}, "Drug": {"text": [["ribavirin"], ["alpha-2b peginterferon"]], "start": [[130], [102]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "11573852_8", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[38]], "entity_id": ["T5"]}, "Effect": {"text": [["seizures"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["amphotericin B"]], "start": [[54]], "entity_id": ["T6"], "Drug": {"text": [["amphotericin B"]], "start": [[54]], "entity_id": ["T3"]}}}]}]}
{"id": "424824_1", "context": "Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[142]], "entity_id": ["T7"]}, "Treatment": {"text": [["methotrexate"]], "start": [[125]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[125]], "entity_id": ["T10"]}}, "Effect": {"text": [["diffuse interstitial pulmonary fibrosis", "bilateral pulmonary infiltrates"]], "start": [[12, 150]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[106]], "entity_id": ["T8"]}, "Speculated": {"text": [["should be considered"]], "start": [[52]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12598508_4", "context": "Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T5"]}, "Treatment": {"text": [["lisinopril"]], "start": [[63]], "entity_id": ["T4"], "Drug": {"text": [["lisinopril"]], "start": [[63]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiorgan failure"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "3449312_2", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[70]], "entity_id": ["T7"]}, "Effect": {"text": [["aplastic anemia"]], "start": [[87]], "entity_id": ["T8"]}, "Subject": {"text": [["Three patients", "rheumatoid arthritis"]], "start": [[0, 49]], "entity_id": ["T10"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T12"]}}, "Treatment": {"text": [["gold salt"]], "start": [[25]], "entity_id": ["T11"], "Drug": {"text": [["gold salt"]], "start": [[25]], "entity_id": ["T13"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[49]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe"]], "start": [[80]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "12092878_2", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[24]], "entity_id": ["T8"]}, "Effect": {"text": [["anaphylactoid"]], "start": [[10]], "entity_id": ["T9"]}, "Treatment": {"text": [["Gelofusine"]], "start": [[58]], "entity_id": ["T10"], "Drug": {"text": [["Gelofusine"]], "start": [[58]], "entity_id": ["T13"]}, "Disorder": {"text": [["non-haemorrhagic hypovolaemia"]], "start": [[87]], "entity_id": ["T14"]}}, "Subject": {"text": [["patient with non-haemorrhagic hypovolaemia"]], "start": [[74]], "entity_id": ["T11"]}}]}]}
{"id": "18717612_3", "context": "We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[87]], "entity_id": ["T5"]}, "Subject": {"text": [["a 54-year-old Turkish woman"]], "start": [[28]], "entity_id": ["T3"], "Age": {"text": [["54-year-old"]], "start": [[30]], "entity_id": ["T7"]}, "Race": {"text": [["Turkish"]], "start": [[42]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[50]], "entity_id": ["T9"]}}, "Treatment": {"text": [["ceftriaxone"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["ceftriaxone"]], "start": [[75]], "entity_id": ["T10"]}}, "Effect": {"text": [["FDE"]], "start": [[95]], "entity_id": ["T6"]}}]}]}
{"id": "6344831_3", "context": "Nonoliguric acute renal failure after captopril therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["captopril"]], "start": [[38]], "entity_id": ["T4"], "Drug": {"text": [["captopril"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["Nonoliguric acute renal failure"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "4014301_4", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[48]], "entity_id": ["T5"]}, "Effect": {"text": [["cardiac failure"]], "start": [[56]], "entity_id": ["T6"]}, "Treatment": {"text": [["insulin"]], "start": [[40]], "entity_id": ["T7"], "Drug": {"text": [["insulin"]], "start": [[40]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient without underlying heart disease"]], "start": [[75]], "entity_id": ["T8"]}}]}]}
{"id": "16765687_2", "context": "Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[6]], "entity_id": ["T6"]}, "Treatment": {"text": [["methylprednisolone and mannitol"]], "start": [[67]], "entity_id": ["T5"], "Disorder": {"text": [["topiramate-induced angle-closure glaucoma"]], "start": [[20]], "entity_id": ["T7"]}, "Drug": {"text": [["methylprednisolone"], ["mannitol"]], "start": [[67], [90]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["methylprednisolone"], ["mannitol"]], "start": [[67], [90]], "entity_id": ["T9", "T10"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T11"]}, "Treatment": {"text": [["topiramate"]], "start": [[20]], "entity_id": ["T12"], "Drug": {"text": [["topiramate"]], "start": [[20]], "entity_id": ["T13"]}}, "Effect": {"text": [["angle-closure glaucoma"]], "start": [[39]], "entity_id": ["T14"]}}]}]}
{"id": "19217693_3", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[61]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with type 2 diabetes mellitus"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["persistent hypoglycemia"]], "start": [[177]], "entity_id": ["T6"]}, "Treatment": {"text": [["antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis"]], "start": [[78]], "entity_id": ["T5"], "Disorder": {"text": [["type 2 diabetes mellitus"], ["severe plaque psoriasis"]], "start": [[25], [140]], "entity_id": ["T7", "T9"]}, "Drug": {"text": [["etanercept"]], "start": [[125]], "entity_id": ["T8"]}}}]}]}
{"id": "7098384_1", "context": "A 66-year-old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["took"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["A 66-year-old mand suffering from severe coronary heart disease"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["66-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["mand"]], "start": [[14]], "entity_id": ["T8"]}, "Disorder": {"text": [["coronary heart disease"]], "start": [[41]], "entity_id": ["T9"]}}, "Treatment": {"text": [["digoxin"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["digoxin"]], "start": [[69]], "entity_id": ["T10"]}}, "Effect": {"text": [["complete atrioventricular block"]], "start": [[129]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[105]], "entity_id": ["T12"]}, "Subject": {"text": [["A 66-year-old mand suffering from severe coronary heart disease"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["66-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["mand"]], "start": [[14]], "entity_id": ["T8"]}, "Disorder": {"text": [["coronary heart disease"]], "start": [[41]], "entity_id": ["T9"]}}, "Treatment": {"text": [["digoxin-specific antibody fragments"]], "start": [[166]], "entity_id": ["T13"], "Disorder": {"text": [["complete atrioventricular block"]], "start": [[129]], "entity_id": ["T11"]}, "Drug": {"text": [["digoxin-specific antibody fragments"]], "start": [[166]], "entity_id": ["T14"]}}}]}]}
{"id": "16116136_1", "context": "A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T4"]}, "Effect": {"text": [["CNS lymphoma"]], "start": [[76]], "entity_id": ["T6"]}, "Treatment": {"text": [["MM", "after 3 years of treatment"]], "start": [[59, 89]], "entity_id": ["T12"], "Time_elapsed": {"text": [["3 years"]], "start": [[95]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["managed"]], "start": [[46]], "entity_id": ["T11"]}, "Subject": {"text": [["A patient with generalized MG"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["MM"]], "start": [[59]], "entity_id": ["T5"], "Disorder": {"text": [["generalized MG"]], "start": [[15]], "entity_id": ["T9"]}, "Drug": {"text": [["MM"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "11568758_1", "context": "Lichenoid drug eruption to salsalate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["eruption"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Lichenoid drug eruption"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["salsalate"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["salsalate"]], "start": [[27]], "entity_id": ["T6"]}}}]}]}
{"id": "12540009_4", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["doxycycline"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["doxycycline"]], "start": [[28]], "entity_id": ["T12"]}}, "Effect": {"text": [["hypoglycemia"]], "start": [[48]], "entity_id": ["T7"]}, "Subject": {"text": [["a young nondiabetic man"]], "start": [[64]], "entity_id": ["T8"], "Age": {"text": [["young"]], "start": [[66]], "entity_id": ["T9"]}, "Disorder": {"text": [["nondiabetic"]], "start": [[72]], "entity_id": ["T10"]}, "Gender": {"text": [["man"]], "start": [[84]], "entity_id": ["T11"]}}}]}]}
{"id": "897744_1", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[52]], "entity_id": ["T9"]}, "Effect": {"text": [["Focal glomerulonephritis and interstitial nephritis"]], "start": [[0]], "entity_id": ["T13"]}, "Treatment": {"text": [["methicillin"]], "start": [[55]], "entity_id": ["T10"], "Disorder": {"text": [["heroin-related infective endocarditis"]], "start": [[76]], "entity_id": ["T12"]}, "Drug": {"text": [["methicillin"]], "start": [[55]], "entity_id": ["T11"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[83]], "entity_id": ["T14"]}, "Treatment": {"text": [["heroin"]], "start": [[76]], "entity_id": ["T15"], "Drug": {"text": [["heroin"]], "start": [[76]], "entity_id": ["T16"]}}, "Effect": {"text": [["infective endocarditis"]], "start": [[91]], "entity_id": ["T17"]}}]}]}
{"id": "11352235_4", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["loss"]], "start": [[48]], "entity_id": ["T7"]}, "Effect": {"text": [["weight loss"]], "start": [[41]], "entity_id": ["T3"]}, "Subject": {"text": [["patients"]], "start": [[56]], "entity_id": ["T4"]}, "Treatment": {"text": [["leflunomide"]], "start": [[78]], "entity_id": ["T6"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[94]], "entity_id": ["T5"]}, "Drug": {"text": [["leflunomide"]], "start": [[78]], "entity_id": ["T8"]}}}]}]}
{"id": "11328247_1", "context": "CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[62]], "entity_id": ["T6"]}, "Effect": {"text": [["increased libido"]], "start": [[68]], "entity_id": ["T3"]}, "Subject": {"text": [["some patients"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[46]], "entity_id": ["T7"]}}}]}]}
{"id": "110153_2", "context": "When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[104]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[173]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[173]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute manic state is characterized by marked psychotic symptoms and intense anxiety"]], "start": [[9]], "entity_id": ["T9"]}, "Speculated": {"text": [["may"]], "start": [[97]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "11804071_1", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["a leading cause"]], "start": [[14]], "entity_id": ["T3"]}, "Effect": {"text": [["drug eruptions"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["INH"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["INH"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "10610018_1", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["risperidone"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["risperidone"]], "start": [[58]], "entity_id": ["T6"]}, "Disorder": {"text": [["Elevated serum triglycerides with clozapine"]], "start": [[0]], "entity_id": ["T7"]}}, "Subject": {"text": [["four patients"]], "start": [[73]], "entity_id": ["T1"], "Age": {"text": [["four"]], "start": [[73]], "entity_id": ["T2"]}}}]}]}
{"id": "11724089_5", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["toxic epidermal necrolysis"]], "start": [[31]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[13]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "15554737_1", "context": "In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[66]], "entity_id": ["T9"]}, "Effect": {"text": [["subcutaneous changes", "presented as localized panniculitis in the area around the injection sites"]], "start": [[45, 115]], "entity_id": ["T7"]}, "Treatment": {"text": [["repeated glatiramer acetate injection"]], "start": [[76]], "entity_id": ["T8"], "Drug": {"text": [["glatiramer acetate"]], "start": [[85]], "entity_id": ["T12"]}, "Route": {"text": [["injection"]], "start": [[104]], "entity_id": ["T13"]}}, "Subject": {"text": [["a 46-year-old female patient"]], "start": [[194]], "entity_id": ["T6"], "Age": {"text": [["46-year-old"]], "start": [[196]], "entity_id": ["T10"]}, "Gender": {"text": [["female"]], "start": [[208]], "entity_id": ["T11"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[231]], "entity_id": ["T17"]}, "Subject": {"text": [["a 46-year-old female patient"]], "start": [[194]], "entity_id": ["T6"], "Age": {"text": [["46-year-old"]], "start": [[196]], "entity_id": ["T10"]}, "Gender": {"text": [["female"]], "start": [[208]], "entity_id": ["T11"]}}, "Treatment": {"text": [["glatiramer acetate for 18 months"]], "start": [[244]], "entity_id": ["T18"], "Drug": {"text": [["glatiramer acetate"]], "start": [[244]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["18 months."]], "start": [[267]], "entity_id": ["T14"]}}}]}]}
{"id": "23624139_9", "context": "The present report first highlights the potentially life-threatening side effects associated with over-the-counter NSAIDs during DDAVP replacement therapy for central DI.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["NSAIDs"]], "start": [[115]], "entity_id": ["T8"], "Drug": {"text": [["NSAIDs"], ["DDAVP"]], "start": [[115], [129]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[122]], "entity_id": ["T13"]}, "Drug": {"text": [["NSAIDs"], ["DDAVP"]], "start": [[115], [129]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["potentially life-threatening side effects"]], "start": [[40]], "entity_id": ["T10"]}}]}]}
{"id": "16580907_1", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[23]], "entity_id": ["T9"]}, "Effect": {"text": [["Severe arrhythmia"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["interaction of cetirizine and pilsicainide"]], "start": [[37]], "entity_id": ["T10"], "Drug": {"text": [["cetirizine"], ["pilsicainide"]], "start": [[52], [67]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[37]], "entity_id": ["T14"]}, "Drug": {"text": [["cetirizine"], ["pilsicainide"]], "start": [[52], [67]], "entity_id": ["T15", "T16"]}}]}, "Subject": {"text": [["a patient with renal insufficiency"]], "start": [[83]], "entity_id": ["T11"], "Disorder": {"text": [["renal insufficiency"]], "start": [[98]], "entity_id": ["T12"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T13"], "value": "Medium"}}]}]}
{"id": "8832451_3", "context": "We also describe a new, noninvasive method to assess magnesium-induced neuromuscular block when curariform muscle relaxant was given simultaneously.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[63]], "entity_id": ["T3"]}, "Treatment": {"text": [["magnesium", "curariform muscle relaxant"]], "start": [[53, 96]], "entity_id": ["T5"], "Drug": {"text": [["magnesium"], ["curariform"]], "start": [[53], [96]], "entity_id": ["T6", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["simultaneously"]], "start": [[133]], "entity_id": ["T7"]}, "Drug": {"text": [["magnesium"], ["curariform"]], "start": [[53], [96]], "entity_id": ["T6", "T8"]}}]}, "Effect": {"text": [["neuromuscular block"]], "start": [[71]], "entity_id": ["T4"]}}]}]}
{"id": "17083890_5", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[65]], "entity_id": ["T9"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[25]], "entity_id": ["T7"], "Route": {"text": [["chemotherapy"]], "start": [[25]], "entity_id": ["T11"]}}, "Subject": {"text": [["patient"]], "start": [[43]], "entity_id": ["T8"]}, "Effect": {"text": [["a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin"]], "start": [[75]], "entity_id": ["T10"]}}]}]}
{"id": "17241588_1", "context": "RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["owing"]], "start": [[53]], "entity_id": ["T5"]}, "Effect": {"text": [["ixed drug eruption"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["PDE5 inhibitor tadalafil (Cialis)"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["tadalafil"]], "start": [[88]], "entity_id": ["T7"]}}}]}]}
{"id": "12111771_2", "context": "Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[112]], "entity_id": ["T8"]}, "Subject": {"text": [["all patients who develop unexplained lung disease"]], "start": [[56]], "entity_id": ["T6"], "Disorder": {"text": [["lung disease"]], "start": [[93]], "entity_id": ["T10"]}}, "Effect": {"text": [["Fludarabine induced lung toxicity"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["fludarabine"]], "start": [[122]], "entity_id": ["T9"], "Drug": {"text": [["fludarabine"]], "start": [[122]], "entity_id": ["T11"]}}}]}]}
{"id": "8007037_1", "context": "Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[135]], "entity_id": ["T5"]}, "Treatment": {"text": [["methyl nitrite"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["methyl nitrite"]], "start": [[62]], "entity_id": ["T7"]}}, "Effect": {"text": [["occupational methemoglobinemia"]], "start": [[144]], "entity_id": ["T6"]}}]}]}
{"id": "14530108_1", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[23]], "entity_id": ["T3"]}, "Effect": {"text": [["Renal tubular acidosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["FK506"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["FK506"]], "start": [[36]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[81]], "entity_id": ["T6"]}}]}]}
{"id": "15482394_4", "context": "In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[191]], "entity_id": ["T5"]}, "Treatment": {"text": [["initiating warfarin therapy regardless of the dosage"]], "start": [[197]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[208]], "entity_id": ["T6"]}}, "Effect": {"text": [["haemorrhage"]], "start": [[179]], "entity_id": ["T4"]}, "Severity": {"text": [["fatal"]], "start": [[173]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "18262450_10", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[40]], "entity_id": ["T9"]}, "Treatment": {"text": [["Oxycodone-gabapentin"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["pain"]], "start": [[49]], "entity_id": ["T10"]}, "Drug": {"text": [["Oxycodone-gabapentin"]], "start": [[0]], "entity_id": ["T11"]}}}]}]}
{"id": "9602881_1", "context": "We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[32]], "entity_id": ["T4"]}, "Subject": {"text": [["a 76-year-old man"]], "start": [[10]], "entity_id": ["T3"], "Age": {"text": [["76-year-old"]], "start": [[12]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute blistering eruption"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose penicillin treatment"]], "start": [[81]], "entity_id": ["T6"], "Dosage": {"text": [["high-dose"]], "start": [[81]], "entity_id": ["T9"]}, "Drug": {"text": [["penicillin"]], "start": [[91]], "entity_id": ["T10"]}}}]}]}
{"id": "16615675_1", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[62]], "entity_id": ["T3"]}, "Treatment": {"text": [["HCQ"]], "start": [[54]], "entity_id": ["T4"], "Drug": {"text": [["HCQ"]], "start": [[54]], "entity_id": ["T6"]}}, "Effect": {"text": [["ventricular tachycardia"]], "start": [[92]], "entity_id": ["T5"]}, "Subject": {"text": [["her"]], "start": [[88]], "entity_id": ["T7"], "Gender": {"text": [["her"]], "start": [[88]], "entity_id": ["T8"]}}}]}]}
{"id": "11414270_14", "context": "We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[87]], "entity_id": ["T7"]}, "Treatment": {"text": [["succinylcholine"]], "start": [[111]], "entity_id": ["T6"], "Drug": {"text": [["succinylcholine"]], "start": [[111]], "entity_id": ["T10"]}}, "Effect": {"text": [["fatal hyperkalemia"]], "start": [[68]], "entity_id": ["T8"]}, "Subject": {"text": [["mucositis"]], "start": [[16]], "entity_id": ["T9"], "Disorder": {"text": [["mucositis"]], "start": [[16]], "entity_id": ["T11"]}}}]}]}
{"id": "11147747_1", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contributed"]], "start": [[112]], "entity_id": ["T6"]}, "Subject": {"text": [["the patients"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium carbonate and beta-blockers"]], "start": [[50]], "entity_id": ["T4"], "Drug": {"text": [["lithium carbonate"], ["beta-blockers"]], "start": [[50], [72]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[68]], "entity_id": ["T9"]}, "Drug": {"text": [["lithium carbonate"], ["beta-blockers"]], "start": [[50], [72]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["incontinence"]], "start": [[131]], "entity_id": ["T5"]}}]}]}
{"id": "14679124_1", "context": "Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["administered"]], "start": [[65]], "entity_id": ["T11"]}, "Treatment": {"text": [["Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Epirubicin-cyclophosphamide"], ["tamoxifen"]], "start": [[0], [55]], "entity_id": ["T13", "T15"]}, "Disorder": {"text": [["postmenopausal node-positive breast cancer"]], "start": [[142]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[50]], "entity_id": ["T14"]}, "Drug": {"text": [["Epirubicin-cyclophosphamide"], ["tamoxifen"]], "start": [[0], [55]], "entity_id": ["T13", "T15"]}}]}, "Subject": {"text": [["postmenopausal node-positive breast cancer patients"]], "start": [[142]], "entity_id": ["T10"]}}]}]}
{"id": "3628148_1", "context": "Rupture of a cerebral aneurysm associated with nifedipine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["nifedipine"]], "start": [[47]], "entity_id": ["T3"], "Drug": {"text": [["nifedipine"]], "start": [[47]], "entity_id": ["T6"]}}, "Effect": {"text": [["Rupture of a cerebral aneurysm"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "15157248_1", "context": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["immediate hemolytic reaction"]], "start": [[3]], "entity_id": ["T3"]}, "Treatment": {"text": [["repeated", "oxaliplatin"]], "start": [[43, 70]], "entity_id": ["T5"], "Drug": {"text": [["oxaliplatin"]], "start": [[70]], "entity_id": ["T6"]}}}]}]}
{"id": "15286697_2", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[44]], "entity_id": ["T5"]}, "Effect": {"text": [["Pulmonary fibrosis is a severe complication"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["bis-chloronitrosourea (BCNU) therapy"]], "start": [[60]], "entity_id": ["T6"], "Drug": {"text": [["bis-chloronitrosourea"]], "start": [[60]], "entity_id": ["T7"]}}}]}]}
{"id": "3159106_1", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[7]], "entity_id": ["T6"]}, "Subject": {"text": [["a black African"]], "start": [[62]], "entity_id": ["T3"], "Race": {"text": [["black African"]], "start": [[64]], "entity_id": ["T7"]}}, "Treatment": {"text": [["allopurinol"]], "start": [[10]], "entity_id": ["T4"], "Drug": {"text": [["allopurinol"]], "start": [[10]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypersensitivity"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "990658_1", "context": "A fatal case of pancytopenia due to levomepromazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["pancytopenia"]], "start": [[16]], "entity_id": ["T3"]}, "Treatment": {"text": [["levomepromazine"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["levomepromazine"]], "start": [[36]], "entity_id": ["T7"]}}, "Subject": {"text": [["A fatal case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "20130478_2", "context": "Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[25]], "entity_id": ["T7"]}, "Effect": {"text": [["Reversible heart failure"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["etanercept"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["etanercept"]], "start": [[48]], "entity_id": ["T8"]}, "Disorder": {"text": [["ankylosing spondylitis."]], "start": [[63]], "entity_id": ["T9"]}}}]}]}
{"id": "6865827_2", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[105]], "entity_id": ["T6"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methimazole"]], "start": [[22]], "entity_id": ["T4"], "Drug": {"text": [["methimazole"]], "start": [[22]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["10 weeks late"]], "start": [[67]], "entity_id": ["T8"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[83]], "entity_id": ["T5"]}}]}]}
{"id": "18042092_3", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[186]], "entity_id": ["T4"]}, "Treatment": {"text": [["glatiramer acetate"]], "start": [[163]], "entity_id": ["T3"], "Drug": {"text": [["glatiramer acetate"]], "start": [[163]], "entity_id": ["T7"]}, "Route": {"text": [["subcutaneous"]], "start": [[53]], "entity_id": ["T8"]}}, "Effect": {"text": [["skin necrosis"]], "start": [[193]], "entity_id": ["T5"]}, "Subject": {"text": [["the patient himself"]], "start": [[135]], "entity_id": ["T6"]}}]}]}
{"id": "458006_1", "context": "Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[60]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[73]], "entity_id": ["T4"], "Drug": {"text": [["5-fluorouracil"]], "start": [[73]], "entity_id": ["T6"]}}, "Effect": {"text": [["Squamous-cell carcinoma arising"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "11545487_3", "context": "Papillary necrosis associated with the HIV protease inhibitor indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["indinavir"]], "start": [[62]], "entity_id": ["T3"], "Drug": {"text": [["indinavir"]], "start": [[62]], "entity_id": ["T7"]}, "Disorder": {"text": [["HIV"]], "start": [[39]], "entity_id": ["T1"]}}, "Effect": {"text": [["Papillary necrosis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "16284443_1", "context": "Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[59]], "entity_id": ["T3"], "Drug": {"text": [["insulin"]], "start": [[59]], "entity_id": ["T6"]}}, "Effect": {"text": [["lipohypertrophy"]], "start": [[75]], "entity_id": ["T5"]}}]}]}
{"id": "8305778_6", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse-effect"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["an adverse-effect profile involving many different organ systems"]], "start": [[46]], "entity_id": ["T6"]}}]}]}
{"id": "21729965_4", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["having"]], "start": [[82]], "entity_id": ["T9"]}, "Subject": {"text": [["an HIV-positive woman"]], "start": [[34]], "entity_id": ["T7"], "Gender": {"text": [["woman"]], "start": [[50]], "entity_id": ["T12"]}}, "Treatment": {"text": [["antiretroviral"]], "start": [[59]], "entity_id": ["T8"], "Disorder": {"text": [["HIV-positive"]], "start": [[37]], "entity_id": ["T11"]}, "Drug": {"text": [["antiretroviral"], ["Implanon"]], "start": [[59], [138]], "entity_id": ["T13", "T14"]}}, "Effect": {"text": [["tubal pregnancies"]], "start": [[89]], "entity_id": ["T10"]}}]}]}
{"id": "19567656_2", "context": "DISCUSSION: The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[63]], "entity_id": ["T6"]}, "Treatment": {"text": [["sertraline"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["sertraline"]], "start": [[84]], "entity_id": ["T7"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[122]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[54]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "14677199_1", "context": "Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[28]], "entity_id": ["T6"]}, "Effect": {"text": [["Raynaud's phenomenon"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["yohimbine"]], "start": [[33]], "entity_id": ["T4"], "Drug": {"text": [["yohimbine"]], "start": [[33]], "entity_id": ["T7"]}, "Disorder": {"text": [["erectile dysfunction"]], "start": [[55]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "15595320_4", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[86]], "entity_id": ["T8"]}, "Treatment": {"text": [["MTX"]], "start": [[51]], "entity_id": ["T7"], "Drug": {"text": [["MTX"]], "start": [[51]], "entity_id": ["T10"]}}, "Effect": {"text": [["enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease"]], "start": [[98]], "entity_id": ["T9"]}}]}]}
{"id": "921427_2", "context": "Circulating anticoagulant in the procainamide-induced lupus syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["procainamide"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["procainamide"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus syndrome"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "17526968_3", "context": "We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[75]], "entity_id": ["T12"]}, "Subject": {"text": [["a child with yolk sac tumor"]], "start": [[10]], "entity_id": ["T9"], "Age": {"text": [["child"]], "start": [[12]], "entity_id": ["T13"]}}, "Effect": {"text": [["localized pigmentation"]], "start": [[52]], "entity_id": ["T10"]}, "Treatment": {"text": [["the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin"]], "start": [[81]], "entity_id": ["T11"], "Duration": {"text": [["the first course"]], "start": [[81]], "entity_id": ["T15"]}, "Drug": {"text": [["cisplatin"], ["etoposide"], ["bleomycin"]], "start": [[136], [147], [161]], "entity_id": ["T17", "T18", "T19"]}, "Disorder": {"text": [["yolk sac tumor"]], "start": [[23]], "entity_id": ["T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["included"]], "start": [[127]], "entity_id": ["T16"]}, "Drug": {"text": [["cisplatin"], ["etoposide"], ["bleomycin"]], "start": [[136], [147], [161]], "entity_id": ["T17", "T18", "T19"]}}]}}]}]}
{"id": "17034541_1", "context": "Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["rituximab"]], "start": [[49]], "entity_id": ["T4"], "Disorder": {"text": [["low-grade cutaneous B-cell lymphoma"]], "start": [[72]], "entity_id": ["T5"]}, "Drug": {"text": [["rituximab"]], "start": [[49]], "entity_id": ["T7"]}}, "Effect": {"text": [["Late lethal hepatitis B virus reactivation"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15482394_3", "context": "Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[166]], "entity_id": ["T5"]}, "Treatment": {"text": [["low dosage of warfarin"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[26]], "entity_id": ["T6"]}, "Dosage": {"text": [["low dosage"], ["1.15"], ["11.28"]], "start": [[12], [100], [108]], "entity_id": ["T7", "T8", "T9"]}, "Duration": {"text": [["4 days"]], "start": [[123]], "entity_id": ["T10"]}}, "Effect": {"text": [["international normalized ratio (INR) was markedly elevated", "bleeding symptoms"]], "start": [[36, 135]], "entity_id": ["T4"]}}]}]}
{"id": "11144696_11", "context": "We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inducing"]], "start": [[168]], "entity_id": ["T7"]}, "Effect": {"text": [["seizures"]], "start": [[181]], "entity_id": ["T8"]}, "Treatment": {"text": [["interaction between venlafaxine and trimipramine"]], "start": [[62]], "entity_id": ["T9"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[82], [98]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[62]], "entity_id": ["T14"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[82], [98]], "entity_id": ["T12", "T13"]}}]}, "Speculated": {"text": [["hypothesize"]], "start": [[3]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "17090724_1", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[61]], "entity_id": ["T8"]}, "Treatment": {"text": [["Amphotericin B deoxycholate", "conventional dosages and infusion rates"]], "start": [[12, 252]], "entity_id": ["T7"], "Drug": {"text": [["Amphotericin B deoxycholate"]], "start": [[12]], "entity_id": ["T15"]}, "Dosage": {"text": [["conventional dosages"]], "start": [[252]], "entity_id": ["T16"]}, "Route": {"text": [["infusion"]], "start": [[277]], "entity_id": ["T17"]}}, "Effect": {"text": [["cardiac toxicity, with ventricular arrhythmias and bradycardia"]], "start": [[81]], "entity_id": ["T9"]}, "Subject": {"text": [["in children and in adults with preexisting cardiac disease"]], "start": [[166]], "entity_id": ["T10"], "Age": {"text": [["in children and in adults"]], "start": [[166]], "entity_id": ["T12"]}, "Disorder": {"text": [["preexisting cardiac disease"]], "start": [[197]], "entity_id": ["T13"]}}}]}]}
{"id": "1635565_2", "context": "CONCLUSIONS: The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["prostaglandin E1"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["prostaglandin E1"]], "start": [[35]], "entity_id": ["T11"]}}, "Subject": {"text": [["neonates"]], "start": [[55]], "entity_id": ["T6"], "Age": {"text": [["neonates"]], "start": [[55]], "entity_id": ["T9"]}}, "Effect": {"text": [["gastric-outlet obstruction due to antral hyperplasia"]], "start": [[74]], "entity_id": ["T8"]}, "Speculated": {"text": [["can"]], "start": [[64]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "3688031_3", "context": "The patient's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T5"]}, "Treatment": {"text": [["methimazole"]], "start": [[36]], "entity_id": ["T3"], "Drug": {"text": [["methimazole"]], "start": [[36]], "entity_id": ["T6"]}}, "Effect": {"text": [["teratogenicity"]], "start": [[48]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[22]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12663440_12", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improves"]], "start": [[106]], "entity_id": ["T9"]}, "Subject": {"text": [["a small subgroup of patients defined by rhodamine 123 efflux"]], "start": [[126]], "entity_id": ["T11"]}, "Treatment": {"text": [["quinine"]], "start": [[17]], "entity_id": ["T14"], "Drug": {"text": [["quinine"]], "start": [[17]], "entity_id": ["T20"]}, "Disorder": {"text": [["rhodamine 123 efflux"]], "start": [[166]], "entity_id": ["T15"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improve"]], "start": [[34]], "entity_id": ["T18"]}, "Treatment": {"text": [["quinine"]], "start": [[17]], "entity_id": ["T12"], "Drug": {"text": [["quinine"]], "start": [[17]], "entity_id": ["T13"]}, "Disorder": {"text": [["de novo AML"]], "start": [[78]], "entity_id": ["T19"]}}, "Negated": {"text": [["not"]], "start": [[30]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "18580694_2", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[54]], "entity_id": ["T5"]}, "Effect": {"text": [["tardive seizures"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["piperacillin and cefotiam"]], "start": [[65]], "entity_id": ["T6"], "Drug": {"text": [["piperacillin"], ["cefotiam"]], "start": [[65], [82]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[78]], "entity_id": ["T9"]}, "Drug": {"text": [["piperacillin"], ["cefotiam"]], "start": [[65], [82]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "18515982_3", "context": "Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[68]], "entity_id": ["T4"]}, "Effect": {"text": [["sclerosing glomerulonephritis"]], "start": [[13]], "entity_id": ["T3"]}, "Subject": {"text": [["patient"]], "start": [[60]], "entity_id": ["T5"]}, "Treatment": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T7"]}}}]}]}
{"id": "6873616_1", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[63]], "entity_id": ["T7"]}, "Subject": {"text": [["A 55-yr-old man"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["55-yr-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[12]], "entity_id": ["T10"]}}, "Treatment": {"text": [["a course of thiabendazole"]], "start": [[69]], "entity_id": ["T6"], "Drug": {"text": [["thiabendazole"]], "start": [[81]], "entity_id": ["T12"]}}, "Effect": {"text": [["prolonged jaundice and sicca complex"]], "start": [[26]], "entity_id": ["T8"]}}]}]}
{"id": "267281_1", "context": "A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[79]], "entity_id": ["T12"]}, "Treatment": {"text": [["busulphan for 4-5 years"]], "start": [[54]], "entity_id": ["T11"], "Disorder": {"text": [["chronic myeloid leukaemia"]], "start": [[15]], "entity_id": ["T10"]}, "Drug": {"text": [["busulphan"]], "start": [[54]], "entity_id": ["T14"]}, "Duration": {"text": [["4-5 years"]], "start": [[68]], "entity_id": ["T15"]}}, "Effect": {"text": [["busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice"]], "start": [[98]], "entity_id": ["T13"]}, "Subject": {"text": [["A patient with chronic myeloid leukaemia"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "18487000_1", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["symptomatic hyponatremia"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["sibutramine"]], "start": [[39]], "entity_id": ["T5"], "Dosage": {"text": [["sibutramine"]], "start": [[39]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "17655376_2", "context": "Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[141]], "entity_id": ["T10"]}, "Treatment": {"text": [["Oral dapsone"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["dapsone"]], "start": [[5]], "entity_id": ["T13"]}, "Route": {"text": [["Oral"]], "start": [[0]], "entity_id": ["T14"]}, "Disorder": {"text": [["dermatitis herpetiformis"], ["Hansen's disease"]], "start": [[240], [269]], "entity_id": ["T15", "T16"]}}, "Effect": {"text": [["dose-dependent haematological reactions"]], "start": [[147]], "entity_id": ["T11"]}}]}]}
{"id": "1580986_1", "context": "Enalapril-induced anemia in two kidney transplant recipients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Enalapril"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Enalapril"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["kidney transplant"]], "start": [[32]], "entity_id": ["T7"]}}, "Subject": {"text": [["two kidney transplant recipients"]], "start": [[28]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[28]], "entity_id": ["T9"]}}, "Effect": {"text": [["anemia"]], "start": [[18]], "entity_id": ["T12"]}}]}]}
{"id": "12410494_1", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implicated"]], "start": [[35]], "entity_id": ["T9"]}, "Treatment": {"text": [["Simvastatin-nelfinavir interaction"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Simvastatin"], ["nelfinavir"]], "start": [[0], [12]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[23]], "entity_id": ["T12"]}, "Drug": {"text": [["nelfinavir"], ["Simvastatin"]], "start": [[12], [0]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["rhabdomyolysis and death"]], "start": [[49]], "entity_id": ["T8"]}}]}]}
{"id": "18344734_1", "context": "Photo-onycholysis caused by olanzapine and aripiprazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[18]], "entity_id": ["T5"]}, "Effect": {"text": [["Photo-onycholysis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine and aripiprazole"]], "start": [[28]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"], ["aripiprazole"]], "start": [[28], [43]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["olanzapine"], ["aripiprazole"]], "start": [[28], [43]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "17083890_4", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[82]], "entity_id": ["T11"]}, "Treatment": {"text": [["5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone)"]], "start": [[95]], "entity_id": ["T10"], "Disorder": {"text": [["stage III multiple myeloma"]], "start": [[46]], "entity_id": ["T14"]}, "Dosage": {"text": [["5-monthly cycles"]], "start": [[95]], "entity_id": ["T15"]}, "Drug": {"text": [["vincristine"], ["adriamycin"], ["dexamathasone"]], "start": [[120], [133], [148]], "entity_id": ["T16", "T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[144]], "entity_id": ["T19"]}, "Drug": {"text": [["dexamathasone"], ["adriamycin"], ["vincristine"]], "start": [[148], [133], [120]], "entity_id": ["T18", "T17", "T16"]}}]}, "Subject": {"text": [["a 52-year-old male diagnosed with stage III multiple myeloma"]], "start": [[12]], "entity_id": ["T8"], "Age": {"text": [["52-year-old"]], "start": [[14]], "entity_id": ["T12"]}, "Gender": {"text": [["male"]], "start": [[26]], "entity_id": ["T13"]}}}]}]}
{"id": "2028358_1", "context": "Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T6"]}, "Subject": {"text": [["Four patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["pulmonary oedema"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["tocolysis with hexoprenaline"]], "start": [[56]], "entity_id": ["T1"], "Drug": {"text": [["hexoprenaline"]], "start": [[71]], "entity_id": ["T8"]}}}]}]}
{"id": "8404753_2", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[45]], "entity_id": ["T14"]}, "Effect": {"text": [["movement disorders"]], "start": [[13]], "entity_id": ["T11"]}, "Treatment": {"text": [["carbamazepine (CBZ)"]], "start": [[71]], "entity_id": ["T12"], "Drug": {"text": [["carbamazepine"]], "start": [[71]], "entity_id": ["T17"]}, "Disorder": {"text": [["Tourette's syndrome"]], "start": [[216]], "entity_id": ["T1"]}}, "Subject": {"text": [["adults and children", "in patients with underlying Tourette's syndrome or other movement disorders"], ["movement disorders"]], "start": [[102, 188], [245]], "entity_id": ["T13", "T19"], "Age": {"text": [["adults"], ["children"]], "start": [[102], [113]], "entity_id": ["T15", "T16"]}}}]}]}
{"id": "7495990_1", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[33]], "entity_id": ["T6"]}, "Treatment": {"text": [["Used injudiciously, naloxone"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["naloxone"]], "start": [[20]], "entity_id": ["T8"]}}, "Effect": {"text": [["withdrawal syndrome, return of severe pain, and other adverse effects"]], "start": [[41]], "entity_id": ["T7"]}}]}]}
{"id": "21515865_4", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[37]], "entity_id": ["T4"]}, "Subject": {"text": [["he", "bladder cancer"]], "start": [[30, 124]], "entity_id": ["T7"], "Gender": {"text": [["he"]], "start": [[30]], "entity_id": ["T8"]}}, "Treatment": {"text": [["the third of six serial weekly BCG bladder instillations"]], "start": [[46]], "entity_id": ["T5"], "Route": {"text": [["bladder instillations"]], "start": [[81]], "entity_id": ["T9"]}, "Disorder": {"text": [["bladder cancer"]], "start": [[124]], "entity_id": ["T10"]}, "Drug": {"text": [["BCG"]], "start": [[77]], "entity_id": ["T11"]}, "Freq": {"text": [["weekly"]], "start": [[70]], "entity_id": ["T12"]}}}]}]}
{"id": "8700794_3", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[28]], "entity_id": ["T7"]}, "Effect": {"text": [["vague symptoms", "hyponatremia"]], "start": [[5, 57]], "entity_id": ["T5"]}, "Treatment": {"text": [["desmopressin"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["desmopressin"]], "start": [[35]], "entity_id": ["T9"]}}, "Speculated": {"text": [["must be considered"]], "start": [[70]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10870485_1", "context": "Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[94]], "entity_id": ["T6"]}, "Effect": {"text": [["multiple abscesses occurred in the muscles of both thighs"]], "start": [[36]], "entity_id": ["T3"]}, "Subject": {"text": [["the patient"]], "start": [[100]], "entity_id": ["T4"]}, "Treatment": {"text": [["Three months following splenectomy", "third course of the CHOP regimen"]], "start": [[0, 130]], "entity_id": ["T5"], "Duration": {"text": [["Three months"]], "start": [[0]], "entity_id": ["T7"]}, "Drug": {"text": [["splenectomy"], ["CHOP"]], "start": [[23], [150]], "entity_id": ["T8", "T10"]}, "Dosage": {"text": [["third course"]], "start": [[130]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[116]], "entity_id": ["T11"]}, "Drug": {"text": [["CHOP"], ["splenectomy"]], "start": [[150], [23]], "entity_id": ["T10", "T8"]}}]}}]}]}
{"id": "14514135_1", "context": "Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[87]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[103]], "entity_id": ["T4"], "Disorder": {"text": [["lupus"]], "start": [[70]], "entity_id": ["T7"]}, "Drug": {"text": [["cyclophosphamide"]], "start": [[103]], "entity_id": ["T8"]}}, "Effect": {"text": [["Neutrophilic eccrine hidradenitis"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a lupus patient"]], "start": [[68]], "entity_id": ["T6"]}}]}]}
{"id": "10656221_1", "context": "Gliclazide-induced acute hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gliclazide"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gliclazide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute hepatitis"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "1414247_2", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T3"]}, "Treatment": {"text": [["Valproic acid"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Valproic acid"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["coma"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["adult patient without a history of metabolic disease"]], "start": [[46]], "entity_id": ["T6"], "Age": {"text": [["adult"]], "start": [[46]], "entity_id": ["T7"]}}}]}]}
{"id": "19390192_2", "context": "The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[146]], "entity_id": ["T3"]}, "Effect": {"text": [["leukopenia"]], "start": [[159]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term use of adequately-dosed AZA and stable non-toxic metabolite levels"]], "start": [[18]], "entity_id": ["T4"], "Drug": {"text": [["AZA"]], "start": [[52]], "entity_id": ["T8"]}}, "Negated": {"text": [["not"]], "start": [[101]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17381671_9", "context": "CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[122]], "entity_id": ["T31"]}, "Subject": {"text": [["65-year-old patient"]], "start": [[16]], "entity_id": ["T29"], "Age": {"text": [["65-year-old"]], "start": [[16]], "entity_id": ["T30"]}}, "Effect": {"text": [["confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome"]], "start": [[132]], "entity_id": ["T6"]}, "Treatment": {"text": [["chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram", "following initiation of fentanyl"]], "start": [[36, 247]], "entity_id": ["T4"], "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[271], [111]], "entity_id": ["T33", "T8"]}, "Duration": {"text": [["chronically"]], "start": [[36]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["following"]], "start": [[247]], "entity_id": ["T7"]}, "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[271], [111]], "entity_id": ["T33", "T8"]}}]}}]}]}
{"id": "10203437_1", "context": "Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Lupus-like syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["5-aminosalicylic acid"]], "start": [[30]], "entity_id": ["T8"], "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[30]], "entity_id": ["T11"]}, "Disorder": {"text": [["inflammatory bowel disease"]], "start": [[69]], "entity_id": ["T12"]}}, "Subject": {"text": [["patients with inflammatory bowel disease"]], "start": [[55]], "entity_id": ["T9"]}}]}]}
{"id": "566977_1", "context": "Fatal acute tubular necrosis occurred in 1 patient in whom intravesical formalin was used to control massive persistent hemorrhage from radiation cystitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[29]], "entity_id": ["T5"]}, "Effect": {"text": [["acute tubular necrosis"]], "start": [[6]], "entity_id": ["T3"]}, "Subject": {"text": [["1 patient"]], "start": [[41]], "entity_id": ["T4"], "Population": {"text": [["1"]], "start": [[41]], "entity_id": ["T8"]}}, "Treatment": {"text": [["intravesical formalin"]], "start": [[59]], "entity_id": ["T6"], "Disorder": {"text": [["massive persistent hemorrhage from radiation cystitis"]], "start": [[101]], "entity_id": ["T7"]}, "Route": {"text": [["intravesical"]], "start": [[59]], "entity_id": ["T9"]}, "Drug": {"text": [["formalin"]], "start": [[72]], "entity_id": ["T10"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "12196666_1", "context": "The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["susceptibility"]], "start": [[115]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproic acid-induced"]], "start": [[133]], "entity_id": ["T4"], "Drug": {"text": [["valproic acid"]], "start": [[133]], "entity_id": ["T8"]}}, "Subject": {"text": [["three families", "all the siblings"]], "start": [[21, 69]], "entity_id": ["T5"], "Population": {"text": [["three"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["FVS"]], "start": [[62]], "entity_id": ["T6"]}}]}]}
{"id": "8404753_1", "context": "Carbamazepine-induced tics.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T5"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["tics"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "1655228_3", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[69]], "entity_id": ["T6"]}, "Subject": {"text": [["Three patients are reported without a history of angina pectoris"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["myocardial ischemia"]], "start": [[119]], "entity_id": ["T4"]}, "Treatment": {"text": [["during and immediately after BCNU infusion"]], "start": [[139]], "entity_id": ["T5"], "Drug": {"text": [["BCNU"]], "start": [[168]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["immediately"]], "start": [[150]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[173]], "entity_id": ["T10"]}}}]}]}
{"id": "2669373_1", "context": "A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[65]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["probable cisplatin and bleomycin"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["bleomycin"], ["cisplatin"]], "start": [[55], [41]], "entity_id": ["T9", "T6"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[51]], "entity_id": ["T10"]}, "Drug": {"text": [["cisplatin"], ["bleomycin"]], "start": [[41], [55]], "entity_id": ["T6", "T9"]}}]}, "Effect": {"text": [["TMA"]], "start": [[73]], "entity_id": ["T8"]}}]}]}
{"id": "18562412_2", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[73]], "entity_id": ["T8"]}, "Effect": {"text": [["Restless legs syndrome"], ["periodic limb movements during sleep"]], "start": [[0], [27]], "entity_id": ["T5", "T6"]}, "Treatment": {"text": [["olanzapine"]], "start": [[89]], "entity_id": ["T9"], "Drug": {"text": [["olanzapine"]], "start": [[89]], "entity_id": ["T11"]}}}]}]}
{"id": "11850606_3", "context": "Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication of"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha treatment"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["interferon alpha"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Polymyositis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "19363904_1", "context": "Anaphylactic reaction to bacitracin ointment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["bacitracin ointment"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["bacitracin"]], "start": [[25]], "entity_id": ["T6"]}}, "Effect": {"text": [["Anaphylactic"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "536461_1", "context": "Five cases of clindamycin-associated pseudomembranous colitis in leukaemic patients are reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["clindamycin"]], "start": [[14]], "entity_id": ["T3"], "Drug": {"text": [["clindamycin"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["leukaemic patients"]], "start": [[65]], "entity_id": ["T6"], "Disorder": {"text": [["leukaemic"]], "start": [[65]], "entity_id": ["T9"]}}}]}]}
{"id": "10573314_14", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["initiated"]], "start": [[124]], "entity_id": ["T7"]}, "Treatment": {"text": [["tolterodine therapy"]], "start": [[101]], "entity_id": ["T8"], "Drug": {"text": [["tolterodine"], ["warfarin"]], "start": [[101], [161]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[84]], "entity_id": ["T14"]}, "Drug": {"text": [["tolterodine"], ["warfarin"]], "start": [[101], [161]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["possible drug interaction"]], "start": [[70]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient"]], "start": [[137]], "entity_id": ["T9"]}, "Speculated": {"text": [["possible"]], "start": [[70]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "633424_1", "context": "Acute leukopenia associated with silver sulfadiazine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute leukopenia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["silver sulfadiazine"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["silver sulfadiazine"]], "start": [[33]], "entity_id": ["T6"]}}}]}]}
{"id": "8301877_4", "context": "We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T6"]}, "Treatment": {"text": [["L-dopa"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["L-dopa"]], "start": [[31]], "entity_id": ["T10"]}, "Disorder": {"text": [["parkinsonism"]], "start": [[82]], "entity_id": ["T11"]}}, "Effect": {"text": [["myoclonus and seizures"]], "start": [[46]], "entity_id": ["T7"]}, "Subject": {"text": [["case of parkinsonism"]], "start": [[74]], "entity_id": ["T9"]}}]}]}
{"id": "12590235_5", "context": "We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["elevation"]], "start": [[34]], "entity_id": ["T7"]}, "Effect": {"text": [["significant elevation of serum transaminases"]], "start": [[22]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[70]], "entity_id": ["T4"]}, "Treatment": {"text": [["6-TG"]], "start": [[93]], "entity_id": ["T6"], "Disorder": {"text": [["a flare of Crohn's disease"]], "start": [[102]], "entity_id": ["T5"]}, "Drug": {"text": [["6-TG"]], "start": [[93]], "entity_id": ["T8"]}}}]}]}
{"id": "8104147_2", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["documented"]], "start": [[26]], "entity_id": ["T7"]}, "Subject": {"text": [["an 81-year-old woman"]], "start": [[40]], "entity_id": ["T3"], "Age": {"text": [["81-year-old"]], "start": [[43]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[55]], "entity_id": ["T9"]}}, "Treatment": {"text": [["adjunctive ibopamine 100 mg t.i.d."]], "start": [[74]], "entity_id": ["T4"], "Disorder": {"text": [["chronic congestive heart failure"]], "start": [[113]], "entity_id": ["T5"]}, "Drug": {"text": [["ibopamine"]], "start": [[85]], "entity_id": ["T10"]}, "Dosage": {"text": [["100 mg"]], "start": [[95]], "entity_id": ["T11"]}}, "Effect": {"text": [["Reversible leukopenia"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15863610_1", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[59]], "entity_id": ["T7"]}, "Treatment": {"text": [["raloxifene"]], "start": [[66]], "entity_id": ["T4"], "Drug": {"text": [["raloxifene"]], "start": [[66]], "entity_id": ["T8"]}}, "Effect": {"text": [["Malignant mixed mullerian tumor of the uterus"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[49]], "entity_id": ["T6"]}}]}]}
{"id": "7889679_1", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed to"]], "start": [[116]], "entity_id": ["T7"]}, "Effect": {"text": [["generalized cutaneous sclerosis associated with muscle and oesophageal involvement"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["herbicides containing bromocil, diuron and aminotriazole"]], "start": [[127]], "entity_id": ["T6"], "Drug": {"text": [["bromocil"], ["diuron"], ["aminotriazole"]], "start": [[149], [159], [170]], "entity_id": ["T8", "T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[166]], "entity_id": ["T11"]}, "Drug": {"text": [["diuron"], ["bromocil"], ["aminotriazole"]], "start": [[159], [149], [170]], "entity_id": ["T9", "T8", "T10"]}}]}}]}]}
{"id": "8313300_9", "context": "The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[17]], "entity_id": ["T7"]}, "Treatment": {"text": [["within 72 hours of the withdrawal of lithium"]], "start": [[39]], "entity_id": ["T4"], "Disorder": {"text": [["exophthalmos"]], "start": [[4]], "entity_id": ["T5"]}, "Drug": {"text": [["lithium"]], "start": [[76]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["within 72 hours"]], "start": [[39]], "entity_id": ["T8"]}}}]}]}
{"id": "1711090_1", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[181]], "entity_id": ["T7"]}, "Treatment": {"text": [["Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia"]], "start": [[0]], "entity_id": ["T9"], "Disorder": {"text": [["hepatocellular carcinoma"]], "start": [[194]], "entity_id": ["T8"]}, "Route": {"text": [["arterial injection"]], "start": [[23]], "entity_id": ["T11"]}, "Drug": {"text": [["SMANCS"], ["ADR"]], "start": [[80], [91]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[87]], "entity_id": ["T14"]}, "Drug": {"text": [["ADR"], ["SMANCS"]], "start": [[91], [80]], "entity_id": ["T13", "T12"]}}]}}]}]}
{"id": "10656221_4", "context": "A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T9"]}, "Subject": {"text": [["A 60-year-old woman with diabetes mellitus (type 2)"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["60-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T11"]}}, "Treatment": {"text": [["6 weeks after the initiation of gliclazide therapy"]], "start": [[102]], "entity_id": ["T7"], "Time_elapsed": {"text": [["6 weeks"]], "start": [[102]], "entity_id": ["T13"]}, "Drug": {"text": [["gliclazide"]], "start": [[134]], "entity_id": ["T14"]}, "Disorder": {"text": [["diabetes mellitus (type 2)"]], "start": [[25]], "entity_id": ["T15"]}}, "Effect": {"text": [["an acute icteric hepatitis-like illness"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "7594371_1", "context": "Acute sensorineural hearing loss following intravenous ketoralac administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[33]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute sensorineural hearing loss"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous ketoralac"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["ketoralac"]], "start": [[55]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[43]], "entity_id": ["T7"]}}}]}]}
{"id": "11642488_1", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Cicatricial entropion"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["chronic dipivefrin application"]], "start": [[38]], "entity_id": ["T5"], "Drug": {"text": [["dipivefrin"]], "start": [[46]], "entity_id": ["T6"]}}}]}]}
{"id": "7174620_1", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffering from"]], "start": [[24]], "entity_id": ["T6"]}, "Subject": {"text": [["Nine delirious patients"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["delirious"]], "start": [[5]], "entity_id": ["T7"]}, "Population": {"text": [["Nine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["lithium intoxication"]], "start": [[39]], "entity_id": ["T4"]}, "Treatment": {"text": [["lithium"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[39]], "entity_id": ["T9"]}}}]}]}
{"id": "11712064_1", "context": "Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["8-methoxypsoralen (8-MOP)"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["8-methoxypsoralen"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["Systemic allergic contact dermatitis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "14684937_1", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased"]], "start": [[173]], "entity_id": ["T4"]}, "Effect": {"text": [["serum level of calcium and urinary excretion of calcium"]], "start": [[117]], "entity_id": ["T3"]}, "Treatment": {"text": [["After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["skin lesions"]], "start": [[94]], "entity_id": ["T6"]}, "Drug": {"text": [["vitamin D3"]], "start": [[28]], "entity_id": ["T7"]}, "Route": {"text": [["topical"]], "start": [[20]], "entity_id": ["T9"]}, "Dosage": {"text": [["10 g/"]], "start": [[77]], "entity_id": ["T8"]}, "Freq": {"text": [["/day"]], "start": [[81]], "entity_id": ["T10"]}}}]}]}
{"id": "19789166_1", "context": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[235]], "entity_id": ["T4"]}, "Effect": {"text": [["toxic liver damage"]], "start": [[216]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[245]], "entity_id": ["T5"], "Drug": {"text": [["nitrofurantoin"]], "start": [[245]], "entity_id": ["T6"]}}, "Speculated": {"text": [["probably"]], "start": [[195]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8597009_3", "context": "Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[90]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin", "antituberculosis"]], "start": [[135, 192]], "entity_id": ["T3"], "Drug": {"text": [["phenytoin"], ["antituberculosis"]], "start": [[135], [192]], "entity_id": ["T4", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["together with"]], "start": [[178]], "entity_id": ["T9"]}, "Drug": {"text": [["antituberculosis"], ["phenytoin"]], "start": [[192], [135]], "entity_id": ["T8", "T4"]}}]}, "Effect": {"text": [["clinical and biochemical features of phenytoin toxicity"]], "start": [[98]], "entity_id": ["T5"]}, "Speculated": {"text": [["likely"]], "start": [[80]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "736591_3", "context": "Progressive interstitial lung disease from prolonged methotrexate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[38]], "entity_id": ["T5"]}, "Effect": {"text": [["Progressive interstitial lung disease"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["prolonged methotrexate therapy"]], "start": [[43]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[53]], "entity_id": ["T6"]}}}]}]}
{"id": "6958210_2", "context": "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["penicillamine therapy"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T7"]}, "Disorder": {"text": [["rheumatoid arthritis."]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "19183077_3", "context": "We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["tenofovir (TDF)"]], "start": [[23]], "entity_id": ["T4"], "Disorder": {"text": [["HIV-infected"]], "start": [[80]], "entity_id": ["T8"]}, "Drug": {"text": [["tenofovir"]], "start": [[23]], "entity_id": ["T11"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[50]], "entity_id": ["T6"]}, "Subject": {"text": [["perinatally HIV-infected adolescents"]], "start": [[68]], "entity_id": ["T7"], "Age": {"text": [["adolescents"]], "start": [[93]], "entity_id": ["T9"]}}}]}]}
{"id": "12221670_1", "context": "The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T6"]}, "Subject": {"text": [["70-year-old man"]], "start": [[26]], "entity_id": ["T3"], "Age": {"text": [["70-year-old"]], "start": [[26]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[38]], "entity_id": ["T8"]}}, "Effect": {"text": [["aplastic anemia"]], "start": [[63]], "entity_id": ["T4"]}, "Treatment": {"text": [["7 weeks after treatment with 500 mg of ticlopidine daily"]], "start": [[79]], "entity_id": ["T5"], "Dosage": {"text": [["500 mg"]], "start": [[108]], "entity_id": ["T9"]}, "Drug": {"text": [["ticlopidine"]], "start": [[118]], "entity_id": ["T10"]}, "Freq": {"text": [["daily"]], "start": [[130]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["7 weeks after"]], "start": [[79]], "entity_id": ["T12"]}}, "Severity": {"text": [["severe"]], "start": [[56]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "16685112_2", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[71]], "entity_id": ["T4"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[59]], "entity_id": ["T3"]}, "Effect": {"text": [["radiation recall in rectus abdominus muscles"]], "start": [[79]], "entity_id": ["T5"]}}]}]}
{"id": "16046172_2", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[95]], "entity_id": ["T7"]}, "Subject": {"text": [["an 80-year-old woman"]], "start": [[16]], "entity_id": ["T4"], "Age": {"text": [["80-year-old"]], "start": [[19]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[31]], "entity_id": ["T9"]}}, "Effect": {"text": [["Staphylococcus aureus knee arthritis"]], "start": [[58]], "entity_id": ["T5"]}, "Treatment": {"text": [["sodium hyaluronate and corticosteroids"]], "start": [[138]], "entity_id": ["T6"], "Drug": {"text": [["sodium hyaluronate"], ["corticosteroids"]], "start": [[138], [161]], "entity_id": ["T10", "T11"]}, "Route": {"text": [["injections"]], "start": [[124]], "entity_id": ["T13"]}, "Freq": {"text": [["several"]], "start": [[101]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[157]], "entity_id": ["T12"]}, "Drug": {"text": [["sodium hyaluronate"], ["corticosteroids"]], "start": [[138], [161]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "6731466_5", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Association"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["zomepirac"]], "start": [[15]], "entity_id": ["T6"], "Drug": {"text": [["zomepirac"]], "start": [[15]], "entity_id": ["T4"]}}, "Effect": {"text": [["renal cortical necrosis"]], "start": [[45]], "entity_id": ["T7"]}}]}]}
{"id": "9579301_1", "context": "Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[26]], "entity_id": ["T7"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[82]], "entity_id": ["T3"], "Drug": {"text": [["venlafaxine"]], "start": [[82]], "entity_id": ["T9"]}}, "Effect": {"text": [["Increased ocular pressure"]], "start": [[0]], "entity_id": ["T6"]}, "Subject": {"text": [["two patients with narrow angle glaucoma"]], "start": [[29]], "entity_id": ["T5"], "Disorder": {"text": [["narrow angle glaucoma"]], "start": [[47]], "entity_id": ["T4"]}, "Population": {"text": [["two"]], "start": [[29]], "entity_id": ["T8"]}}}]}]}
{"id": "2250853_1", "context": "Glaucoma secondary to epithelial downgrowth and 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[9]], "entity_id": ["T4"]}, "Effect": {"text": [["Glaucoma", "epithelial downgrowth"]], "start": [[0, 22]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil"]], "start": [[48]], "entity_id": ["T6"]}}}]}]}
{"id": "17319250_1", "context": "Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of methadone, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["at"]], "start": [[77]], "entity_id": ["T4"]}, "Effect": {"text": [["fluctuation of the QT interval"]], "start": [[46]], "entity_id": ["T3"]}, "Subject": {"text": [["this patient"]], "start": [[26]], "entity_id": ["T5"]}, "Treatment": {"text": [["a stable dose of methadone"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["methadone"]], "start": [[97]], "entity_id": ["T7"]}, "Dosage": {"text": [["a stable dose"]], "start": [[80]], "entity_id": ["T8"]}}}]}]}
{"id": "22047557_1", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[19]], "entity_id": ["T8"]}, "Treatment": {"text": [["CFTR potentiator"]], "start": [[2]], "entity_id": ["T5"], "Disorder": {"text": [["cystic fibrosis"]], "start": [[36]], "entity_id": ["T7"]}, "Drug": {"text": [["CFTR potentiato"]], "start": [[2]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with cystic fibrosis and the G551D mutation"]], "start": [[22]], "entity_id": ["T6"], "Disorder": {"text": [["G551D mutation"]], "start": [[60]], "entity_id": ["T1"]}}}]}]}
{"id": "9497597_1", "context": "Prothipendylhydrochloride-induced priapism: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["Prothipendylhydrochloride"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Prothipendylhydrochloride"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["priapism"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "15331204_1", "context": "Possible induction of diabetes by treatment of hypertension with indapamide (with four case reports).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[9]], "entity_id": ["T8"]}, "Effect": {"text": [["diabetes"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["indapamide"]], "start": [[65]], "entity_id": ["T10"], "Disorder": {"text": [["hypertension"]], "start": [[47]], "entity_id": ["T9"]}, "Drug": {"text": [["indapamide"]], "start": [[65]], "entity_id": ["T11"]}}}]}]}
{"id": "15588385_2", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["control"]], "start": [[132]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[118]], "entity_id": ["T3"], "Disorder": {"text": [["hyperthyroidism"]], "start": [[140]], "entity_id": ["T5"]}, "Drug": {"text": [["amiodarone"]], "start": [[118]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with PTU-induced fulminant hepatitis"]], "start": [[159]], "entity_id": ["T6"], "Disorder": {"text": [["PTU-induced fulminant hepatitis"]], "start": [[174]], "entity_id": ["T13"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[178]], "entity_id": ["T10"]}, "Treatment": {"text": [["PTU"]], "start": [[174]], "entity_id": ["T12"], "Drug": {"text": [["PTU"]], "start": [[174]], "entity_id": ["T7"]}}, "Effect": {"text": [["fulminant hepatitis"]], "start": [[186]], "entity_id": ["T11"]}}]}]}
{"id": "889156_7", "context": "While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction to oleic acid, a dispersing agent in the aerosol freon vehicle, is a strong possibility.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse reaction"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["oleic acid"]], "start": [[110]], "entity_id": ["T6"], "Drug": {"text": [["oleic acid"]], "start": [[110]], "entity_id": ["T10"]}}, "Effect": {"text": [["adverse reaction"]], "start": [[90]], "entity_id": ["T7"]}, "Speculated": {"text": [["strong possibility"]], "start": [[176]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "8903300_1", "context": "She had just finished a 3-week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[87]], "entity_id": ["T5"]}, "Treatment": {"text": [["a 3-week course of intravenous tobramycin"]], "start": [[22]], "entity_id": ["T3"], "Drug": {"text": [["tobramycin"]], "start": [[53]], "entity_id": ["T7"]}, "Duration": {"text": [["3-week course"]], "start": [[24]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous"]], "start": [[41]], "entity_id": ["T9"]}, "Disorder": {"text": [["bronchiectasis"]], "start": [[68]], "entity_id": ["T10"]}}, "Effect": {"text": [["elevated serum tobramycin trough level 1 week before the onset of tetany"]], "start": [[94]], "entity_id": ["T6"]}}]}]}
{"id": "19995690_2", "context": "Acetaminophen is a widely used analgesic that can cause acute liver failure when consumed above a maximum daily dose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[50]], "entity_id": ["T7"]}, "Treatment": {"text": [["Acetaminophen"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Acetaminophen"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute liver failure"]], "start": [[56]], "entity_id": ["T8"]}}]}]}
{"id": "9007910_6", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reverse"]], "start": [[161]], "entity_id": ["T14"]}, "Subject": {"text": [["DPD-deficient patients with severe acute 5-FU reactions"]], "start": [[28]], "entity_id": ["T12"]}, "Treatment": {"text": [["thymidine"]], "start": [[135]], "entity_id": ["T13"], "Drug": {"text": [["thymidine"]], "start": [[135]], "entity_id": ["T17"]}, "Disorder": {"text": [["severe acute 5-FU reactions"]], "start": [[56]], "entity_id": ["T18"]}}, "Effect": {"text": [["5-FU-induced neurologic symptoms such as encephalopathy and coma"]], "start": [[176]], "entity_id": ["T15"]}, "Severity": {"text": [["severe"]], "start": [[169]], "entity_id": ["T19"], "value": "High"}, "Speculated": {"text": [["may"]], "start": [[157]], "entity_id": ["T20"], "value": true}}]}]}
{"id": "6788011_4", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[4]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["therapy with gold"]], "start": [[56]], "entity_id": ["T7"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[78]], "entity_id": ["T6"]}, "Drug": {"text": [["gold"]], "start": [[69]], "entity_id": ["T8"]}}}]}]}
{"id": "1115340_6", "context": "There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[33]], "entity_id": ["T8"]}, "Effect": {"text": [["convulsions"]], "start": [[21]], "entity_id": ["T7"]}, "Subject": {"text": [["susceptible patients"]], "start": [[46]], "entity_id": ["T9"]}, "Treatment": {"text": [["the use of the new anaesthetic agents which are capable of inducing CNS excitability"]], "start": [[77]], "entity_id": ["T10"], "Drug": {"text": [["anaesthetic"]], "start": [[96]], "entity_id": ["T1"]}}}]}]}
{"id": "7379406_7", "context": "After ruling out a hydrotelluric source of fluorine, the patient's fluorosis was linked to chronic use of niflumic acid, following the publication in 1978 of the 2 previously reported cases affected by this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linked to"]], "start": [[81]], "entity_id": ["T8"]}, "Effect": {"text": [["fluorosis"]], "start": [[67]], "entity_id": ["T6"]}, "Subject": {"text": [["the patient's", "2 previously reported cases"]], "start": [[53, 162]], "entity_id": ["T7"], "Population": {"text": [["2"]], "start": [[162]], "entity_id": ["T12"]}}, "Treatment": {"text": [["chronic use of niflumic acid"]], "start": [[91]], "entity_id": ["T9"], "Dosage": {"text": [["chronic use"]], "start": [[91]], "entity_id": ["T10"]}, "Drug": {"text": [["niflumic acid"]], "start": [[106]], "entity_id": ["T11"]}}}]}]}
{"id": "18504683_3", "context": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[109]], "entity_id": ["T8"]}, "Subject": {"text": [["3 cases of children with acute lymphoblastic leukemia"]], "start": [[10]], "entity_id": ["T5"], "Population": {"text": [["3"]], "start": [[10]], "entity_id": ["T9"]}, "Age": {"text": [["children"]], "start": [[21]], "entity_id": ["T10"]}}, "Effect": {"text": [["seizures and altered sensorium"]], "start": [[78]], "entity_id": ["T6"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[115]], "entity_id": ["T7"], "Drug": {"text": [["L-asparaginase"]], "start": [[115]], "entity_id": ["T12"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[35]], "entity_id": ["T13"]}}}]}]}
{"id": "15840734_2", "context": "OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[68]], "entity_id": ["T7"]}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[31]], "entity_id": ["T8"]}, "Treatment": {"text": [["fluphenazine"]], "start": [[84]], "entity_id": ["T9"], "Drug": {"text": [["fluphenazine"]], "start": [[84]], "entity_id": ["T12"]}, "Disorder": {"text": [["schizophrenic"]], "start": [[102]], "entity_id": ["T13"]}}, "Subject": {"text": [["schizophrenic patient"]], "start": [[102]], "entity_id": ["T10"]}}]}]}
{"id": "8551001_3", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[66]], "entity_id": ["T4"]}, "Treatment": {"text": [["56 days therapy", "The azathioprine dose was low (1 mg/kg)"]], "start": [[72, 0]], "entity_id": ["T3"], "Time_elapsed": {"text": [["56 days"]], "start": [[72]], "entity_id": ["T6"]}, "Drug": {"text": [["azathioprine"]], "start": [[4]], "entity_id": ["T7"]}, "Dosage": {"text": [["1 mg/kg"]], "start": [[31]], "entity_id": ["T8"]}}, "Effect": {"text": [["pancytopenia"]], "start": [[44]], "entity_id": ["T5"]}}]}]}
{"id": "1743388_2", "context": "This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[79]], "entity_id": ["T5"]}, "Effect": {"text": [["chemical cellulitis and ulceration"]], "start": [[89]], "entity_id": ["T6"]}, "Subject": {"text": [["a renal transplant patient with Pneumocystis pneumonia"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["intravenous pentamidine"]], "start": [[155]], "entity_id": ["T7"], "Drug": {"text": [["pentamidine"]], "start": [[167]], "entity_id": ["T11"]}, "Route": {"text": [["intravenous"]], "start": [[155]], "entity_id": ["T12"]}, "Disorder": {"text": [["Pneumocystis pneumonia"]], "start": [[52]], "entity_id": ["T13"]}}}]}]}
{"id": "9701106_2", "context": "Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[162]], "entity_id": ["T7"]}, "Treatment": {"text": [["theophylline therapy"]], "start": [[48]], "entity_id": ["T4"], "Drug": {"text": [["theophylline"]], "start": [[48]], "entity_id": ["T8"]}, "Dosage": {"text": [["99.9 and 149.9 micromol/L"], ["18 and 27 microg/mL"]], "start": [[228], [255]], "entity_id": ["T9", "T10"]}}, "Subject": {"text": [["patient"]], "start": [[131]], "entity_id": ["T5"]}, "Effect": {"text": [["reaction to the drug became more toxic"]], "start": [[141]], "entity_id": ["T6"]}}]}]}
{"id": "8696525_1", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Metipranolol"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Metipranolol"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["granulomatous anterior uveitis"]], "start": [[24]], "entity_id": ["T5"]}}]}]}
{"id": "18445989_2", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["Clomiphene"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Clomiphene"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["anovulation"]], "start": [[41]], "entity_id": ["T9"]}}}]}]}
{"id": "12460237_5", "context": "Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[181]], "entity_id": ["T11"]}, "Treatment": {"text": [["high-dose cytarabine"]], "start": [[89]], "entity_id": ["T12"], "Dosage": {"text": [["high-dose"]], "start": [[89]], "entity_id": ["T16"]}, "Drug": {"text": [["cytarabine"]], "start": [[99]], "entity_id": ["T17"]}, "Disorder": {"text": [["haematologic malignancies"]], "start": [[287]], "entity_id": ["T1"]}}, "Effect": {"text": [["PPE"]], "start": [[134]], "entity_id": ["T14"]}, "Speculated": {"text": [["potential"]], "start": [[171]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "20118434_1", "context": "Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicated"]], "start": [[90]], "entity_id": ["T4"]}, "Treatment": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neuropsychiatric symptoms"]], "start": [[129]], "entity_id": ["T5"]}}]}]}
{"id": "18676387_1", "context": "Serotonin toxicity caused by an interaction between fentanyl and paroxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Serotonin toxicity"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["an interaction between fentanyl and paroxetine"]], "start": [[29]], "entity_id": ["T8"], "Drug": {"text": [["fentanyl"], ["paroxetine"]], "start": [[52], [65]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[32]], "entity_id": ["T11"]}, "Drug": {"text": [["fentanyl"], ["paroxetine"]], "start": [[52], [65]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "15316423_3", "context": "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causation"]], "start": [[122]], "entity_id": ["T7"]}, "Effect": {"text": [["venous thrombosis"]], "start": [[139]], "entity_id": ["T8"]}, "Treatment": {"text": [["hypersensitivity to infliximab"]], "start": [[84]], "entity_id": ["T9"], "Drug": {"text": [["infliximab"]], "start": [[104]], "entity_id": ["T10"]}}}]}]}
{"id": "8071504_7", "context": "RESULTS: Ethambutol, and to a lesser extent isoniazid, are both implicated in the development of visually related side effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[82]], "entity_id": ["T7"]}, "Treatment": {"text": [["Ethambutol", "isoniazid"]], "start": [[9, 44]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"], ["Ethambutol"]], "start": [[44], [9]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[21]], "entity_id": ["T11"]}, "Drug": {"text": [["Ethambutol"], ["isoniazid"]], "start": [[9], [44]], "entity_id": ["T10", "T9"]}}]}, "Effect": {"text": [["visually related side effects"]], "start": [[97]], "entity_id": ["T8"]}}]}]}
{"id": "24163322_2", "context": "We report a case of an inadvertent increase in the international normalized ratio (INR) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[88]], "entity_id": ["T9"]}, "Treatment": {"text": [["addition of bismuth subsalicylate", "warfarin therapy"]], "start": [[98, 200]], "entity_id": ["T10"], "Disorder": {"text": [["diarrhea"]], "start": [[153]], "entity_id": ["T14"]}, "Drug": {"text": [["bismuth subsalicylate"], ["warfarin"]], "start": [[110], [200]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[98]], "entity_id": ["T15"]}, "Drug": {"text": [["bismuth subsalicylate"], ["warfarin"]], "start": [[110], [200]], "entity_id": ["T16", "T17"]}}]}, "Effect": {"text": [["inadvertent increase in the international normalized ratio (INR)"]], "start": [[23]], "entity_id": ["T13"]}, "Subject": {"text": [["diarrhea in an enterally fed patient"]], "start": [[153]], "entity_id": ["T12"]}}]}]}
{"id": "16580907_9", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causing"]], "start": [[43]], "entity_id": ["T19"]}, "Subject": {"text": [["patients with renal insufficiency"]], "start": [[152]], "entity_id": ["T14"], "Disorder": {"text": [["renal insufficiency"]], "start": [[166]], "entity_id": ["T15"]}}, "Effect": {"text": [["arrhythmias"]], "start": [[51]], "entity_id": ["T16"]}, "Treatment": {"text": [["cetirizine"]], "start": [[9]], "entity_id": ["T17"], "Drug": {"text": [["cetirizine"]], "start": [[9]], "entity_id": ["T22"]}}, "Speculated": {"text": [["potential"]], "start": [[29]], "entity_id": ["T20"], "value": true}, "Negated": {"text": [["less"]], "start": [[24]], "entity_id": ["T21"], "value": true}}]}]}
{"id": "16012330_9", "context": "Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[61]], "entity_id": ["T10"]}, "Subject": {"text": [["Nineteen cases", "children"]], "start": [[0, 107]], "entity_id": ["T7"], "Population": {"text": [["Nineteen"]], "start": [[0]], "entity_id": ["T11"]}, "Age": {"text": [["children"]], "start": [[107]], "entity_id": ["T12"]}}, "Effect": {"text": [["unusual enhanced vincristine neurotoxicity"]], "start": [[18]], "entity_id": ["T8"]}, "Treatment": {"text": [["itraconazole"]], "start": [[72]], "entity_id": ["T9"], "Drug": {"text": [["itraconazole"]], "start": [[72]], "entity_id": ["T13"]}}}]}]}
{"id": "10435399_1", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[24]], "entity_id": ["T7"]}, "Effect": {"text": [["neutropenia and agranulocytosis"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["clozapine"]], "start": [[117]], "entity_id": ["T6"], "Drug": {"text": [["clozapine"]], "start": [[117]], "entity_id": ["T8"]}}}]}]}
{"id": "7468565_4", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[189]], "entity_id": ["T5"]}, "Treatment": {"text": [["barbiturates"]], "start": [[131]], "entity_id": ["T4"], "Drug": {"text": [["barbiturates"]], "start": [[131]], "entity_id": ["T8"]}}, "Effect": {"text": [["submassive hepatic necrosis"]], "start": [[195]], "entity_id": ["T6"]}, "Subject": {"text": [["The patient's"]], "start": [[0]], "entity_id": ["T9"]}, "Speculated": {"text": [["can"]], "start": [[185]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18648015_1", "context": "Cephalosporin-induced leukopenia following rechallenge with cefoxitin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["rechallenge with cefoxitin", "Cephalosporin"]], "start": [[43, 0]], "entity_id": ["T3"], "Drug": {"text": [["cefoxitin"], ["Cephalosporin"]], "start": [[60], [0]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[55]], "entity_id": ["T8"]}, "Drug": {"text": [["cefoxitin"], ["Cephalosporin"]], "start": [[60], [0]], "entity_id": ["T6", "T7"]}}]}, "Effect": {"text": [["leukopenia"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "17827338_2", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[94]], "entity_id": ["T7"]}, "Treatment": {"text": [["Vicriviroc (SCH 417690), a CCR5 receptor antagonist"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Vicriviroc"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["human immunodeficiency virus infection"]], "start": [[107]], "entity_id": ["T11"]}}}]}]}
{"id": "15316423_2", "context": "Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with Crohn's disease"]], "start": [[17]], "entity_id": ["T11"]}, "Treatment": {"text": [["infliximab infusion"]], "start": [[201]], "entity_id": ["T13"], "Drug": {"text": [["infliximab"]], "start": [[201]], "entity_id": ["T16"]}, "Route": {"text": [["infusion"]], "start": [[212]], "entity_id": ["T17"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[32]], "entity_id": ["T18"]}, "Time_elapsed": {"text": [["1 day later"]], "start": [[119]], "entity_id": ["T19"]}}, "Effect": {"text": [["infliximab infusion reaction", "swelling of the forearm and hand ipsilateral"]], "start": [[71, 141]], "entity_id": ["T12"]}, "Severity": {"text": [["severe"], ["severe"]], "start": [[64], [134]], "entity_id": ["T15", "T20"], "value": "High"}}]}]}
{"id": "11026106_2", "context": "Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["sporadic autoimmune hepatitis"]], "start": [[65]], "entity_id": ["T6"]}, "Drug": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["autoimmune hepatitis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "2621382_3", "context": "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[103]], "entity_id": ["T9"]}, "Subject": {"text": [["Two cases of lepromatous leprosy with erythema nodosum leprosum"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T11"]}}, "Treatment": {"text": [["high doses of clofazimine"]], "start": [[76]], "entity_id": ["T8"], "Disorder": {"text": [["lepromatous leprosy with erythema nodosum leprosum"]], "start": [[13]], "entity_id": ["T12"]}, "Drug": {"text": [["clofazimine"]], "start": [[90]], "entity_id": ["T13"]}, "Dosage": {"text": [["high doses"]], "start": [[76]], "entity_id": ["T14"]}}, "Effect": {"text": [["discoloration of nail plate, subungual hyperkeratosis and onycholysis"]], "start": [[110]], "entity_id": ["T10"]}}]}]}
{"id": "14711147_1", "context": "Doxycycline-induced photo-onycholysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Doxycycline"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Doxycycline"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["photo-onycholysis"]], "start": [[20]], "entity_id": ["T6"]}}]}]}
{"id": "15224368_1", "context": "Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["sargramostim (granulocyte-macrophage colony stimulating factor) treatment"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["sargramostim"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["Sweet's syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "16416684_1", "context": "This is a rare case of ARDS associated with lithium intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["ARDS"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[44]], "entity_id": ["T6"]}}}]}]}
{"id": "8520081_1", "context": "Intravenous haloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[100]], "entity_id": ["T5"]}, "Treatment": {"text": [["Intravenous haloperidol"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["multiform ventricular tachycardia"]], "start": [[57]], "entity_id": ["T4"]}}]}]}
{"id": "7865488_3", "context": "We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[51]], "entity_id": ["T6"]}, "Effect": {"text": [["noncardiogenic pulmonary edema"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["EO"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["EO"]], "start": [[88]], "entity_id": ["T8"]}, "Disorder": {"text": [["esophageal varix"]], "start": [[115]], "entity_id": ["T9"]}}}]}]}
{"id": "18364401_2", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["hyperglycemia"]], "start": [[49]], "entity_id": ["T3"]}, "Subject": {"text": [["a geriatric patient"]], "start": [[80]], "entity_id": ["T4"], "Age": {"text": [["geriatric"]], "start": [[82]], "entity_id": ["T7"]}}, "Treatment": {"text": [["olanzapine"]], "start": [[128]], "entity_id": ["T5"], "Time_elapsed": {"text": [["3 days"]], "start": [[100]], "entity_id": ["T8"]}, "Drug": {"text": [["olanzapine"]], "start": [[128]], "entity_id": ["T9"]}}}]}]}
{"id": "18562412_1", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aggravated"]], "start": [[42]], "entity_id": ["T3"]}, "Treatment": {"text": [["Increasing the olanzapine dosage"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["olanzapine"]], "start": [[15]], "entity_id": ["T7"]}}, "Effect": {"text": [["symptoms of RLS"]], "start": [[57]], "entity_id": ["T5"]}, "Severity": {"text": [["severely"]], "start": [[33]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "16404563_3", "context": "Corticosteroids may be useful for therapy of some features of this syndrome, such as thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["be useful"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["Corticosteroids"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Corticosteroids"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["thrombocytopenia"]], "start": [[85]], "entity_id": ["T11"]}}, "Speculated": {"text": [["may"]], "start": [[16]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "15183980_1", "context": "Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["bladder instillation with dimethyl sulfoxide"]], "start": [[28]], "entity_id": ["T3"], "Drug": {"text": [["dimethyl sulfoxide"]], "start": [[54]], "entity_id": ["T6"]}, "Route": {"text": [["bladder instillation"]], "start": [[28]], "entity_id": ["T7"]}}, "Effect": {"text": [["Eosinophilic cystitis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "17665812_3", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[75]], "entity_id": ["T5"]}, "Treatment": {"text": [["clozapine"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["clozapine"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["dangerous side effects such as agranulocytosis"]], "start": [[82]], "entity_id": ["T4"]}}]}]}
{"id": "11881322_1", "context": "Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[79]], "entity_id": ["T7"]}, "Effect": {"text": [["ductopenia"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["itraconazole"]], "start": [[57]], "entity_id": ["T6"], "Disorder": {"text": [["prolonged drug-induced cholangiopathy"]], "start": [[113]], "entity_id": ["T8"]}, "Drug": {"text": [["itraconazole"]], "start": [[57]], "entity_id": ["T9"]}}, "Subject": {"text": [["two"]], "start": [[36]], "entity_id": ["T11"]}, "Speculated": {"text": [["might be"]], "start": [[70]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19531696_2", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[73]], "entity_id": ["T9"]}, "Treatment": {"text": [["interaction between warfarin and marijuana smoking"]], "start": [[21]], "entity_id": ["T8"], "Drug": {"text": [["warfarin"], ["marijuana"]], "start": [[41], [54]], "entity_id": ["T11", "T13"]}, "Route": {"text": [["smoking"]], "start": [[64]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[21]], "entity_id": ["T12"]}, "Drug": {"text": [["warfarin"], ["marijuana"]], "start": [[41], [54]], "entity_id": ["T11", "T13"]}}]}, "Effect": {"text": [["increased international normalized ratio (INR) values and bleeding complications"]], "start": [[86]], "entity_id": ["T10"]}, "Speculated": {"text": [["probable"]], "start": [[12]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "19653965_2", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[30]], "entity_id": ["T7"]}, "Effect": {"text": [["Transient cardiac arrhythmias"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["lopinavir/ritonavir"]], "start": [[41]], "entity_id": ["T5"], "Disorder": {"text": [["HIV infection"]], "start": [[82]], "entity_id": ["T9"]}, "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[41], [51]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[50]], "entity_id": ["T12"]}, "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[41], [51]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["two patients with HIV infection"]], "start": [[64]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[64]], "entity_id": ["T8"]}}}]}]}
{"id": "2051906_1", "context": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[97]], "entity_id": ["T3"]}, "Subject": {"text": [["A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["67-year-old"]], "start": [[2]], "entity_id": ["T1"]}}, "Treatment": {"text": [["3 months after initiation of azathioprine"]], "start": [[163]], "entity_id": ["T5"], "Drug": {"text": [["azathioprine"]], "start": [[192]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["3 months"]], "start": [[163]], "entity_id": ["T8"]}, "Disorder": {"text": [["primary polymyositis"]], "start": [[28]], "entity_id": ["T9"]}}, "Effect": {"text": [["cholestasis"]], "start": [[151]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[144]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "18676387_4", "context": "A 60-yr-old woman, established on paroxetine for depression, underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["established"]], "start": [[19]], "entity_id": ["T7"]}, "Subject": {"text": [["A 60-yr-old woman", "depression"]], "start": [[0, 49]], "entity_id": ["T6"], "Age": {"text": [["60-yr-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[12]], "entity_id": ["T11"]}}, "Treatment": {"text": [["paroxetine", "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction"]], "start": [[34, 61]], "entity_id": ["T8"], "Drug": {"text": [["paroxetine"]], "start": [[34]], "entity_id": ["T12"]}, "Disorder": {"text": [["depression"], ["myxofibrosarcoma"]], "start": [[49], [96]], "entity_id": ["T13", "T14"]}}}]}]}
{"id": "9103523_2", "context": "The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mediate"]], "start": [[102]], "entity_id": ["T6"]}, "Treatment": {"text": [["volatile anesthetic halothane"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["halothane"]], "start": [[24]], "entity_id": ["T8"]}, "Route": {"text": [["volatile"]], "start": [[4]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[110]], "entity_id": ["T7"]}}]}]}
{"id": "7387219_2", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse"]], "start": [[118]], "entity_id": ["T5"]}, "Subject": {"text": [["These cases"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[139]], "entity_id": ["T6"], "Drug": {"text": [["D-penicillamine"]], "start": [[139]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[58]], "entity_id": ["T7"]}}]}]}
{"id": "1261772_3", "context": "These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[65]], "entity_id": ["T7"]}, "Effect": {"text": [["submassive hepatic necrosis"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[92]], "entity_id": ["T6"], "Drug": {"text": [["propylthiouracil"]], "start": [[92]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[61]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7071645_2", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["not related"]], "start": [[124]], "entity_id": ["T11"]}, "Subject": {"text": [["a man with classic rheumatoid arthritis"]], "start": [[18]], "entity_id": ["T9"], "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T13"]}}, "Effect": {"text": [["membranous nephropathy associated with nephrotic syndrome"]], "start": [[66]], "entity_id": ["T10"]}, "Treatment": {"text": [["gold or penicillamine therapy"]], "start": [[139]], "entity_id": ["T12"], "Drug": {"text": [["gold"], ["penicillamine"]], "start": [[139], [147]], "entity_id": ["T15", "T16"]}, "Disorder": {"text": [["classic rheumatoid arthritis"]], "start": [[29]], "entity_id": ["T17"]}}, "Negated": {"text": [["not"]], "start": [[124]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "11675845_9", "context": "Furthermore, the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["due to"]], "start": [[87]], "entity_id": ["T8"]}, "Treatment": {"text": [["the warfarin dose was again increased after discontinuation of ropinirole"]], "start": [[13]], "entity_id": ["T7"], "Disorder": {"text": [["gastrointestinal adverse effects"]], "start": [[101]], "entity_id": ["T6"]}, "Drug": {"text": [["warfarin"]], "start": [[17]], "entity_id": ["T9"]}}}]}]}
{"id": "11700998_2", "context": "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[211]], "entity_id": ["T6"]}, "Subject": {"text": [["an elderly woman"]], "start": [[96]], "entity_id": ["T3"], "Age": {"text": [["elderly"]], "start": [[99]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[107]], "entity_id": ["T8"]}}, "Effect": {"text": [["nonconvulsive generalized status epilepticus"]], "start": [[166]], "entity_id": ["T4"]}, "Treatment": {"text": [["acute withdrawal of lorazepam"]], "start": [[221]], "entity_id": ["T5"], "Drug": {"text": [["lorazepam"]], "start": [[241]], "entity_id": ["T9"]}}}]}]}
{"id": "9352164_5", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[47]], "entity_id": ["T10"]}, "Treatment": {"text": [["excessive dose of AZ"]], "start": [[26]], "entity_id": ["T8"], "Dosage": {"text": [["excessive dose"]], "start": [[26]], "entity_id": ["T12"]}, "Drug": {"text": [["AZ"]], "start": [[44]], "entity_id": ["T13"]}}, "Effect": {"text": [["destroyed the gastric mucosal barrier or thrombocytopenia", "hemorrhagic gastritis"]], "start": [[60, 192]], "entity_id": ["T9"]}, "Speculated": {"text": [["probably"]], "start": [[51]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "2357706_1", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[147]], "entity_id": ["T5"]}, "Effect": {"text": [["tardive dyskinesia"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["sulpiride"]], "start": [[164]], "entity_id": ["T4"], "Drug": {"text": [["sulpiride"]], "start": [[164]], "entity_id": ["T6"]}}}]}]}
{"id": "18176653_11", "context": "This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["antiretroviral medication"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["antiretroviral medication"]], "start": [[93]], "entity_id": ["T8"]}}, "Effect": {"text": [["reactions in the oral cavity"]], "start": [[57]], "entity_id": ["T7"]}, "Speculated": {"text": [["possible"]], "start": [[48]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "21712512_11", "context": "This case highlights rapid onset of adrenal insufficiency in a patient with CF-related liver disease treated briefly with a moderate CYP3A4 inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [[27]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient with CF-related liver disease"]], "start": [[61]], "entity_id": ["T9"]}, "Treatment": {"text": [["briefly with a moderate CYP3A4 inhibitor"]], "start": [[109]], "entity_id": ["T10"], "Drug": {"text": [["CYP3A4 inhibitor"]], "start": [[133]], "entity_id": ["T14"]}, "Disorder": {"text": [["CF-related liver disease"]], "start": [[76]], "entity_id": ["T15"]}}, "Effect": {"text": [["rapid onset of adrenal insufficiency"]], "start": [[21]], "entity_id": ["T11"]}}]}]}
{"id": "12951892_2", "context": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["four day course of lethargy with unexplained high lithium levels"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[75]], "entity_id": ["T7"]}}, "Subject": {"text": [["newborn"]], "start": [[4]], "entity_id": ["T6"], "Age": {"text": [["newborn"]], "start": [[4]], "entity_id": ["T8"]}}}]}]}
{"id": "8891729_3", "context": "The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[46]], "entity_id": ["T3"]}, "Treatment": {"text": [["fludarabine"]], "start": [[59]], "entity_id": ["T4"], "Drug": {"text": [["fludarabine"]], "start": [[59]], "entity_id": ["T9"]}, "Disorder": {"text": [["CLL"]], "start": [[33]], "entity_id": ["T10"]}}, "Effect": {"text": [["severe AIHA"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["CLL patients"]], "start": [[33]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[18]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "19034138_4", "context": "Corneal endothelial dysfunction associated with amantadine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Corneal endothelial dysfunction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["amantadine"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[48]], "entity_id": ["T6"]}}}]}]}
{"id": "10367184_3", "context": "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interact"]], "start": [[111]], "entity_id": ["T4"]}, "Subject": {"text": [["humans."]], "start": [[183]], "entity_id": ["T6"]}, "Effect": {"text": [["severe clinical myotonia"]], "start": [[155]], "entity_id": ["T3"]}, "Treatment": {"text": [["pravastatin"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["pravastatin"]], "start": [[40]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[107]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["severe"]], "start": [[155]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "20412003_6", "context": "We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and soft tissue infection and was treated with TMP-SMX.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[112]], "entity_id": ["T3"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[125]], "entity_id": ["T4"], "Disorder": {"text": [["CA-MRSA skin and soft tissue infection"]], "start": [[65]], "entity_id": ["T6"]}, "Drug": {"text": [["TMP"], ["SMX"]], "start": [[125], [129]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[128]], "entity_id": ["T11"]}, "Drug": {"text": [["SMX"], ["TMP"]], "start": [[129], [125]], "entity_id": ["T10", "T9"]}}]}, "Subject": {"text": [["a relatively healthy, 9-year-old boy"]], "start": [[12]], "entity_id": ["T5"], "Age": {"text": [["9-year-old"]], "start": [[34]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[45]], "entity_id": ["T8"]}}}]}]}
{"id": "10897389_2", "context": "Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[58]], "entity_id": ["T6"], "Disorder": {"text": [["ulcerative colitis"]], "start": [[89]], "entity_id": ["T5"]}, "Drug": {"text": [["cyclosporine"]], "start": [[58]], "entity_id": ["T9"]}}, "Effect": {"text": [["Recurrent septicemia"]], "start": [[0]], "entity_id": ["T7"]}, "Severity": {"text": [["lethal"]], "start": [[26]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "3620420_5", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resulted"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["Systemic cyclosporin (10 mg/kg/day)"]], "start": [[0]], "entity_id": ["T4"], "Dosage": {"text": [["10 mg/kg/day"]], "start": [[22]], "entity_id": ["T8"]}, "Drug": {"text": [["Systemic cyclosporin"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["resolution of the corneal ulceration"]], "start": [[48]], "entity_id": ["T5"]}, "Subject": {"text": [["patient"]], "start": [[134]], "entity_id": ["T7"]}}]}]}
{"id": "16767537_3", "context": "We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["spontaneous splenic infarction"]], "start": [[34]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient", "of migraine headache"]], "start": [[10, 112]], "entity_id": ["T5"]}, "Treatment": {"text": [["sumatriptan"]], "start": [[82]], "entity_id": ["T6"], "Drug": {"text": [["sumatriptan"]], "start": [[82]], "entity_id": ["T8"]}, "Disorder": {"text": [["migraine headache"]], "start": [[115]], "entity_id": ["T9"]}}}]}]}
{"id": "9497597_2", "context": "We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[53]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[29]], "entity_id": ["T3"]}, "Effect": {"text": [["priapism"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["oral intake of the phenothiazine prothipendylhydrochloride"]], "start": [[59]], "entity_id": ["T5"], "Route": {"text": [["oral intake"]], "start": [[59]], "entity_id": ["T7"]}, "Drug": {"text": [["prothipendylhydrochloride"]], "start": [[92]], "entity_id": ["T8"]}}}]}]}
{"id": "14711147_4", "context": "We present a case of photo-onycholysis in a patient treated with doxycycline for acne vulgaris.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["doxycycline"]], "start": [[65]], "entity_id": ["T9"], "Disorder": {"text": [["acne vulgaris"]], "start": [[81]], "entity_id": ["T11"]}, "Drug": {"text": [["doxycycline"]], "start": [[65]], "entity_id": ["T12"]}}, "Subject": {"text": [["a case of photo-onycholysis in a patient"]], "start": [[11]], "entity_id": ["T7"]}, "Effect": {"text": [["photo-onycholysis"]], "start": [[21]], "entity_id": ["T13"]}}]}]}
{"id": "11428480_1", "context": "Adenosine-induced ventricular fibrillation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["ventricular fibrillation"]], "start": [[18]], "entity_id": ["T4"]}, "Treatment": {"text": [["Adenosine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Adenosine"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "14723711_5", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[76]], "entity_id": ["T6"]}, "Treatment": {"text": [["minocycline"]], "start": [[64]], "entity_id": ["T7"], "Drug": {"text": [["minocycline"]], "start": [[64]], "entity_id": ["T12"]}, "Disorder": {"text": [["acne vulgaris"]], "start": [[28]], "entity_id": ["T13"]}}, "Subject": {"text": [["two patients with acne vulgaris"]], "start": [[10]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T10"]}}, "Effect": {"text": [["fourth type of", "cutaneous pigmentation"]], "start": [[49, 84]], "entity_id": ["T9"]}}]}]}
{"id": "8485005_1", "context": "Complete regression of iatrogenic Kaposi's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["regression"]], "start": [[9]], "entity_id": ["T10"]}, "Treatment": {"text": [["corticosteroid"]], "start": [[58]], "entity_id": ["T9"], "Disorder": {"text": [["Kaposi's sarcoma"]], "start": [[34]], "entity_id": ["T12"]}, "Drug": {"text": [["corticosteroid"]], "start": [[58]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient with tubercular pericarditis"]], "start": [[86]], "entity_id": ["T7"], "Disorder": {"text": [["tubercular pericarditis"]], "start": [[101]], "entity_id": ["T8"]}}}]}]}
{"id": "18580694_1", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[56]], "entity_id": ["T3"]}, "Effect": {"text": [["prolonged ECT seizure"]], "start": [[34]], "entity_id": ["T5"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["ciprofloxacin"]], "start": [[67]], "entity_id": ["T6"]}}}]}]}
{"id": "3620420_1", "context": "Cyclosporin therapy in Mooren's ulcer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cyclosporin"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Cyclosporin"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["Mooren's ulcer"]], "start": [[23]], "entity_id": ["T8"]}}}]}]}
{"id": "19145124_2", "context": "These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["evidence"]], "start": [[140]], "entity_id": ["T7"]}, "Treatment": {"text": [["ethambutol"]], "start": [[154]], "entity_id": ["T5"], "Drug": {"text": [["ethambutol"]], "start": [[154]], "entity_id": ["T8"]}}, "Effect": {"text": [["damages the retina"]], "start": [[165]], "entity_id": ["T6"]}}]}]}
{"id": "11886466_2", "context": "Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[192]], "entity_id": ["T15"]}, "Effect": {"text": [["risk of arterial or venous thrombosis."]], "start": [[205]], "entity_id": ["T16"]}, "Treatment": {"text": [["Porcine factor VIII (pFVIII)"]], "start": [[0]], "entity_id": ["T17"], "Disorder": {"text": [["high-titre neutralizing antibodies to human FVIII"], ["bleeding"], ["congenital or acquired haemophilia"]], "start": [[125], [55], [81]], "entity_id": ["T21", "T28", "T19"]}, "Drug": {"text": [["Porcine factor VIII"]], "start": [[0]], "entity_id": ["T24"]}}, "Subject": {"text": [["patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII"]], "start": [[67]], "entity_id": ["T18"]}, "Speculated": {"text": [["risk"]], "start": [[205]], "entity_id": ["T23"], "value": true}, "Negated": {"text": [["not"]], "start": [[179]], "entity_id": ["T22"], "value": true}}]}]}
{"id": "10410183_10", "context": "CONCLUSIONS: Marked elevation of serum CK may be a possible complication of olanzapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[60]], "entity_id": ["T7"]}, "Effect": {"text": [["Marked elevation of serum CK"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine therapy"]], "start": [[76]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[76]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible"]], "start": [[51]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7789881_2", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[98]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[114]], "entity_id": ["T5"], "Drug": {"text": [["tamoxifen"]], "start": [[114]], "entity_id": ["T8"]}}, "Effect": {"text": [["low-grade endometrial carcinoma"]], "start": [[24]], "entity_id": ["T7"]}}]}]}
{"id": "12494253_1", "context": "After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T4"]}, "Subject": {"text": [["she"]], "start": [[41]], "entity_id": ["T3"], "Gender": {"text": [["she"]], "start": [[41]], "entity_id": ["T7"]}}, "Effect": {"text": [["severe anaphylaxis"]], "start": [[55]], "entity_id": ["T5"]}, "Treatment": {"text": [["cisplatin"]], "start": [[77]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"]], "start": [[77]], "entity_id": ["T8"]}}}]}]}
{"id": "7937287_1", "context": "Cefuroxime-induced acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cefuroxime"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Cefuroxime"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "6610943_4", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[52]], "entity_id": ["T6"]}, "Treatment": {"text": [["vasopressin"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["vasopressin"]], "start": [[58]], "entity_id": ["T7"]}, "Disorder": {"text": [["gastrointestinal hemorrhage"]], "start": [[78]], "entity_id": ["T8"]}}, "Effect": {"text": [["gastrointestinal hemorrhage"]], "start": [[78]], "entity_id": ["T5"]}}]}]}
{"id": "847572_3", "context": "Two fatal cases of poisoning by paracetamol are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[29]], "entity_id": ["T3"]}, "Treatment": {"text": [["paracetamol"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["paracetamol"]], "start": [[32]], "entity_id": ["T8"]}}, "Subject": {"text": [["Two fatal cases"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["poisoning"]], "start": [[19]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[4]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "1792646_1", "context": "Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["Pneumocystis carinii pneumonia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T6"]}, "Disorder": {"text": [["asthma"]], "start": [[78]], "entity_id": ["T7"]}}}]}]}
{"id": "16609346_1", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[86]], "entity_id": ["T4"]}, "Effect": {"text": [["myasthenic syndrome"]], "start": [[59]], "entity_id": ["T3"]}, "Treatment": {"text": [["statin treatment"]], "start": [[102]], "entity_id": ["T5"], "Drug": {"text": [["statin"]], "start": [[102]], "entity_id": ["T6"]}}, "Speculated": {"text": [["may"]], "start": [[79]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "21658326_2", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatments"]], "start": [[117]], "entity_id": ["T10"]}, "Treatment": {"text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [[22]], "entity_id": ["T13"], "Disorder": {"text": [["moderate to severe psoriasis"]], "start": [[168]], "entity_id": ["T12"]}, "Drug": {"text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [[22]], "entity_id": ["T16"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatments"]], "start": [[117]], "entity_id": ["T10"]}, "Treatment": {"text": [["Topical imiquimod"]], "start": [[0]], "entity_id": ["T9"], "Disorder": {"text": [["non-melanoma skin cancer (NMSC)"]], "start": [[132]], "entity_id": ["T11"]}, "Route": {"text": [["Topical"]], "start": [[0]], "entity_id": ["T14"]}, "Drug": {"text": [["imiquimod"]], "start": [[8]], "entity_id": ["T15"]}}}]}]}
{"id": "6731466_1", "context": "Focal renal cortical necrosis associated with zomepirac.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["Focal renal cortical necrosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["zomepirac"]], "start": [[46]], "entity_id": ["T6"], "Drug": {"text": [["zomepirac"]], "start": [[46]], "entity_id": ["T7"]}}}]}]}
{"id": "2113320_1", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[48]], "entity_id": ["T5"]}, "Subject": {"text": [["A patient with Wegener's granulomatosis"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["circumferential subglottic stenosis", "resolution of systemic symptoms and pulmonary infiltrates"]], "start": [[60, 148]], "entity_id": ["T6"]}, "Treatment": {"text": [["cyclophosphamide regimen"]], "start": [[107]], "entity_id": ["T7"], "Drug": {"text": [["cyclophosphamide"]], "start": [[107]], "entity_id": ["T8"]}, "Disorder": {"text": [["Wegener's granulomatosis"]], "start": [[15]], "entity_id": ["T10"]}}}]}]}
{"id": "20349794_4", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["episodes"]], "start": [[69]], "entity_id": ["T9"]}, "Treatment": {"text": [["Carboplatin was substituted for cisplatin"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Carboplatin"], ["cisplatin"]], "start": [[0], [32]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["substituted"]], "start": [[16]], "entity_id": ["T12"]}, "Drug": {"text": [["Carboplatin"], ["cisplatin"]], "start": [[0], [32]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["SIADH"]], "start": [[81]], "entity_id": ["T8"]}, "Negated": {"text": [["no further"]], "start": [[58]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "19745701_1", "context": "Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[46]], "entity_id": ["T6"]}, "Effect": {"text": [["LPD"]], "start": [[60]], "entity_id": ["T3"]}, "Subject": {"text": [["rheumatoid arthritis patients"]], "start": [[93]], "entity_id": ["T4"]}, "Treatment": {"text": [["MTX"]], "start": [[136]], "entity_id": ["T5"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[93]], "entity_id": ["T7"]}, "Drug": {"text": [["MTX"]], "start": [[136]], "entity_id": ["T8"]}}}]}]}
{"id": "16371793_11", "context": "CONCLUSIONS: Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy-resistant cystoid macular edema after penetrating keratoplasty.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[96]], "entity_id": ["T6"]}, "Treatment": {"text": [["Intravitreal injection of triamcinolone acetonide"]], "start": [[13]], "entity_id": ["T4"], "Disorder": {"text": [["therapy-resistant cystoid macular edema"]], "start": [[109]], "entity_id": ["T5"]}, "Route": {"text": [["Intravitreal injection"]], "start": [[13]], "entity_id": ["T8"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[39]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[63]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17009081_1", "context": "A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[49]], "entity_id": ["T6"]}, "Subject": {"text": [["A 43-year-old woman with multiple sclerosis (MS)"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["43-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[53]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon (IFN)-beta-1b (subcutaneous administration)"]], "start": [[112]], "entity_id": ["T5"], "Time_elapsed": {"text": [["21 months"]], "start": [[72]], "entity_id": ["T10"]}, "Drug": {"text": [["interferon (IFN)-beta-1b"]], "start": [[112]], "entity_id": ["T11"]}, "Route": {"text": [["subcutaneous"]], "start": [[138]], "entity_id": ["T12"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[25]], "entity_id": ["T13"]}}}]}]}
{"id": "19690222_1", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["considered"]], "start": [[96]], "entity_id": ["T6"]}, "Effect": {"text": [["Spontaneous hemothorax"], ["acute respiratory distress"]], "start": [[13], [119]], "entity_id": ["T3", "T5"]}, "Treatment": {"text": [["LMWH"]], "start": [[77]], "entity_id": ["T4"], "Drug": {"text": [["LMWH"]], "start": [[77]], "entity_id": ["T7"]}}}]}]}
{"id": "7606071_6", "context": "OBJECTIVE: To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[63]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraperitoneal cisplatin"]], "start": [[66]], "entity_id": ["T4"], "Route": {"text": [["intraperitoneal"]], "start": [[66]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[82]], "entity_id": ["T9"]}}, "Subject": {"text": [["3 patients."]], "start": [[95]], "entity_id": ["T5"], "Population": {"text": [["3"]], "start": [[95]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylactoid reactions"]], "start": [[39]], "entity_id": ["T6"]}}]}]}
{"id": "11144696_12", "context": "Clinicians should be aware of the proepileptogenic effect of venlafaxine and trimipramine at therapeutic doses and that this combination may eventually increase the risk of seizures.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["eventually"]], "start": [[141]], "entity_id": ["T12"]}, "Effect": {"text": [["increase the risk of seizures"]], "start": [[152]], "entity_id": ["T10"]}, "Treatment": {"text": [["venlafaxine and trimipramine at therapeutic doses"]], "start": [[61]], "entity_id": ["T11"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[61], [77]], "entity_id": ["T13", "T14"]}, "Dosage": {"text": [["therapeutic doses"]], "start": [[93]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T15"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[61], [77]], "entity_id": ["T13", "T14"]}}]}, "Speculated": {"text": [["may"]], "start": [[137]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "16298824_6", "context": "We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T6"]}, "Treatment": {"text": [["single infusion of rituximab"]], "start": [[168]], "entity_id": ["T5"], "Drug": {"text": [["rituximab"]], "start": [[187]], "entity_id": ["T12"]}, "Route": {"text": [["infusion"]], "start": [[175]], "entity_id": ["T13"]}, "Dosage": {"text": [["single"]], "start": [[168]], "entity_id": ["T14"]}, "Disorder": {"text": [["ITP refractory to steroids and intravenous immunoglobulin"]], "start": [[45]], "entity_id": ["T15"]}}, "Effect": {"text": [["acute respiratory distress syndrome (ARDS)"]], "start": [[117]], "entity_id": ["T7"]}, "Subject": {"text": [["the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin"]], "start": [[10]], "entity_id": ["T8"], "Age": {"text": [["43-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[36]], "entity_id": ["T10"]}}}]}]}
{"id": "16923659_6", "context": "METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presenting"]], "start": [[123]], "entity_id": ["T15"]}, "Treatment": {"text": [["a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine)"]], "start": [[25]], "entity_id": ["T13"], "Drug": {"text": [["venlafaxine"], ["topiramate"], ["divalproex sodium"], ["risperidone"], ["carbamazepine"]], "start": [[47], [60], [72], [91], [108]], "entity_id": ["T16", "T18", "T19", "T20", "T21"]}, "Dosage": {"text": [["overdose"]], "start": [[37]], "entity_id": ["T17"]}, "Disorder": {"text": [["undifferentiated SS/NMS in critical care settings"]], "start": [[239]], "entity_id": ["T22"]}}, "Effect": {"text": [["mixed SS/NMS features"]], "start": [[139]], "entity_id": ["T14"]}}]}]}
{"id": "17352036_2", "context": "Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[116]], "entity_id": ["T5"]}, "Effect": {"text": [["pancreatitis"]], "start": [[124]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone"]], "start": [[105]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"]], "start": [[105]], "entity_id": ["T10"]}}, "Subject": {"text": [["only four cases"]], "start": [[86]], "entity_id": ["T8"], "Population": {"text": [["four"]], "start": [[91]], "entity_id": ["T9"]}}}]}]}
{"id": "11672959_1", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[19]], "entity_id": ["T11"]}, "Subject": {"text": [["A 34-year-old lady", "sero-negative rheumatoid arthritis"]], "start": [[0, 163]], "entity_id": ["T9"], "Age": {"text": [["34-year-old"]], "start": [[2]], "entity_id": ["T14"]}, "Gender": {"text": [["lady"]], "start": [[14]], "entity_id": ["T15"]}}, "Effect": {"text": [["a constellation of dermatitis, fever, lymphadenopathy and hepatitis"]], "start": [[29]], "entity_id": ["T10"]}, "Treatment": {"text": [["a course of oral sulphasalazine"]], "start": [[127]], "entity_id": ["T12"], "Route": {"text": [["oral"]], "start": [[139]], "entity_id": ["T16"]}, "Drug": {"text": [["sulphasalazine"]], "start": [[144]], "entity_id": ["T17"]}, "Disorder": {"text": [["sero-negative rheumatoid arthritis"]], "start": [[163]], "entity_id": ["T18"]}, "Time_elapsed": {"text": [["on the 17th day"]], "start": [[108]], "entity_id": ["T19"]}}}]}]}
{"id": "17167851_2", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[97]], "entity_id": ["T6"]}, "Treatment": {"text": [["CPA"]], "start": [[103]], "entity_id": ["T3"], "Drug": {"text": [["CPA"]], "start": [[103]], "entity_id": ["T11"]}}, "Effect": {"text": [["severe hepatotoxic reactions"]], "start": [[60]], "entity_id": ["T4"]}, "Subject": {"text": [["Three male patients aged 78-83 years"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[6]], "entity_id": ["T8"]}, "Age": {"text": [["aged 78-83 years"]], "start": [[20]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[60]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "16237130_1", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["apecitabine"]], "start": [[1]], "entity_id": ["T3"], "Drug": {"text": [["Capecitabine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["multifocal leukoencephalopathy"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["five cases"]], "start": [[65]], "entity_id": ["T6"], "Population": {"text": [["five"]], "start": [[65]], "entity_id": ["T7"]}}}]}]}
{"id": "8828999_2", "context": "Lithium-induced Creutzfeldt-Jakob syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["Creutzfeldt-Jakob syndrome"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "17667887_1", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[72]], "entity_id": ["T13"]}, "Subject": {"text": [["elderly patients"]], "start": [[22]], "entity_id": ["T9"], "Age": {"text": [["elderly"]], "start": [[22]], "entity_id": ["T14"]}}, "Treatment": {"text": [["atypical antipsychotics", "antidepressants"]], "start": [[77, 105]], "entity_id": ["T11"], "Disorder": {"text": [["psychotic depression"], ["Serotonin syndrome"]], "start": [[51], [0]], "entity_id": ["T10", "T15"]}, "Drug": {"text": [["atypical antipsychotics"], ["antidepressants"]], "start": [[77], [105]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[101]], "entity_id": ["T18"]}, "Drug": {"text": [["atypical antipsychotics"], ["antidepressants"]], "start": [[77], [105]], "entity_id": ["T16", "T17"]}}]}}]}]}
{"id": "12659609_2", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[50]], "entity_id": ["T10"]}, "Effect": {"text": [["chloroquine toxicity"]], "start": [[38]], "entity_id": ["T7"]}, "Treatment": {"text": [["chloroquine"]], "start": [[38]], "entity_id": ["T9"], "Drug": {"text": [["chloroquine"]], "start": [[38]], "entity_id": ["T11"]}}, "Subject": {"text": [["high-grade chloroquine-resistant Plasmodium vivax"]], "start": [[78]], "entity_id": ["T1"], "Disorder": {"text": [["high-grade chloroquine-resistant Plasmodium vivax"]], "start": [[78]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[31]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "2523364_2", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["bromocriptine"]], "start": [[49]], "entity_id": ["T6"], "Drug": {"text": [["bromocriptine"]], "start": [[49]], "entity_id": ["T11"]}}, "Effect": {"text": [["morphea"]], "start": [[28]], "entity_id": ["T7"]}, "Subject": {"text": [["A 57-year-old man"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["57-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T10"]}}}]}]}
{"id": "12013364_1", "context": "A 53-year-old man developed NMS without rigidity while taking olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T4"]}, "Subject": {"text": [["A 53-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["NMS without rigidity"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[62]], "entity_id": ["T9"]}}}]}]}
{"id": "18765315_2", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[25]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute coronary syndromes"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["the first infusion of rituximab"]], "start": [[38]], "entity_id": ["T4"], "Route": {"text": [["infusion"]], "start": [[48]], "entity_id": ["T6"]}, "Drug": {"text": [["rituximab"]], "start": [[60]], "entity_id": ["T7"]}}}]}]}
{"id": "10715308_11", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["related"]], "start": [[133]], "entity_id": ["T13"]}, "Treatment": {"text": [["tirapazamine"]], "start": [[144]], "entity_id": ["T12"], "Drug": {"text": [["tirapazamine"]], "start": [[144]], "entity_id": ["T16"]}}, "Effect": {"text": [["no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths"]], "start": [[11]], "entity_id": ["T14"]}, "Negated": {"text": [["no"]], "start": [[11]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "3136101_2", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T5"]}, "Subject": {"text": [["Two infants"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T8"]}, "Age": {"text": [["infants"]], "start": [[4]], "entity_id": ["T9"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["shortly after cessation of prolonged ACTH therapy"]], "start": [[35]], "entity_id": ["T7"], "Disorder": {"text": [["infantile spasms"]], "start": [[89]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["shortly after"]], "start": [[35]], "entity_id": ["T10"]}, "Dosage": {"text": [["cessation"]], "start": [[49]], "entity_id": ["T11"]}, "Drug": {"text": [["ACTH"]], "start": [[72]], "entity_id": ["T12"]}}}]}]}
{"id": "3301251_4", "context": "They continued to rise for five more days before salicylate hepatotoxicity was suspected.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["salicylate"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["salicylate"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[60]], "entity_id": ["T4"]}}]}]}
{"id": "8832451_2", "context": "The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[92]], "entity_id": ["T9"]}, "Effect": {"text": [["neuromuscular blockade", "potentiation of muscle relaxants"]], "start": [[18, 59]], "entity_id": ["T7"]}, "Treatment": {"text": [["magnesium sulfate"]], "start": [[99]], "entity_id": ["T8"], "Drug": {"text": [["magnesium sulfate (MgSO4)"]], "start": [[99]], "entity_id": ["T10"]}}}]}]}
{"id": "11034877_1", "context": "Gabapentin-induced mood changes with hypomanic features in adults.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T9"]}, "Subject": {"text": [["adults"]], "start": [[59]], "entity_id": ["T6"], "Age": {"text": [["adults"]], "start": [[59]], "entity_id": ["T10"]}}, "Effect": {"text": [["mood changes with hypomanic features"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T11"]}}}]}]}
{"id": "18751717_1", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[51]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute syphilitic posterior placoid chorioretinitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravitreal triamcinolone acetonide injection"]], "start": [[61]], "entity_id": ["T5"], "Route": {"text": [["intravitreal", "injection"]], "start": [[61, 98]], "entity_id": ["T6"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[74]], "entity_id": ["T7"]}}}]}]}
{"id": "18465737_1", "context": "Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["Incomplete posterior hyaloid detachment"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ntravitreal pegaptanib injection in diabetic macular edema"]], "start": [[47]], "entity_id": ["T4"], "Disorder": {"text": [["diabetic macular edema"]], "start": [[83]], "entity_id": ["T5"]}, "Drug": {"text": [["pegaptanib"]], "start": [[59]], "entity_id": ["T7"]}, "Route": {"text": [["intravitreal", "injection"]], "start": [[46, 70]], "entity_id": ["T8"]}}}]}]}
{"id": "7724306_5", "context": "OBJECTIVES: To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["neurotoxicity"]], "start": [[80]], "entity_id": ["T5"]}, "Effect": {"text": [["isoniazid (INH) neurotoxicity"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["isoniazid (INH)"]], "start": [[64]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "7139589_2", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["can"]], "start": [[35]], "entity_id": ["T4"]}, "Treatment": {"text": [["intramuscular L-asparaginase"]], "start": [[60]], "entity_id": ["T3"], "Drug": {"text": [["L-asparaginase"]], "start": [[74]], "entity_id": ["T7"]}, "Route": {"text": [["intramuscular"]], "start": [[60]], "entity_id": ["T8"]}}, "Effect": {"text": [["Delayed pseudocyst of the pancreas"]], "start": [[0]], "entity_id": ["T5"]}, "Speculated": {"text": [["can"]], "start": [[35]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "20185472_1", "context": "The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["tremor"]], "start": [[33]], "entity_id": ["T4"]}, "Subject": {"text": [["five cases"]], "start": [[19]], "entity_id": ["T7"], "Population": {"text": [["five"]], "start": [[19]], "entity_id": ["T8"]}}, "Treatment": {"text": [["itraconazole therapy, which occurred within 1-12 months of initiating treatment"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["itraconazole"]], "start": [[51]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["1-12 months"]], "start": [[95]], "entity_id": ["T10"]}}}]}]}
{"id": "1295628_3", "context": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["normalized"]], "start": [[33]], "entity_id": ["T8"]}, "Effect": {"text": [["Clinical symptoms and leukopenia normalized"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["discontinuation of CBZ and administration of prednisolone at 40 mg"]], "start": [[50]], "entity_id": ["T9"], "Drug": {"text": [["CBZ"], ["prednisolone"]], "start": [[69], [95]], "entity_id": ["T11", "T12"]}, "Dosage": {"text": [["40 mg"]], "start": [[111]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["prednisolone"]], "start": [[69], [95]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "1918672_1", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolve"]], "start": [[126]], "entity_id": ["T4"]}, "Treatment": {"text": [["discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment"]], "start": [[14]], "entity_id": ["T3"], "Disorder": {"text": [["ulcers"]], "start": [[146]], "entity_id": ["T5"]}, "Drug": {"text": [["piroxicam"]], "start": [[28]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient's"]], "start": [[134]], "entity_id": ["T6"]}}]}]}
{"id": "9988365_2", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["encountered"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["clozapine"]], "start": [[55]], "entity_id": ["T3"], "Drug": {"text": [["clozapine"]], "start": [[55]], "entity_id": ["T7"]}}, "Effect": {"text": [["Eosinophilia"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["patients"]], "start": [[73]], "entity_id": ["T5"]}}]}]}
{"id": "527355_2", "context": "Severe acidosis from acetazolamide in a diabetic patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[16]], "entity_id": ["T5"]}, "Subject": {"text": [["a diabetic patient"]], "start": [[38]], "entity_id": ["T3"], "Disorder": {"text": [["diabetic"]], "start": [[40]], "entity_id": ["T9"]}}, "Effect": {"text": [["acidosis"]], "start": [[7]], "entity_id": ["T4"]}, "Treatment": {"text": [["acetazolamide"]], "start": [[21]], "entity_id": ["T6"], "Drug": {"text": [["acetazolamide"]], "start": [[21]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "17157086_5", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causal"]], "start": [[18]], "entity_id": ["T8"]}, "Treatment": {"text": [["additives and montelukast"]], "start": [[137]], "entity_id": ["T5"], "Drug": {"text": [["montelukast"], ["additives"]], "start": [[151], [137]], "entity_id": ["T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["synergy"]], "start": [[117]], "entity_id": ["T10"]}, "Drug": {"text": [["additives"], ["montelukast"]], "start": [[137], [151]], "entity_id": ["T11", "T9"]}}]}, "Effect": {"text": [["the fatal hepatitis"]], "start": [[82]], "entity_id": ["T13"]}, "Speculated": {"text": [["speculate"]], "start": [[3]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "20338114_2", "context": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[78]], "entity_id": ["T3"]}, "Effect": {"text": [["transient intraoperative hypertension immediately"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["inadvertent submucosal injection of concentrated epinephrine"]], "start": [[84]], "entity_id": ["T6"], "Drug": {"text": [["concentrated epinephrine"]], "start": [[120]], "entity_id": ["T5"]}, "Route": {"text": [["injection"], ["submucosal"]], "start": [[107], [96]], "entity_id": ["T7", "T8"]}, "Time_elapsed": {"text": [["immediately"]], "start": [[66]], "entity_id": ["T9"]}}}]}]}
{"id": "25157214_2", "context": "The effectiveness of sugammadex in reversing rocuronium-induced neuromuscular blockade (NMB) in the presence of drugs that may potentiate NMB remains to be fully established.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[56]], "entity_id": ["T8"]}, "Treatment": {"text": [["rocuronium"]], "start": [[45]], "entity_id": ["T9"], "Drug": {"text": [["rocuronium"]], "start": [[45]], "entity_id": ["T11"]}}, "Effect": {"text": [["neuromuscular blockade (NMB)"]], "start": [[64]], "entity_id": ["T10"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversing"]], "start": [[35]], "entity_id": ["T13"]}, "Treatment": {"text": [["sugammadex", "in the presence of drugs that may potentiate NMB"]], "start": [[21, 93]], "entity_id": ["T12"], "Disorder": {"text": [["rocuronium-induced neuromuscular blockade (NMB)"]], "start": [[45]], "entity_id": ["T14"]}, "Drug": {"text": [["sugammadex"]], "start": [[21]], "entity_id": ["T15"]}}, "Speculated": {"text": [["remains to be fully established"]], "start": [[142]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "8771575_2", "context": "Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["are"]], "start": [[44]], "entity_id": ["T7"]}, "Effect": {"text": [["Acute pulmonary reactions", "can cause minor or life-threatening pulmonary dysfunction"]], "start": [[0, 87]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[29]], "entity_id": ["T6"], "Drug": {"text": [["nitrofurantoin"]], "start": [[29]], "entity_id": ["T10"]}}, "Speculated": {"text": [["can"]], "start": [[87]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["minor or life-threatening"]], "start": [[97]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "10698143_2", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["characterized"]], "start": [[30]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ibuprofen overdose"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Ibuprofen"]], "start": [[0]], "entity_id": ["T10"]}, "Dosage": {"text": [["overdose"]], "start": [[10]], "entity_id": ["T11"]}}, "Effect": {"text": [["GI upset, dizziness, and mild sedation"]], "start": [[47]], "entity_id": ["T9"]}}]}]}
{"id": "20628041_5", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["administered"]], "start": [[132]], "entity_id": ["T9"]}, "Subject": {"text": [["His"]], "start": [[0]], "entity_id": ["T7"], "Gender": {"text": [["His"]], "start": [[0]], "entity_id": ["T10"]}}, "Treatment": {"text": [["pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily", "via nasogastric tube"]], "start": [[20, 145]], "entity_id": ["T8"], "Disorder": {"text": [["PD"]], "start": [[4]], "entity_id": ["T11"]}, "Drug": {"text": [["pramipexole"], ["entacapone"], ["immediate-release levodopa"], ["carbidopa"]], "start": [[20], [33], [49], [76]], "entity_id": ["T12", "T13", "T15", "T16"]}, "Route": {"text": [["nasogastric tube"], ["tablets"]], "start": [[149], [104]], "entity_id": ["T14", "T21"]}, "Dosage": {"text": [["100 mg"], ["25 mg"]], "start": [[86], [93]], "entity_id": ["T17", "T18"]}, "Freq": {"text": [["4 times daily"]], "start": [[112]], "entity_id": ["T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[45]], "entity_id": ["T20"]}, "Drug": {"text": [["pramipexole"], ["entacapone"], ["immediate-release levodopa"], ["carbidopa"]], "start": [[20], [33], [49], [76]], "entity_id": ["T12", "T13", "T15", "T16"]}}]}}]}]}
{"id": "8586895_1", "context": "However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effects"]], "start": [[102]], "entity_id": ["T5"]}, "Treatment": {"text": [["halofantrine"]], "start": [[141]], "entity_id": ["T6"], "Drug": {"text": [["halofantrine"], ["antimalarial treatment"]], "start": [[141], [113]], "entity_id": ["T11", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[136]], "entity_id": ["T12"]}, "Drug": {"text": [["halofantrine"], ["antimalarial treatment"]], "start": [[141], [113]], "entity_id": ["T11", "T13"]}}]}, "Subject": {"text": [["400 patients on the Thai-Burmese border"]], "start": [[45]], "entity_id": ["T7"], "Population": {"text": [["400"]], "start": [[45]], "entity_id": ["T10"]}}, "Effect": {"text": [["cardiac effects", "sudden death"]], "start": [[94, 169]], "entity_id": ["T8"]}}]}]}
{"id": "10679548_4", "context": "The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[128]], "entity_id": ["T7"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[113]], "entity_id": ["T6"], "Drug": {"text": [["nitrofurantoin"]], "start": [[113]], "entity_id": ["T10"]}}, "Effect": {"text": [["BOOP"]], "start": [[136]], "entity_id": ["T8"]}, "Subject": {"text": [["two patients"]], "start": [[32]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[32]], "entity_id": ["T9"]}}}]}]}
{"id": "9094821_1", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[113]], "entity_id": ["T7"]}, "Effect": {"text": [["endometrial carcinoma and endometriosis"]], "start": [[129]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[103]], "entity_id": ["T6"], "Drug": {"text": [["tamoxifen"]], "start": [[103]], "entity_id": ["T9"]}}, "Speculated": {"text": [["possible"]], "start": [[4]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "24477376_4", "context": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[72]], "entity_id": ["T8"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["previously on phenytoin and was initiated on ticagrelor", "following stent placement"]], "start": [[16, 97]], "entity_id": ["T9"], "Drug": {"text": [["phenytoin"], ["ticagrelor"]], "start": [[30], [61]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["antiplatelet"]], "start": [[76]], "entity_id": ["T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[40]], "entity_id": ["T12"]}, "Drug": {"text": [["phenytoin"], ["ticagrelor"]], "start": [[30], [61]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "8239963_1", "context": "Clonidine-induced bradycardia in patients with spinal cord injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clonidine"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["spinal cord injury"]], "start": [[47]], "entity_id": ["T7"]}, "Drug": {"text": [["Clonidine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["bradycardia"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with spinal cord injury"]], "start": [[33]], "entity_id": ["T6"]}}]}]}
{"id": "18364401_4", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[80]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine was stopped"]], "start": [[94]], "entity_id": ["T3"], "Disorder": {"text": [["hyperglycemia (fasting blood glucose 138 mg/dL)"]], "start": [[27]], "entity_id": ["T2"]}, "Drug": {"text": [["olanzapine"]], "start": [[94]], "entity_id": ["T4"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[164]], "entity_id": ["T7"]}, "Effect": {"text": [["hyperglycemia", "recurred (fasting blood glucose 150 mg/dL)"]], "start": [[27, 121]], "entity_id": ["T6"]}, "Treatment": {"text": [["2 days of rechallenge with olanzapine 2.5 mg twice daily"]], "start": [[170]], "entity_id": ["T8"], "Time_elapsed": {"text": [["2 days"]], "start": [[170]], "entity_id": ["T9"]}, "Drug": {"text": [["olanzapine"]], "start": [[197]], "entity_id": ["T10"]}, "Dosage": {"text": [["2.5 mg"]], "start": [[208]], "entity_id": ["T11"]}, "Freq": {"text": [["twice daily"]], "start": [[215]], "entity_id": ["T12"]}}}]}]}
{"id": "6093724_3", "context": "To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[135]], "entity_id": ["T7"]}, "Effect": {"text": [["isolated paresthesia and peripheral neuropathy"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulindac administration"]], "start": [[148]], "entity_id": ["T6"], "Drug": {"text": [["sulindac"]], "start": [[148]], "entity_id": ["T8"]}}}]}]}
{"id": "10803790_5", "context": "CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["In"]], "start": [[12]], "entity_id": ["T8"]}, "Subject": {"text": [["some abstainers"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["take cyanamide for several years"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["cyanamide"]], "start": [[40]], "entity_id": ["T9"]}, "Freq": {"text": [["several years"]], "start": [[54]], "entity_id": ["T10"]}}, "Effect": {"text": [["thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes"]], "start": [[69]], "entity_id": ["T7"]}}]}]}
{"id": "15359206_2", "context": "In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[56]], "entity_id": ["T5"]}, "Effect": {"text": [["prolonged hypotension and hypoxemia"]], "start": [[69]], "entity_id": ["T7"]}, "Treatment": {"text": [["nimodipine overdosage"]], "start": [[34]], "entity_id": ["T6"], "Drug": {"text": [["nimodipine"]], "start": [[34]], "entity_id": ["T8"]}, "Dosage": {"text": [["overdosage"]], "start": [[45]], "entity_id": ["T9"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[129]], "entity_id": ["T12"]}, "Treatment": {"text": [["calcium gluconate"]], "start": [[142]], "entity_id": ["T13"], "Drug": {"text": [["calcium gluconate"]], "start": [[142]], "entity_id": ["T14"]}, "Disorder": {"text": [["prolonged hypotension and hypoxemia"]], "start": [[69]], "entity_id": ["T11"]}}}]}]}
{"id": "18805724_1", "context": "DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effects"]], "start": [[29]], "entity_id": ["T15"]}, "Treatment": {"text": [["leflunomide"]], "start": [[40]], "entity_id": ["T13"], "Drug": {"text": [["leflunomide"]], "start": [[40]], "entity_id": ["T16"]}}, "Effect": {"text": [["diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions"]], "start": [[63]], "entity_id": ["T14"]}}]}]}
{"id": "2549018_6", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[118]], "entity_id": ["T6"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[107]], "entity_id": ["T5"], "Drug": {"text": [["fluoxetine"]], "start": [[107]], "entity_id": ["T9"]}}, "Effect": {"text": [["akathisia"]], "start": [[126]], "entity_id": ["T7"]}, "Subject": {"text": [["Three patients who had experienced neuroleptic-induced akathisia in the past"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["neuroleptic-induced akathisia"]], "start": [[35]], "entity_id": ["T14"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[47]], "entity_id": ["T11"]}, "Treatment": {"text": [["neuroleptic"]], "start": [[35]], "entity_id": ["T10"], "Drug": {"text": [["neuroleptic"]], "start": [[35]], "entity_id": ["T13"]}}, "Effect": {"text": [["akathisia"]], "start": [[55]], "entity_id": ["T12"]}}]}]}
{"id": "1445134_3", "context": "In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["incidence"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["gestational diabetes"]], "start": [[69]], "entity_id": ["T3"]}, "Subject": {"text": [["pregnancies"]], "start": [[93]], "entity_id": ["T5"]}, "Treatment": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T6"], "Disorder": {"text": [["pregnancies"]], "start": [[93]], "entity_id": ["T7"]}, "Drug": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T9"]}}}]}]}
{"id": "9972383_3", "context": "Reversible nonthrombocytopenic palpable purpura associated with metoclopramide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[64]], "entity_id": ["T4"], "Drug": {"text": [["metoclopramide"]], "start": [[64]], "entity_id": ["T6"]}}, "Effect": {"text": [["Reversible nonthrombocytopenic palpable purpura"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "9191742_2", "context": "We describe a patient who became hypothyroid while taking ferrous sulfate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[26]], "entity_id": ["T5"]}, "Effect": {"text": [["hypothyroid"]], "start": [[33]], "entity_id": ["T3"]}, "Treatment": {"text": [["ferrous sulfate"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["ferrous sulfate"]], "start": [[58]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "1772299_2", "context": "The Center for Disease Control has received numerous reports of an eosinophilia-myalgia syndrome related to products containing L-tryptophan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[97]], "entity_id": ["T5"]}, "Treatment": {"text": [["products containing L-tryptophan"]], "start": [[108]], "entity_id": ["T3"], "Drug": {"text": [["L-tryptophan"]], "start": [[128]], "entity_id": ["T6"]}}, "Effect": {"text": [["eosinophilia-myalgia syndrome"]], "start": [[67]], "entity_id": ["T4"]}}]}]}
{"id": "8726608_5", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[60]], "entity_id": ["T5"]}, "Effect": {"text": [["serum lithium level had increased 4-fold"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["acyclovir"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["acyclovir"], ["lithium"]], "start": [[67], [25]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[60]], "entity_id": ["T9"]}, "Drug": {"text": [["lithium"], ["acyclovir"]], "start": [[25], [67]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "3195622_1", "context": "A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[76]], "entity_id": ["T3"]}, "Treatment": {"text": [["dapsone"]], "start": [[89]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[89]], "entity_id": ["T7"]}, "Disorder": {"text": [["spider bite"]], "start": [[117]], "entity_id": ["T8"]}}, "Effect": {"text": [["the hypersensitivity syndrome"]], "start": [[17]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[60]], "entity_id": ["T6"]}}]}]}
{"id": "12494253_3", "context": "Anaphylaxis to cisplatin is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[82]], "entity_id": ["T6"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T4"], "Drug": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[96]], "entity_id": ["T5"]}}]}]}
{"id": "17316160_1", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Decreased"]], "start": [[0]], "entity_id": ["T11"]}, "Effect": {"text": [["Decreased serum linezolid levels"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["a critically ill patient"]], "start": [[36]], "entity_id": ["T9"], "Disorder": {"text": [["critically ill"]], "start": [[38]], "entity_id": ["T12"]}}, "Treatment": {"text": [["concomitant linezolid and rifampin"]], "start": [[71]], "entity_id": ["T10"], "Drug": {"text": [["linezolid"], ["rifampin"]], "start": [[83], [97]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[71]], "entity_id": ["T15"]}, "Drug": {"text": [["linezolid"], ["rifampin"]], "start": [[83], [97]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "8329789_2", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[74]], "entity_id": ["T7"]}, "Treatment": {"text": [["amphotericin B overdose"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["amphotericin B"]], "start": [[45]], "entity_id": ["T10"]}, "Dosage": {"text": [["overdose"]], "start": [[60]], "entity_id": ["T11"]}}, "Effect": {"text": [["cardiac complications"]], "start": [[84]], "entity_id": ["T8"]}, "Subject": {"text": [["a pediatric population"]], "start": [[109]], "entity_id": ["T9"], "Age": {"text": [["pediatric"]], "start": [[111]], "entity_id": ["T5"]}}}]}]}
{"id": "2320800_6", "context": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[39]], "entity_id": ["T5"]}, "Effect": {"text": [["tubulopathies."]], "start": [[57]], "entity_id": ["T6"]}, "Treatment": {"text": [["Ifosfamide"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Ifosfamide"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "11737689_1", "context": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G-CSF.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T4"]}, "Subject": {"text": [["A boy with chronic neutropenia and recurrent inflammatory skin lesions"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["boy"]], "start": [[2]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiple erythematous nodules"]], "start": [[81]], "entity_id": ["T5"]}, "Treatment": {"text": [["G-CSF"]], "start": [[139]], "entity_id": ["T6"], "Disorder": {"text": [["chronic neutropenia and recurrent inflammatory skin lesions"]], "start": [[11]], "entity_id": ["T9"]}, "Drug": {"text": [["G-CSF"]], "start": [[139]], "entity_id": ["T10"]}}}]}]}
{"id": "10405480_3", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[70]], "entity_id": ["T5"]}, "Effect": {"text": [["acute generalized exanthematous pustulosis (AGEP)"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["salazosulfapyridine"]], "start": [[81]], "entity_id": ["T4"], "Drug": {"text": [["salazosulfapyridine"]], "start": [[81]], "entity_id": ["T8"]}, "Disorder": {"text": [["ulcerative colitis"]], "start": [[119]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with ulcerative colitis"]], "start": [[104]], "entity_id": ["T6"]}}]}]}
{"id": "8013261_4", "context": "We report a case of IDDM which occurred during interferon therapy for chronic hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[31]], "entity_id": ["T4"]}, "Effect": {"text": [["IDDM"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon therapy"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["interferon"]], "start": [[47]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic hepatitis."]], "start": [[70]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "19275460_6", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["continued"]], "start": [[115]], "entity_id": ["T11"]}, "Treatment": {"text": [["intravenous hydration", "broad-spectrum antibiotics"]], "start": [[49, 75]], "entity_id": ["T8"], "Disorder": {"text": [["confused", "agitated", "despondent"]], "start": [[140, 150, 164]], "entity_id": ["T10"]}, "Route": {"text": [["intravenous"]], "start": [[49]], "entity_id": ["T12"]}, "Drug": {"text": [["hydration"], ["antibiotics"]], "start": [[61], [90]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[71]], "entity_id": ["T15"]}, "Drug": {"text": [["hydration"], ["antibiotics"]], "start": [[61], [90]], "entity_id": ["T13", "T14"]}}]}, "Subject": {"text": [["patient"]], "start": [[107]], "entity_id": ["T9"]}}]}]}
{"id": "20180933_1", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receiving"]], "start": [[83]], "entity_id": ["T9"]}, "Subject": {"text": [["African children"]], "start": [[66]], "entity_id": ["T7"], "Race": {"text": [["African"]], "start": [[66]], "entity_id": ["T11"]}, "Age": {"text": [["children"]], "start": [[74]], "entity_id": ["T12"]}}, "Treatment": {"text": [["artemether-lumefantrine crushed or dispersible tablets (Coartem)"]], "start": [[93]], "entity_id": ["T10"], "Disorder": {"text": [["acute uncomplicated Plasmodium falciparum malaria"]], "start": [[162]], "entity_id": ["T13"]}, "Drug": {"text": [["artemether"], ["lumefantrine"]], "start": [[93], [104]], "entity_id": ["T14", "T15"]}, "Route": {"text": [["dispersible tablets"], ["crushed", "tablets"]], "start": [[128], [117, 140]], "entity_id": ["T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[103]], "entity_id": ["T16"]}, "Drug": {"text": [["lumefantrine"], ["artemether"]], "start": [[104], [93]], "entity_id": ["T15", "T14"]}}]}}]}]}
{"id": "15827071_2", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[45]], "entity_id": ["T8"]}, "Subject": {"text": [["2 cases of serotonin toxicity (ST)"]], "start": [[10]], "entity_id": ["T7"], "Population": {"text": [["2"]], "start": [[10]], "entity_id": ["T10"]}}, "Treatment": {"text": [["concomitant use of linezolid and serotonergic drugs"]], "start": [[61]], "entity_id": ["T9"], "Drug": {"text": [["linezolid"], ["serotonergic"]], "start": [[80], [94]], "entity_id": ["T12", "T14"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[61]], "entity_id": ["T13"]}, "Drug": {"text": [["linezolid"], ["serotonergic"]], "start": [[80], [94]], "entity_id": ["T12", "T14"]}}]}, "Effect": {"text": [["serotonin toxicity (ST)"]], "start": [[21]], "entity_id": ["T11"]}}]}]}
{"id": "14641354_2", "context": "We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T11"]}, "Subject": {"text": [["a 43-year-old woman"]], "start": [[10]], "entity_id": ["T10"], "Age": {"text": [["43-year-old"]], "start": [[12]], "entity_id": ["T15"]}, "Gender": {"text": [["woman"]], "start": [[24]], "entity_id": ["T16"]}}, "Effect": {"text": [["sore throat, swelling of the lips and oral cavity and dysphagia"]], "start": [[44]], "entity_id": ["T12"]}, "Treatment": {"text": [["2 weeks after the use of budesonide spray (Budefat)"]], "start": [[109]], "entity_id": ["T13"], "Time_elapsed": {"text": [["2 weeks after"]], "start": [[109]], "entity_id": ["T17"]}, "Drug": {"text": [["budesonide"], ["Budefat"]], "start": [[134], [152]], "entity_id": ["T18", "T19"]}, "Disorder": {"text": [["bronchial asthma."]], "start": [[178]], "entity_id": ["T20"]}, "Route": {"text": [["spray"]], "start": [[145]], "entity_id": ["T21"]}}}]}]}
{"id": "7496198_9", "context": "Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appear to"]], "start": [[36]], "entity_id": ["T12"]}, "Treatment": {"text": [["prescription of thiabendazole", "during the melarsoprol cure"]], "start": [[76, 132]], "entity_id": ["T9"], "Disorder": {"text": [["strongyloidiasis"]], "start": [[115]], "entity_id": ["T11"]}, "Drug": {"text": [["thiabendazole"], ["the melarsoprol cure"]], "start": [[92], [139]], "entity_id": ["T14", "T15"]}}, "Effect": {"text": [["increase the risk of ARE"]], "start": [[46]], "entity_id": ["T10"]}, "Subject": {"text": [["patients"]], "start": [[203]], "entity_id": ["T13"]}}]}]}
{"id": "20234160_1", "context": "Severe vancomycin-induced anaphylactic reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[18]], "entity_id": ["T4"]}, "Treatment": {"text": [["vancomycin"]], "start": [[7]], "entity_id": ["T3"], "Drug": {"text": [["vancomycin"]], "start": [[7]], "entity_id": ["T6"]}}, "Effect": {"text": [["anaphylactic reaction"]], "start": [[26]], "entity_id": ["T5"]}}]}]}
{"id": "9758325_1", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[9]], "entity_id": ["T5"]}, "Subject": {"text": [["two patients with probable Alzheimer's disease"]], "start": [[21]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[21]], "entity_id": ["T7"]}}, "Treatment": {"text": [["long-term treatment with metrifonate"]], "start": [[87]], "entity_id": ["T4"], "Drug": {"text": [["metrifonate"]], "start": [[112]], "entity_id": ["T9"]}, "Duration": {"text": [["long-term"]], "start": [[87]], "entity_id": ["T10"]}, "Disorder": {"text": [["Alzheimer's disease"]], "start": [[48]], "entity_id": ["T11"]}}, "Effect": {"text": [["Seizures"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "17987285_12", "context": "Caution should be exercised, especially in patients who are given voriconazole or fluconazole during long-lasting fentanyl treatment, because insidiously elevated fentanyl concentration may lead to respiratory depression.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[190]], "entity_id": ["T10"]}, "Subject": {"text": [["patients"]], "start": [[43]], "entity_id": ["T8"]}, "Treatment": {"text": [["fentanyl"]], "start": [[114]], "entity_id": ["T9"], "Drug": {"text": [["voriconazole"], ["fluconazole"], ["fentanyl"]], "start": [[66], [82], [163]], "entity_id": ["T12", "T13", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[94]], "entity_id": ["T14"]}, "Drug": {"text": [["voriconazole"], ["fluconazole"]], "start": [[66], [82]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["respiratory depression"]], "start": [[198]], "entity_id": ["T11"]}}]}]}
{"id": "17473920_8", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[62]], "entity_id": ["T8"]}, "Subject": {"text": [["nine out of ten patients"]], "start": [[37]], "entity_id": ["T6"], "Population": {"text": [["nine out of ten"]], "start": [[37]], "entity_id": ["T10"]}}, "Treatment": {"text": [["nevirapine"]], "start": [[15]], "entity_id": ["T7"], "Drug": {"text": [["nevirapine"]], "start": [[15]], "entity_id": ["T11"]}}, "Effect": {"text": [["abstinence syndrome"]], "start": [[86]], "entity_id": ["T9"]}}]}]}
{"id": "7439122_1", "context": "Clofibrate-induced myopathy in patients with diabetes insipidus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clofibrate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Clofibrate"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["diabetes insipidus"]], "start": [[45]], "entity_id": ["T9"]}}, "Effect": {"text": [["myopathy"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with diabetes insipidus"]], "start": [[31]], "entity_id": ["T6"]}}]}]}
{"id": "17473493_2", "context": "This is the first histologically confirmed case of NASH that was aggravated by raloxifene.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aggravated"]], "start": [[65]], "entity_id": ["T4"]}, "Effect": {"text": [["NASH"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["raloxifene"]], "start": [[79]], "entity_id": ["T5"], "Drug": {"text": [["raloxifene"]], "start": [[79]], "entity_id": ["T6"]}}}]}]}
{"id": "16192734_2", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ritodrine hydrochloride"]], "start": [[79]], "entity_id": ["T4"], "Drug": {"text": [["ritodrine hydrochloride."]], "start": [[79]], "entity_id": ["T6"]}}}]}]}
{"id": "515777_1", "context": "Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[55]], "entity_id": ["T7"]}, "Effect": {"text": [["Hyperglycemia and diabetic coma"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["propranolol"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["propranolol"]], "start": [[67]], "entity_id": ["T8"]}}}]}]}
{"id": "18628507_5", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[55]], "entity_id": ["T5"]}, "Treatment": {"text": [["Voriconazole (VRC)"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Voriconazole"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["angio-oedema"]], "start": [[61]], "entity_id": ["T6"]}, "Negated": {"text": [["not"]], "start": [[23]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "10573314_5", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[53]], "entity_id": ["T7"]}, "Treatment": {"text": [["levofloxacin", "tolterodine"]], "start": [[66, 100]], "entity_id": ["T6"], "Disorder": {"text": [["prostatitis"]], "start": [[30]], "entity_id": ["T8"]}, "Drug": {"text": [["levofloxacin"], ["tolterodine"]], "start": [[66], [100]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["prior to"]], "start": [[91]], "entity_id": ["T13"]}, "Drug": {"text": [["levofloxacin"], ["tolterodine"]], "start": [[66], [100]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "10808214_1", "context": "A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T6"]}, "Effect": {"text": [["sudden cutaneous reaction"]], "start": [[89]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with an allergy to a macrolide antibiotic"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["allergy to a macrolide antibiotic"]], "start": [[18]], "entity_id": ["T8"]}}, "Treatment": {"text": [["given tacrolimus"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["tacrolimus"]], "start": [[62]], "entity_id": ["T9"]}}}]}]}
{"id": "16393774_5", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["initiation"]], "start": [[58]], "entity_id": ["T6"]}, "Subject": {"text": [["The first patient"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["IFN-beta"]], "start": [[72]], "entity_id": ["T7"], "Drug": {"text": [["IFN-beta"]], "start": [[72]], "entity_id": ["T9"]}}, "Effect": {"text": [["monoarthritis"]], "start": [[30]], "entity_id": ["T8"]}}]}]}
{"id": "16863495_1", "context": "Olanzapine-associated neuroleptic malignant syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "11180704_1", "context": "Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[76]], "entity_id": ["T5"]}, "Treatment": {"text": [["Oral intake and acarbose"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["acarbose"]], "start": [[16]], "entity_id": ["T7"]}, "Route": {"text": [["Oral intake"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["the ileus spontaneously resolved"]], "start": [[43]], "entity_id": ["T4"]}}]}]}
{"id": "9205466_1", "context": "Although its side effects are few, tamoxifen increases the incidence of proliferative lesions of the endometrium, which theoretically should be preventable with progestational agents.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increases"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["tamoxifen"]], "start": [[35]], "entity_id": ["T7"]}}, "Effect": {"text": [["proliferative lesions of the endometrium"]], "start": [[72]], "entity_id": ["T4"]}, "Speculated": {"text": [["incidence"]], "start": [[59]], "entity_id": ["T12"], "value": true}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["preventable"]], "start": [[144]], "entity_id": ["T8"]}, "Treatment": {"text": [["progestational agents"]], "start": [[161]], "entity_id": ["T9"], "Disorder": {"text": [["proliferative lesions of the endometrium"]], "start": [[72]], "entity_id": ["T11"]}, "Drug": {"text": [["progestational agents"]], "start": [[161]], "entity_id": ["T10"]}}, "Speculated": {"text": [["theoretically should"]], "start": [[120]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11283125_9", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["decrease"]], "start": [[132]], "entity_id": ["T16"]}, "Treatment": {"text": [["HD Ara-C", "HD MTX"]], "start": [[63, 81]], "entity_id": ["T7"], "Drug": {"text": [["Ara-C"], ["MTX"]], "start": [[66], [84]], "entity_id": ["T11", "T12"]}, "Dosage": {"text": [["HD"], ["HD"]], "start": [[81], [63]], "entity_id": ["T13", "T14"]}, "Disorder": {"text": [["CNS relapse"], ["DFS"]], "start": [[158], [196]], "entity_id": ["T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[72]], "entity_id": ["T15"]}, "Drug": {"text": [["Ara-C"], ["MTX"]], "start": [[66], [84]], "entity_id": ["T11", "T12"]}}]}, "Negated": {"text": [["failed"]], "start": [[114]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12504711_3", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[49]], "entity_id": ["T4"]}, "Effect": {"text": [["unusual paradoxical effect"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["brimonidine"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["brimonidine"]], "start": [[52]], "entity_id": ["T6"]}}}]}]}
{"id": "15735923_1", "context": "Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T7"]}, "Effect": {"text": [["myelodysplastic syndrome"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["temozolomide"]], "start": [[49]], "entity_id": ["T8"], "Drug": {"text": [["temozolomide"]], "start": [[49]], "entity_id": ["T10"]}, "Disorder": {"text": [["recurrent high-grade glioma"]], "start": [[66]], "entity_id": ["T11"]}}}]}]}
{"id": "17387702_1", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[14]], "entity_id": ["T6"]}, "Effect": {"text": [["Renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["high-dose methotrexate"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[30]], "entity_id": ["T7"]}, "Dosage": {"text": [["high-dose"]], "start": [[20]], "entity_id": ["T9"]}}, "Subject": {"text": [["a child homozygous for MTHFR C677T polymorphism"]], "start": [[46]], "entity_id": ["T5"], "Disorder": {"text": [["MTHFR C677T polymorphism"]], "start": [[69]], "entity_id": ["T8"]}, "Age": {"text": [["child"]], "start": [[48]], "entity_id": ["T1"]}}}]}]}
{"id": "7538828_8", "context": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[38]], "entity_id": ["T6"]}, "Effect": {"text": [["extensive skin rash"]], "start": [[18]], "entity_id": ["T5"]}, "Treatment": {"text": [["MTX"]], "start": [[65]], "entity_id": ["T7"], "Drug": {"text": [["MTX"]], "start": [[65]], "entity_id": ["T8"]}}}]}]}
{"id": "20126479_3", "context": "Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["before"]], "start": [[112]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxychloroquine"]], "start": [[76]], "entity_id": ["T3"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[76]], "entity_id": ["T6"]}}, "Effect": {"text": [["symptomatic vision loss"]], "start": [[119]], "entity_id": ["T4"]}}]}]}
{"id": "17509184_2", "context": "Ethambutol toxicity manifesting as acute onset psychosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute onset psychosis"]], "start": [[35]], "entity_id": ["T5"]}}]}]}
{"id": "11788010_6", "context": "We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[93]], "entity_id": ["T6"]}, "Effect": {"text": [["hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis"]], "start": [[20]], "entity_id": ["T3"]}, "Subject": {"text": [["a 37 year old male with acromegaly"]], "start": [[96]], "entity_id": ["T4"], "Age": {"text": [["37 year old"]], "start": [[98]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[110]], "entity_id": ["T8"]}}, "Treatment": {"text": [["octreotide"]], "start": [[150]], "entity_id": ["T5"], "Drug": {"text": [["octreotide"]], "start": [[150]], "entity_id": ["T10"]}, "Disorder": {"text": [["acromegaly"]], "start": [[120]], "entity_id": ["T11"]}}}]}]}
{"id": "12889716_1", "context": "Enoxaparin-induced generalized exanthem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Effect": {"text": [["generalized exanthem"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["Enoxaparin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Enoxaparin"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "12869178_2", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[159]], "entity_id": ["T4"]}, "Subject": {"text": [["Most cardiac surgical patients"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["cardiac surgical"]], "start": [[5]], "entity_id": ["T7"]}}, "Treatment": {"text": [["heparin"]], "start": [[61]], "entity_id": ["T6"], "Drug": {"text": [["heparin"]], "start": [[61]], "entity_id": ["T8"]}}, "Effect": {"text": [["heparin-induced thrombocytopenia (HIT)"]], "start": [[170]], "entity_id": ["T5"]}}]}]}
{"id": "3659584_5", "context": "Although rare, massive pulmonary embolus must be considered to be a major risk of thrombolytic therapy for deep venous thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[74]], "entity_id": ["T8"]}, "Effect": {"text": [["massive pulmonary embolus"]], "start": [[15]], "entity_id": ["T7"]}, "Treatment": {"text": [["thrombolytic"]], "start": [[82]], "entity_id": ["T9"], "Drug": {"text": [["thrombolytic"]], "start": [[82]], "entity_id": ["T10"]}}}]}]}
{"id": "18751717_4", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[65]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients with ocular inflammation"]], "start": [[9]], "entity_id": ["T3"], "Disorder": {"text": [["ocular inflammation"]], "start": [[27]], "entity_id": ["T4"]}, "Population": {"text": [["Two"]], "start": [[9]], "entity_id": ["T8"]}}, "Treatment": {"text": [["IVTA injection"]], "start": [[104]], "entity_id": ["T6"], "Drug": {"text": [["IVTA"]], "start": [[104]], "entity_id": ["T10"]}, "Route": {"text": [["injection"]], "start": [[109]], "entity_id": ["T11"]}}, "Effect": {"text": [["severe chorioretinitis"]], "start": [[75]], "entity_id": ["T7"]}, "Severity": {"text": [["severe"]], "start": [[75]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "2857534_3", "context": "Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium-responsive manic episodes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[88]], "entity_id": ["T6"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["a bipolar disorder"]], "start": [[65]], "entity_id": ["T10"]}}, "Treatment": {"text": [["alprazolam"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["alprazolam"]], "start": [[26]], "entity_id": ["T9"]}}, "Effect": {"text": [["lithium-responsive manic episodes"]], "start": [[98]], "entity_id": ["T7"]}}]}]}
{"id": "6833205_1", "context": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["SIADH"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["desipramine treatment"]], "start": [[32]], "entity_id": ["T5"], "Disorder": {"text": [["depressed"]], "start": [[68]], "entity_id": ["T8"]}, "Drug": {"text": [["desipramine"]], "start": [[32]], "entity_id": ["T10"]}}, "Subject": {"text": [["an elderly depressed woman"]], "start": [[57]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[60]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[78]], "entity_id": ["T9"]}}}]}]}
{"id": "10458196_2", "context": "An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[21]], "entity_id": ["T8"]}, "Subject": {"text": [["An 11-day-old infant"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["11-day-old"], ["infant"]], "start": [[3], [14]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["lethargic and apneic"]], "start": [[28]], "entity_id": ["T6"]}, "Treatment": {"text": [["a single drop of brimonidine"]], "start": [[55]], "entity_id": ["T7"], "Dosage": {"text": [["single drop"]], "start": [[57]], "entity_id": ["T9"]}, "Drug": {"text": [["brimonidine"]], "start": [[72]], "entity_id": ["T10"]}}}]}]}
{"id": "16615675_2", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["QT prolongation and refractory ventricular arrhythmia"]], "start": [[47]], "entity_id": ["T6"]}, "Treatment": {"text": [["Chronic hydroxychloroquine"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[8]], "entity_id": ["T8"]}, "Dosage": {"text": [["Chronic"]], "start": [[0]], "entity_id": ["T9"]}}}]}]}
{"id": "1124417_1", "context": "Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["acute renal failure"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["acetazolamide therapy for glaucoma"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["acetazolamide"]], "start": [[54]], "entity_id": ["T6"]}, "Disorder": {"text": [["glaucoma"]], "start": [[80]], "entity_id": ["T7"]}}}]}]}
{"id": "16680561_10", "context": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[206]], "entity_id": ["T14"]}, "Treatment": {"text": [["desipramine or cinacalcet"]], "start": [[248]], "entity_id": ["T13"], "Drug": {"text": [["desipramine"], ["cinacalcet"]], "start": [[248], [263]], "entity_id": ["T15", "T19"]}}, "Effect": {"text": [["nausea and headache"]], "start": [[175]], "entity_id": ["T12"]}}]}]}
{"id": "14742791_2", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[58]], "entity_id": ["T5"]}, "Effect": {"text": [["general malaise"]], "start": [[65]], "entity_id": ["T3"]}, "Treatment": {"text": [["taking pantoprazole", "After 5 weeks of therapy"]], "start": [[38, 0]], "entity_id": ["T4"], "Time_elapsed": {"text": [["5 weeks"]], "start": [[6]], "entity_id": ["T6"]}, "Drug": {"text": [["pantoprazole"]], "start": [[45]], "entity_id": ["T7"]}}}]}]}
{"id": "1688693_4", "context": "Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["controlled"]], "start": [[59]], "entity_id": ["T7"]}, "Treatment": {"text": [["Esmolol, an ultrashort-acting beta 1-selective antagonist"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation"]], "start": [[74]], "entity_id": ["T8"]}, "Drug": {"text": [["Esmolol"]], "start": [[0]], "entity_id": ["T10"]}}, "Subject": {"text": [["her"]], "start": [[70]], "entity_id": ["T9"]}}]}]}
{"id": "12692521_1", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["Systemic capillary leak syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["granulocyte colony-stimulating factor (G-CSF)"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["granulocyte colony-stimulating factor"]], "start": [[39]], "entity_id": ["T7"]}}}]}]}
{"id": "6519218_2", "context": "Interstitial pneumopathy and low-dosage amiodarone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["and"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["low-dosage amiodarone"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[40]], "entity_id": ["T6"]}, "Dosage": {"text": [["low-dosage"]], "start": [[29]], "entity_id": ["T7"]}}, "Effect": {"text": [["Interstitial pneumopathy"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12149193_1", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[57]], "entity_id": ["T9"]}, "Subject": {"text": [["myeloma patients"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["doxorubicin", "thalidomide"]], "start": [[25, 67]], "entity_id": ["T8"], "Disorder": {"text": [["myeloma"]], "start": [[40]], "entity_id": ["T10"]}, "Drug": {"text": [["doxorubicin"], ["thalidomide"]], "start": [[25], [67]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["Thrombogenic activity"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "19826099_2", "context": "Severe apnea in an infant exposed to lamotrigine in breast milk.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[13]], "entity_id": ["T6"]}, "Effect": {"text": [["apnea"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamotrigine"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["lamotrigine"]], "start": [[37]], "entity_id": ["T8"]}, "Route": {"text": [["breast milk"]], "start": [[52]], "entity_id": ["T9"]}}, "Subject": {"text": [["an infant"]], "start": [[16]], "entity_id": ["T5"], "Age": {"text": [["infant"]], "start": [[19]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "15773973_2", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[59]], "entity_id": ["T4"]}, "Treatment": {"text": [["flucloxacillin"]], "start": [[27]], "entity_id": ["T3"], "Drug": {"text": [["flucloxacillin"]], "start": [[27]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatic injury"]], "start": [[75]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[42]], "entity_id": ["T7"], "value": true}, "Severity": {"text": [["fatal"]], "start": [[69]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "2894766_3", "context": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[119]], "entity_id": ["T13"]}, "Subject": {"text": [["a 43-year-old man"]], "start": [[132]], "entity_id": ["T9"], "Age": {"text": [["43-year-old"]], "start": [[134]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[146]], "entity_id": ["T15"]}}, "Treatment": {"text": [["long-term sulfasalazine"]], "start": [[169]], "entity_id": ["T11"], "Disorder": {"text": [["chronic ulcerative colitis"]], "start": [[205]], "entity_id": ["T10"]}, "Drug": {"text": [["sulfasalazine"]], "start": [[179]], "entity_id": ["T16"]}}, "Effect": {"text": [["Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies"]], "start": [[0]], "entity_id": ["T12"]}}]}]}
{"id": "3967536_1", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[29]], "entity_id": ["T7"]}, "Effect": {"text": [["Hypotension and sinus arrest"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["nifedipine"]], "start": [[34]], "entity_id": ["T6"], "Disorder": {"text": [["pulmonary hypertension"]], "start": [[48]], "entity_id": ["T8"]}, "Drug": {"text": [["nifedipine"]], "start": [[34]], "entity_id": ["T9"]}}}]}]}
{"id": "16641839_2", "context": "Angioedema, a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["Angioedema", "involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins"]], "start": [[0, 49]], "entity_id": ["T3"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["carbamazepine"]], "start": [[34]], "entity_id": ["T6"]}}}]}]}
{"id": "18343993_1", "context": "A diagnosis of trastuzumab-induced pneumonitis was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[27]], "entity_id": ["T4"]}, "Treatment": {"text": [["trastuzumab"]], "start": [[15]], "entity_id": ["T3"], "Drug": {"text": [["trastuzumab"]], "start": [[15]], "entity_id": ["T6"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[35]], "entity_id": ["T5"]}}]}]}
{"id": "17034541_2", "context": "Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B-cell lymphomas.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[45]], "entity_id": ["T4"]}, "Effect": {"text": [["Several such HBV reactivations"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["combined rituximab and multiagent chemotherapy for B-cell lymphomas"]], "start": [[51]], "entity_id": ["T5"], "Disorder": {"text": [["B-cell lymphoma"]], "start": [[102]], "entity_id": ["T6"]}, "Drug": {"text": [["rituximab"], ["multiagent"]], "start": [[60], [74]], "entity_id": ["T7", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[70]], "entity_id": ["T8"]}, "Drug": {"text": [["rituximab"], ["multiagent"]], "start": [[60], [74]], "entity_id": ["T7", "T9"]}}]}}]}]}
{"id": "8636829_1", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T6"]}, "Effect": {"text": [["macrophage activation syndrome"]], "start": [[2]], "entity_id": ["T5"]}, "Treatment": {"text": [["methotrexate toxicity"]], "start": [[54]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[54]], "entity_id": ["T11"]}, "Disorder": {"text": [["systemic juvenile rheumatoid arthritis"]], "start": [[101]], "entity_id": ["T12"]}}, "Subject": {"text": [["a boy with systemic juvenile rheumatoid arthritis"]], "start": [[90]], "entity_id": ["T8"], "Gender": {"text": [["boy"]], "start": [[92]], "entity_id": ["T9"]}}, "Speculated": {"text": [["possibly"]], "start": [[34]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "10082597_1", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[48]], "entity_id": ["T6"]}, "Subject": {"text": [["two cases"]], "start": [[19]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[19]], "entity_id": ["T8"]}}, "Effect": {"text": [["pseudoporphyria"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["naproxen and oxaprozin"]], "start": [[58]], "entity_id": ["T7"], "Drug": {"text": [["naproxen"], ["oxaprozin"]], "start": [[58], [71]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[67]], "entity_id": ["T9"]}, "Drug": {"text": [["oxaprozin"], ["naproxen"]], "start": [[71], [58]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "18691992_2", "context": "Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[189]], "entity_id": ["T4"]}, "Treatment": {"text": [["hydroxyurea chemotherapy"]], "start": [[138]], "entity_id": ["T3"], "Drug": {"text": [["hydroxyurea"], ["hydroxyurea"]], "start": [[90], [138]], "entity_id": ["T6", "T7"]}, "Route": {"text": [["chemotherapy"]], "start": [[150]], "entity_id": ["T8"]}}, "Effect": {"text": [["myeloproliferative disorder"]], "start": [[204]], "entity_id": ["T5"]}}]}]}
{"id": "7673653_2", "context": "Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[28]], "entity_id": ["T5"]}, "Effect": {"text": [["Extrapyramidal side effects"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["fluoxetine"], ["sertraline"]], "start": [[98], [113]], "entity_id": ["T9", "T10"]}, "Disorder": {"text": [["depression and obsessive-compulsive disorder (OCD)"]], "start": [[172]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[109]], "entity_id": ["T11"]}, "Drug": {"text": [["fluoxetine"], ["sertraline"]], "start": [[98], [113]], "entity_id": ["T9", "T10"]}}]}, "Subject": {"text": [["patients with depression and obsessive-compulsive disorder (OCD)"]], "start": [[158]], "entity_id": ["T7"]}}]}]}
{"id": "9291634_6", "context": "Ten-17 days after receiving chemotherapy, five patients (4 males and 1 female) with acute lymphoblastic leukemia developed incapacitating myalgias in neck, thighs and arms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[113]], "entity_id": ["T7"]}, "Subject": {"text": [["five patients (4 males and 1 female) with acute lymphoblastic leukemia"]], "start": [[42]], "entity_id": ["T8"], "Population": {"text": [["4"], ["1"]], "start": [[57], [69]], "entity_id": ["T12", "T14"]}, "Gender": {"text": [["males"], ["female"]], "start": [[59], [71]], "entity_id": ["T13", "T15"]}}, "Effect": {"text": [["incapacitating myalgias in neck, thighs and arms"]], "start": [[123]], "entity_id": ["T9"]}, "Treatment": {"text": [["Ten-17 days after receiving chemotherapy"]], "start": [[0]], "entity_id": ["T10"], "Route": {"text": [["chemotherapy"]], "start": [[28]], "entity_id": ["T17"]}, "Time_elapsed": {"text": [["Ten-17 days"]], "start": [[0]], "entity_id": ["T18"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[84]], "entity_id": ["T19"]}}}]}]}
{"id": "9681092_2", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T11"]}, "Effect": {"text": [["QT prolongation"]], "start": [[20]], "entity_id": ["T10"]}, "Treatment": {"text": [["concomitant cyclobenzaprine and fluoxetine administration"]], "start": [[52]], "entity_id": ["T12"], "Drug": {"text": [["cyclobenzaprine"], ["fluoxetine"]], "start": [[64], [84]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[52]], "entity_id": ["T13"]}, "Drug": {"text": [["cyclobenzaprine"], ["fluoxetine"]], "start": [[64], [84]], "entity_id": ["T14", "T15"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["potentiated"]], "start": [[141]], "entity_id": ["T17"]}, "Effect": {"text": [["torsade de pointes"]], "start": [[122]], "entity_id": ["T16"]}, "Treatment": {"text": [["droperidol"]], "start": [[156]], "entity_id": ["T18"], "Drug": {"text": [["droperidol"]], "start": [[156]], "entity_id": ["T19"]}}}]}]}
{"id": "21597286_2", "context": "We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[65]], "entity_id": ["T5"]}, "Subject": {"text": [["a woman", "a T-lymphoblastic lymphoma"]], "start": [[57, 124]], "entity_id": ["T6"], "Gender": {"text": [["woman"]], "start": [[59]], "entity_id": ["T9"]}}, "Treatment": {"text": [["a first injection of high-dose methotrexate"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[107]], "entity_id": ["T10"]}, "Dosage": {"text": [["high-dose"]], "start": [[97]], "entity_id": ["T11"]}, "Route": {"text": [["injection"]], "start": [[84]], "entity_id": ["T12"]}, "Disorder": {"text": [["T-lymphoblastic lymphoma"]], "start": [[126]], "entity_id": ["T13"]}, "Time_elapsed": {"text": [["first"]], "start": [[78]], "entity_id": ["T14"]}}, "Effect": {"text": [["potential drug-drug interaction"]], "start": [[22]], "entity_id": ["T15"]}}]}]}
{"id": "3211830_2", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["diltiazem"]], "start": [[48]], "entity_id": ["T3"], "Drug": {"text": [["diltiazem"]], "start": [[48]], "entity_id": ["T6"]}}, "Effect": {"text": [["cutaneous vasculitis"]], "start": [[11]], "entity_id": ["T5"]}}]}]}
{"id": "6597713_3", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[62]], "entity_id": ["T5"]}, "Effect": {"text": [["hyperchloremic metabolic acidosis"]], "start": [[24]], "entity_id": ["T3"]}, "Treatment": {"text": [["cholestyramine"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["cholestyramine"]], "start": [[75]], "entity_id": ["T6"]}}, "Speculated": {"text": [["presumed"]], "start": [[6]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17133571_1", "context": "Liver transplantation for fulminant hepatitis related to nevirapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[46]], "entity_id": ["T4"]}, "Effect": {"text": [["Liver transplantation for fulminant hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["nevirapine therapy"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["nevirapine"]], "start": [[57]], "entity_id": ["T6"]}}}]}]}
{"id": "7718983_4", "context": "This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of Graves' hyperthyroidism during IFN therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[135]], "entity_id": ["T5"]}, "Effect": {"text": [["Graves' hyperthyroidism"]], "start": [[149]], "entity_id": ["T3"]}, "Treatment": {"text": [["IFN therapy"]], "start": [[180]], "entity_id": ["T4"], "Drug": {"text": [["IFN"]], "start": [[180]], "entity_id": ["T6"]}}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "11568758_2", "context": "This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["emerged"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["eruption"]], "start": [[5]], "entity_id": ["T3"]}, "Treatment": {"text": [["after 1 month of therapy with salsalate"]], "start": [[22]], "entity_id": ["T5"], "Time_elapsed": {"text": [["1 month"]], "start": [[28]], "entity_id": ["T7"]}, "Drug": {"text": [["salsalate"]], "start": [[52]], "entity_id": ["T8"]}}}]}]}
{"id": "10803790_7", "context": "When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develops"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["cyanamide"]], "start": [[5]], "entity_id": ["T3"], "Drug": {"text": [["cyanamide"]], "start": [[5]], "entity_id": ["T8"]}, "Disorder": {"text": [["alcoholics"]], "start": [[23]], "entity_id": ["T9"]}}, "Effect": {"text": [["inflammation"]], "start": [[69]], "entity_id": ["T4"]}, "Subject": {"text": [["cyanamide-treated alcoholics"]], "start": [[5]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[62]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "10579985_2", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["between"]], "start": [[17]], "entity_id": ["T6"]}, "Effect": {"text": [["lymphoma"]], "start": [[50]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T5"], "Disorder": {"text": [["Crohn's disease"]], "start": [[62]], "entity_id": ["T7"]}, "Drug": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T4"]}}}]}]}
{"id": "8467620_2", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[133]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[44]], "entity_id": ["T3"], "Drug": {"text": [["methotrexate"]], "start": [[44]], "entity_id": ["T9"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[95]], "entity_id": ["T10"]}}, "Effect": {"text": [["immunosuppression"]], "start": [[9]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with rheumatoid arthritis"]], "start": [[81]], "entity_id": ["T6"]}, "Speculated": {"text": [["probably"]], "start": [[65]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["mild"]], "start": [[4]], "entity_id": ["T11"], "value": "Low"}}]}]}
{"id": "19512997_1", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["Divalproex sodium"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Divalproex sodium"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["eosinophilic pleural effusion"]], "start": [[26]], "entity_id": ["T5"]}}]}]}
{"id": "19537383_1", "context": "Localized dyskeratotic plaque with milia associated with sorafenib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["sorafenib"]], "start": [[57]], "entity_id": ["T7"]}}, "Effect": {"text": [["Localized dyskeratotic plaque with milia"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "889156_4", "context": "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["replacement"]], "start": [[80]], "entity_id": ["T6"]}, "Effect": {"text": [["development of adrenal insufficiency"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["systemic steroids"]], "start": [[95]], "entity_id": ["T7"], "Drug": {"text": [["steroids"]], "start": [[104]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[52]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "12181031_3", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["cladribine"]], "start": [[139]], "entity_id": ["T6"], "Drug": {"text": [["cladribine"]], "start": [[139]], "entity_id": ["T11"]}}, "Effect": {"text": [["systemic vasculitis with associated thrombocytopenia"]], "start": [[54]], "entity_id": ["T7"]}, "Subject": {"text": [["a 73-year-old woman"]], "start": [[12]], "entity_id": ["T8"], "Age": {"text": [["73-year-old"]], "start": [[14]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[26]], "entity_id": ["T10"]}}}]}]}
{"id": "17083890_8", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["etiologic agents"]], "start": [[153]], "entity_id": ["T9"]}, "Effect": {"text": [["All changes disappeared"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["4 months after the discontinuation", "adriamycin and vincristine"]], "start": [[24, 114]], "entity_id": ["T8"], "Drug": {"text": [["vincristine"], ["adriamycin"]], "start": [[129], [114]], "entity_id": ["T11", "T12"]}, "Time_elapsed": {"text": [["4 months after"]], "start": [[24]], "entity_id": ["T13"]}, "Dosage": {"text": [["discontinuation"]], "start": [[43]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[125]], "entity_id": ["T10"]}, "Drug": {"text": [["adriamycin"], ["vincristine"]], "start": [[114], [129]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "7408538_2", "context": "Unusual pigmentary changes associated with 5-fluorouracil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Unusual pigmentary changes"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil"]], "start": [[43]], "entity_id": ["T6"]}}}]}]}
{"id": "18453852_14", "context": "The study showed a high incidence of adverse events when a higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin"]], "start": [[59]], "entity_id": ["T6"], "Dosage": {"text": [["higher than standard dose"]], "start": [[59]], "entity_id": ["T10"]}, "Drug": {"text": [["rifampicin"], ["lopinavir"], ["ritonavir"]], "start": [[142], [96], [106]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[128]], "entity_id": ["T9"]}, "Drug": {"text": [["ritonavir"], ["lopinavir"], ["rifampicin"]], "start": [[106], [96], [142]], "entity_id": ["T13", "T12", "T11"]}}]}, "Effect": {"text": [["adverse events"]], "start": [[37]], "entity_id": ["T7"]}}]}]}
{"id": "19499966_3", "context": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Onset"]], "start": [[0]], "entity_id": ["T7"]}, "Effect": {"text": [["gynaecomastia"]], "start": [[14]], "entity_id": ["T3"]}, "Subject": {"text": [["male", "a patient"]], "start": [[9, 31]], "entity_id": ["T4"], "Gender": {"text": [["male"]], "start": [[9]], "entity_id": ["T9"]}}, "Treatment": {"text": [["sunitinib for metastatic renal cell carcinoma"]], "start": [[54]], "entity_id": ["T5"], "Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [[68]], "entity_id": ["T6"]}, "Drug": {"text": [["sunitinib"]], "start": [[54]], "entity_id": ["T8"]}}}]}]}
{"id": "4082283_1", "context": "Rifampicin-induced renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["renal failure"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "15920338_1", "context": "A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[148]], "entity_id": ["T8"]}, "Treatment": {"text": [["adjuvant tamoxifen"]], "start": [[161]], "entity_id": ["T7"], "Drug": {"text": [["tamoxifen"]], "start": [[170]], "entity_id": ["T11"]}, "Disorder": {"text": [["high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth"]], "start": [[10]], "entity_id": ["T1"]}}, "Subject": {"text": [["a woman with a history of breast cancer"]], "start": [[100]], "entity_id": ["T6"], "Gender": {"text": [["woman"]], "start": [[102]], "entity_id": ["T9"]}, "Disorder": {"text": [["breast cancer"]], "start": [[126]], "entity_id": ["T5"]}}}]}]}
{"id": "7978578_1", "context": "Response of a promethazine-induced coma to flumazenil.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["promethazine"]], "start": [[14]], "entity_id": ["T6"], "Drug": {"text": [["promethazine"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["coma"]], "start": [[35]], "entity_id": ["T8"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Response"]], "start": [[0]], "entity_id": ["T14"]}, "Treatment": {"text": [["flumazenil"]], "start": [[43]], "entity_id": ["T12"], "Drug": {"text": [["flumazenil"]], "start": [[43]], "entity_id": ["T13"]}, "Disorder": {"text": [["promethazine-induced coma"]], "start": [[14]], "entity_id": ["T11"]}}}]}]}
{"id": "16978752_1", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[96]], "entity_id": ["T9"]}, "Effect": {"text": [["neutropenia or agranulocytosis"]], "start": [[65]], "entity_id": ["T7"]}, "Treatment": {"text": [["olanzapine (Zyprexa)"]], "start": [[118]], "entity_id": ["T8"], "Drug": {"text": [["olanzapine"]], "start": [[118]], "entity_id": ["T10"]}}}]}]}
{"id": "18607107_2", "context": "Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Development"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["copaxone"]], "start": [[81]], "entity_id": ["T3"], "Drug": {"text": [["copaxone"]], "start": [[81]], "entity_id": ["T8"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[49]], "entity_id": ["T9"]}}, "Effect": {"text": [["Crohn's disease"]], "start": [[15]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with multiple sclerosis"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "19281746_1", "context": "Aliskiren-associated acute renal failure with hyperkalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Aliskiren"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Aliskiren"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "17823522_5", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["involved"]], "start": [[57]], "entity_id": ["T7"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[33]], "entity_id": ["T6"], "Drug": {"text": [["interferon alpha"]], "start": [[33]], "entity_id": ["T9"]}}, "Effect": {"text": [["lichen nitidus"]], "start": [[89]], "entity_id": ["T8"]}, "Speculated": {"text": [["speculate"], ["may"]], "start": [[18], [50]], "entity_id": ["T5", "T10"], "value": true}}]}]}
{"id": "3718111_3", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[90]], "entity_id": ["T6"]}, "Effect": {"text": [["hyperkalemia"]], "start": [[7]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with radiation pneumonitis and glaucoma"]], "start": [[32]], "entity_id": ["T4"], "Disorder": {"text": [["glaucoma"]], "start": [[73]], "entity_id": ["T11"]}}, "Treatment": {"text": [["prednisone"]], "start": [[106]], "entity_id": ["T5"], "Drug": {"text": [["prednisone"]], "start": [[106]], "entity_id": ["T9"]}, "Disorder": {"text": [["radiation pneumonitis"]], "start": [[47]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["beginning"]], "start": [[96]], "entity_id": ["T12"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "15941649_2", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[29]], "entity_id": ["T3"]}, "Treatment": {"text": [["VGB"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["VGB"]], "start": [[25]], "entity_id": ["T9"]}}, "Effect": {"text": [["visual dysfunction"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["pediatric patients"]], "start": [[62]], "entity_id": ["T6"], "Age": {"text": [["pediatric"]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "2862137_1", "context": "A case is presented in which a 68-year-old man became delirious after being withdrawn from a low dosage of alprazolam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["68-year-old man"]], "start": [[31]], "entity_id": ["T3"], "Age": {"text": [["68-year-old"]], "start": [[31]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[43]], "entity_id": ["T8"]}}, "Treatment": {"text": [["withdrawn from a low dosage of alprazolam"]], "start": [[76]], "entity_id": ["T4"], "Drug": {"text": [["alprazolam"]], "start": [[107]], "entity_id": ["T9"]}, "Dosage": {"text": [["low dosage"]], "start": [[93]], "entity_id": ["T10"]}}, "Effect": {"text": [["delirious"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "16160485_2", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["Rituximab"]], "start": [[57]], "entity_id": ["T4"], "Drug": {"text": [["Rituximab"]], "start": [[57]], "entity_id": ["T6"]}}, "Effect": {"text": [["CD20-negative tumors"]], "start": [[10]], "entity_id": ["T5"]}}]}]}
{"id": "9792602_2", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Tubulointerstitial nephritis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["pranlukast"]], "start": [[76]], "entity_id": ["T5"], "Drug": {"text": [["pranlukast"]], "start": [[76]], "entity_id": ["T6"]}}}]}]}
{"id": "15863610_4", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosed"]], "start": [[75]], "entity_id": ["T6"]}, "Subject": {"text": [["a women"]], "start": [[20]], "entity_id": ["T7"], "Gender": {"text": [["women"]], "start": [[22]], "entity_id": ["T10"]}}, "Effect": {"text": [["a malignant mixed mesodermal tumor"]], "start": [[36]], "entity_id": ["T8"]}, "Treatment": {"text": [["while she was taking raloxifene"]], "start": [[85]], "entity_id": ["T9"], "Drug": {"text": [["raloxifene"]], "start": [[106]], "entity_id": ["T11"]}}}]}]}
{"id": "17420198_5", "context": "He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T6"]}, "Effect": {"text": [["episodic movements possibly consistent with EPS"]], "start": [[13]], "entity_id": ["T7"]}, "Treatment": {"text": [["secondary to aripiprazole usage"]], "start": [[61]], "entity_id": ["T8"], "Drug": {"text": [["aripiprazole"]], "start": [[74]], "entity_id": ["T11"]}}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T9"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "9760614_1", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[39]], "entity_id": ["T4"]}, "Treatment": {"text": [["repeated injections of tPA"]], "start": [[45]], "entity_id": ["T3"], "Drug": {"text": [["tPA"]], "start": [[68]], "entity_id": ["T6"]}, "Route": {"text": [["injections"]], "start": [[54]], "entity_id": ["T7"]}}, "Effect": {"text": [["1 eye had vitreous hemorrhage"]], "start": [[9]], "entity_id": ["T5"]}}]}]}
{"id": "19579947_2", "context": "Priapism associated with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Effect": {"text": [["Priapism"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "9883483_2", "context": "Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T6"]}, "Treatment": {"text": [["pirmenol"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["pirmenol"]], "start": [[71]], "entity_id": ["T8"]}}, "Effect": {"text": [["QT prolongation and T wave inversion on the electrocardiogram"]], "start": [[88]], "entity_id": ["T7"]}}]}]}
{"id": "9674820_1", "context": "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["transitioning from phenelzine to venlafaxine"]], "start": [[30]], "entity_id": ["T6"], "Drug": {"text": [["phenelzine"], ["venlafaxine"]], "start": [[49], [63]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["transitioning"]], "start": [[30]], "entity_id": ["T9"]}, "Drug": {"text": [["phenelzine"], ["venlafaxine"]], "start": [[49], [63]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["four patient"]], "start": [[76]], "entity_id": ["T7"], "Age": {"text": [["four"]], "start": [[76]], "entity_id": ["T8"]}}}]}]}
{"id": "15944830_4", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aware"]], "start": [[27]], "entity_id": ["T7"]}, "Effect": {"text": [["ocular side effects", "hypoalbuminemia and thrombocytopenia"]], "start": [[40, 137]], "entity_id": ["T8"]}, "Treatment": {"text": [["IFN"]], "start": [[63]], "entity_id": ["T10"], "Drug": {"text": [["IFN"]], "start": [[63]], "entity_id": ["T12"]}}, "Subject": {"text": [["patients"]], "start": [[97]], "entity_id": ["T9"]}, "Speculated": {"text": [["possible"]], "start": [[114]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "8145359_1", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffering"]], "start": [[196]], "entity_id": ["T6"]}, "Effect": {"text": [["respiratory distress syndrome"]], "start": [[211]], "entity_id": ["T4"]}, "Treatment": {"text": [["relatively high dose of methotrimeprazine meleate (Levemepromazine)"]], "start": [[42]], "entity_id": ["T5"], "Dosage": {"text": [["high dose"]], "start": [[53]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrimeprazine meleate"]], "start": [[66]], "entity_id": ["T11"]}}, "Subject": {"text": [["An 11-year-old boy"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["11-year-old"]], "start": [[3]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[15]], "entity_id": ["T9"]}}}]}]}
{"id": "8313300_6", "context": "A severe form of exophthalmos resulting from lithium therapy has not been described in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["exophthalmos"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["lithium"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["lithium"]], "start": [[45]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[2]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "21448111_3", "context": "Many types of medicaments can cause akathisia as an adverse event of their use and they include: antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse event"]], "start": [[52]], "entity_id": ["T10"]}, "Treatment": {"text": [["antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances"]], "start": [[97]], "entity_id": ["T9"], "Drug": {"text": [["antipsychotics"], ["antidepressants"], ["antiemetics"], ["antihistamines"], ["psychoactive substances."]], "start": [[97], [113], [130], [143], [163]], "entity_id": ["T12", "T13", "T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[159]], "entity_id": ["T17"]}, "Drug": {"text": [["antipsychotics"], ["antidepressants"], ["antiemetics"], ["antihistamines"], ["psychoactive substances."]], "start": [[97], [113], [130], [143], [163]], "entity_id": ["T12", "T13", "T14", "T15", "T16"]}}]}, "Effect": {"text": [["akathisia"]], "start": [[36]], "entity_id": ["T11"]}}]}]}
{"id": "1509179_1", "context": "A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exacerbation"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenobarbital", "partially suppressed by chlorpromazine"]], "start": [[10, 75]], "entity_id": ["T4"], "Drug": {"text": [["phenobarbital"], ["chlorpromazine"]], "start": [[10], [99]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["suppressed"]], "start": [[85]], "entity_id": ["T3"]}, "Drug": {"text": [["phenobarbital"], ["chlorpromazine"]], "start": [[10], [99]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["exacerbation of a preexisting maladaptive behavior"]], "start": [[24]], "entity_id": ["T5"]}, "Subject": {"text": [["preexisting maladaptive behavior"]], "start": [[42]], "entity_id": ["T7"], "Disorder": {"text": [["preexisting maladaptive behavior"]], "start": [[42]], "entity_id": ["T10"]}}}]}]}
{"id": "14632592_1", "context": "Colchicine-induced myopathy in a teenager with familial Mediterranean fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["Mediterranean fever"]], "start": [[56]], "entity_id": ["T8"]}, "Drug": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["myopathy"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["a teenager with familial Mediterranean fever"]], "start": [[31]], "entity_id": ["T6"], "Age": {"text": [["teenager"]], "start": [[33]], "entity_id": ["T7"]}}}]}]}
{"id": "18585545_4", "context": "Levofloxacin-induced delirium with psychotic features.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["delirium with psychotic features"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "6303138_1", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[25]], "entity_id": ["T7"]}, "Effect": {"text": [["Marked sinus tachycardia"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["marijuana and nortriptyline"]], "start": [[67]], "entity_id": ["T8"], "Drug": {"text": [["marijuana"], ["nortriptyline"]], "start": [[67], [81]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[77]], "entity_id": ["T11"]}, "Drug": {"text": [["marijuana"], ["nortriptyline"]], "start": [[67], [81]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "17373180_1", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[91]], "entity_id": ["T5"]}, "Effect": {"text": [["osteomyelitis"]], "start": [[77]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab"]], "start": [[96]], "entity_id": ["T6"], "Drug": {"text": [["Infliximab"], ["infliximab"]], "start": [[0], [96]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "9491301_3", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[39]], "entity_id": ["T4"]}, "Effect": {"text": [["Stroke"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["heroin addiction"]], "start": [[55]], "entity_id": ["T5"], "Drug": {"text": [["heroin"]], "start": [[55]], "entity_id": ["T6"]}}}]}]}
{"id": "8445549_3", "context": "The patient described in this paper was a 78-year-old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[100]], "entity_id": ["T5"]}, "Treatment": {"text": [["institution of glibenclamide"]], "start": [[110]], "entity_id": ["T3"], "Drug": {"text": [["glibenclamide"]], "start": [[125]], "entity_id": ["T10"]}, "Disorder": {"text": [["diabetic"]], "start": [[54]], "entity_id": ["T11"]}}, "Subject": {"text": [["The patient described in this paper was a 78-year-old diabetic man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["78-year-old"]], "start": [[42]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[63]], "entity_id": ["T9"]}}, "Effect": {"text": [["oral lesions of PV"]], "start": [[81]], "entity_id": ["T6"]}}]}]}
{"id": "4014301_1", "context": "Insulin-induced cardiac failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T5"]}, "Treatment": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["cardiac failure"]], "start": [[16]], "entity_id": ["T6"]}}]}]}
{"id": "9337441_14", "context": "To our knowledge, this case report represents only the third description of laxative-induced TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[85]], "entity_id": ["T4"]}, "Treatment": {"text": [["laxative"]], "start": [[76]], "entity_id": ["T5"], "Drug": {"text": [["laxative"]], "start": [[76]], "entity_id": ["T7"]}}, "Effect": {"text": [["TEN"]], "start": [[93]], "entity_id": ["T6"]}}]}]}
{"id": "21417793_2", "context": "Prompted by the advent of potentially life-threatening neuromuscular symptoms following initiation of linezolid therapy in two patients receiving treatment with a serotonin reuptake inhibitor antidepressant, an evaluation was conducted to determine the incidence and characteristics of symptomatic serotonin toxicity among hospitalized patients receiving combined treatment with these medications.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[78]], "entity_id": ["T17"]}, "Treatment": {"text": [["linezolid", "a serotonin reuptake inhibitor antidepressant"]], "start": [[102, 161]], "entity_id": ["T15"], "Drug": {"text": [["linezolid"], ["serotonin reuptake inhibitor"]], "start": [[102], [163]], "entity_id": ["T19", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[156]], "entity_id": ["T21"]}, "Drug": {"text": [["serotonin reuptake inhibitor"], ["linezolid"]], "start": [[163], [102]], "entity_id": ["T20", "T19"]}}]}, "Effect": {"text": [["neuromuscular symptoms"]], "start": [[55]], "entity_id": ["T16"]}, "Subject": {"text": [["two patients"]], "start": [[123]], "entity_id": ["T14"], "Population": {"text": [["two"]], "start": [[123]], "entity_id": ["T18"]}}, "Speculated": {"text": [["potentially"]], "start": [[26]], "entity_id": ["T22"], "value": true}, "Severity": {"text": [["life-threatening"]], "start": [[38]], "entity_id": ["T23"], "value": "High"}}]}]}
{"id": "8244201_3", "context": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[45]], "entity_id": ["T8"]}, "Subject": {"text": [["patients with lymphoid malignancy"]], "start": [[116]], "entity_id": ["T7"], "Disorder": {"text": [["lymphoid malignancy"]], "start": [[130]], "entity_id": ["T10"]}}, "Effect": {"text": [["Hyperkalaemia with renal tubular dysfunction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia"]], "start": [[48]], "entity_id": ["T6"], "Disorder": {"text": [["Pneumocystis carinii pneumonia"]], "start": [[82]], "entity_id": ["T9"]}, "Drug": {"text": [["sulfamethoxazole-trimethoprim"]], "start": [[48]], "entity_id": ["T11"]}}}]}]}
{"id": "19540093_2", "context": "Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T8"]}, "Treatment": {"text": [["7 days of tigecycline"]], "start": [[10]], "entity_id": ["T7"], "Time_elapsed": {"text": [["7 days"]], "start": [[10]], "entity_id": ["T10"]}, "Drug": {"text": [["tigecycline"]], "start": [[20]], "entity_id": ["T11"]}}, "Effect": {"text": [["abdominal pain and elevated pancreatic enzymes"]], "start": [[53]], "entity_id": ["T9"]}, "Subject": {"text": [["she"]], "start": [[32]], "entity_id": ["T12"]}, "Severity": {"text": [["severe"]], "start": [[46]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "6625005_1", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[37]], "entity_id": ["T4"]}, "Effect": {"text": [["withdrawal dyskinesia"]], "start": [[15]], "entity_id": ["T3"]}, "Treatment": {"text": [["amoxapine"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["amoxapine"]], "start": [[53]], "entity_id": ["T6"]}}, "Subject": {"text": [["Case"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "18644535_2", "context": "This is a case report of possible association of methylphenidate and enuresis in an 11-year-old boy with attention deficit hyperactivity disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[49]], "entity_id": ["T3"], "Disorder": {"text": [["attention deficit hyperactivity disorder"]], "start": [[105]], "entity_id": ["T9"]}, "Drug": {"text": [["methylphenidate"]], "start": [[49]], "entity_id": ["T10"]}}, "Effect": {"text": [["enuresis"]], "start": [[69]], "entity_id": ["T4"]}, "Subject": {"text": [["an 11-year-old boy with attention deficit hyperactivity disorder"]], "start": [[81]], "entity_id": ["T5"], "Age": {"text": [["11-year-old"]], "start": [[84]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[96]], "entity_id": ["T8"]}}}]}]}
{"id": "6738830_1", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["A 56-year-old male parkinsonian patient"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["56-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[14]], "entity_id": ["T8"]}, "Disorder": {"text": [["parkinsonian"]], "start": [[19]], "entity_id": ["T9"]}}, "Effect": {"text": [["a unique behavioral change"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["the oral administration of cinepazide, a cerebral vasodilator"]], "start": [[87]], "entity_id": ["T6"], "Drug": {"text": [["cinepazide"]], "start": [[114]], "entity_id": ["T11"]}, "Route": {"text": [["oral administration"]], "start": [[91]], "entity_id": ["T12"]}}}]}]}
{"id": "9517515_1", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Development"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient"]], "start": [[44]], "entity_id": ["T4"]}, "Effect": {"text": [["essential thrombocythemia"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["interferon alfa", "pentostatin"]], "start": [[67, 87]], "entity_id": ["T8"], "Disorder": {"text": [["hairy cell leukemia"]], "start": [[103]], "entity_id": ["T5"]}, "Drug": {"text": [["interferon alfa"], ["pentostatin"]], "start": [[67], [87]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[83]], "entity_id": ["T11"]}, "Drug": {"text": [["pentostatin"], ["interferon alfa"]], "start": [[87], [67]], "entity_id": ["T10", "T9"]}}]}}]}]}
{"id": "440873_3", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[147]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[74]], "entity_id": ["T3"], "Drug": {"text": [["carbamazepine"]], "start": [[74]], "entity_id": ["T6"]}}, "Effect": {"text": [["dystonia"]], "start": [[181]], "entity_id": ["T4"]}}]}]}
{"id": "12042592_2", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[101]], "entity_id": ["T4"]}, "Treatment": {"text": [["Metamizole"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Metamizole"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[109]], "entity_id": ["T5"]}}]}]}
{"id": "11406880_3", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[61]], "entity_id": ["T9"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["methadone"]], "start": [[24]], "entity_id": ["T7"], "Disorder": {"text": [["cancer-associated pain"]], "start": [[38]], "entity_id": ["T8"]}, "Drug": {"text": [["methadone"]], "start": [[24]], "entity_id": ["T11"]}}, "Effect": {"text": [["myoclonus"]], "start": [[71]], "entity_id": ["T10"]}}]}]}
{"id": "1680596_1", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[131]], "entity_id": ["T6"]}, "Subject": {"text": [["a woman with classical rheumatoid arthritis"]], "start": [[29]], "entity_id": ["T4"], "Gender": {"text": [["woman"]], "start": [[31]], "entity_id": ["T8"]}}, "Treatment": {"text": [["during introduction of sulphasalazine (SASP) therapy"]], "start": [[78]], "entity_id": ["T5"], "Drug": {"text": [["sulphasalazine"]], "start": [[101]], "entity_id": ["T10"]}, "Disorder": {"text": [["classical rheumatoid arthritis"]], "start": [[42]], "entity_id": ["T11"]}}, "Effect": {"text": [["psoriasis-like skin reaction"]], "start": [[162]], "entity_id": ["T7"]}, "Severity": {"text": [["severe"]], "start": [[143]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "19112808_1", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[38]], "entity_id": ["T4"]}, "Effect": {"text": [["Interstitial granulomatous dermatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["darifenacin"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["darifenacin"]], "start": [[54]], "entity_id": ["T6"]}}}]}]}
{"id": "20925534_3", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["believed"]], "start": [[34]], "entity_id": ["T9"]}, "Treatment": {"text": [["Proton-pump inhibitors (PPIs)"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Proton-pump inhibitors (PPIs)"], ["antiplatelet"]], "start": [[0], [157]], "entity_id": ["T11", "T12"]}}}]}]}
{"id": "278642_2", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[92]], "entity_id": ["T5"]}, "Treatment": {"text": [["chlorambucil"]], "start": [[10]], "entity_id": ["T3"], "Drug": {"text": [["chlorambucil"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["wbc count began to slowly rise"], ["clinical AML"]], "start": [[45], [102]], "entity_id": ["T4", "T6"]}, "Subject": {"text": [["the patient"]], "start": [[80]], "entity_id": ["T8"]}}]}]}
{"id": "11283125_8", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Prevention"]], "start": [[0]], "entity_id": ["T14"]}, "Subject": {"text": [["children"]], "start": [[106]], "entity_id": ["T11"], "Age": {"text": [["children"]], "start": [[106]], "entity_id": ["T10"]}}, "Treatment": {"text": [["HD IV MTX and intrathecal injections of MTX"]], "start": [[59]], "entity_id": ["T12"], "Disorder": {"text": [["CNS relapse"]], "start": [[14]], "entity_id": ["T13"]}, "Route": {"text": [["intrathecal injections"], ["HD IV"]], "start": [[73], [59]], "entity_id": ["T16", "T18"]}, "Drug": {"text": [["MTX", "MTX"]], "start": [[65, 99]], "entity_id": ["T19"]}}}]}]}
{"id": "17675030_2", "context": "Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["oxcarbazepine"]], "start": [[20]], "entity_id": ["T6"]}}, "Effect": {"text": [["angioneurotic edema"]], "start": [[42]], "entity_id": ["T5"]}}]}]}
{"id": "8253700_1", "context": "BACKGROUND: Fluoxetine, a highly specific serotonin reuptake inhibitor, has been reported to cause sexual dysfunction in a minority of patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[93]], "entity_id": ["T3"]}, "Effect": {"text": [["sexual dysfunction"]], "start": [[99]], "entity_id": ["T4"]}, "Treatment": {"text": [["Fluoxetine"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Fluoxetine"]], "start": [[12]], "entity_id": ["T6"]}}, "Subject": {"text": [["in a minority of patients"]], "start": [[118]], "entity_id": ["T7"]}}]}]}
{"id": "3947272_4", "context": "One patient had severe temporary weakness after an ampicillin sodium challenge.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["temporary weakness"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["an ampicillin sodium challenge"]], "start": [[48]], "entity_id": ["T6"], "Drug": {"text": [["ampicillin sodium"]], "start": [[51]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[16]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "11142491_1", "context": "Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute myeloid leukemia and lung cancer"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a chronic lymphocytic leukemia patient"]], "start": [[52]], "entity_id": ["T7"]}, "Treatment": {"text": [["fludarabine and autologous peripheral blood stem-cell transplantation"]], "start": [[104]], "entity_id": ["T8"], "Disorder": {"text": [["chronic lymphocytic leukemia"]], "start": [[54]], "entity_id": ["T10"]}, "Drug": {"text": [["fludarabine"], ["autologous peripheral blood stem-cell"]], "start": [[104], [120]], "entity_id": ["T11", "T12"]}, "Route": {"text": [["transplantation"]], "start": [[158]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[116]], "entity_id": ["T14"]}, "Drug": {"text": [["autologous peripheral blood stem-cell"], ["fludarabine"]], "start": [[120], [104]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "8396491_2", "context": "The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T5"]}, "Treatment": {"text": [["CPH82"]], "start": [[37]], "entity_id": ["T6"], "Drug": {"text": [["CPH82"]], "start": [[37]], "entity_id": ["T10"]}}, "Effect": {"text": [["suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism"]], "start": [[63]], "entity_id": ["T7"]}}]}]}
{"id": "16816519_7", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[57]], "entity_id": ["T7"]}, "Treatment": {"text": [["3.8 mg cumulative dose of vincristin"]], "start": [[13]], "entity_id": ["T6"], "Dosage": {"text": [["3.8 mg cumulative dose"]], "start": [[13]], "entity_id": ["T10"]}, "Drug": {"text": [["vincristin"]], "start": [[39]], "entity_id": ["T11"]}}, "Effect": {"text": [["ptosis"]], "start": [[72]], "entity_id": ["T8"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "19745701_3", "context": "She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[100]], "entity_id": ["T8"]}, "Effect": {"text": [["Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD)"]], "start": [[23]], "entity_id": ["T7"]}, "Treatment": {"text": [["immunodeficiency caused by MTX administration"]], "start": [[107]], "entity_id": ["T9"], "Drug": {"text": [["MTX"]], "start": [[134]], "entity_id": ["T10"]}}}]}]}
{"id": "17285101_1", "context": "Pulmonary hypertension during lithium therapy: clinical case study.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium therapy"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["Pulmonary hypertension"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "2429270_3", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[106]], "entity_id": ["T4"]}, "Treatment": {"text": [["procainamide"]], "start": [[112]], "entity_id": ["T5"], "Drug": {"text": [["procainamide"]], "start": [[112]], "entity_id": ["T6"]}}, "Effect": {"text": [["tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods"]], "start": [[17]], "entity_id": ["T3"]}}]}]}
{"id": "16484748_2", "context": "This is the first case of TMP-SMX-induced hypersensitivity syndrome associated with the reactivation of a latent viral infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["TMP-SMX"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypersensitivity syndrome", "reactivation of a latent viral infection"]], "start": [[42, 88]], "entity_id": ["T5"]}, "Subject": {"text": [["first case"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "8276031_5", "context": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre, is also discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptomatology"]], "start": [[4]], "entity_id": ["T8"]}, "Subject": {"text": [["18 other paediatric cases"]], "start": [[22]], "entity_id": ["T5"], "Population": {"text": [["18"]], "start": [[22]], "entity_id": ["T9"]}, "Age": {"text": [["paediatric"]], "start": [[31]], "entity_id": ["T10"]}}, "Effect": {"text": [["naphthylimidazoline exposure"]], "start": [[51]], "entity_id": ["T6"]}, "Treatment": {"text": [["naphthylimidazoline"]], "start": [[51]], "entity_id": ["T7"], "Drug": {"text": [["naphthylimidazoline"]], "start": [[51]], "entity_id": ["T11"]}, "Route": {"text": [["exposure"]], "start": [[71]], "entity_id": ["T12"]}}}]}]}
{"id": "85289_1", "context": "Anterior spinal artery syndrome--a complication of cervical intrathecal phenol injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Anterior spinal artery syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cervical intrathecal phenol injection"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["phenol"]], "start": [[72]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[79]], "entity_id": ["T7"]}}}]}]}
{"id": "3677571_16", "context": "Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[190]], "entity_id": ["T7"]}, "Effect": {"text": [["swelling of the face and legs and pruritus"]], "start": [[147]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin 1 g i.v."]], "start": [[53]], "entity_id": ["T5"], "Disorder": {"text": [["a tonic-clonic seizure"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["phenytoin"]], "start": [[53]], "entity_id": ["T10"]}, "Dosage": {"text": [["1 g"]], "start": [[63]], "entity_id": ["T11"]}, "Route": {"text": [["i.v."]], "start": [[67]], "entity_id": ["T12"]}}}]}]}
{"id": "12702914_5", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["deteriorated"]], "start": [[95]], "entity_id": ["T6"]}, "Treatment": {"text": [["40 mg/day of prednisolone"]], "start": [[6]], "entity_id": ["T3"], "Disorder": {"text": [["hepatic dysfunction"]], "start": [[41]], "entity_id": ["T11"]}, "Drug": {"text": [["prednisolone"]], "start": [[19]], "entity_id": ["T7"]}, "Dosage": {"text": [["40 mg/day"]], "start": [[6]], "entity_id": ["T8"]}}, "Effect": {"text": [["diabetic milieu deteriorated"]], "start": [[79]], "entity_id": ["T4"]}, "Severity": {"text": [["seriously"]], "start": [[108]], "entity_id": ["T10"], "value": "High"}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[32]], "entity_id": ["T9"]}, "Treatment": {"text": [["40 mg/day of prednisolone"]], "start": [[6]], "entity_id": ["T3"], "Disorder": {"text": [["hepatic dysfunction"]], "start": [[41]], "entity_id": ["T11"]}, "Drug": {"text": [["prednisolone"]], "start": [[19]], "entity_id": ["T7"]}, "Dosage": {"text": [["40 mg/day"]], "start": [[6]], "entity_id": ["T8"]}}}]}]}
{"id": "589261_3", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[42]], "entity_id": ["T9"]}, "Subject": {"text": [["five out of six patients"]], "start": [[51]], "entity_id": ["T5"], "Population": {"text": [["five out of six"]], "start": [[51]], "entity_id": ["T6"]}}, "Treatment": {"text": [["cardiac glycoside"]], "start": [[101]], "entity_id": ["T7"], "Drug": {"text": [["cardiac glycoside"]], "start": [[101]], "entity_id": ["T8"]}}, "Effect": {"text": [["Minor electrocardiographical changes"]], "start": [[0]], "entity_id": ["T4"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[42]], "entity_id": ["T9"]}, "Effect": {"text": [["Minor electrocardiographical changes"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["four out of six"]], "start": [[123]], "entity_id": ["T10"], "Population": {"text": [["four out of six"]], "start": [[123]], "entity_id": ["T11"]}}, "Treatment": {"text": [["ouabain"]], "start": [[158]], "entity_id": ["T12"], "Drug": {"text": [["ouabain"]], "start": [[158]], "entity_id": ["T13"]}}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[42]], "entity_id": ["T9"]}, "Effect": {"text": [["Minor electrocardiographical changes"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["none of the 16"]], "start": [[171]], "entity_id": ["T14"], "Population": {"text": [["none of the 16"]], "start": [[171]], "entity_id": ["T18"]}}, "Treatment": {"text": [["digoxin"]], "start": [[205]], "entity_id": ["T15"], "Drug": {"text": [["digoxin"]], "start": [[205]], "entity_id": ["T16"]}}, "Negated": {"text": [["none"]], "start": [[171]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "11961411_3", "context": "To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[105]], "entity_id": ["T4"]}, "Effect": {"text": [["histological abnormalities of the glomerulus"]], "start": [[60]], "entity_id": ["T3"]}, "Treatment": {"text": [["postoperative IFN-beta therapy"]], "start": [[121]], "entity_id": ["T5"], "Drug": {"text": [["IFN-beta"]], "start": [[135]], "entity_id": ["T7"]}, "Disorder": {"text": [["malignant melanoma"]], "start": [[160]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["postoperative"]], "start": [[121]], "entity_id": ["T9"]}}}]}]}
{"id": "717931_2", "context": "Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Marked hyperkalemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["an infusion of arginine monohydrochloride"]], "start": [[62]], "entity_id": ["T5"], "Disorder": {"text": [["hepatic disease"]], "start": [[132]], "entity_id": ["T8"]}, "Route": {"text": [["infusion"]], "start": [[65]], "entity_id": ["T10"]}, "Drug": {"text": [["arginine monohydrochloride"]], "start": [[77]], "entity_id": ["T11"]}}, "Subject": {"text": [["two patients with severe hepatic disease and moderate renal insufficiency"]], "start": [[107]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[107]], "entity_id": ["T7"]}, "Disorder": {"text": [["renal insufficiency"]], "start": [[161]], "entity_id": ["T12"]}}}]}]}
{"id": "2140997_3", "context": "Severe hepatitis caused by cyproterone acetate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["hepatitis"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyproterone acetate"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["cyproterone acetate"]], "start": [[27]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "11414270_7", "context": "Before ICU admission, the patient had suffered from painful mucositis causing severe dysphagia and bleeding, which was thought to be the result of chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[137]], "entity_id": ["T9"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[147]], "entity_id": ["T8"], "Route": {"text": [["chemotherapy"]], "start": [[147]], "entity_id": ["T13"]}}, "Effect": {"text": [["severe dysphagia and bleeding"]], "start": [[78]], "entity_id": ["T11"]}, "Subject": {"text": [["the patient had suffered from painful mucositis"]], "start": [[22]], "entity_id": ["T10"], "Disorder": {"text": [["mucositis"]], "start": [[60]], "entity_id": ["T12"]}}}]}]}
{"id": "17504225_2", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["use"]], "start": [[94]], "entity_id": ["T5"]}, "Subject": {"text": [["renal transplant recipients"]], "start": [[43]], "entity_id": ["T7"], "Disorder": {"text": [["renal transplant"]], "start": [[43]], "entity_id": ["T6"]}}, "Treatment": {"text": [["antimicrobial agents"]], "start": [[101]], "entity_id": ["T10"], "Disorder": {"text": [["Bacterial infection"]], "start": [[0]], "entity_id": ["T8"]}, "Drug": {"text": [["antimicrobial agents"]], "start": [[101]], "entity_id": ["T9"]}}}]}]}
{"id": "12854039_5", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["alpha interferon"]], "start": [[45]], "entity_id": ["T3"], "Drug": {"text": [["alpha interferon"]], "start": [[45]], "entity_id": ["T6"]}}, "Effect": {"text": [["Multiple sclerosis-like disease"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "17921794_4", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[120]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with mild chronic renal insufficiency"]], "start": [[20]], "entity_id": ["T6"], "Disorder": {"text": [["mild chronic renal insufficiency"]], "start": [[35]], "entity_id": ["T11"]}}, "Treatment": {"text": [["taking simvastatin for over a year", "3 weeks after the start of treatment with colchicine for acute gouty bursitis"]], "start": [[81, 152]], "entity_id": ["T7"], "Disorder": {"text": [["acute gouty bursitis"]], "start": [[209]], "entity_id": ["T10"]}, "Drug": {"text": [["simvastatin"], ["colchicine"]], "start": [[88], [194]], "entity_id": ["T12", "T15"]}, "Time_elapsed": {"text": [["over a year"], ["3 weeks"]], "start": [[104], [152]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["within"]], "start": [[145]], "entity_id": ["T18"]}, "Drug": {"text": [["simvastatin"], ["colchicine"]], "start": [[88], [194]], "entity_id": ["T12", "T15"]}}]}, "Effect": {"text": [["acute weakness"]], "start": [[130]], "entity_id": ["T9"]}}]}]}
{"id": "16978752_3", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[93]], "entity_id": ["T7"]}, "Effect": {"text": [["neutropenia"]], "start": [[28]], "entity_id": ["T4"]}, "Subject": {"text": [["a schizophrenia patient"]], "start": [[69]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine and thiazide"]], "start": [[103]], "entity_id": ["T6"], "Disorder": {"text": [["schizophrenia"]], "start": [[71]], "entity_id": ["T8"]}, "Drug": {"text": [["olanzapine"], ["thiazide"]], "start": [[103], [118]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[114]], "entity_id": ["T11"]}, "Drug": {"text": [["olanzapine"], ["thiazide"]], "start": [[103], [118]], "entity_id": ["T9", "T10"]}}]}, "Severity": {"text": [["fatal"]], "start": [[60]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11834188_4", "context": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[70]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[25]], "entity_id": ["T3"]}, "Effect": {"text": [["a cutaneous reaction"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[81]], "entity_id": ["T6"], "Drug": {"text": [["captopril"]], "start": [[81]], "entity_id": ["T7"]}}}]}]}
{"id": "18354950_3", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effect"]], "start": [[71]], "entity_id": ["T7"]}, "Subject": {"text": [["a 29-year Nigerian female patient with generalized tonic-elonic seizures"]], "start": [[118]], "entity_id": ["T3"], "Race": {"text": [["Nigerian"]], "start": [[128]], "entity_id": ["T8"]}, "Gender": {"text": [["female"]], "start": [[137]], "entity_id": ["T9"]}, "Age": {"text": [["29-year"]], "start": [[120]], "entity_id": ["T10"]}}, "Effect": {"text": [["syndrome of inappropriate antidiuresis"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[86]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"]], "start": [[86]], "entity_id": ["T12"]}, "Disorder": {"text": [["tonic-elonic seizures"]], "start": [[169]], "entity_id": ["T13"]}}}]}]}
{"id": "3470173_1", "context": "Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[127]], "entity_id": ["T5"]}, "Effect": {"text": [["cerebellar toxicity"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["HDARAC"]], "start": [[130]], "entity_id": ["T4"], "Drug": {"text": [["HDARAC"]], "start": [[130]], "entity_id": ["T6"]}}}]}]}
{"id": "2746565_3", "context": "We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen treatment"]], "start": [[49]], "entity_id": ["T4"], "Drug": {"text": [["ibuprofen"]], "start": [[49]], "entity_id": ["T10"]}, "Disorder": {"text": [["lupus erythematosus"]], "start": [[102]], "entity_id": ["T11"]}}, "Effect": {"text": [["a case of ulcerative proctitis"]], "start": [[12]], "entity_id": ["T5"]}, "Subject": {"text": [["a girl with juvenile systemic lupus erythematosus"]], "start": [[72]], "entity_id": ["T6"], "Gender": {"text": [["girl"]], "start": [[74]], "entity_id": ["T7"]}, "Age": {"text": [["juvenile"]], "start": [[84]], "entity_id": ["T9"]}}}]}]}
{"id": "9337441_18", "context": "Clinicians should include phenolphthalein in their list of possible causes of drug-induced TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[83]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenolphthalein"]], "start": [[26]], "entity_id": ["T7"], "Drug": {"text": [["phenolphthalein"]], "start": [[26]], "entity_id": ["T9"]}}, "Effect": {"text": [["TEN"]], "start": [[91]], "entity_id": ["T8"]}, "Speculated": {"text": [["possible"]], "start": [[59]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "424824_4", "context": "Methotrexate-induced diffuse interstitial pulmonary fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["diffuse interstitial pulmonary fibrosis"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "12452753_3", "context": "Fluorouracil for allergic reactions to capecitabine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[36]], "entity_id": ["T6"]}, "Effect": {"text": [["allergic reactions"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["capecitabine"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["capecitabine"]], "start": [[39]], "entity_id": ["T9"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[13]], "entity_id": ["T8"]}, "Treatment": {"text": [["Fluorouracil"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["allergic reactions to capecitabine"]], "start": [[17]], "entity_id": ["T10"]}, "Drug": {"text": [["Fluorouracil"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "11059196_1", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute pancreatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a child with idiopathic ulcerative colitis"]], "start": [[22]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[24]], "entity_id": ["T7"]}}, "Treatment": {"text": [["long-term 5-aminosalicylic acid therapy"]], "start": [[68]], "entity_id": ["T6"], "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[78]], "entity_id": ["T9"]}, "Disorder": {"text": [["idiopathic ulcerative colitis"]], "start": [[35]], "entity_id": ["T10"]}, "Duration": {"text": [["long-term"]], "start": [[68]], "entity_id": ["T11"]}}}]}]}
{"id": "11722307_2", "context": "CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["using"]], "start": [[136]], "entity_id": ["T6"]}, "Treatment": {"text": [["quetiapine"]], "start": [[142]], "entity_id": ["T3"], "Drug": {"text": [["quetiapine"]], "start": [[142]], "entity_id": ["T8"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[114]], "entity_id": ["T4"]}, "Speculated": {"text": [["possibility"]], "start": [[99]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "1751354_3", "context": "We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[130]], "entity_id": ["T5"]}, "Subject": {"text": [["one"]], "start": [[69]], "entity_id": ["T6"], "Population": {"text": [["one"]], "start": [[69]], "entity_id": ["T7"]}}, "Effect": {"text": [["had an aggravation of the condition"]], "start": [[77]], "entity_id": ["T12"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T11"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T8"]}}, "Subject": {"text": [["three"]], "start": [[25]], "entity_id": ["T9"], "Population": {"text": [["three"]], "start": [[25]], "entity_id": ["T10"]}}, "Effect": {"text": [["psoriasis"]], "start": [[55]], "entity_id": ["T3"]}}]}]}
{"id": "1661260_1", "context": "Reactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and azathioprine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[41]], "entity_id": ["T3"]}, "Effect": {"text": [["Reactivation of cytomegalovirus"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["corticosteroids and azathioprine"]], "start": [[97]], "entity_id": ["T5"], "Disorder": {"text": [["Wegener's granulomatosis"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[97], [117]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[113]], "entity_id": ["T9"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[97], [117]], "entity_id": ["T7", "T8"]}}]}, "Speculated": {"text": [["probably"]], "start": [[32]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19423476_6", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[64]], "entity_id": ["T7"]}, "Effect": {"text": [["opportunistic infections"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["immunosuppressive therapy with alemtuzumab"]], "start": [[70]], "entity_id": ["T6"], "Drug": {"text": [["alemtuzumab"]], "start": [[101]], "entity_id": ["T8"]}}}]}]}
{"id": "11696132_1", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[76]], "entity_id": ["T4"]}, "Effect": {"text": [["anisocoria"]], "start": [[61]], "entity_id": ["T3"]}, "Treatment": {"text": [["transdermal scopolamine patch"]], "start": [[91]], "entity_id": ["T5"], "Drug": {"text": [["scopolamine"]], "start": [[103]], "entity_id": ["T6"]}, "Route": {"text": [["transdermal"], ["patch"]], "start": [[91], [115]], "entity_id": ["T7", "T9"]}, "Disorder": {"text": [["weaning off the opioid"]], "start": [[148]], "entity_id": ["T8"]}}}]}]}
{"id": "1954704_2", "context": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptoms began"]], "start": [[49]], "entity_id": ["T5"]}, "Effect": {"text": [["myositis"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["within 10 days of receiving leuprolide acetate therapy"]], "start": [[64]], "entity_id": ["T4"], "Drug": {"text": [["leuprolide acetate"]], "start": [[92]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["10 days"]], "start": [[71]], "entity_id": ["T9"]}, "Disorder": {"text": [["prostate cancer"]], "start": [[123]], "entity_id": ["T10"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T7"]}}]}]}
{"id": "15863610_5", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosed"]], "start": [[45]], "entity_id": ["T12"]}, "Effect": {"text": [["A malignant mixed mesodermal tumor"]], "start": [[6]], "entity_id": ["T8"]}, "Treatment": {"text": [["raloxifene"]], "start": [[124]], "entity_id": ["T9"], "Drug": {"text": [["raloxifene"]], "start": [[124]], "entity_id": ["T16"]}, "Disorder": {"text": [["osteoporosis"]], "start": [[139]], "entity_id": ["T17"]}}, "Subject": {"text": [["a 64-year-old woman with a bicornuate uterus"]], "start": [[58]], "entity_id": ["T11"], "Age": {"text": [["64-year-old"]], "start": [[60]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[72]], "entity_id": ["T14"]}, "Disorder": {"text": [["bicornuate uterus"]], "start": [[85]], "entity_id": ["T15"]}}}]}]}
{"id": "17122225_4", "context": "We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug (phenelzine in one case and duloxetine in the other).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T12"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[30]], "entity_id": ["T11"]}, "Treatment": {"text": [["cyclobenzaprine", "receiving", "phenelzine"]], "start": [[82, 132, 174]], "entity_id": ["T13"], "Drug": {"text": [["cyclobenzaprine"], ["phenelzine"]], "start": [[82], [174]], "entity_id": ["T15", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[132]], "entity_id": ["T19"]}, "Drug": {"text": [["cyclobenzaprine"], ["phenelzine"]], "start": [[82], [174]], "entity_id": ["T15", "T17"]}}]}, "Subject": {"text": [["postoperative patients"]], "start": [[101]], "entity_id": ["T10"], "Disorder": {"text": [["postoperative"]], "start": [[101]], "entity_id": ["T14"]}}}, {"event_id": "E4", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T12"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[30]], "entity_id": ["T11"]}, "Subject": {"text": [["postoperative patients"]], "start": [[101]], "entity_id": ["T10"], "Disorder": {"text": [["postoperative"]], "start": [[101]], "entity_id": ["T14"]}}, "Treatment": {"text": [["cyclobenzaprine", "receiving", "duloxetine"]], "start": [[82, 132, 201]], "entity_id": ["T22"], "Drug": {"text": [["cyclobenzaprine"], ["duloxetine"]], "start": [[82], [201]], "entity_id": ["T16", "T18"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[132]], "entity_id": ["T19"]}, "Drug": {"text": [["cyclobenzaprine"], ["duloxetine"]], "start": [[82], [201]], "entity_id": ["T16", "T18"]}}]}, "Severity": {"text": [["severe"]], "start": [[23]], "entity_id": ["T21"], "value": "High"}}]}]}
{"id": "8496127_1", "context": "Acute dystonic reaction with low-dose pimozide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["low-dose pimozide"]], "start": [[29]], "entity_id": ["T3"], "Dosage": {"text": [["low-dose"]], "start": [[29]], "entity_id": ["T6"]}, "Drug": {"text": [["pimozide"]], "start": [[38]], "entity_id": ["T7"]}}, "Effect": {"text": [["Acute dystonic reaction"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "22372628_2", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[107]], "entity_id": ["T11"]}, "Subject": {"text": [["patients with uncontrolled partial-onset seizures"]], "start": [[110]], "entity_id": ["T10"]}, "Treatment": {"text": [["long-term (up to 5 years exposure)", "lacosamide as adjunctive therapy", "taking one to three concomitant antiepileptic drugs (AEDs)"]], "start": [[16, 74, 160]], "entity_id": ["T9"], "Drug": {"text": [["lacosamide"], ["antiepileptic drugs (AEDs)"]], "start": [[74], [192]], "entity_id": ["T13", "T14"]}, "Disorder": {"text": [["uncontrolled partial-onset seizures"]], "start": [[124]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["adjunctive"]], "start": [[88]], "entity_id": ["T16"]}, "Drug": {"text": [["lacosamide"], ["antiepileptic drugs (AEDs)"]], "start": [[74], [192]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "3430507_1", "context": "D-penicillamine induced crescentic glomerulonephritis: report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T5"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["D-penicillamine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["crescentic glomerulonephritis"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "19423610_4", "context": "We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["between"]], "start": [[91]], "entity_id": ["T8"]}, "Effect": {"text": [["adverse interaction"]], "start": [[71]], "entity_id": ["T6"]}, "Treatment": {"text": [["paroxetine and other agent(s)"]], "start": [[99]], "entity_id": ["T7"], "Disorder": {"text": [["anaesthesia"]], "start": [[155]], "entity_id": ["T9"]}, "Drug": {"text": [["paroxetine"], ["other agent(s)"]], "start": [[99], [114]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[110]], "entity_id": ["T12"]}, "Drug": {"text": [["paroxetine"], ["other agent(s)"]], "start": [[99], [114]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "19331262_3", "context": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["fatal idiosynchratic reaction"]], "start": [[62]], "entity_id": ["T15"]}, "Effect": {"text": [["Neuroleptic malignant syndrome", "muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis"]], "start": [[0, 157]], "entity_id": ["T11"]}, "Treatment": {"text": [["antipsychotic drugs"]], "start": [[95]], "entity_id": ["T12"], "Drug": {"text": [["antipsychotic"]], "start": [[95]], "entity_id": ["T16"]}}, "Speculated": {"text": [["potentially"]], "start": [[50]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "8678015_1", "context": "Albendazole-induced pseudomembranous colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Albendazole"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Albendazole"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "12181031_2", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[54]], "entity_id": ["T5"]}, "Treatment": {"text": [["cladribine"]], "start": [[69]], "entity_id": ["T3"], "Drug": {"text": [["cladribine"]], "start": [[69]], "entity_id": ["T7"]}, "Disorder": {"text": [["hairy cell leukaemia"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["Systemic vasculitis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "18661248_2", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[19]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with collapsing focal glomeruloesclerosis (collapsing FGS)"]], "start": [[30]], "entity_id": ["T5"], "Disorder": {"text": [["collapsing focal glomeruloesclerosis (collapsing FGS)"]], "start": [[45]], "entity_id": ["T8"]}}, "Treatment": {"text": [["cyclosporine (CSA)"]], "start": [[142]], "entity_id": ["T4"], "Drug": {"text": [["cyclosporine"]], "start": [[142]], "entity_id": ["T9"]}}, "Effect": {"text": [["PRES"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "11202801_2", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[21]], "entity_id": ["T5"]}, "Effect": {"text": [["Hepatic angiosarcoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide therapy"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["cyclophosphamide"]], "start": [[37]], "entity_id": ["T6"]}}}]}]}
{"id": "17366681_1", "context": "A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[56]], "entity_id": ["T5"]}, "Effect": {"text": [["melanonychia and onycholysis"]], "start": [[21]], "entity_id": ["T6"]}, "Treatment": {"text": [["pemetrexed for lung cancer"]], "start": [[71]], "entity_id": ["T7"], "Disorder": {"text": [["lung cancer"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["pemetrexed"]], "start": [[71]], "entity_id": ["T9"]}}}]}]}
{"id": "640344_2", "context": "Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[33]], "entity_id": ["T4"]}, "Subject": {"text": [["a woman with Crohn's disease"]], "start": [[46]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[48]], "entity_id": ["T7"]}}, "Effect": {"text": [["histological osteomalacia"]], "start": [[7]], "entity_id": ["T5"]}, "Treatment": {"text": [["2 years after ileal resection and the start of cholestyramine"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["cholestyramine"]], "start": [[122]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["start"]], "start": [[113]], "entity_id": ["T10"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[59]], "entity_id": ["T11"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11435808_1", "context": "Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[63]], "entity_id": ["T4"]}, "Effect": {"text": [["seizures"]], "start": [[49]], "entity_id": ["T3"]}, "Treatment": {"text": [["a complication of CBZ OD"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["CBZ OD"]], "start": [[90]], "entity_id": ["T6"]}}}]}]}
{"id": "7379406_8", "context": "The fluorine contained in niflumic acid induced a marked densification of trabecular bone in all 3 cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["fluorine", "niflumic acid"]], "start": [[4, 26]], "entity_id": ["T5"], "Drug": {"text": [["fluorine"], ["niflumic acid"]], "start": [[4], [26]], "entity_id": ["T10", "T11"]}}, "Effect": {"text": [["marked densification of trabecular bone"]], "start": [[50]], "entity_id": ["T7"]}, "Subject": {"text": [["all 3 cases"]], "start": [[93]], "entity_id": ["T8"], "Population": {"text": [["3"]], "start": [[97]], "entity_id": ["T9"]}}}]}]}
{"id": "15773973_1", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["Flucloxacillin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Flucloxacillin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["aplastic anaemia and liver failure"]], "start": [[23]], "entity_id": ["T7"]}}]}]}
{"id": "18855892_8", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[114]], "entity_id": ["T8"]}, "Subject": {"text": [["patients with cancer"]], "start": [[65]], "entity_id": ["T6"], "Disorder": {"text": [["cancer"]], "start": [[79]], "entity_id": ["T10"]}}, "Treatment": {"text": [["methotrexate"]], "start": [[101]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[101]], "entity_id": ["T11"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[122]], "entity_id": ["T9"]}}]}]}
{"id": "9788533_2", "context": "A 53-year-old Caucasian male victim of suicide was suspected of overdose with sertraline and alprazolam after death-scene investigation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["overdose"]], "start": [[64]], "entity_id": ["T11"]}, "Subject": {"text": [["A 53-year-old Caucasian male"]], "start": [[0]], "entity_id": ["T8"], "Race": {"text": [["Caucasian"]], "start": [[14]], "entity_id": ["T12"]}, "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["male"]], "start": [[24]], "entity_id": ["T14"]}}, "Treatment": {"text": [["overdose with sertraline and alprazolam"]], "start": [[64]], "entity_id": ["T10"], "Drug": {"text": [["sertraline"], ["alprazolam"]], "start": [[78], [93]], "entity_id": ["T15", "T16"]}, "Dosage": {"text": [["overdose"]], "start": [[64]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[89]], "entity_id": ["T17"]}, "Drug": {"text": [["sertraline"], ["alprazolam"]], "start": [[78], [93]], "entity_id": ["T15", "T16"]}}]}, "Speculated": {"text": [["suspected"]], "start": [[51]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "15507779_1", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[80]], "entity_id": ["T11"]}, "Subject": {"text": [["an HIV carrier"]], "start": [[57]], "entity_id": ["T8"]}, "Treatment": {"text": [["nevirapine"]], "start": [[85]], "entity_id": ["T9"], "Drug": {"text": [["nevirapine"]], "start": [[85]], "entity_id": ["T13"]}, "Disorder": {"text": [["HIV carrier"]], "start": [[60]], "entity_id": ["T14"]}}, "Effect": {"text": [["leukopenia"]], "start": [[7]], "entity_id": ["T10"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "1711090_2", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effect and safety"]], "start": [[13]], "entity_id": ["T8"]}, "Treatment": {"text": [["Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)"]], "start": [[34]], "entity_id": ["T9"], "Drug": {"text": [["Lp"]], "start": [[34]], "entity_id": ["T16"]}, "Route": {"text": [["TAE"]], "start": [[37]], "entity_id": ["T15"]}, "Disorder": {"text": [["cirrhosis of the liver"]], "start": [[196]], "entity_id": ["T17"]}}, "Subject": {"text": [["20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver"]], "start": [[132]], "entity_id": ["T10"], "Population": {"text": [["20"]], "start": [[132]], "entity_id": ["T11"]}, "Disorder": {"text": [["hepatocellular carcinoma"]], "start": [[149]], "entity_id": ["T14"]}}}]}]}
{"id": "6702890_1", "context": "A 69-year-old man developed pure red cell aplasia after taking fenoprofen for ten months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[50]], "entity_id": ["T4"]}, "Subject": {"text": [["A 69-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["69-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["pure red cell aplasia"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["taking fenoprofen for ten months"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["fenoprofen"]], "start": [[63]], "entity_id": ["T9"]}, "Duration": {"text": [["ten months"]], "start": [[78]], "entity_id": ["T10"]}}}]}]}
{"id": "16599252_2", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["zafirlukast therapy."]], "start": [[50]], "entity_id": ["T4"], "Drug": {"text": [["zafirlukast"]], "start": [[50]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypereosinophilia"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[11]], "entity_id": ["T6"]}}]}]}
{"id": "9039216_2", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[97]], "entity_id": ["T14"]}, "Effect": {"text": [["Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis"]], "start": [[0]], "entity_id": ["T13"]}, "Treatment": {"text": [["minocycline"]], "start": [[109]], "entity_id": ["T15"], "Drug": {"text": [["minocycline"]], "start": [[109]], "entity_id": ["T16"]}}, "Severity": {"text": [["severe"]], "start": [[82]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "11008259_2", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["reduction in tiagabine dosages"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["tiagabine"]], "start": [[80]], "entity_id": ["T6"]}}, "Effect": {"text": [["non-convulsive status epilepticus subsided"]], "start": [[14]], "entity_id": ["T3"]}}]}]}
{"id": "7655130_1", "context": "CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[165]], "entity_id": ["T7"]}, "Effect": {"text": [["hypothyroidism with increased serum thyroid-stimulating hormone"]], "start": [[80]], "entity_id": ["T3"]}, "Treatment": {"text": [["levothyroxine"]], "start": [[188]], "entity_id": ["T4"], "Disorder": {"text": [["stable hypothyroidism"]], "start": [[34]], "entity_id": ["T6"]}, "Drug": {"text": [["levothyroxine"]], "start": [[188]], "entity_id": ["T9"]}}, "Subject": {"text": [["Two patients with stable hypothyroidism"]], "start": [[16]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[16]], "entity_id": ["T8"]}}}]}]}
{"id": "19583682_3", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[39]], "entity_id": ["T8"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T7"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[20]], "entity_id": ["T10"]}, "Treatment": {"text": [["interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin"]], "start": [[86]], "entity_id": ["T9"], "Drug": {"text": [["selective serotonin-reuptake inhibitors"], ["ciprofloxacin"]], "start": [[123], [183]], "entity_id": ["T13", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interactions"]], "start": [[86]], "entity_id": ["T14"]}, "Drug": {"text": [["ciprofloxacin"], ["selective serotonin-reuptake inhibitors"]], "start": [[183], [123]], "entity_id": ["T15", "T13"]}}]}, "Speculated": {"text": [["possibly"]], "start": [[174]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "10755579_2", "context": "The medical examiner's report indicated death caused by fluoxetine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[46]], "entity_id": ["T7"]}, "Effect": {"text": [["death"]], "start": [[40]], "entity_id": ["T8"]}, "Treatment": {"text": [["fluoxetine toxicity"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["fluoxetine"]], "start": [[56]], "entity_id": ["T9"]}}}]}]}
{"id": "17448102_4", "context": "Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effective"]], "start": [[47]], "entity_id": ["T7"]}, "Treatment": {"text": [["Hypertonic sodium bicarbonate"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["hypotension and arrhythmias"]], "start": [[69]], "entity_id": ["T6"]}, "Drug": {"text": [["sodium bicarbonate"]], "start": [[11]], "entity_id": ["T8"]}}}]}]}
{"id": "12218252_1", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T3"]}, "Effect": {"text": [["Generalised pustular psoriasis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cyclosporin a withdrawal"]], "start": [[42]], "entity_id": ["T4"], "Drug": {"text": [["cyclosporin a"]], "start": [[42]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responding"]], "start": [[67]], "entity_id": ["T10"]}, "Treatment": {"text": [["tumour necrosis factor alpha inhibitor etanercept"]], "start": [[85]], "entity_id": ["T6"], "Disorder": {"text": [["Generalised pustular psoriasis induced by cyclosporin a withdrawal"]], "start": [[0]], "entity_id": ["T8"]}, "Drug": {"text": [["etanercept"]], "start": [[124]], "entity_id": ["T9"]}}}]}]}
{"id": "788666_2", "context": "Gentamicin-associated acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Gentamicin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Gentamicin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "15944830_5", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[76]], "entity_id": ["T5"]}, "Effect": {"text": [["visual acuity had decreased"]], "start": [[48]], "entity_id": ["T4"]}, "Treatment": {"text": [["IFN"]], "start": [[101]], "entity_id": ["T6"], "Drug": {"text": [["IFN"]], "start": [[101]], "entity_id": ["T8"]}}, "Subject": {"text": [["The former patient"]], "start": [[0]], "entity_id": ["T7"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[154]], "entity_id": ["T13"]}, "Subject": {"text": [["patient"]], "start": [[129]], "entity_id": ["T10"]}, "Treatment": {"text": [["IFN therapy"]], "start": [[161]], "entity_id": ["T11"], "Drug": {"text": [["IFN"]], "start": [[161]], "entity_id": ["T9"]}}, "Effect": {"text": [["visual acuity had decreased"]], "start": [[182]], "entity_id": ["T12"]}}]}]}
{"id": "10573314_3", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[110]], "entity_id": ["T13"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T11"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T15"]}, "Disorder": {"text": [["chronic atrial fibrillation"]], "start": [[81]], "entity_id": ["T1"]}}, "Treatment": {"text": [["receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "after the initiation of tolterodine for urinary disorders"]], "start": [[19, 136]], "entity_id": ["T14"], "Disorder": {"text": [["stroke"], ["urinary disorders"]], "start": [[42], [176]], "entity_id": ["T16", "T19"]}, "Drug": {"text": [["tolterodine"], ["warfarin"]], "start": [[160], [29]], "entity_id": ["T12", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["after"]], "start": [[136]], "entity_id": ["T18"]}, "Drug": {"text": [["tolterodine"], ["warfarin"]], "start": [[160], [29]], "entity_id": ["T12", "T17"]}}]}, "Effect": {"text": [["adverse effects"]], "start": [[120]], "entity_id": ["T20"]}}]}]}
{"id": "19798640_2", "context": "Primary central nervous system lymphoma in a patient treated with natalizumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[53]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[43]], "entity_id": ["T3"]}, "Effect": {"text": [["Primary central nervous system lymphoma"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["natalizumab"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["natalizumab"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "20666169_9", "context": "We presume the cause for multiple organ failure could be the result of drug-drug interaction, atorvastatin and verapamil, as verapamil is known to increase the serum concentration of atorvastatin significantly.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[15]], "entity_id": ["T13"]}, "Effect": {"text": [["multiple organ failure"]], "start": [[25]], "entity_id": ["T11"]}, "Treatment": {"text": [["interaction, atorvastatin and verapamil"]], "start": [[81]], "entity_id": ["T12"], "Drug": {"text": [["atorvastatin"], ["verapamil"]], "start": [[94], [111]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[81]], "entity_id": ["T16"]}, "Drug": {"text": [["atorvastatin"], ["verapamil"]], "start": [[94], [111]], "entity_id": ["T14", "T15"]}}]}, "Speculated": {"text": [["presume", "could"]], "start": [[3, 48]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "6725214_1", "context": "A case of priapism associated with trazodone is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["priapism"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["trazodone"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["trazodone"]], "start": [[35]], "entity_id": ["T7"]}}}]}]}
{"id": "16678268_1", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["adenovirus pneumonia"]], "start": [[7]], "entity_id": ["T5"]}, "Treatment": {"text": [["infliximab infusion"]], "start": [[44]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"]], "start": [[44]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[55]], "entity_id": ["T10"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[85]], "entity_id": ["T11"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "21762153_9", "context": "The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["inhibits"]], "start": [[66]], "entity_id": ["T8"]}, "Treatment": {"text": [["zinc/o-cymen-5-ol system"]], "start": [[4]], "entity_id": ["T6"], "Drug": {"text": [["zinc"], ["o-cymen-5-ol"]], "start": [[4], [9]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["system"]], "start": [[22]], "entity_id": ["T12"]}, "Drug": {"text": [["zinc"], ["o-cymen-5-ol"]], "start": [[4], [9]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["antimicrobial effects"], ["inhibits oral disease-related processes"]], "start": [[40], [66]], "entity_id": ["T7", "T9"]}}]}]}
{"id": "1388041_2", "context": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti-depressant activity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["possessing"]], "start": [[55]], "entity_id": ["T6"]}, "Treatment": {"text": [["Paroxetine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Paroxetine"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["anti-depressant activity"]], "start": [[66]], "entity_id": ["T1"]}}}]}]}
{"id": "7776854_2", "context": "Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["benzarone"]], "start": [[33]], "entity_id": ["T4"], "Drug": {"text": [["benzarone"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[7]], "entity_id": ["T5"]}, "Subject": {"text": [["three cases"]], "start": [[56]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[56]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "15331204_2", "context": "OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[20]], "entity_id": ["T12"]}, "Treatment": {"text": [["indapamide"]], "start": [[33]], "entity_id": ["T11"], "Disorder": {"text": [["carbohydrate metabolism"], ["hypertension"]], "start": [[54], [91]], "entity_id": ["T13", "T18"]}, "Drug": {"text": [["indapamide"]], "start": [[33]], "entity_id": ["T17"]}}, "Subject": {"text": [["essential hypertension patients"]], "start": [[81]], "entity_id": ["T14"]}, "Speculated": {"text": [["study"]], "start": [[14]], "entity_id": ["T16"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[181]], "entity_id": ["T20"]}, "Effect": {"text": [["diabetes"]], "start": [[172]], "entity_id": ["T19"]}, "Treatment": {"text": [["indapamide"]], "start": [[192]], "entity_id": ["T21"], "Drug": {"text": [["indapamide"]], "start": [[192]], "entity_id": ["T22"]}}}]}]}
{"id": "12796597_1", "context": "Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[95]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha (IFNalpha)"]], "start": [[53]], "entity_id": ["T4"], "Drug": {"text": [["interferon alpha (IFNalpha)"]], "start": [[53]], "entity_id": ["T7"]}}, "Effect": {"text": [["renal dysfunction"]], "start": [[111]], "entity_id": ["T6"]}}]}]}
{"id": "17277758_2", "context": "CONCLUSIONS: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[55]], "entity_id": ["T5"]}, "Effect": {"text": [["Infectious endophthalmitis"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["bevacizumab"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["bevacizumab"]], "start": [[84]], "entity_id": ["T7"]}}, "Speculated": {"text": [["potential"]], "start": [[45]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10348150_3", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T4"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["hydroxyurea"]], "start": [[26]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute interstitial pneumonitis"]], "start": [[46]], "entity_id": ["T5"]}}]}]}
{"id": "15863610_3", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["involved"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[18]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[18]], "entity_id": ["T7"]}}, "Effect": {"text": [["pathogenesis"]], "start": [[47]], "entity_id": ["T6"]}}]}]}
{"id": "9634122_3", "context": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["illustrates"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["potential decoupling of PSA response"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["flutamide withdrawa"]], "start": [[86]], "entity_id": ["T4"], "Drug": {"text": [["flutamide"]], "start": [[86]], "entity_id": ["T6"]}}}]}]}
{"id": "3400849_1", "context": "Myoclonic spasms following intrathecal morphine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Myoclonic spasms"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal morphine"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["morphine."]], "start": [[39]], "entity_id": ["T6"]}}}]}]}
{"id": "18262450_1", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["enhances"]], "start": [[28]], "entity_id": ["T8"]}, "Treatment": {"text": [["Prolonged-release oxycodone", "gabapentin therapy"]], "start": [[0, 61]], "entity_id": ["T6"], "Drug": {"text": [["Prolonged-release oxycodone"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["diabetic neuropathy"]], "start": [[91]], "entity_id": ["T11"]}}, "Subject": {"text": [["painful diabetic neuropathy patients"]], "start": [[83]], "entity_id": ["T7"]}}]}]}
{"id": "22010004_2", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["led"]], "start": [[102]], "entity_id": ["T10"]}, "Treatment": {"text": [["warfarin and extended-release niacin"]], "start": [[51]], "entity_id": ["T9"], "Drug": {"text": [["warfarin"], ["niacin"]], "start": [[51], [81]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[31]], "entity_id": ["T14"]}, "Drug": {"text": [["niacin"], ["warfarin"]], "start": [[81], [51]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["synergistic coagulopathy"]], "start": [[109]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[93]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "19838099_2", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Dasatinib"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Dasatinib"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pleural effusions"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "1477441_3", "context": "Fixed drug eruption of the scrotum due to methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Fixed drug eruption of the scrotum"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "3470173_2", "context": "Cytarabine-induced cerebellar syndrome: case report and literature review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cytarabine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cytarabine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["cerebellar syndrome"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["case"]], "start": [[40]], "entity_id": ["T7"]}}]}]}
{"id": "19555801_2", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient of organic bipolar affective disorder"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["hiccups"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["the atypical antipsychotic aripiprazole"]], "start": [[85]], "entity_id": ["T5"], "Drug": {"text": [["aripiprazole"]], "start": [[112]], "entity_id": ["T8"]}, "Disorder": {"text": [["organic bipolar affective disorder"]], "start": [[23]], "entity_id": ["T1"]}}}]}]}
{"id": "19249953_5", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[215]], "entity_id": ["T7"]}, "Effect": {"text": [["elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level", "rhabdomyolysis"]], "start": [[87, 200]], "entity_id": ["T6"]}, "Treatment": {"text": [["statin"]], "start": [[228]], "entity_id": ["T8"], "Drug": {"text": [["statin"]], "start": [[228]], "entity_id": ["T9"]}}}]}]}
{"id": "20120657_3", "context": "Zidovudine induced pure red cell aplasia: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pure red cell aplasia"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "12455453_2", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resulted"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["Reduction of methylprednisolone dosage rather than insulin therapy"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["methylprednisolone"]], "start": [[13]], "entity_id": ["T6"]}, "Dosage": {"text": [["Reduction"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["glycemia"]], "start": [[97]], "entity_id": ["T1"]}}}]}]}
{"id": "7893301_1", "context": "Albuterol-induced hypokalemia and its potential cardiac toxicity are discussed briefly.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Albuterol"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Albuterol"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypokalemia and its potential cardiac toxicity"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "12503933_6", "context": "OBJECTIVE: To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[78]], "entity_id": ["T5"]}, "Effect": {"text": [["fulminant liver failure"]], "start": [[42]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[21]], "entity_id": ["T6"]}, "Treatment": {"text": [["clarithromycin"]], "start": [[91]], "entity_id": ["T4"], "Drug": {"text": [["clarithromycin"]], "start": [[91]], "entity_id": ["T7"]}, "Disorder": {"text": [["pneumonia"]], "start": [[110]], "entity_id": ["T8"]}}}]}]}
{"id": "16757971_2", "context": "Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["temozolomide"]], "start": [[74]], "entity_id": ["T8"], "Drug": {"text": [["temozolomide"]], "start": [[74]], "entity_id": ["T10"]}}, "Effect": {"text": [["Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "7619765_2", "context": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[54]], "entity_id": ["T6"]}, "Treatment": {"text": [["chemotherapy containing etoposide"]], "start": [[60]], "entity_id": ["T3"], "Drug": {"text": [["etoposide"]], "start": [[84]], "entity_id": ["T8"]}}, "Effect": {"text": [["myocardial infarction"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a man with no risk factors for coronary heart disease"]], "start": [[98]], "entity_id": ["T5"], "Gender": {"text": [["man"]], "start": [[100]], "entity_id": ["T7"]}}}]}]}
{"id": "8186884_1", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T6"]}, "Effect": {"text": [["frequent shocks"]], "start": [[81]], "entity_id": ["T3"]}, "Treatment": {"text": [["during oral procainamide therapy"]], "start": [[97]], "entity_id": ["T4"], "Disorder": {"text": [["a transvenous cardioverter defibrillator system"]], "start": [[23]], "entity_id": ["T9"]}, "Route": {"text": [["oral"]], "start": [[104]], "entity_id": ["T10"]}, "Drug": {"text": [["procainamide"]], "start": [[109]], "entity_id": ["T11"]}}, "Subject": {"text": [["A 78-year-old man with a transvenous cardioverter defibrillator system"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["78-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}}]}]}
{"id": "8485005_3", "context": "We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (prednisolone 25 mg/day) for pericardial effusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T10"]}, "Subject": {"text": [["a case of", "a 71-year-old man", "for pericardial effusion"]], "start": [[10, 88, 181]], "entity_id": ["T9"], "Age": {"text": [["71-year-old"]], "start": [[90]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[102]], "entity_id": ["T14"]}}, "Effect": {"text": [["Kaposi's sarcoma (KS)"]], "start": [[33]], "entity_id": ["T11"]}, "Treatment": {"text": [["6 months with corticosteroid therapy (prednisolone 25 mg/day)"]], "start": [[119]], "entity_id": ["T12"], "Duration": {"text": [["6 months"]], "start": [[119]], "entity_id": ["T16"]}, "Dosage": {"text": [["25 mg/day"]], "start": [[170]], "entity_id": ["T17"]}, "Drug": {"text": [["prednisolone"]], "start": [[157]], "entity_id": ["T19"]}, "Disorder": {"text": [["pericardial effusion"]], "start": [[185]], "entity_id": ["T20"]}}}]}]}
{"id": "9533061_10", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[92]], "entity_id": ["T13"]}, "Treatment": {"text": [["clindamycin phosphate vaginal cream"]], "start": [[35]], "entity_id": ["T10"], "Drug": {"text": [["clindamycin phosphate"]], "start": [[35]], "entity_id": ["T11"]}, "Route": {"text": [["vaginal cream"]], "start": [[57]], "entity_id": ["T12"]}}, "Effect": {"text": [["CDIC"]], "start": [[101]], "entity_id": ["T14"]}, "Speculated": {"text": [["probable"]], "start": [[83]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "8691927_3", "context": "Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Growth and adrenal suppression"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["asthmatic children"]], "start": [[34]], "entity_id": ["T4"], "Age": {"text": [["children"]], "start": [[44]], "entity_id": ["T8"]}}, "Treatment": {"text": [["high-dose fluticasone propionate"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["fluticasone propionate"]], "start": [[76]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[66]], "entity_id": ["T10"]}, "Disorder": {"text": [["asthmatic"]], "start": [[34]], "entity_id": ["T11"]}}}]}]}
{"id": "14674674_1", "context": "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "9360190_2", "context": "Magnesium tocolysis as the cause of urinary calculus during pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[27]], "entity_id": ["T3"]}, "Treatment": {"text": [["Magnesium tocolysis"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Magnesium tocolysis"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["urinary calculus during pregnancy"]], "start": [[36]], "entity_id": ["T5"]}}]}]}
{"id": "12504711_1", "context": "A paradoxical ocular effect of brimonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[28]], "entity_id": ["T5"]}, "Effect": {"text": [["paradoxical ocular effect"]], "start": [[2]], "entity_id": ["T3"]}, "Treatment": {"text": [["brimonidine"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["brimonidine"]], "start": [[31]], "entity_id": ["T6"]}}}]}]}
{"id": "12699871_2", "context": "Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linked"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["speech loss"]], "start": [[24]], "entity_id": ["T3"]}, "Treatment": {"text": [["FK506"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["FK506"]], "start": [[46]], "entity_id": ["T6"]}}}]}]}
{"id": "8979664_3", "context": "Uveitis associated with rifabutin therapy: a clinical alert.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[8]], "entity_id": ["T4"]}, "Effect": {"text": [["Uveitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rifabutin therapy"]], "start": [[24]], "entity_id": ["T5"], "Drug": {"text": [["rifabutin"]], "start": [[24]], "entity_id": ["T6"]}}}]}]}
{"id": "7249424_2", "context": "Nephrotic syndrome associated with lithium therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium therapy"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[35]], "entity_id": ["T6"]}}}]}]}
{"id": "10728450_1", "context": "We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T4"]}, "Subject": {"text": [["2 patients"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["2"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["polyarteritis nodosa"]], "start": [[35]], "entity_id": ["T5"]}, "Treatment": {"text": [["vaccination against hepatitis B"]], "start": [[66]], "entity_id": ["T6"], "Drug": {"text": [["vaccination against hepatitis B"]], "start": [[66]], "entity_id": ["T8"]}}}]}]}
{"id": "7081289_1", "context": "Hepatitis following cimetidine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[10]], "entity_id": ["T4"]}, "Effect": {"text": [["Hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cimetidine"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["cimetidine"]], "start": [[20]], "entity_id": ["T6"]}}}]}]}
{"id": "16211208_2", "context": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[93]], "entity_id": ["T10"]}, "Treatment": {"text": [["dofetilide"]], "start": [[100]], "entity_id": ["T7"], "Drug": {"text": [["dofetilide"]], "start": [[100]], "entity_id": ["T14"]}, "Disorder": {"text": [["atrial fibrillation"]], "start": [[115]], "entity_id": ["T15"]}}, "Subject": {"text": [["an elderly man", "atrial fibrillation"]], "start": [[78, 115]], "entity_id": ["T8"], "Age": {"text": [["elderly"]], "start": [[81]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[89]], "entity_id": ["T12"]}}, "Effect": {"text": [["Marked QT prolongation and torsades de pointes secondary to acute ischemia"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "16355099_4", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develops"]], "start": [[16]], "entity_id": ["T5"]}, "Treatment": {"text": [["heparin"]], "start": [[32]], "entity_id": ["T3"], "Drug": {"text": [["heparin"]], "start": [[32]], "entity_id": ["T6"]}}, "Effect": {"text": [["thrombosis", "HITTs"]], "start": [[5, 78]], "entity_id": ["T4"]}, "Speculated": {"text": [["suspect"]], "start": [[70]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18431096_1", "context": "Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methylphenidate and dextroamphetamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Methylphenidate"], ["dextroamphetamine"]], "start": [[0], [20]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[16]], "entity_id": ["T9"]}, "Drug": {"text": [["Methylphenidate"], ["dextroamphetamine"]], "start": [[0], [20]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["peripheral vasculopathy"]], "start": [[46]], "entity_id": ["T6"]}}]}]}
{"id": "3620420_8", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effective"]], "start": [[56]], "entity_id": ["T9"]}, "Treatment": {"text": [["cyclosporin"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporin"]], "start": [[38]], "entity_id": ["T11"]}, "Disorder": {"text": [["sight threatening Mooren's ulcer"]], "start": [[96]], "entity_id": ["T8"]}}, "Subject": {"text": [["patients with severe sight threatening Mooren's ulcer"]], "start": [[75]], "entity_id": ["T7"]}}]}]}
{"id": "1316047_1", "context": "Hemodynamic collapse following labetalol administration in preeclampsia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Hemodynamic collapse"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["labetalol"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["labetalol"]], "start": [[31]], "entity_id": ["T7"]}, "Disorder": {"text": [["preeclampsia"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "18801826_3", "context": "We report a case of a 35-year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T10"]}, "Subject": {"text": [["35-year old female"]], "start": [[22]], "entity_id": ["T9"], "Age": {"text": [["35-year old"]], "start": [[22]], "entity_id": ["T13"]}, "Gender": {"text": [["female"]], "start": [[34]], "entity_id": ["T14"]}}, "Effect": {"text": [["type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure"]], "start": [[65]], "entity_id": ["T11"]}, "Treatment": {"text": [["treatment with a SGA"]], "start": [[163]], "entity_id": ["T12"], "Drug": {"text": [["SGA"]], "start": [[180]], "entity_id": ["T15"]}}}]}]}
{"id": "11302479_1", "context": "She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[4]], "entity_id": ["T3"]}, "Effect": {"text": [["urticarial rash"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["Enoxaparin"]], "start": [[84]], "entity_id": ["T5"], "Time_elapsed": {"text": [["3 weeks following"]], "start": [[39]], "entity_id": ["T6"]}, "Drug": {"text": [["Enoxaparin"]], "start": [[84]], "entity_id": ["T7"]}}, "Severity": {"text": [["severe"]], "start": [[16]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "11033836_2", "context": "Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL, and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["preventing"]], "start": [[200]], "entity_id": ["T15"]}, "Subject": {"text": [["patients with nonmyeloid malignancies"]], "start": [[120]], "entity_id": ["T12"], "Disorder": {"text": [["nonmyeloid malignancies"]], "start": [[134]], "entity_id": ["T17"]}}, "Treatment": {"text": [["recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega])"]], "start": [[38]], "entity_id": ["T11"], "Disorder": {"text": [["postchemotherapy platelet nadirs of < or = 20,000/microL"]], "start": [[211]], "entity_id": ["T16"]}, "Drug": {"text": [["recombinant human interleukin-11"]], "start": [[38]], "entity_id": ["T13"]}}}]}]}
{"id": "115078_1", "context": "A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["acute intrahepatic cholestasis"]], "start": [[49]], "entity_id": ["T5"]}, "Treatment": {"text": [["100 mg of sodium aurothiomalate"]], "start": [[86]], "entity_id": ["T8"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[15]], "entity_id": ["T4"]}, "Dosage": {"text": [["100 mg"]], "start": [[86]], "entity_id": ["T10"]}, "Drug": {"text": [["sodium aurothiomalate"]], "start": [[96]], "entity_id": ["T11"]}}}]}]}
{"id": "17965530_2", "context": "We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[77]], "entity_id": ["T7"]}, "Treatment": {"text": [["calcium polystyrene sulfonate and sorbitol"]], "start": [[109]], "entity_id": ["T8"], "Drug": {"text": [["calcium polystyrene sulfonate"], ["sorbitol"]], "start": [[109], [143]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[139]], "entity_id": ["T12"]}, "Drug": {"text": [["sorbitol"], ["calcium polystyrene sulfonate"]], "start": [[143], [109]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["colonic ulcer and the sigmoidovesical fistula"]], "start": [[22]], "entity_id": ["T9"]}}]}]}
{"id": "17420198_17", "context": "The patient's movements resolved following diphenhydramine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["diphenhydramine administration"]], "start": [[43]], "entity_id": ["T6"], "Drug": {"text": [["diphenhydramine"]], "start": [[43]], "entity_id": ["T7"]}}, "Subject": {"text": [["The patient's"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "21802143_5", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[151]], "entity_id": ["T17"]}, "Subject": {"text": [["An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma"]], "start": [[0]], "entity_id": ["T7"], "Race": {"text": [["Japanese"]], "start": [[15]], "entity_id": ["T11"]}, "Age": {"text": [["18-year-old"]], "start": [[3]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T13"]}}, "Treatment": {"text": [["received continuous IV administration of TAC", "allogeneic bone marrow transplantation (BMT)"]], "start": [[82, 213]], "entity_id": ["T9"], "Disorder": {"text": [["cell lymphoma"]], "start": [[68]], "entity_id": ["T14"]}, "Drug": {"text": [["TAC"]], "start": [[123]], "entity_id": ["T15"]}, "Route": {"text": [["IV administration"]], "start": [[102]], "entity_id": ["T16"]}}, "Effect": {"text": [["graft-versus-host disease (GVHD)"]], "start": [[171]], "entity_id": ["T10"]}}]}]}
{"id": "10723699_2", "context": "We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attribute"]], "start": [[79]], "entity_id": ["T8"]}, "Treatment": {"text": [["minocycline"]], "start": [[103]], "entity_id": ["T9"], "Drug": {"text": [["minocycline"]], "start": [[103]], "entity_id": ["T13"]}, "Disorder": {"text": [["acne"]], "start": [[119]], "entity_id": ["T14"]}}, "Subject": {"text": [["a young adolescent"]], "start": [[13]], "entity_id": ["T7"], "Age": {"text": [["young adolescent"]], "start": [[15]], "entity_id": ["T12"]}}, "Effect": {"text": [["benign intracranial hypertension"]], "start": [[37]], "entity_id": ["T11"]}}]}]}
{"id": "3259776_2", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Thrombo-embolic complication"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["streptokinase"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["streptokinase"]], "start": [[35]], "entity_id": ["T7"]}, "Disorder": {"text": [["pulmonary emboli."]], "start": [[60]], "entity_id": ["T8"]}}}]}]}
{"id": "9247841_4", "context": "We report 3 patients who developed cutaneous vasculitis which is a rare and serious side-effect during antithyroid drug therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T7"]}, "Subject": {"text": [["3 patients"]], "start": [[10]], "entity_id": ["T6"], "Population": {"text": [["3"]], "start": [[10]], "entity_id": ["T10"]}}, "Effect": {"text": [["cutaneous vasculitis"]], "start": [[35]], "entity_id": ["T8"]}, "Treatment": {"text": [["during antithyroid drug therapy"]], "start": [[96]], "entity_id": ["T9"], "Drug": {"text": [["antithyroid"]], "start": [[103]], "entity_id": ["T11"]}}}]}]}
{"id": "1621023_3", "context": "Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[74]], "entity_id": ["T6"]}, "Effect": {"text": [["Prominent eye movements during NREM sleep and REM sleep behavior disorder"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["fluoxetine treatment"]], "start": [[90]], "entity_id": ["T7"], "Drug": {"text": [["fluoxetine"]], "start": [[90]], "entity_id": ["T11"]}, "Disorder": {"text": [["depression"], ["obsessive-compulsive disorder"]], "start": [[114], [129]], "entity_id": ["T12", "T13"]}}, "Subject": {"text": [["depression and obsessive-compulsive disorder"]], "start": [[114]], "entity_id": ["T8"]}}]}]}
{"id": "10963515_1", "context": "Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Allergic reaction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["gemfibrozil"]], "start": [[21]], "entity_id": ["T3"], "Drug": {"text": [["gemfibrozil"]], "start": [[21]], "entity_id": ["T6"]}}, "Effect": {"text": [["eosinophilic gastroenteritis"]], "start": [[48]], "entity_id": ["T4"]}}]}]}
{"id": "16620273_2", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["metformin"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["metformin"]], "start": [[35]], "entity_id": ["T7"]}}, "Effect": {"text": [["acidosis"]], "start": [[7]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[19]], "entity_id": ["T6"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "16728538_4", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[43]], "entity_id": ["T6"]}, "Effect": {"text": [["hepatitis"]], "start": [[73]], "entity_id": ["T7"]}, "Treatment": {"text": [["long-acting somatostatin-analog octreotide", "GH receptor antagonist pegvisomant"]], "start": [[118, 169]], "entity_id": ["T8"], "Disorder": {"text": [["acromegaly"]], "start": [[28]], "entity_id": ["T5"]}, "Drug": {"text": [["pegvisomant"], ["octreotide"]], "start": [[192], [150]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined treatment"]], "start": [[90]], "entity_id": ["T9"]}, "Drug": {"text": [["pegvisomant"], ["octreotide"]], "start": [[192], [150]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["a patient with acromegaly"]], "start": [[13]], "entity_id": ["T4"]}, "Severity": {"text": [["severe"]], "start": [[53]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "19915794_4", "context": "We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[97]], "entity_id": ["T7"]}, "Treatment": {"text": [["oral administration of garenoxacin"]], "start": [[103]], "entity_id": ["T8"], "Drug": {"text": [["garenoxacin"]], "start": [[126]], "entity_id": ["T14"]}, "Route": {"text": [["oral administration"]], "start": [[103]], "entity_id": ["T15"]}, "Disorder": {"text": [["pneumonia"]], "start": [[229]], "entity_id": ["T16"]}}, "Subject": {"text": [["an 82-year-old man"]], "start": [[10]], "entity_id": ["T9"], "Age": {"text": [["82-year-old"]], "start": [[13]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[25]], "entity_id": ["T13"]}}, "Effect": {"text": [["ventricular tachycardia and Torsades de Pointes (TdP)"]], "start": [[43]], "entity_id": ["T10"]}}]}]}
{"id": "19212144_1", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[53]], "entity_id": ["T4"]}, "Subject": {"text": [["A 58-year-old man with advanced renal cell carcinoma"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["58-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency"]], "start": [[63]], "entity_id": ["T5"]}, "Treatment": {"text": [["five days after temsirolimus infusion"]], "start": [[149]], "entity_id": ["T6"], "Disorder": {"text": [["renal cell carcinoma"]], "start": [[32]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["five days"]], "start": [[149]], "entity_id": ["T11"]}, "Drug": {"text": [["temsirolimus"]], "start": [[165]], "entity_id": ["T12"]}, "Route": {"text": [["infusion"]], "start": [[178]], "entity_id": ["T13"]}}}]}]}
{"id": "18166746_1", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[20]], "entity_id": ["T5"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[1]], "entity_id": ["T4"]}, "Treatment": {"text": [["methylene blue infusion during parathyroidectomy"]], "start": [[30]], "entity_id": ["T6"], "Drug": {"text": [["methylene blue"]], "start": [[30]], "entity_id": ["T7"]}, "Route": {"text": [["infusion"]], "start": [[45]], "entity_id": ["T8"]}}}]}]}
{"id": "21512888_8", "context": "After treatment with levetiracetam, seizures recurred and intravenous loading with valproic acid was administered, but resulted in a rapid increase in international normalized ratio (INR) to 7.6.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurred"]], "start": [[45]], "entity_id": ["T7"]}, "Effect": {"text": [["seizures"]], "start": [[36]], "entity_id": ["T8"]}, "Treatment": {"text": [["levetiracetam"]], "start": [[21]], "entity_id": ["T9"], "Drug": {"text": [["levetiracetam"]], "start": [[21]], "entity_id": ["T10"]}}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[119]], "entity_id": ["T13"]}, "Treatment": {"text": [["intravenous loading with valproic acid"]], "start": [[58]], "entity_id": ["T12"], "Disorder": {"text": [["seizures"]], "start": [[36]], "entity_id": ["T11"]}, "Route": {"text": [["intravenous"]], "start": [[58]], "entity_id": ["T15"]}, "Drug": {"text": [["valproic acid"]], "start": [[83]], "entity_id": ["T16"]}}, "Effect": {"text": [["a rapid increase in international normalized ratio (INR) to 7.6"]], "start": [[131]], "entity_id": ["T14"]}}]}]}
{"id": "18672645_1", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["seven cycles of treatment", "drug toxicity of bleomycin"]], "start": [[26, 109]], "entity_id": ["T4"], "Duration": {"text": [["seven cycles"]], "start": [[26]], "entity_id": ["T7"]}, "Drug": {"text": [["bleomycin"]], "start": [[126]], "entity_id": ["T6"]}}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["expired"]], "start": [[12]], "entity_id": ["T8"]}}]}]}
{"id": "12149193_8", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[14]], "entity_id": ["T7"]}, "Effect": {"text": [["DVT"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["combination chemotherapy including doxorubicin (P =.02)"]], "start": [[59]], "entity_id": ["T6"], "Drug": {"text": [["doxorubicin"]], "start": [[94]], "entity_id": ["T8"]}}}]}]}
{"id": "3753891_2", "context": "In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[147]], "entity_id": ["T7"]}, "Effect": {"text": [["myocardial necrosis", "cardiotoxicity"]], "start": [[78, 155]], "entity_id": ["T5"]}, "Treatment": {"text": [["amsacrine"]], "start": [[137]], "entity_id": ["T6"], "Drug": {"text": [["amsacrine"]], "start": [[137]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible"]], "start": [[103]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "18775393_1", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[126]], "entity_id": ["T5"]}, "Treatment": {"text": [["a probable interaction between topical econazole lotion 1% and acenocoumarol"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["econazole"], ["acenocoumarol"]], "start": [[83], [107]], "entity_id": ["T10", "T11"]}, "Route": {"text": [["lotion"]], "start": [[93]], "entity_id": ["T12"]}, "Dosage": {"text": [["1%"]], "start": [[100]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[55]], "entity_id": ["T9"]}, "Drug": {"text": [["econazole"], ["acenocoumarol"]], "start": [[83], [107]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["overanticoagulation and a life-threatening laryngeal hematoma"]], "start": [[138]], "entity_id": ["T6"]}, "Subject": {"text": [["elderly patient"]], "start": [[208]], "entity_id": ["T7"], "Age": {"text": [["elderly"]], "start": [[208]], "entity_id": ["T8"]}}, "Speculated": {"text": [["probable"]], "start": [[46]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "15461766_2", "context": "The harlequin color change and association with prostaglandin E1.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[31]], "entity_id": ["T4"]}, "Effect": {"text": [["harlequin color change"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["prostaglandin E1"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["prostaglandin E1"]], "start": [[48]], "entity_id": ["T6"]}}}]}]}
{"id": "19336028_1", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[69]], "entity_id": ["T8"]}, "Treatment": {"text": [["Efalizumab and Etanercept"]], "start": [[39]], "entity_id": ["T5"], "Disorder": {"text": [["refractory palmopustular psoriasis and psoriatic arthritis"]], "start": [[82]], "entity_id": ["T6"]}, "Drug": {"text": [["Efalizumab"], ["Etanercept"]], "start": [[39], [54]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[50]], "entity_id": ["T11"]}, "Drug": {"text": [["Efalizumab"], ["Etanercept"]], "start": [[39], [54]], "entity_id": ["T9", "T10"]}}]}, "Subject": {"text": [["a patient"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["tuberculosis"]], "start": [[10]], "entity_id": ["T7"]}}]}]}
{"id": "8438851_1", "context": "A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[81]], "entity_id": ["T3"]}, "Treatment": {"text": [["continuous intravenous infusion of vasopressin"]], "start": [[105]], "entity_id": ["T4"], "Route": {"text": [["intravenous"]], "start": [[116]], "entity_id": ["T8"]}, "Drug": {"text": [["vasopressin"]], "start": [[140]], "entity_id": ["T9"]}, "Freq": {"text": [["continuous"]], "start": [[105]], "entity_id": ["T10"]}, "Disorder": {"text": [["acute esophageal variceal bleeding"]], "start": [[15]], "entity_id": ["T11"]}}, "Subject": {"text": [["A patient with acute esophageal variceal bleeding"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[66]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[60]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "9934637_1", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[11]], "entity_id": ["T5"]}, "Effect": {"text": [["burn injury"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["use of drugs that contain psoralens."]], "start": [[46]], "entity_id": ["T4"], "Drug": {"text": [["psoralens"]], "start": [[72]], "entity_id": ["T6"]}}}]}]}
{"id": "8124920_2", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["an"]], "start": [[140]], "entity_id": ["T9"]}, "Subject": {"text": [["patient suffering from rheumatoid arthritis"]], "start": [[5]], "entity_id": ["T5"]}, "Effect": {"text": [["acute megaloblastic anaemia and a pneumonitis"]], "start": [[143]], "entity_id": ["T7"]}, "Treatment": {"text": [["low-dose methotrexate"]], "start": [[117]], "entity_id": ["T8"], "Drug": {"text": [["methotrexate"]], "start": [[126]], "entity_id": ["T10"]}, "Dosage": {"text": [["low-dose"]], "start": [[117]], "entity_id": ["T11"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[28]], "entity_id": ["T12"]}}}]}]}
{"id": "2611886_1", "context": "It is suggested that the fatal stroke may have resulted from arterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[76]], "entity_id": ["T6"]}, "Effect": {"text": [["stroke", "arterial spasm"]], "start": [[31, 61]], "entity_id": ["T5"]}, "Treatment": {"text": [["ergotamine overdosage"]], "start": [[86]], "entity_id": ["T7"], "Drug": {"text": [["ergotamine"]], "start": [[86]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[38]], "entity_id": ["T9"], "value": true}, "Severity": {"text": [["fatal"]], "start": [[25]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "3873709_2", "context": "Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurs"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["Pseudomembranous colitis"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["certain population groups"]], "start": [[52]], "entity_id": ["T6"]}, "Treatment": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[88]], "entity_id": ["T7"], "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[88], [101]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[100]], "entity_id": ["T10"]}, "Drug": {"text": [["sulfamethoxazole"], ["trimethoprim"]], "start": [[101], [88]], "entity_id": ["T9", "T8"]}}]}}]}]}
{"id": "8645078_4", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[107]], "entity_id": ["T7"]}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["atypical cholangitis", "liver damage"]], "start": [[45, 118]], "entity_id": ["T9"]}, "Treatment": {"text": [["captopril"]], "start": [[97]], "entity_id": ["T6"], "Drug": {"text": [["captopril"]], "start": [[97]], "entity_id": ["T10"]}}, "Speculated": {"text": [["suspected"]], "start": [[77]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "18071101_1", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[113]], "entity_id": ["T8"]}, "Treatment": {"text": [["quetiapine"]], "start": [[118]], "entity_id": ["T5"], "Drug": {"text": [["quetiapine"]], "start": [[118]], "entity_id": ["T9"]}}, "Effect": {"text": [["leucocytopenia and thrombocytopenia"]], "start": [[77]], "entity_id": ["T6"]}, "Subject": {"text": [["a case"]], "start": [[67]], "entity_id": ["T7"]}}]}]}
{"id": "3720318_1", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["infusion"]], "start": [[51]], "entity_id": ["T5"]}, "Effect": {"text": [["Noncardiogenic pulmonary edema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["mono-octanoin"]], "start": [[63]], "entity_id": ["T4"], "Drug": {"text": [["mono-octanoin"]], "start": [[63]], "entity_id": ["T6"]}}}]}]}
{"id": "20126479_1", "context": "CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[104]], "entity_id": ["T7"]}, "Effect": {"text": [["visual field loss"]], "start": [[86]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxychloroquine"]], "start": [[109]], "entity_id": ["T6"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[109]], "entity_id": ["T8"]}}}]}]}
{"id": "589261_1", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["thought to"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cardiac glycosides"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["doxorubicin"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "10586009_2", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["prescribed"]], "start": [[79]], "entity_id": ["T6"]}, "Treatment": {"text": [["codeine"]], "start": [[20]], "entity_id": ["T3"], "Drug": {"text": [["codeine"]], "start": [[20]], "entity_id": ["T9"]}, "Disorder": {"text": [["cough"]], "start": [[94]], "entity_id": ["T10"]}}, "Subject": {"text": [["in the neonate", "for cough control during an emergency department visit"]], "start": [[41, 90]], "entity_id": ["T4"], "Age": {"text": [["neonate"]], "start": [[48]], "entity_id": ["T7"]}}, "Effect": {"text": [["intoxication"]], "start": [[28]], "entity_id": ["T5"]}}]}]}
{"id": "17260498_2", "context": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[70]], "entity_id": ["T6"]}, "Treatment": {"text": [["Taxanes"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Taxanes"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary injury"]], "start": [[77]], "entity_id": ["T7"]}}]}]}
{"id": "17404582_1", "context": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["Meibomian duct inflammation and blockage"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with no history of eyelid masses in the past"]], "start": [[103]], "entity_id": ["T6"]}, "Speculated": {"text": [["likely"]], "start": [[66]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18755414_1", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[34]], "entity_id": ["T9"]}, "Effect": {"text": [["Hemorrhage from a falx meningioma"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["low-dose aspirin"]], "start": [[56]], "entity_id": ["T8"], "Dosage": {"text": [["low-dose"]], "start": [[56]], "entity_id": ["T7"]}, "Drug": {"text": [["aspirin"]], "start": [[65]], "entity_id": ["T10"]}}}]}]}
{"id": "8316494_1", "context": "Severe abdominal pain in low dosage clofazimine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["low dosage clofazimine"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["clofazimine"]], "start": [[36]], "entity_id": ["T7"]}, "Dosage": {"text": [["low dosage"]], "start": [[25]], "entity_id": ["T8"]}}, "Effect": {"text": [["abdominal pain"]], "start": [[7]], "entity_id": ["T5"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "6671350_2", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Effect": {"text": [["Coagulopathy"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cephalosporin or moxalactam antibiotics"]], "start": [[40]], "entity_id": ["T6"], "Drug": {"text": [["cephalosporin"], ["moxalactam"]], "start": [[40], [57]], "entity_id": ["T8", "T9"]}, "Disorder": {"text": [["acute and chronic renal failure"]], "start": [[83]], "entity_id": ["T10"]}}}]}]}
{"id": "8053440_1", "context": "Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[73]], "entity_id": ["T10"]}, "Treatment": {"text": [["clindamycin and trimethoprim-sulfamethoxazole"]], "start": [[97]], "entity_id": ["T11"], "Drug": {"text": [["clindamycin"], ["trimethoprim"], ["sulfamethoxazole"]], "start": [[97], [113], [126]], "entity_id": ["T13", "T14", "T15"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[109]], "entity_id": ["T17"]}, "Drug": {"text": [["clindamycin"], ["sulfamethoxazole"], ["trimethoprim"]], "start": [[97], [126], [113]], "entity_id": ["T13", "T15", "T14"]}}]}, "Effect": {"text": [["Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)"]], "start": [[0]], "entity_id": ["T12"]}}]}]}
{"id": "9865241_2", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[72]], "entity_id": ["T6"]}, "Effect": {"text": [["hypercalcemia"]], "start": [[58]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[44]], "entity_id": ["T8"]}, "Treatment": {"text": [["acute vitamin D poisoning"]], "start": [[85]], "entity_id": ["T7"], "Drug": {"text": [["vitamin D"]], "start": [[91]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["acute"]], "start": [[85]], "entity_id": ["T11"]}, "Dosage": {"text": [["poisoning"]], "start": [[101]], "entity_id": ["T12"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["considered"]], "start": [[30]], "entity_id": ["T16"]}, "Subject": {"text": [["patients"]], "start": [[44]], "entity_id": ["T8"]}, "Treatment": {"text": [["Pamidronate therapy"]], "start": [[0]], "entity_id": ["T14"], "Drug": {"text": [["Pamidronate"]], "start": [[0]], "entity_id": ["T15"]}, "Disorder": {"text": [["hypercalcemia"]], "start": [[58]], "entity_id": ["T13"]}}}]}]}
{"id": "8162401_2", "context": "Seizures associated with fluoxetine therapy are uncommon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Effect": {"text": [["Seizures"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluoxetine therapy"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["fluoxetine"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "11414270_1", "context": "Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T9"]}, "Treatment": {"text": [["Succinylcholine"]], "start": [[0]], "entity_id": ["T16"], "Disorder": {"text": [["mucositis secondary to chemotherapy"]], "start": [[55]], "entity_id": ["T15"]}, "Drug": {"text": [["Succinylcholine"]], "start": [[0]], "entity_id": ["T14"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[24]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient"]], "start": [[40]], "entity_id": ["T8"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[65]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient"]], "start": [[40]], "entity_id": ["T8"]}, "Effect": {"text": [["mucositis"]], "start": [[55]], "entity_id": ["T13"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[78]], "entity_id": ["T11"]}}]}]}
{"id": "10337682_1", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["prednisone"]], "start": [[91]], "entity_id": ["T3"], "Drug": {"text": [["prednisone"]], "start": [[91]], "entity_id": ["T10"]}, "Disorder": {"text": [["SLE"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["a pruritic bullous eruption"]], "start": [[54]], "entity_id": ["T5"]}, "Subject": {"text": [["A 14-year-old girl with newly diagnosed SLE"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["14-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[14]], "entity_id": ["T9"]}}}]}]}
{"id": "19745701_4", "context": "To our knowledge, this is the first case of spontaneous remission of MTX-associated gastric LPD after discontinuation of MTX therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[73]], "entity_id": ["T5"]}, "Subject": {"text": [["the first case"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["MTX"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["MTX"], ["MTX"]], "start": [[69], [121]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["gastric LPD"]], "start": [[84]], "entity_id": ["T6"]}}]}]}
{"id": "8175330_1", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["Sodium valproate and carbamazepine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"], ["Sodium valproate"]], "start": [[21], [0]], "entity_id": ["T8", "T9"]}}, "Effect": {"text": [["adverse cutaneous reactions"]], "start": [[106]], "entity_id": ["T6"]}}]}]}
{"id": "8604715_3", "context": "Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T8"]}, "Treatment": {"text": [["foscarnet"]], "start": [[142]], "entity_id": ["T5"], "Drug": {"text": [["foscarnet"]], "start": [[142]], "entity_id": ["T9"]}}, "Effect": {"text": [["nephrogenic diabetes insipidus and renal tubular acidosis"]], "start": [[27]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[4]], "entity_id": ["T7"]}}]}]}
{"id": "16132305_1", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T7"]}, "Treatment": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["congenital heart disease"]], "start": [[76]], "entity_id": ["T13"]}}, "Effect": {"text": [["pulmonary infiltrates with eosinophilia"]], "start": [[18]], "entity_id": ["T8"]}, "Subject": {"text": [["an infant with congenital heart disease"]], "start": [[61]], "entity_id": ["T9"], "Age": {"text": [["infant"]], "start": [[64]], "entity_id": ["T10"]}}}]}]}
{"id": "1829999_1", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Exfoliative dermatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["tobramycin sulfate."]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["tobramycin sulfate"]], "start": [[36]], "entity_id": ["T6"]}}}]}]}
{"id": "3579660_4", "context": "Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[33]], "entity_id": ["T6"]}, "Effect": {"text": [["Worsening of neurologic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with Wilson's disease"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["penicillamine therapy"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["penicillamine"]], "start": [[80]], "entity_id": ["T8"]}, "Disorder": {"text": [["Wilson's disease"]], "start": [[50]], "entity_id": ["T9"]}}}]}]}
{"id": "6303138_2", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[16]], "entity_id": ["T10"]}, "Subject": {"text": [["young patient"]], "start": [[2]], "entity_id": ["T7"], "Age": {"text": [["young"]], "start": [[2]], "entity_id": ["T11"]}}, "Effect": {"text": [["sinus tachycardia"]], "start": [[35]], "entity_id": ["T8"]}, "Treatment": {"text": [["nortriptyline"]], "start": [[112]], "entity_id": ["T9"], "Drug": {"text": [["nortriptyline"]], "start": [[112]], "entity_id": ["T12"]}}}]}]}
{"id": "15494638_7", "context": "Patient A reported right leg weakness (foot drop) during week 4 of CAP-XRT (1600 mg/m2).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["Patient A"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["right leg weakness"]], "start": [[19]], "entity_id": ["T6"]}, "Treatment": {"text": [["week 4 of CAP-XRT (1600 mg/m2)"]], "start": [[57]], "entity_id": ["T7"], "Duration": {"text": [["week 4"]], "start": [[57]], "entity_id": ["T9"]}, "Drug": {"text": [["CAP-XRT"]], "start": [[67]], "entity_id": ["T10"]}, "Dosage": {"text": [["1600 mg/m2"]], "start": [[76]], "entity_id": ["T11"]}}}]}]}
{"id": "12587815_2", "context": "Concomitant administration of lithium with olanzapine may place patients at risk for NMS.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["administration"]], "start": [[12]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[64]], "entity_id": ["T6"]}, "Effect": {"text": [["NMS"]], "start": [[85]], "entity_id": ["T7"]}, "Treatment": {"text": [["lithium with olanzapine"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["lithium"], ["olanzapine"]], "start": [[30], [43]], "entity_id": ["T11", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[38]], "entity_id": ["T12"]}, "Drug": {"text": [["lithium"], ["olanzapine"]], "start": [[30], [43]], "entity_id": ["T11", "T13"]}}]}, "Speculated": {"text": [["at risk for"]], "start": [[73]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11077455_3", "context": "PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[61]], "entity_id": ["T4"]}, "Effect": {"text": [["Symptomatic visual field constriction"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin"]], "start": [[77]], "entity_id": ["T5"], "Drug": {"text": [["vigabatrin"]], "start": [[77]], "entity_id": ["T6"]}}}]}]}
{"id": "1477441_4", "context": "OBJECTIVE: To report two cases of fixed drug eruption induced by methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Subject": {"text": [["two cases"]], "start": [[21]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[21]], "entity_id": ["T7"]}}, "Treatment": {"text": [["methylphenidate"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[65]], "entity_id": ["T8"]}}, "Effect": {"text": [["fixed drug eruption"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "17675030_1", "context": "A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric patients aged 16 years and younger.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[131]], "entity_id": ["T4"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[117]], "entity_id": ["T3"], "Drug": {"text": [["oxcarbazepine"]], "start": [[117]], "entity_id": ["T9"]}}, "Effect": {"text": [["angioedema"]], "start": [[142]], "entity_id": ["T5"]}, "Subject": {"text": [["pediatric patients aged 16 years and younger"]], "start": [[156]], "entity_id": ["T6"], "Disorder": {"text": [["pediatric"]], "start": [[156]], "entity_id": ["T7"]}, "Age": {"text": [["aged 16 years and younger"]], "start": [[175]], "entity_id": ["T8"]}}}]}]}
{"id": "16678268_2", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["AVP"]], "start": [[27]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T5"], "Time_elapsed": {"text": [["three weeks"]], "start": [[31]], "entity_id": ["T7"]}, "Drug": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T8"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[107]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[20]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "18487000_3", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[52]], "entity_id": ["T4"]}, "Effect": {"text": [["hyponatremia"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["sibutramine"]], "start": [[68]], "entity_id": ["T5"], "Drug": {"text": [["sibutramine"]], "start": [[68]], "entity_id": ["T9"]}, "Disorder": {"text": [["obese"]], "start": [[90]], "entity_id": ["T10"]}}, "Subject": {"text": [["an obese woman"]], "start": [[87]], "entity_id": ["T6"], "Gender": {"text": [["woman"]], "start": [[96]], "entity_id": ["T7"]}}}]}]}
{"id": "19448237_1", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Polymyoclonus seizure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["accidental injection of tranexamic acid in spinal anesthesia"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["tranexamic acid"]], "start": [[61]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[48]], "entity_id": ["T7"]}}}]}]}
{"id": "6671350_1", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["Cephalosporins"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Cephalosporins"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["Vitamin K deficiency."]], "start": [[47]], "entity_id": ["T5"]}, "Speculated": {"text": [["most likely"]], "start": [[19]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "4051280_2", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["Propranolol"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Propranolol"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypertension"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "8684546_1", "context": "Aluminum intoxication, along with other factors, was considered to be the cause of TC development.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[74]], "entity_id": ["T7"]}, "Treatment": {"text": [["Aluminum intoxication"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Aluminum"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["TC development"]], "start": [[83]], "entity_id": ["T6"]}, "Speculated": {"text": [["considered"]], "start": [[53]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10475726_2", "context": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[4]], "entity_id": ["T5"]}, "Effect": {"text": [["ischaemic events"]], "start": [[46]], "entity_id": ["T3"]}, "Treatment": {"text": [["venlafaxine treatment"]], "start": [[19]], "entity_id": ["T4"], "Drug": {"text": [["venlafaxine"]], "start": [[19]], "entity_id": ["T6"]}}}]}]}
{"id": "8903300_3", "context": "This pattern is suggestive of renal toxicity due to tobramycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[45]], "entity_id": ["T4"]}, "Effect": {"text": [["renal toxicity"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["tobramycin"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["tobramycin"]], "start": [[52]], "entity_id": ["T6"]}}}]}]}
{"id": "4063627_3", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[106]], "entity_id": ["T5"]}, "Treatment": {"text": [["fenclofenac", "aurothiomalate", "sulphasalazine"]], "start": [[117, 140, 159]], "entity_id": ["T6"], "Drug": {"text": [["fenclofenac"], ["aurothiomalate"], ["sulphasalazine"]], "start": [[117], [140], [159]], "entity_id": ["T9", "T10", "T11"]}}, "Effect": {"text": [["remission in rheumatoid arthritis"]], "start": [[72]], "entity_id": ["T7"]}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T12"], "Disorder": {"text": [["selective IgA deficiency"]], "start": [[42]], "entity_id": ["T8"]}}}]}]}
{"id": "11881322_4", "context": "METHODS: Three patients with apparent itraconazole-induced liver injury were studied.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[38]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[38]], "entity_id": ["T8"]}}, "Effect": {"text": [["liver injury"]], "start": [[59]], "entity_id": ["T5"]}, "Subject": {"text": [["Three patients"]], "start": [[9]], "entity_id": ["T6"], "Population": {"text": [["Three"]], "start": [[9]], "entity_id": ["T7"]}}}]}]}
{"id": "16298824_2", "context": "ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T6"]}, "Effect": {"text": [["ARDS"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3"]], "start": [[30]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"], ["gemtuzumab"], ["ozogamicin"], ["OKT3"]], "start": [[89], [101], [112], [128]], "entity_id": ["T8", "T9", "T10", "T11"]}}}]}]}
{"id": "17504225_4", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[209]], "entity_id": ["T8"]}, "Treatment": {"text": [["the concomitant administration of clarithromycin and sirolimus"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["clarithromycin"], ["sirolimus"]], "start": [[62], [81]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[32]], "entity_id": ["T12"]}, "Drug": {"text": [["clarithromycin"], ["sirolimus"]], "start": [[62], [81]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["acute impairment of renal function"]], "start": [[228]], "entity_id": ["T9"]}}]}]}
{"id": "1495728_1", "context": "Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[25]], "entity_id": ["T9"]}, "Treatment": {"text": [["nonsurgical treatment"]], "start": [[28]], "entity_id": ["T7"], "Disorder": {"text": [["ectopic pregnancy"]], "start": [[53]], "entity_id": ["T6"]}}, "Effect": {"text": [["Methotrexate pneumonitis"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "10190739_1", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["readministration"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["riluzole"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["riluzole"]], "start": [[37]], "entity_id": ["T6"]}}, "Effect": {"text": [["the relapse of hepatitis"]], "start": [[62]], "entity_id": ["T5"]}}]}]}
{"id": "3767790_2", "context": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[55]], "entity_id": ["T7"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T9"]}}, "Treatment": {"text": [["receiving Tolazoline by infusion"]], "start": [[22]], "entity_id": ["T6"], "Drug": {"text": [["Tolazoline"]], "start": [[32]], "entity_id": ["T10"]}, "Route": {"text": [["infusion"]], "start": [[46]], "entity_id": ["T11"]}}, "Effect": {"text": [["duodenal ulceration and subsequent intestinal perforation"]], "start": [[65]], "entity_id": ["T8"]}}]}]}
{"id": "25538343_2", "context": "Hyponatremia is a known adverse effect of duloxetine, and it can lead to potentially life-threatening complications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["duloxetine"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["duloxetine"]], "start": [[42]], "entity_id": ["T10"]}}, "Effect": {"text": [["Hyponatremia"], ["potentially life-threatening complications"]], "start": [[0], [73]], "entity_id": ["T6", "T7"]}, "Speculated": {"text": [["potentially"]], "start": [[73]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["life-threatening"]], "start": [[85]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "16432996_3", "context": "Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["pathogenesis"]], "start": [[53]], "entity_id": ["T8"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[69]], "entity_id": ["T9"]}, "Treatment": {"text": [["interferon gamma"]], "start": [[9]], "entity_id": ["T7"], "Drug": {"text": [["interferon gamma"]], "start": [[9]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[114]], "entity_id": ["T15"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[102]], "entity_id": ["T14"]}, "Subject": {"text": [["a few cases"]], "start": [[87]], "entity_id": ["T13"]}, "Treatment": {"text": [["interferon alpha therapy"]], "start": [[130]], "entity_id": ["T16"], "Drug": {"text": [["interferon alpha"]], "start": [[130]], "entity_id": ["T11"]}}}]}]}
{"id": "11373877_2", "context": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[129]], "entity_id": ["T4"]}, "Subject": {"text": [["two patients with histologically confirmed adenocarcinoma of the prostate"]], "start": [[32]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[32]], "entity_id": ["T7"]}}, "Treatment": {"text": [["steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation"]], "start": [[142]], "entity_id": ["T5"], "Disorder": {"text": [["adenocarcinoma of the prostate"]], "start": [[75]], "entity_id": ["T8"]}, "Drug": {"text": [["cyproterone acetate"]], "start": [[189]], "entity_id": ["T9"]}}, "Effect": {"text": [["femoral head avascular necrosis."]], "start": [[291]], "entity_id": ["T6"]}}]}]}
{"id": "4014301_2", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["Self-limited edema"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["insulin"]], "start": [[56]], "entity_id": ["T7"]}}}]}]}
{"id": "7900744_2", "context": "Hemodialysis should be performed for rapid reversal of mannitol-induced ARF.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["mannitol"]], "start": [[55]], "entity_id": ["T3"], "Drug": {"text": [["mannitol"]], "start": [[55]], "entity_id": ["T6"]}}, "Effect": {"text": [["ARF"]], "start": [[72]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["performed"]], "start": [[23]], "entity_id": ["T11"]}, "Treatment": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["mannitol-induced ARF"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "998323_1", "context": "Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[41]], "entity_id": ["T9"]}, "Treatment": {"text": [["Lithium treatment"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["lithium intoxication with a diabetes insipidus-like syndrome"]], "start": [[52]], "entity_id": ["T8"]}}]}]}
{"id": "15061230_1", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contributed"]], "start": [[77]], "entity_id": ["T4"]}, "Treatment": {"text": [["dexamethasone"]], "start": [[27]], "entity_id": ["T3"], "Drug": {"text": [["dexamethasone"]], "start": [[27]], "entity_id": ["T7"]}}, "Effect": {"text": [["osteonecrosis"]], "start": [[111]], "entity_id": ["T5"]}, "Subject": {"text": [["these patients"]], "start": [[128]], "entity_id": ["T6"]}, "Speculated": {"text": [["likely"]], "start": [[11]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11795358_2", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[49]], "entity_id": ["T4"]}, "Effect": {"text": [["endometrial carcinoma in the tamoxifen arm"]], "start": [[60]], "entity_id": ["T5"]}, "Subject": {"text": [["healthy population"]], "start": [[8]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[89]], "entity_id": ["T3"], "Drug": {"text": [["tamoxifen"]], "start": [[89]], "entity_id": ["T7"]}}}]}]}
{"id": "7393795_3", "context": "The induction of hypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[4]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoglycaemia"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["PAS"]], "start": [[36]], "entity_id": ["T4"], "Drug": {"text": [["PAS"]], "start": [[36]], "entity_id": ["T8"]}, "Disorder": {"text": [["diabetes mellitus"]], "start": [[110]], "entity_id": ["T9"]}}, "Subject": {"text": [["this patient"]], "start": [[43]], "entity_id": ["T7"]}}]}]}
{"id": "3115809_1", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["optic neuropathy"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["isoniazid and ethambutol"]], "start": [[62]], "entity_id": ["T7"], "Drug": {"text": [["isoniazid"], ["ethambutol"]], "start": [[62], [76]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[72]], "entity_id": ["T10"]}, "Drug": {"text": [["isoniazid"], ["ethambutol"]], "start": [[62], [76]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "3156465_1", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["have"]], "start": [[71]], "entity_id": ["T4"]}, "Treatment": {"text": [["Isotretinoin, a drug used for the treatment of acne"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Isotretinoin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["teratogenic effects"]], "start": [[76]], "entity_id": ["T5"]}}]}]}
{"id": "1673494_1", "context": "Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[58]], "entity_id": ["T18"]}, "Effect": {"text": [["toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia"]], "start": [[61]], "entity_id": ["T16"]}, "Treatment": {"text": [["Amphotericin B (AmB)"]], "start": [[0]], "entity_id": ["T17"], "Drug": {"text": [["Amphotericin B (AmB)"]], "start": [[0]], "entity_id": ["T19"]}}}]}]}
{"id": "448845_2", "context": "Carbonic anhydrase inhibitors used in the treatment of glaucoma, seizure disorders, and hypertension are rarely associated with blood dyscrasias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["rarely associated"]], "start": [[105]], "entity_id": ["T9"]}, "Treatment": {"text": [["Carbonic anhydrase inhibitors"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Carbonic anhydrase inhibitors"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["glaucoma, seizure disorders, and hypertension"]], "start": [[55]], "entity_id": ["T12"]}}, "Effect": {"text": [["blood dyscrasias"]], "start": [[128]], "entity_id": ["T10"]}}]}]}
{"id": "12751276_2", "context": "Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["is"]], "start": [[27]], "entity_id": ["T8"]}, "Treatment": {"text": [["isoniazid", "commonly prescribed antibiotic"]], "start": [[17, 61]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"]], "start": [[17]], "entity_id": ["T9"]}}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T7"]}, "Severity": {"text": [["possible"]], "start": [[32]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "2104570_5", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T5"]}, "Effect": {"text": [["hematologic malignancy"]], "start": [[51]], "entity_id": ["T6"]}, "Treatment": {"text": [["etoglucid, doxorubicin, and mitomycin C"], ["several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C"]], "start": [[155], [74]], "entity_id": ["T8", "T11"], "Drug": {"text": [["etoglucid"], ["doxorubicin"], ["mitomycin C"]], "start": [[155], [166], [183]], "entity_id": ["T12", "T13", "T14"]}, "Disorder": {"text": [["superficial bladder cancer"]], "start": [[123]], "entity_id": ["T10"]}, "Route": {"text": [["intravesical chemotherapy"]], "start": [[94]], "entity_id": ["T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[179]], "entity_id": ["T15"]}, "Drug": {"text": [["mitomycin C"], ["doxorubicin"], ["etoglucid"]], "start": [[183], [166], [155]], "entity_id": ["T14", "T13", "T12"]}}]}, "Subject": {"text": [["Two cases are reported of patients"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T16"]}}}]}]}
{"id": "18094347_5", "context": "Methotrexate-induced papular eruption following treatment of psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["psoriasis"]], "start": [[61]], "entity_id": ["T8"]}}, "Effect": {"text": [["papular eruption"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "11030530_2", "context": "Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["present"]], "start": [[41]], "entity_id": ["T7"]}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[22]], "entity_id": ["T6"], "Drug": {"text": [["L-asparaginase"]], "start": [[22]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemorrhagic and thrombotic cerebrovascular events"]], "start": [[54]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "14690166_1", "context": "2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accelerate"]], "start": [[90]], "entity_id": ["T10"]}, "Treatment": {"text": [["2-Chloro-deoxyadenosine"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["2-Chloro-deoxyadenosine"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["Castleman's disease"]], "start": [[62]], "entity_id": ["T13"]}}, "Effect": {"text": [["non-Hodgkin's lymphoma"]], "start": [[123]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[86]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "19224802_1", "context": "An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[79]], "entity_id": ["T8"]}, "Effect": {"text": [["bradycardia"]], "start": [[67]], "entity_id": ["T11"]}, "Treatment": {"text": [["high-dose dexmedetomidine"]], "start": [[95]], "entity_id": ["T9"], "Drug": {"text": [["dexmedetomidine"]], "start": [[105]], "entity_id": ["T12"]}, "Dosage": {"text": [["high-dose"]], "start": [[95]], "entity_id": ["T16"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["response"]], "start": [[28]], "entity_id": ["T13"]}, "Treatment": {"text": [["glycopyrrolate"]], "start": [[40]], "entity_id": ["T14"], "Disorder": {"text": [["bradycardia"]], "start": [[67]], "entity_id": ["T17"]}, "Drug": {"text": [["glycopyrrolate"]], "start": [[40]], "entity_id": ["T15"]}}, "Effect": {"text": [["exaggerated hypertensive"]], "start": [[3]], "entity_id": ["T10"]}}]}]}
{"id": "11247558_2", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["regressed"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["within 1 week of meloxicam withdrawal"]], "start": [[50]], "entity_id": ["T3"], "Disorder": {"text": [["Symptoms and endoscopic lesions"]], "start": [[0]], "entity_id": ["T4"]}, "Time_elapsed": {"text": [["1 week"]], "start": [[57]], "entity_id": ["T7"]}, "Drug": {"text": [["meloxicam"]], "start": [[67]], "entity_id": ["T8"]}}}]}]}
{"id": "9920368_1", "context": "Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "7679525_2", "context": "A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening interstitial pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T10"]}, "Subject": {"text": [["A 42 year old man, treated for testicular carcinoma"]], "start": [[0]], "entity_id": ["T7"], "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T11"]}, "Age": {"text": [["42 year old"]], "start": [[2]], "entity_id": ["T12"]}}, "Treatment": {"text": [["combination chemotherapy that included bleomycin,"]], "start": [[57]], "entity_id": ["T8"], "Drug": {"text": [["bleomycin"]], "start": [[96]], "entity_id": ["T15"]}, "Disorder": {"text": [["testicular carcinoma"]], "start": [[31]], "entity_id": ["T16"]}}, "Effect": {"text": [["interstitial pneumonitis"]], "start": [[134]], "entity_id": ["T9"]}, "Severity": {"text": [["life threatening"]], "start": [[117]], "entity_id": ["T14"], "value": "Medium"}}]}]}
{"id": "18675768_4", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[117]], "entity_id": ["T8"]}, "Effect": {"text": [["symptoms of propafenone adverse effects"]], "start": [[124]], "entity_id": ["T7"]}, "Treatment": {"text": [["drug-drug interaction between propafenone and citalopram"]], "start": [[53]], "entity_id": ["T9"], "Drug": {"text": [["propafenone"], ["citalopram"], ["propafenone"]], "start": [[83], [99], [136]], "entity_id": ["T11", "T12", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[63]], "entity_id": ["T10"]}, "Drug": {"text": [["propafenone"], ["citalopram"]], "start": [[83], [99]], "entity_id": ["T11", "T12"]}}]}, "Speculated": {"text": [["potential"]], "start": [[43]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "7949255_1", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[40]], "entity_id": ["T7"]}, "Effect": {"text": [["Temporary neurologic abnormalities"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["one out of 23 patients"]], "start": [[52]], "entity_id": ["T4"], "Population": {"text": [["one out of 23"]], "start": [[52]], "entity_id": ["T8"]}}, "Treatment": {"text": [["chemotherapy with high-dose methotrexate (HD-MTX)"]], "start": [[86]], "entity_id": ["T6"], "Disorder": {"text": [["osteogenic sarcoma"]], "start": [[140]], "entity_id": ["T5"]}, "Dosage": {"text": [["high-dose"]], "start": [[104]], "entity_id": ["T9"]}, "Drug": {"text": [["methotrexate"]], "start": [[114]], "entity_id": ["T10"]}}}]}]}
{"id": "16005413_5", "context": "Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[28]], "entity_id": ["T10"]}, "Subject": {"text": [["Four elderly LTCF residents"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T12"]}, "Age": {"text": [["elderly"]], "start": [[5]], "entity_id": ["T13"]}}, "Treatment": {"text": [["serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids"]], "start": [[41]], "entity_id": ["T11"], "Disorder": {"text": [["LTCF"]], "start": [[13]], "entity_id": ["T15"]}, "Drug": {"text": [["selective serotonin reuptake inhibitor"], ["mirtazapine"], ["opioids"]], "start": [[80], [129], [145]], "entity_id": ["T16", "T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[141]], "entity_id": ["T19"]}, "Drug": {"text": [["opioids"], ["mirtazapine"]], "start": [[145], [129]], "entity_id": ["T18", "T17"]}}]}}]}]}
{"id": "18675768_13", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[93]], "entity_id": ["T11"]}, "Effect": {"text": [["adverse effects (eg, dizziness, falls) and mimicked coronary artery disease"]], "start": [[112]], "entity_id": ["T12"]}, "Treatment": {"text": [["interaction between propafenone and citalopram", "propafenone"]], "start": [[39, 100]], "entity_id": ["T13"], "Drug": {"text": [["propafenone"], ["citalopram"]], "start": [[59], [75]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[39]], "entity_id": ["T14"]}, "Drug": {"text": [["propafenone"], ["citalopram"]], "start": [[59], [75]], "entity_id": ["T15", "T16"]}}]}, "Speculated": {"text": [["possible"]], "start": [[30]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "8496127_2", "context": "This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[111]], "entity_id": ["T7"]}, "Subject": {"text": [["6.9-year-old autistic male"]], "start": [[24]], "entity_id": ["T5"], "Age": {"text": [["6.9-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[46]], "entity_id": ["T11"]}, "Disorder": {"text": [["autistic"]], "start": [[37]], "entity_id": ["T16"]}}, "Effect": {"text": [["repeated episodes of acute dystonic reactions"]], "start": [[65]], "entity_id": ["T6"]}, "Treatment": {"text": [["pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration"]], "start": [[127]], "entity_id": ["T8"], "Drug": {"text": [["pimozide"], ["thioridazine"]], "start": [[127], [276]], "entity_id": ["T12", "T15"]}, "Dosage": {"text": [["0.096 mg/kg/day"], ["0.032 mg/kg/day"]], "start": [[167], [187]], "entity_id": ["T13", "T14"]}, "Time_elapsed": {"text": [["32 hours following pimozide withdrawal"]], "start": [[207]], "entity_id": ["T17"]}}}]}]}
{"id": "16527771_1", "context": "Acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute unilateral total visual loss"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["retrogasserian phenol injection"]], "start": [[41]], "entity_id": ["T5"], "Route": {"text": [["injection"]], "start": [[63]], "entity_id": ["T7"]}, "Drug": {"text": [["retrogasserian phenol"]], "start": [[41]], "entity_id": ["T8"]}, "Disorder": {"text": [["trigeminal neuralgia"]], "start": [[94]], "entity_id": ["T9"]}}}]}]}
{"id": "9840249_1", "context": "Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[34]], "entity_id": ["T3"]}, "Effect": {"text": [["Alveolar-interstitial pneumopathy"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["gold-salts compounds administration"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["gold-salts compounds"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "3892171_1", "context": "Protamine-induced fatal anaphylaxis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["Protamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Protamine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[24]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[18]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "9362107_3", "context": "We diagnosed this case as danazol induced thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["danazol"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["this case"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "15770343_3", "context": "In addition, ethambutol rarely causes visual loss during the early period or when given at lower doses.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["ethambutol"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["visual loss"]], "start": [[38]], "entity_id": ["T5"]}}]}]}
{"id": "11215836_4", "context": "The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["stopped"]], "start": [[28]], "entity_id": ["T19"]}, "Effect": {"text": [["behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused"]], "start": [[98]], "entity_id": ["T20"]}, "Treatment": {"text": [["The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d"]], "start": [[0]], "entity_id": ["T21"], "Drug": {"text": [["clomipramine"], ["clozapine"]], "start": [[66], [14]], "entity_id": ["T24", "T26"]}, "Dosage": {"text": [["150 mg/d"]], "start": [[79]], "entity_id": ["T25"]}, "Time_elapsed": {"text": [["The day after"]], "start": [[0]], "entity_id": ["T27"]}}, "Subject": {"text": [["he"]], "start": [[89]], "entity_id": ["T22"], "Gender": {"text": [["he"]], "start": [[89]], "entity_id": ["T23"]}}}]}]}
{"id": "10656221_2", "context": "There are few reports in the literature related to sulfonylurea-induced hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[64]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulfonylurea"]], "start": [[51]], "entity_id": ["T4"], "Drug": {"text": [["sulfonylurea"]], "start": [[51]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[72]], "entity_id": ["T6"]}}]}]}
{"id": "6362443_2", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[79]], "entity_id": ["T5"]}, "Subject": {"text": [["A depressed woman with no history of bipolar illness"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["manic episode"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[101]], "entity_id": ["T6"], "Drug": {"text": [["fluoxetine"]], "start": [[101]], "entity_id": ["T9"]}, "Disorder": {"text": [["depressed"]], "start": [[2]], "entity_id": ["T10"]}}}]}]}
{"id": "6725214_2", "context": "Priapism associated with trazodone therapy: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Effect": {"text": [["Priapism"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["trazodone therapy"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["trazodone"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "12880504_3", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["obsessive-compulsive symptoms"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["two children"]], "start": [[53]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[53]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[57]], "entity_id": ["T8"]}}}]}]}
{"id": "17285101_3", "context": "This is the first report of pulmonary hypertension in an adult patient during lithium therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[71]], "entity_id": ["T4"]}, "Subject": {"text": [["an adult patient"]], "start": [[54]], "entity_id": ["T3"], "Age": {"text": [["adult"]], "start": [[57]], "entity_id": ["T7"]}}, "Treatment": {"text": [["lithium therapy."]], "start": [[78]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[78]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary hypertension"]], "start": [[28]], "entity_id": ["T6"]}}]}]}
{"id": "7639655_3", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[79]], "entity_id": ["T5"]}, "Effect": {"text": [["anterior ischemic optic neuropathy"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon alfa"]], "start": [[110]], "entity_id": ["T4"], "Drug": {"text": [["interferon alfa"]], "start": [[110]], "entity_id": ["T6"]}}}]}]}
{"id": "8850251_4", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["mequitazine", "due to a relatively low dosage of the drug"]], "start": [[76, 120]], "entity_id": ["T3"], "Drug": {"text": [["mequitazine"]], "start": [[76]], "entity_id": ["T6"]}, "Dosage": {"text": [["low dosage"]], "start": [[140]], "entity_id": ["T7"]}}, "Effect": {"text": [["photosensitivity"]], "start": [[96]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[113]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "8140860_3", "context": "Seven days after the introduction of amoxycillin (500 mg/8 h) for a probable respiratory infection, the patient developed spontaneous bruising, with an INR of 7.1.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[112]], "entity_id": ["T9"]}, "Treatment": {"text": [["Seven days after the introduction of amoxycillin (500 mg/8 h)"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["a probable respiratory infection"]], "start": [[66]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["Seven days after"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["amoxycillin"]], "start": [[37]], "entity_id": ["T12"]}, "Dosage": {"text": [["500 mg/8 h"]], "start": [[50]], "entity_id": ["T13"]}}, "Subject": {"text": [["the patient"]], "start": [[100]], "entity_id": ["T8"]}, "Effect": {"text": [["spontaneous bruising, with an INR of 7.1"]], "start": [[122]], "entity_id": ["T10"]}}]}]}
{"id": "3115809_2", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[18]], "entity_id": ["T9"]}, "Treatment": {"text": [["ethambutol"]], "start": [[34]], "entity_id": ["T6"], "Drug": {"text": [["ethambutol"]], "start": [[34]], "entity_id": ["T7"]}}, "Effect": {"text": [["optic neuropathy"]], "start": [[52]], "entity_id": ["T8"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[95]], "entity_id": ["T14"]}, "Effect": {"text": [["ocular toxicity"]], "start": [[88]], "entity_id": ["T11"]}, "Treatment": {"text": [["isoniazid"]], "start": [[107]], "entity_id": ["T12"], "Drug": {"text": [["isoniazid"]], "start": [[107]], "entity_id": ["T13"]}}, "Speculated": {"text": [["potential"]], "start": [[78]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "412488_7", "context": "These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[304]], "entity_id": ["T12"]}, "Treatment": {"text": [["gold therapy in rheumatoid arthritis"]], "start": [[320]], "entity_id": ["T13"], "Drug": {"text": [["gold"]], "start": [[320]], "entity_id": ["T17"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[336]], "entity_id": ["T14"]}}, "Effect": {"text": [["renal disease"]], "start": [[290]], "entity_id": ["T18"]}, "Speculated": {"text": [["may be"]], "start": [[257]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "17671884_7", "context": "One previous study of four transplant patients whose immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin noted anemia in 13% of them.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[178]], "entity_id": ["T10"]}, "Effect": {"text": [["anemia"]], "start": [[184]], "entity_id": ["T11"]}, "Subject": {"text": [["four transplant patients"]], "start": [[22]], "entity_id": ["T12"], "Population": {"text": [["four"]], "start": [[22]], "entity_id": ["T14"]}, "Disorder": {"text": [["transplant"]], "start": [[27]], "entity_id": ["T20"]}}, "Treatment": {"text": [["immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin"]], "start": [[53]], "entity_id": ["T13"], "Drug": {"text": [["corticosteroids"], ["cyclosporine"], ["MMF"], ["nti-T-lymphocyte globulin"]], "start": [[111], [128], [142], [152]], "entity_id": ["T16", "T17", "T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["utilized"]], "start": [[102]], "entity_id": ["T15"]}, "Drug": {"text": [["corticosteroids"], ["cyclosporine"], ["MMF"], ["nti-T-lymphocyte globulin"]], "start": [[111], [128], [142], [152]], "entity_id": ["T16", "T17", "T18", "T19"]}}]}}]}]}
{"id": "1348483_2", "context": "Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["cabergoline"]], "start": [[101]], "entity_id": ["T3"], "Disorder": {"text": [["Parkinson's disease"]], "start": [[44]], "entity_id": ["T4"]}, "Drug": {"text": [["cabergoline"]], "start": [[101]], "entity_id": ["T7"]}}, "Effect": {"text": [["Pleuropulmonary changes"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "15729090_2", "context": "We report a case of myoclonus induced by quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["myoclonus"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["quetiapine"]], "start": [[41]], "entity_id": ["T6"], "Drug": {"text": [["quetiapine"]], "start": [[41]], "entity_id": ["T7"]}}}]}]}
{"id": "18991509_2", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[170]], "entity_id": ["T6"]}, "Treatment": {"text": [["combination antiretroviral therapy, which included ritonavir", "epidural triamcinolone injections"]], "start": [[104, 231]], "entity_id": ["T5"], "Disorder": {"text": [["human immunodeficiency virus type 1 (HIV-1)"]], "start": [[30]], "entity_id": ["T3"]}, "Drug": {"text": [["triamcinolone"], ["ritonavir"]], "start": [[240], [155]], "entity_id": ["T8", "T11"]}, "Route": {"text": [["epidural", "injections"]], "start": [[231, 254]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[104]], "entity_id": ["T12"]}, "Drug": {"text": [["ritonavir"], ["triamcinolone"]], "start": [[155], [240]], "entity_id": ["T11", "T8"]}}]}, "Effect": {"text": [["Cushing syndrome with profound complications"]], "start": [[180]], "entity_id": ["T7"]}, "Subject": {"text": [["a human immunodeficiency virus type 1 (HIV-1)-infected individual"]], "start": [[28]], "entity_id": ["T1"]}}]}]}
{"id": "18691992_5", "context": "Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["Hydroxyurea"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Hydroxyurea"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas"]], "start": [[28]], "entity_id": ["T7"]}, "Subject": {"text": [["an elderly subject"]], "start": [[129]], "entity_id": ["T8"], "Age": {"text": [["elderly"]], "start": [[132]], "entity_id": ["T9"]}}}]}]}
{"id": "6324592_1", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[26]], "entity_id": ["T5"]}, "Effect": {"text": [["Disulfiram-like reactions"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cefmenoxime"]], "start": [[53]], "entity_id": ["T4"], "Drug": {"text": [["cefmenoxime"]], "start": [[53]], "entity_id": ["T6"]}}}]}]}
{"id": "3149484_1", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[83]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous lorazepam"]], "start": [[61]], "entity_id": ["T5"], "Disorder": {"text": [["atypical absence status seizures"]], "start": [[87]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[61]], "entity_id": ["T10"]}, "Drug": {"text": [["lorazepam"]], "start": [[73]], "entity_id": ["T11"]}}, "Subject": {"text": [["A 10-year-old girl with Lennox-Gastaut syndrome"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["Lennox-Gastaut syndrome"]], "start": [[24]], "entity_id": ["T7"]}, "Age": {"text": [["10-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[14]], "entity_id": ["T9"]}}}]}]}
{"id": "10745478_1", "context": "This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[186]], "entity_id": ["T4"]}, "Treatment": {"text": [["cocaine"]], "start": [[178]], "entity_id": ["T2"], "Drug": {"text": [["cocaine"]], "start": [[178]], "entity_id": ["T10"]}}, "Effect": {"text": [["refractory coronary vasospasm"]], "start": [[194]], "entity_id": ["T3"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[150]], "entity_id": ["T1"]}, "Treatment": {"text": [["use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter"]], "start": [[33]], "entity_id": ["T5"], "Disorder": {"text": [["cocaine-induced refractory coronary vasospasm"]], "start": [[178]], "entity_id": ["T11"]}, "Drug": {"text": [["intracoronary nitroglycerin"]], "start": [[61]], "entity_id": ["T8"]}, "Route": {"text": [["infusion through a 6 French coronary guiding catheter"]], "start": [[89]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[51]], "entity_id": ["T6"]}}}]}]}
{"id": "19915794_2", "context": "Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[43]], "entity_id": ["T7"]}, "Treatment": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["adverse reactions for cardiac rhythms", "TdP"]], "start": [[56, 234]], "entity_id": ["T6"]}, "Subject": {"text": [["hypokalemia"]], "start": [[202]], "entity_id": ["T10"], "Disorder": {"text": [["hypokalemia"]], "start": [[202]], "entity_id": ["T8"]}}}]}]}
{"id": "6292681_1", "context": "Severe neurotoxicity with methyl G: CALGB experience.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[21]], "entity_id": ["T5"]}, "Effect": {"text": [["neurotoxicity"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["methyl G"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["methyl G"]], "start": [[26]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "3628148_2", "context": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[88]], "entity_id": ["T6"]}, "Effect": {"text": [["rupture of a cerebral arterial aneurysm"]], "start": [[12]], "entity_id": ["T3"]}, "Subject": {"text": [["a 32 year old hypertensive woman"]], "start": [[55]], "entity_id": ["T4"], "Age": {"text": [["32 year old"]], "start": [[57]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[82]], "entity_id": ["T9"]}}, "Treatment": {"text": [["nifedipine treatment"]], "start": [[118]], "entity_id": ["T5"], "Disorder": {"text": [["hypertensive"]], "start": [[69]], "entity_id": ["T8"]}, "Drug": {"text": [["nifedipine"]], "start": [[118]], "entity_id": ["T10"]}}}]}]}
{"id": "9634122_1", "context": "Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["withdrawal"]], "start": [[112]], "entity_id": ["T7"]}, "Treatment": {"text": [["flutamide"]], "start": [[102]], "entity_id": ["T8"], "Disorder": {"text": [["progressing metastatic carcinoma of the prostate"]], "start": [[152]], "entity_id": ["T11"]}, "Drug": {"text": [["flutamide"]], "start": [[102]], "entity_id": ["T12"]}}, "Effect": {"text": [["decrease in prostate-specific antigen (PSA)"]], "start": [[52]], "entity_id": ["T9"]}, "Subject": {"text": [["subset of patients with progressing metastatic carcinoma of the prostate"]], "start": [[128]], "entity_id": ["T10"]}}]}]}
{"id": "25671244_13", "context": "Severe serotonin toxicity may result from metaxalone abuse in individuals using a selective serotonin reuptake inhibitor therapeutically.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[30]], "entity_id": ["T7"]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[7]], "entity_id": ["T6"]}, "Treatment": {"text": [["metaxalone abuse", "using a selective serotonin reuptake inhibitor therapeutically"]], "start": [[42, 74]], "entity_id": ["T8"], "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[42], [82]], "entity_id": ["T9", "T11"]}, "Dosage": {"text": [["abuse"]], "start": [[53]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["using"]], "start": [[74]], "entity_id": ["T12"]}, "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[42], [82]], "entity_id": ["T9", "T11"]}}]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "11341670_1", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[209]], "entity_id": ["T6"]}, "Treatment": {"text": [["omeprazole", "within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid"]], "start": [[143, 236]], "entity_id": ["T13"], "Dosage": {"text": [["high doses"]], "start": [[253]], "entity_id": ["T16"]}, "Time_elapsed": {"text": [["8 hr"]], "start": [[243]], "entity_id": ["T22"]}, "Route": {"text": [["continuous infusion"]], "start": [[310]], "entity_id": ["T24"]}, "Drug": {"text": [["omeprazole"]], "start": [[143]], "entity_id": ["T12"]}}, "Effect": {"text": [["peripheral edema"]], "start": [[219]], "entity_id": ["T5"]}, "Subject": {"text": [["three of six young female volunteers"]], "start": [[96]], "entity_id": ["T4"], "Population": {"text": [["three of six"]], "start": [[96]], "entity_id": ["T8"]}, "Gender": {"text": [["female"]], "start": [[115]], "entity_id": ["T9"]}, "Age": {"text": [["young"]], "start": [[109]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[209]], "entity_id": ["T6"]}, "Effect": {"text": [["peripheral edema"]], "start": [[219]], "entity_id": ["T5"]}, "Treatment": {"text": [["pantoprazole", "within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid"]], "start": [[196, 236]], "entity_id": ["T7"], "Dosage": {"text": [["high doses"]], "start": [[253]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["8 hr"]], "start": [[243]], "entity_id": ["T17"]}, "Route": {"text": [["continuous infusion"]], "start": [[310]], "entity_id": ["T23"]}, "Drug": {"text": [["pantoprazole"]], "start": [[196]], "entity_id": ["T14"]}}, "Subject": {"text": [["two young female volunteers"]], "start": [[158]], "entity_id": ["T18"], "Population": {"text": [["two"]], "start": [[158]], "entity_id": ["T19"]}, "Age": {"text": [["young"]], "start": [[162]], "entity_id": ["T20"]}, "Gender": {"text": [["female"]], "start": [[168]], "entity_id": ["T21"]}}}]}]}
{"id": "19296063_3", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[135]], "entity_id": ["T10"]}, "Subject": {"text": [["a 17-year-old male"]], "start": [[22]], "entity_id": ["T7"], "Gender": {"text": [["male"]], "start": [[36]], "entity_id": ["T11"]}, "Age": {"text": [["17-year-old"]], "start": [[24]], "entity_id": ["T12"]}}, "Treatment": {"text": [["a single dose of methylphenidate"]], "start": [[145]], "entity_id": ["T8"], "Dosage": {"text": [["a single dose"]], "start": [[145]], "entity_id": ["T13"]}, "Drug": {"text": [["methylphenidate"]], "start": [[162]], "entity_id": ["T14"]}}, "Effect": {"text": [["chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction"]], "start": [[55]], "entity_id": ["T9"]}}]}]}
{"id": "16997047_3", "context": "Recurrent hyponatremia associated with citalopram and mirtazapine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["Recurrent hyponatremia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["citalopram and mirtazapine"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["citalopram"], ["mirtazapine"]], "start": [[39], [54]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[50]], "entity_id": ["T9"]}, "Drug": {"text": [["citalopram"], ["mirtazapine"]], "start": [[39], [54]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "24429012_2", "context": "A case report of a sharp rise in International Normalized Ratio (INR) values during a patient's concomitant use of warfarin and the antineoplastic agent vismodegib is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[77]], "entity_id": ["T9"]}, "Effect": {"text": [["a sharp rise in International Normalized Ratio (INR) values"]], "start": [[17]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[84]], "entity_id": ["T10"]}, "Treatment": {"text": [["concomitant use of warfarin and the antineoplastic agent vismodegib"]], "start": [[96]], "entity_id": ["T11"], "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[115], [153]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[96]], "entity_id": ["T12"]}, "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[115], [153]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "16099004_4", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["compromise"]], "start": [[103]], "entity_id": ["T9"]}, "Treatment": {"text": [["phenytoin", "quinine"]], "start": [[89, 130]], "entity_id": ["T11"], "Drug": {"text": [["phenytoin"], ["quinine"]], "start": [[89], [130]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["malaria"]], "start": [[158]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[72]], "entity_id": ["T17"]}, "Drug": {"text": [["phenytoin"], ["quinine"]], "start": [[89], [130]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["efficacy of quinine"]], "start": [[118]], "entity_id": ["T12"]}, "Speculated": {"text": [["hypothesise", "may"]], "start": [[48, 99]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19707032_2", "context": "Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[18]], "entity_id": ["T8"]}, "Effect": {"text": [["Acute vision loss"], ["ocular ischemic syndrome"]], "start": [[0], [88]], "entity_id": ["T7", "T10"]}, "Treatment": {"text": [["intravitreal injection of bevacizumab (avastin)"]], "start": [[24]], "entity_id": ["T9"], "Route": {"text": [["intravitreal injection"]], "start": [[24]], "entity_id": ["T11"]}, "Drug": {"text": [["bevacizumab"]], "start": [[50]], "entity_id": ["T12"]}}}]}]}
{"id": "19717383_1", "context": "Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[44]], "entity_id": ["T11"]}, "Subject": {"text": [["a patient with AIDS"]], "start": [[20]], "entity_id": ["T8"], "Disorder": {"text": [["AIDS"]], "start": [[35]], "entity_id": ["T13"]}}, "Treatment": {"text": [["48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH)"]], "start": [[93]], "entity_id": ["T9"], "Drug": {"text": [["etoposide"], ["prednisone"], ["vincristine"], ["cyclophosphamide"], ["doxorubicin"], ["rituximab"]], "start": [[125], [136], [148], [161], [179], [196]], "entity_id": ["T14", "T15", "T16", "T17", "T18", "T19"]}, "Time_elapsed": {"text": [["48 months"]], "start": [[93]], "entity_id": ["T20"]}, "Disorder": {"text": [["diffuse large B-cell lymphoma"]], "start": [[220]], "entity_id": ["T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[120]], "entity_id": ["T10"]}, "Drug": {"text": [["etoposide"], ["prednisone"], ["vincristine"], ["cyclophosphamide"], ["doxorubicin"], ["rituximab"]], "start": [[125], [136], [148], [161], [179], [196]], "entity_id": ["T14", "T15", "T16", "T17", "T18", "T19"]}}]}, "Effect": {"text": [["medical attention with pancytopenia"]], "start": [[57]], "entity_id": ["T12"]}}]}]}
{"id": "12546343_3", "context": "He was later skin tested to confirm allergy to MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[44]], "entity_id": ["T3"]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T4"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["allergy"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["MTX"]], "start": [[47]], "entity_id": ["T6"], "Drug": {"text": [["MTX"]], "start": [[47]], "entity_id": ["T8"]}}}]}]}
{"id": "11319599_1", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[31]], "entity_id": ["T4"]}, "Effect": {"text": [["Indolent aspergillus arthritis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["fludarabine-based non-myeloablative stem cell transplantation"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["fludarabine"]], "start": [[44]], "entity_id": ["T6"]}, "Route": {"text": [["non-myeloablative stem cell transplantation"]], "start": [[62]], "entity_id": ["T7"]}}}]}]}
{"id": "12659609_9", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["over-treatment"]], "start": [[62]], "entity_id": ["T8"]}, "Subject": {"text": [["the patient's"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["chloroquine (902 micro g/L)"]], "start": [[147]], "entity_id": ["T7"], "Drug": {"text": [["chloroquine"]], "start": [[147]], "entity_id": ["T10"]}, "Dosage": {"text": [["902 micro g/L"]], "start": [[160]], "entity_id": ["T11"]}}, "Effect": {"text": [["maximum serum concentration", "in fatal chloroquine overdose"]], "start": [[116, 201]], "entity_id": ["T9"]}, "Severity": {"text": [["fatal"]], "start": [[204]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "6683487_4", "context": "To our knowledge, no prior cases of penicillamine-induced TTP in RA have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[50]], "entity_id": ["T7"]}, "Treatment": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T6"], "Drug": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T9"]}}, "Effect": {"text": [["TTP"]], "start": [[58]], "entity_id": ["T8"]}}]}]}
{"id": "9701106_5", "context": "The noted increase in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[45]], "entity_id": ["T5"]}, "Effect": {"text": [["increase in the theophylline level"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["zafirlukast administration"]], "start": [[51]], "entity_id": ["T6"], "Drug": {"text": [["zafirlukast"]], "start": [[51]], "entity_id": ["T7"]}}}]}]}
{"id": "2320800_2", "context": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[87]], "entity_id": ["T10"]}, "Subject": {"text": [["A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["sixty-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[17]], "entity_id": ["T14"]}}, "Effect": {"text": [["an irreversible lethal renal failure with anuria"]], "start": [[97]], "entity_id": ["T11"]}, "Treatment": {"text": [["the day after 5 g/m2 bolus ifosfamide"]], "start": [[147]], "entity_id": ["T12"], "Disorder": {"text": [["advanced breast cancer"]], "start": [[28]], "entity_id": ["T15"]}, "Drug": {"text": [["cisplatin"], ["ifosfamide"]], "start": [[76], [174]], "entity_id": ["T16", "T17"]}, "Dosage": {"text": [["5 g/m2"]], "start": [[161]], "entity_id": ["T18"]}}}]}]}
{"id": "25540831_1", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[29]], "entity_id": ["T7"]}, "Effect": {"text": [["Transient serotonin syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["tramadol", "selective serotonin reuptake inhibitor"]], "start": [[57, 70]], "entity_id": ["T8"], "Drug": {"text": [["tramadol"], ["selective serotonin reuptake inhibitor"]], "start": [[57], [70]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["tramadol"], ["selective serotonin reuptake inhibitor"]], "start": [[57], [70]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "8672829_6", "context": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[69]], "entity_id": ["T4"]}, "Effect": {"text": [["nonconvulsive status epilepticus"]], "start": [[36]], "entity_id": ["T3"]}, "Treatment": {"text": [["ifosfamide"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["ifosfamide"]], "start": [[80]], "entity_id": ["T6"]}}}]}]}
{"id": "7718983_5", "context": "We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T6"]}, "Effect": {"text": [["Graves' hyperthyroidism"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term interferon (IFN) therapy"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["interferon"]], "start": [[65]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["long-term"]], "start": [[55]], "entity_id": ["T9"]}}}]}]}
{"id": "17266059_1", "context": "The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[12]], "entity_id": ["T9"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T10"]}, "Effect": {"text": [["fulminant microangiopathic hemolytic anemia and thrombocytopenia"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole"]], "start": [[92]], "entity_id": ["T8"], "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[132], [145]], "entity_id": ["T11", "T12"]}, "Time_elapsed": {"text": [["within 48 hr"]], "start": [[92]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[127]], "entity_id": ["T14"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[132], [145]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "1792646_2", "context": "Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[66]], "entity_id": ["T11"]}, "Effect": {"text": [["Pneumocystis pneumonia", "fever, pulmonary infiltrates, and hypoxia"]], "start": [[0, 103]], "entity_id": ["T9"]}, "Treatment": {"text": [["methotrexate"]], "start": [[73]], "entity_id": ["T10"], "Drug": {"text": [["methotrexate"]], "start": [[73]], "entity_id": ["T15"]}, "Disorder": {"text": [["asthmatic"]], "start": [[47]], "entity_id": ["T16"]}}, "Subject": {"text": [["asthmatic patients"]], "start": [[47]], "entity_id": ["T12"]}, "Speculated": {"text": [["should"]], "start": [[23]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "11576059_1", "context": "Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consequence"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Vocal cord paralysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["peritonsillar infiltration with bupivacaine"]], "start": [[41]], "entity_id": ["T5"], "Route": {"text": [["peritonsillar infiltration"]], "start": [[41]], "entity_id": ["T6"]}, "Drug": {"text": [["bupivacaine"]], "start": [[73]], "entity_id": ["T7"]}}}]}]}
{"id": "2956288_3", "context": "Optic neuropathy in ethambutol-treated renal tuberculosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Optic neuropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ethambutol"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["ethambutol"]], "start": [[20]], "entity_id": ["T7"]}, "Disorder": {"text": [["renal tuberculosis"]], "start": [[39]], "entity_id": ["T8"]}}}]}]}
{"id": "7779233_2", "context": "This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["sodium warfarin"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["sodium warfarin-"]], "start": [[58]], "entity_id": ["T8"]}}, "Effect": {"text": [["necrotizing fasciitis and myonecrosis"]], "start": [[82]], "entity_id": ["T7"]}}]}]}
{"id": "4095247_3", "context": "Two of these patients, who also received the anti-emetic prochlorperazine, lost consciousness for 48-72 h and then fully recovered.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lost"]], "start": [[75]], "entity_id": ["T6"]}, "Subject": {"text": [["Two of these patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["anti-emetic prochlorperazine"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["prochlorperazine"]], "start": [[57]], "entity_id": ["T8"]}}, "Effect": {"text": [["lost consciousness for 48-72 h and then fully recovered"]], "start": [[75]], "entity_id": ["T5"]}}]}]}
{"id": "7379406_3", "context": "The case report discussed is, to our knowledge, the third of its kind regarding bone fluorosis resulting from use of this nicotinic derivative.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[110]], "entity_id": ["T4"]}, "Treatment": {"text": [["nicotinic derivative"]], "start": [[122]], "entity_id": ["T5"], "Drug": {"text": [["nicotinic derivative"]], "start": [[122]], "entity_id": ["T7"]}}, "Effect": {"text": [["bone fluorosis"]], "start": [[80]], "entity_id": ["T6"]}, "Subject": {"text": [["case", "the third"]], "start": [[4, 48]], "entity_id": ["T8"], "Population": {"text": [["third"]], "start": [[52]], "entity_id": ["T9"]}}}]}]}
{"id": "15093850_2", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[76]], "entity_id": ["T8"]}, "Treatment": {"text": [["pilocarpine"]], "start": [[51]], "entity_id": ["T7"], "Route": {"text": [["oral"]], "start": [[46]], "entity_id": ["T10"]}, "Drug": {"text": [["pilocarpine"]], "start": [[51]], "entity_id": ["T11"]}}, "Effect": {"text": [["bradycardia, mild hypotension, and muscarinic symptoms"]], "start": [[88]], "entity_id": ["T9"]}}]}]}
{"id": "12854039_2", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[160]], "entity_id": ["T7"]}, "Treatment": {"text": [["a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C."]], "start": [[166]], "entity_id": ["T8"], "Time_elapsed": {"text": [["a seven-month"]], "start": [[166]], "entity_id": ["T13"]}, "Drug": {"text": [["recombinant interferon alpha-2a"]], "start": [[187]], "entity_id": ["T14"]}, "Disorder": {"text": [["chronic active hepatitis C"]], "start": [[223]], "entity_id": ["T15"]}}, "Subject": {"text": [["a 62-year-old woman"]], "start": [[8]], "entity_id": ["T9"], "Age": {"text": [["62-year-old"]], "start": [[10]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[22]], "entity_id": ["T12"]}}, "Effect": {"text": [["bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities"]], "start": [[39]], "entity_id": ["T10"]}}]}]}
{"id": "11468878_3", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[70]], "entity_id": ["T6"]}, "Treatment": {"text": [["metformin"]], "start": [[60]], "entity_id": ["T3"], "Drug": {"text": [["metformin"]], "start": [[60]], "entity_id": ["T7"]}}, "Subject": {"text": [["patient"]], "start": [[78]], "entity_id": ["T4"]}, "Effect": {"text": [["Digestive hemorrhage caused by a Meckel's diverticulum"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "8551001_5", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["azathioprine"]], "start": [[41]], "entity_id": ["T3"], "Drug": {"text": [["azathioprine"]], "start": [[41]], "entity_id": ["T6"]}}, "Effect": {"text": [["myelosuppression"]], "start": [[69]], "entity_id": ["T5"]}, "Severity": {"text": [["severe"]], "start": [[62]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "22550162_3", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[102]], "entity_id": ["T11"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["placed on omeprazole after his first cycle of high-dose methotrexate"]], "start": [[16]], "entity_id": ["T9"], "Disorder": {"text": [["stress ulcer"]], "start": [[89]], "entity_id": ["T10"]}, "Drug": {"text": [["omeprazole"], ["methotrexate"]], "start": [[26], [72]], "entity_id": ["T12", "T13"]}, "Dosage": {"text": [["high-dose"]], "start": [[62]], "entity_id": ["T14"]}}}]}]}
{"id": "18344455_4", "context": "These toxicities resolved after the cessation of anticonvulsants, and her seizures were managed acutely with scheduled lorazepam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["managed"]], "start": [[88]], "entity_id": ["T6"]}, "Treatment": {"text": [["lorazepam"]], "start": [[119]], "entity_id": ["T7"], "Disorder": {"text": [["seizures"]], "start": [[74]], "entity_id": ["T5"]}, "Drug": {"text": [["lorazepam"]], "start": [[119]], "entity_id": ["T8"]}}}]}]}
{"id": "10679548_1", "context": "Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[93]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrofurantoin was withdrawn and corticosteroid treatment commenced"]], "start": [[107]], "entity_id": ["T6"], "Drug": {"text": [["corticosteroid"], ["nitrofurantoin"]], "start": [[140], [107]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["impaired lung function"]], "start": [[9]], "entity_id": ["T13"]}}, "Subject": {"text": [["Both had impaired lung function and abnormal computed tomographic scans"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Both"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["abnormal computed tomographic scans"]], "start": [[36]], "entity_id": ["T10"]}}}]}]}
{"id": "18691992_6", "context": "OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment, and to describe a successful therapeutic approach using imiquimod 5%.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[150]], "entity_id": ["T6"]}, "Effect": {"text": [["multiple squamous cell carcinomas and diffuse nail hyperpigmentation"]], "start": [[81]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[166]], "entity_id": ["T7"], "Drug": {"text": [["hydroxyurea"]], "start": [[166]], "entity_id": ["T8"]}}}]}]}
{"id": "14998226_7", "context": "Lovastatin also reportedly has caused increases in INR when coadministered with warfarin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["Lovastatin"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Lovastatin"], ["warfarin"]], "start": [[0], [80]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[60]], "entity_id": ["T11"]}, "Drug": {"text": [["Lovastatin"], ["warfarin"]], "start": [[0], [80]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["increases in INR"]], "start": [[38]], "entity_id": ["T8"]}}]}]}
{"id": "2442958_1", "context": "Multicentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[38]], "entity_id": ["T4"]}, "Effect": {"text": [["Multicentric hepatocellular carcinoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phosphate diethylstilbestrol"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["phosphate diethylstilbestrol"]], "start": [[48]], "entity_id": ["T7"]}, "Disorder": {"text": [["prostatic cance"]], "start": [[89]], "entity_id": ["T8"]}}}]}]}
{"id": "9013348_2", "context": "Mesalamine-induced hypersensitivity pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity pneumonitis"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "1711090_6", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effects"]], "start": [[9]], "entity_id": ["T9"]}, "Treatment": {"text": [["Lp-TAE combined with HT"]], "start": [[25]], "entity_id": ["T7"], "Drug": {"text": [["Lp"]], "start": [[25]], "entity_id": ["T10"]}, "Route": {"text": [["TAE"]], "start": [[28]], "entity_id": ["T11"]}}, "Effect": {"text": [["low-grade fever, localized pain, myelo-suppression and liver dysfunction"]], "start": [[54]], "entity_id": ["T8"]}}]}]}
{"id": "8053440_4", "context": "This is the first description, to our knowledge, of ductopenia apparently caused by clindamycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[74]], "entity_id": ["T4"]}, "Effect": {"text": [["ductopenia"]], "start": [[52]], "entity_id": ["T3"]}, "Treatment": {"text": [["clindamycin"]], "start": [[84]], "entity_id": ["T5"], "Drug": {"text": [["clindamycin"]], "start": [[84]], "entity_id": ["T6"]}}}]}]}
{"id": "14968106_2", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["following"]], "start": [[54]], "entity_id": ["T6"]}, "Treatment": {"text": [["intrathecal injection of doxorubicin"]], "start": [[88]], "entity_id": ["T4"], "Disorder": {"text": [["toxic myelopathy"]], "start": [[64]], "entity_id": ["T3"]}, "Drug": {"text": [["doxorubicin"]], "start": [[113]], "entity_id": ["T7"]}, "Route": {"text": [["intrathecal injection"]], "start": [[88]], "entity_id": ["T8"]}}, "Effect": {"text": [["Neurological improvement and rehabilitation potential"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7249424_1", "context": "Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[106]], "entity_id": ["T11"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute renal failure and tubulo-interstitial disease", "proteinuria or nephrotic syndrome"]], "start": [[26, 123]], "entity_id": ["T12"]}}]}]}
{"id": "15028964_7", "context": "Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection, we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements, particularly if concomitantly treated with amiodarone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["changes"]], "start": [[204]], "entity_id": ["T9"]}, "Effect": {"text": [["significant thyroid disorders"]], "start": [[11]], "entity_id": ["T7"]}, "Treatment": {"text": [["warfarin", "with amiodarone"]], "start": [[215, 281]], "entity_id": ["T8"], "Drug": {"text": [["warfarin"], ["amiodarone"]], "start": [[215], [286]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitantly"]], "start": [[259]], "entity_id": ["T12"]}, "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[286], [215]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "14964753_1", "context": "Cutaneous vasculitis secondary to ramipril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["ramipril"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["ramipril"]], "start": [[34]], "entity_id": ["T7"]}}, "Effect": {"text": [["Cutaneous vasculitis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "16889287_3", "context": "We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[51]], "entity_id": ["T6"]}, "Subject": {"text": [["a 21-year-old female patient"]], "start": [[22]], "entity_id": ["T3"], "Age": {"text": [["21-year-old"]], "start": [[24]], "entity_id": ["T7"]}, "Gender": {"text": [["female"]], "start": [[36]], "entity_id": ["T8"]}}, "Treatment": {"text": [["dapsone"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[56]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[64]], "entity_id": ["T5"]}}]}]}
{"id": "22233409_5", "context": "The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["ribavirin"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["ribavirin"]], "start": [[30]], "entity_id": ["T9"]}, "Disorder": {"text": [["hepatitis C"]], "start": [[86]], "entity_id": ["T10"]}}, "Effect": {"text": [["adverse events"]], "start": [[4]], "entity_id": ["T8"]}}]}]}
{"id": "16620273_1", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[97]], "entity_id": ["T4"]}, "Treatment": {"text": [["metformin"]], "start": [[81]], "entity_id": ["T3"], "Drug": {"text": [["metformin"]], "start": [[81]], "entity_id": ["T6"]}, "Disorder": {"text": [["Type 2 diabetes"]], "start": [[42]], "entity_id": ["T7"]}}, "Effect": {"text": [["lactic acidosis"]], "start": [[121]], "entity_id": ["T5"]}}]}]}
{"id": "417679_1", "context": "Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat (Intralipid 20%).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[52]], "entity_id": ["T6"]}, "Effect": {"text": [["fat embolism"]], "start": [[14]], "entity_id": ["T3"]}, "Subject": {"text": [["Four cases", "infants"]], "start": [[0, 44]], "entity_id": ["T4"], "Age": {"text": [["infants"], ["Four"]], "start": [[44], [0]], "entity_id": ["T7", "T8"]}}, "Treatment": {"text": [["prolonged intravenous infusion of fat (Intralipid 20%)"]], "start": [[62]], "entity_id": ["T5"], "Route": {"text": [["intravenous infusion"]], "start": [[72]], "entity_id": ["T9"]}, "Drug": {"text": [["Intralipid"]], "start": [[101]], "entity_id": ["T10"]}}}]}]}
{"id": "25295553_4", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[34]], "entity_id": ["T9"]}, "Treatment": {"text": [["Pregabalin was added to clozapine"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["clozapine"], ["Pregabalin"]], "start": [[24], [0]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["anxiety symptoms"], ["schizophrenia"]], "start": [[98], [53]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[15]], "entity_id": ["T13"]}, "Drug": {"text": [["Pregabalin"], ["clozapine"]], "start": [[0], [24]], "entity_id": ["T15", "T14"]}}]}, "Subject": {"text": [["2 patients with schizophrenia, who both suffered from severe anxiety symptoms"]], "start": [[37]], "entity_id": ["T8"], "Population": {"text": [["2"]], "start": [[37]], "entity_id": ["T10"]}}}]}]}
{"id": "18523232_4", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed to"]], "start": [[78]], "entity_id": ["T7"]}, "Effect": {"text": [["acute cytolytic hepatitis"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[68]], "entity_id": ["T6"]}, "Treatment": {"text": [["pulse itraconazole therapy for 24 weeks"]], "start": [[89]], "entity_id": ["T8"], "Drug": {"text": [["itraconazole"]], "start": [[95]], "entity_id": ["T9"]}, "Duration": {"text": [["24 weeks"]], "start": [[120]], "entity_id": ["T10"]}, "Route": {"text": [["pulse"]], "start": [[89]], "entity_id": ["T16"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[201]], "entity_id": ["T14"]}, "Treatment": {"text": [["itraconazole"]], "start": [[188]], "entity_id": ["T13"], "Drug": {"text": [["itraconazole"]], "start": [[188]], "entity_id": ["T11"]}}, "Effect": {"text": [["hepatitis"]], "start": [[209]], "entity_id": ["T15"]}}]}]}
{"id": "15279668_3", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[45]], "entity_id": ["T7"]}, "Effect": {"text": [["toxicity"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["second course of FLA and sixth course of Ara-C containing chemotherapy"]], "start": [[65]], "entity_id": ["T8"], "Drug": {"text": [["FLA"], ["Ara-C"]], "start": [[82], [106]], "entity_id": ["T9", "T10"]}, "Time_elapsed": {"text": [["sixth course"]], "start": [[90]], "entity_id": ["T11"]}, "Route": {"text": [["chemotherapy"]], "start": [[123]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[86]], "entity_id": ["T13"]}, "Drug": {"text": [["FLA"], ["Ara-C"]], "start": [[82], [106]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "3565435_2", "context": "Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[65]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen", "prolonged therapy"]], "start": [[45, 71]], "entity_id": ["T4"], "Drug": {"text": [["ibuprofen"]], "start": [[45]], "entity_id": ["T6"]}}, "Effect": {"text": [["systemic hypersensitivity reaction"]], "start": [[7]], "entity_id": ["T5"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "17420198_19", "context": "A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[97]], "entity_id": ["T10"]}, "Effect": {"text": [["EPS"]], "start": [[93]], "entity_id": ["T9"]}, "Treatment": {"text": [["initiation of aripiprazole"]], "start": [[107]], "entity_id": ["T11"], "Drug": {"text": [["aripiprazole"]], "start": [[121]], "entity_id": ["T13"]}}, "Subject": {"text": [["A patient with developmental disabilities who had no history of movement disorders"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["developmental disabilities"]], "start": [[15]], "entity_id": ["T1"]}}}]}]}
{"id": "15368548_1", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["leukemia"]], "start": [[105]], "entity_id": ["T10"]}, "Drug": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T13"]}}, "Effect": {"text": [["pancreatitis"]], "start": [[23]], "entity_id": ["T7"]}}]}]}
{"id": "20178709_2", "context": "Methotrexate may rarely provoke serositis, even with low doses and after just a few weeks of therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoke"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}, "Dosage": {"text": [["low doses"]], "start": [[53]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["after just a few weeks"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["serositis"]], "start": [[32]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[13]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "21597286_6", "context": "Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[177]], "entity_id": ["T9"]}, "Treatment": {"text": [["methotrexate and proton pump inhibitors (PPI)"]], "start": [[127]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"], ["proton pump inhibitors (PPI)"]], "start": [[127], [144]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[107]], "entity_id": ["T12"]}, "Drug": {"text": [["methotrexate"], ["proton pump inhibitors (PPI)"]], "start": [[127], [144]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["renal failure"]], "start": [[198]], "entity_id": ["T8"]}}]}]}
{"id": "12851279_14", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effect"]], "start": [[32]], "entity_id": ["T11"]}, "Subject": {"text": [["patients with severe sepsis and high INR"]], "start": [[65]], "entity_id": ["T8"]}, "Treatment": {"text": [["tifacogin"]], "start": [[15]], "entity_id": ["T10"], "Drug": {"text": [["tifacogin"]], "start": [[15]], "entity_id": ["T14"]}, "Disorder": {"text": [["sepsis and high INR"]], "start": [[86]], "entity_id": ["T16"]}}, "Negated": {"text": [["no"]], "start": [[29]], "entity_id": ["T9"], "value": true}, "Severity": {"text": [["severe"]], "start": [[79]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "18795_2", "context": "Asthma and urticaria during disodium cromoglycate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Asthma and urticaria"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["disodium cromoglycate treatment"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["disodium cromoglycate"]], "start": [[28]], "entity_id": ["T8"]}}}]}]}
{"id": "9399776_1", "context": "Acute pancreatitis after long-term 5-aminosalicylic acid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute pancreatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term 5-aminosalicylic acid therapy"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[35]], "entity_id": ["T6"]}, "Duration": {"text": [["long-term"]], "start": [[25]], "entity_id": ["T7"]}}}]}]}
